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Vaccine-preventable diseases cause considerable childhood morbidity and mortality in low- and 
middle-income countries (LMICs). To inform scaled use of mobile phone-based interventions 
(mHealth) to improve pediatric vaccination uptake in LMICs, we evaluated the following: 
    
i. Using current evidence, do short message service (SMS) reminders improve 
vaccination uptake? 
ii. Can SMS reminders with unconditional mobile money (mMoney) incentives improve 
first-dose measles-containing vaccine (MCV1) uptake?  




1) A systematic review and meta-analysis of the impact of SMS reminders on pediatric 
vaccination uptake. 
 
2) A randomized controlled trial in Kenya to assess the impact of SMS reminders with or 
without unconditional mMoney incentives on MCV1 uptake (the M-SIMI study). 
Participants received no interventions (Control), SMS reminders alone, or SMS 






3) A post-trial follow-up study (the MSBC study) in Kenya to assess vaccine-seeking after 
withdrawal of SMS reminders and incentives among former M-SIMU study participants.1  
 
Systematic review and meta-analysis (11 studies): SMS reminders significantly improved 
third-dose diphtheria, tetanus and pertussis (DTP3) timeliness but not DTP3 uptake and full 
vaccination by age 12 months. Insufficient number of studies precluded meta-analysis for MCVs. 
 
M-SIMI study (N= 455): Compared to Control infants, MCV1 coverage within four weeks of 
the recommended age was significantly higher among SMS+150KES infants but not among 
SMS only infants. Neither intervention significantly improved MCV1 coverage by age 12 
months. 
 
MSBC study (N= 218): Withdrawal of SMS reminders and incentives was associated with 
statistically insignificant decreases in MCV1-seeking for subsequent children (SC) and 
statistically significant decreases in MCV2-seeking for some former M-SIMU children. 
Decreased MCV1-seeking translated to lower-than-expected coverage among SC of former M-
SIMU intervention caregivers compared to Control SC. 
 
                                                 
1 Gibson DG, Ochieng B, Kagucia EW, et al. Mobile phone-delivered reminders and incentives to improve 
childhood immunisation coverage and timeliness in Kenya (M-SIMU): a cluster randomised controlled trial. Lancet 
Glob Heal. 2017;5(4):e428-e438. 
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SMS reminders can increase vaccination uptake. Unconditional incentives may have no added 
effect on MCV1 uptake over SMS reminders alone. Withdrawal of SMS reminders and 
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1.1. Project rationale 
Vaccines continue to contribute towards reductions in mortality and morbidity globally. 
Annually, vaccines prevent up to three million global child deaths.1 Vaccination against 
smallpox was crucial for elimination of smallpox in 1980; prior to its eradication, smallpox 
caused an estimated 300 million total deaths and hundreds of millions illnesses globally.2 
Vaccines against polio - a disease targeted for eradication - are estimated to avert 8 million 
deaths world-wide between 1988 and 2035.3 Measles-containing vaccines (MCVs) have averted 
20.4 million measles deaths globally between 2000 and 2016.4 Vaccine-associated gains have 
been observed across high- and low-resource settings. In the US, vaccines averted an estimated 
26 million cases of illness between 2001 and 2011.5 In Gavi-supported low- and middle-income 
countries (LMICs), use of 10 vaccines is expected to avert 20 million deaths and 500 million 
illnesses in 2001-2020. Beyond avoiding death and disease, vaccines can avert substantial costs 
associated with mortality and illness, for example, vaccines are projected to save an estimated 
$820 billion in Gavi-supported LMICs between 2001 and 2020.6 Furthermore, vaccines can 
alleviate poverty resulting from catastrophic health expenditures,7 increase educational 
attainment8,9 and avert cognitive impairment caused by vaccine-preventable illnesses.10,11 
Moreover, vaccines can contribute towards achievement of the Sustainable Development Goals 
(SDGs) by promoting good health and well-being, reducing poverty and increasing the 
likelihood of high educational attainment, among other benefits.12–15   
 
The 2011-2020 Global Vaccine Action Plan (GVAP) offers a roadmap towards realizing the full 
public health value of vaccination.16 However, global progress towards achieving the 2020 
targets of the GVAP is unsatisfactory, with only one target – introduction of a new vaccine in 
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each LMIC – having been met.17 Certification of polio eradication by 2018 is unattainable as the 
African (AFRO) and Eastern Mediterranean (EMRO) regions of the World Health Organization 
(WHO) are not yet certified polio-free and at best, would achieve certification in 2019 and 2021, 
respectively.18 In 2018, only the WHO Americas region has eliminated measles out five WHO 
regions targeted to eliminate measles by 2020. In addition, as of 2016 (the last year with a 
published global review of measles control progress), none of the countries in AFRO or in 
EMRO had eliminated measles.4 Of 194 member states providing national 2016 third dose 
diphtheria, tetanus and pertussis (DTP3) vaccination coverage data to WHO, 68 had <90% 
coverage, yet 90% and 80% national coverage and district-level coverage, respectively, are 
expected by 2020.19 
 
In 2016, 96% of LMIC inhabitants and 75% of people living in Africa owned a mobile 
telephone.20 An even larger percentage of LMIC inhabitants have access to a mobile phone as 
phone sharing is prevalent in these settings.21,22 Vaccination reminders and incentives can 
increase demand for vaccination.23–26 High levels of mobile phone access afford an opportunity 
to reach more people with mobile phone-based vaccination reminders and incentives compared 
to reminders and incentives delivered via traditional avenues. Of studies assessing the impact of 
demand-side mobile-phone based interventions (mHealth) to improve vaccination uptake in 
LMICs,27–29 the Mobile Solutions for Immunization (M-SIMU) study – a cluster randomized 
controlled trial conducted in rural western Kenya in 2013 to 2015 – was novel in that it assessed 
the impact of two mHealth interventions i.e., SMS reminders alone or when coupled with small 
conditional mobile-money (mMoney) incentives, on vaccination coverage and timeliness. The 
M-SIMU study found that SMS reminders coupled with the larger of two conditional mMoney 
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incentives significantly improved first dose MCV (MCV1) coverage from 84% to 90% by age 12 
months (coverage endpoint). In assessment of the timeliness endpoint, SMS reminders with or 
without conditional mMoney incentives significantly increased the proportion of children 
receiving MCV1 within two weeks of the recommended age within the Kenya Expanded 
Programme on Immunization (KEPI) by as much as 21% while SMS reminders coupled with the 
larger of two conditional mMoney incentives significantly improved DTP3 timely coverage by 
9%.30 The implication of findings from the M-SIMU study is that SMS reminders with or 
without small incentives can be used to reduce the proportion of children susceptible to disease 
by increasing vaccination timeliness and that these interventions can be used to increase 
vaccination coverage even among ‘last-mile’ populations who have relatively high, though sub-
optimal, vaccination coverage.  
 
Findings from the M-SIMU study present a case for implementing SMS reminders with or 
without incentives, at scale so as to improve vaccination uptake. However, stakeholders in 
LMICs may have scientific and technical concerns. First, there is no information on the summary 
effect of SMS reminders on vaccination in LMICs. Current summary effect estimates are from 
predominantly high-income settings23 and current systematic and scoping reviews focused on 
LMICs have performed only qualitative syntheses.27–29 Second, the M-SIMU study demonstrated 
an added effect of conditional incentives over SMS reminders alone but the use of conditional 
incentives requires near real-time verification of vaccination status, which in most LMICs is 
impossible due to the lack of centralized, accurate electronic vaccination records. Third, the 
long-term impact of SMS reminders alone or when coupled with conditional monetary incentives 
on vaccine-seeking is not known. Specifically, might SMS reminders and/or incentives cause a 
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negative rebound in vaccine-seeking behavior when withdrawn? Or might their impact be 
sustained such that families who received SMS reminders and/or incentives are more likely to 
vaccinate subsequent children, even in the absence of reminders/incentives? This dissertation 
aims to provide rigorous evidence to inform at scale implementation of SMS reminders alone or 
in combination with small monetary incentives for improvement of vaccination uptake in 
LMICs. 
 
1.2. Specific aims 
Aim 1. To assess the pooled quantitative effect of SMS reminders on vaccination coverage 
and timeliness in low- and middle-income countries.  
To assess this aim, we conducted a systematic review and meta-analysis of the effect of SMS 
reminders on pediatric vaccination coverage and timeliness in LMICs. As mentioned previously, 
currently no meta-analysis of the effect of SMS reminders on vaccination coverage or timeliness 
in LMICs has been performed. 
 
Aim 2. To evaluate if SMS reminders, with or without an unconditional mobile-money 
incentive, can significantly increase the proportion of children receiving MCV1 by age 10 
months as compared to control arm children in rural Siaya County, Kenya.  
This aim was assessed using data from a randomized controlled study, the Mobile and Scalable 
Innovations for Measles Immunization (M-SIMI) study. The M-SIMI study was conducted 
between 2016 and 2017 in the same setting as the M-SIMU trial. Whereas the SMS reminders 
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coupled with conditional incentives were shown to improve MCV1 uptake in the M-SIMU 
study,30 the impact of SMS reminders coupled with unconditional incentives has not been 
previously evaluated. Unlike conditional incentives, unconditional incentives do not require real-
time verification of vaccination status and thus could present a scalable intervention by 
eliminating the need for employing staff to verify infants’ vaccination status in real time. 
Measles vaccination was used to illustrate the potential impact of SMS reminders with or without 
unconditional incentives on vaccine uptake.  
 
Aim 3. To assess whether MCV1 timeliness and coverage significantly differ between 
subsequent born children of M-SIMU caregivers in rural Siaya County, Kenya who 
received SMS reminders alone or coupled with small mobile-money incentives compared to 
children of Control M-SIMU caregivers who did not receive any interventions.  
This aim was assessed using data from the M-SIMU Subsequent Born Children (MSBC) study. 
A post-trial follow-up study, the MSBC study conducted a vaccination survey among children 
born to M-SIMU caregivers after their participation in the M-SIMU study so as to allow 
comparison of vaccine-seeking among M-SIMU caregivers after SMS reminders and monetary 
incentives were withdrawn, compared to during the M-SIMU study. The MSBC study was 
conducted in 2017 in the same area where the M-SIMU study was conducted. Measles vaccine-
seeking was the illustrative case used to demonstrate the potential long-term impact of SMS 




1.3. Thesis organization 
Chapter 1 describes the rationale of the dissertation project and outlines the specific aims of the 
dissertation.  
 
Chapter 2 is a compilation of relevant background information. It describes measles disease, 
global measles prevention and control efforts as well as supply- and demand-side barriers to 
MCV uptake. It also includes a review of the literature on the use of non-SMS reminders and 
incentives to improve vaccination coverage in LMICs. In addition, it provides a detailed review 
of the M-SIMU study and a description of the study setting. The M-SIMU study was conducted 
prior to the commencement of this dissertation but is relevant as it is the precursor to both the M-
SIMI (Aim 2) and MSBC (Aim 3) studies. Finally, Chapter 2 also describes the research setting 
wherein the M-SIMI, MSBC and M-SIMU trials were conducted.   
 
Chapters 3-5 describe the methods and findings from analyses of the specific aims. Specifically, 
Chapter 3 presents the systematic review and meta-analysis of the impact of SMS reminders on 
vaccination coverage and timeliness in LMICs. Chapter 4 presents the analysis of the impact of 
SMS reminders with or without unconditional mMoney incentives on MCV1 uptake (the M-
SIMI study) while Chapter 5 describes the analysis of differences in MCV1 uptake among 
children subsequently born to M-SIMU intervention caregivers compared to control caregivers 




Chapter 6 presents a summary of the findings from the specific aims and a contemplation of the 
implication of these findings to measles control programs and to vaccination programs in 
general. Chapter 6 also discusses the strengths and limitations of the analyses and 
recommendations for future studies.  
 
In Chapter 7 (Appendices), readers can find supplementary documents.          
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Measles remains a major cause of morbidity and mortality. Despite substantial reductions in 
measles mortality and morbidity since 2000, there were an estimated 89,780 global measles 
deaths and approximately 132,000 measles cases (likely an underestimate) reported to the World 
Health Organization (WHO) in 2016. All but 1,880 of global measles deaths occurred in the 
Africa (AFRO), South-East Asia (SEARO) and Eastern Mediterranean (EMRO) regions of the 
WHO.1 At the same time, most measles deaths occur in children <5 years old.2 Vaccination is 
key for measles prevention yet 21 million children worldwide did not receive first dose measles-
containing vaccine (MCV1) in 2016. Of those 21 million, 18 million children lived in AFRO, 
SEARO and EMRO. Third dose of diphtheria, tetanus and pertussis (DTP3) vaccine coverage in 
these regions points to suboptimal routine immunization performance. In 2016, regional DTP3 
coverage was 74%, 80% and 88% in AFRO, SEARO and EMRO, respectively.3 Well-
functioning routine immunization systems are expected to achieve DTP3 coverage of ≥90% 
nationally and ≥80% at the district level.4 
 
Barriers at the health system level (supply-side) and at the health service user level (demand-
side) contribute to reduced immunization system performance and have been well characterized 
in low- and middle-income countries (LMICs).5–9 Interventions that overcome supply-side and 
demand-side barriers to vaccination are critical to improving vaccination coverage in LMICs so 
as to avert deaths, illnesses and their associated costs and sequelae. Results from meta-analyses 
suggest that vaccination reminders and incentives increase vaccination uptake in high income 
settings10–13 while in LMICs there is some evidence for the effectiveness of reminders but mixed 
evidence for incentives.14,15 Increasingly high levels of mobile phone ownership16 and access17,18 
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in LMICs present an opportunity for evaluating the impact of reminders and incentives delivered 
via mobile phones as they may reach more health service users, including those from 
traditionally disadvantaged populations. 
 
This chapter provides an overview of the burden of disease due to measles and global measles 
control efforts. Barriers to measles vaccination are also reviewed as well as the historical use of 
reminders and incentives to improve vaccination uptake. In addition, a short discussion on 
metrics used to measure vaccination uptake and the potential role of mobile phone delivered 
reminders and incentives to improve vaccination uptake are briefly presented, followed by an 
exploration of the theoretical mechanisms through which reminders and incentives may 
influence vaccine-seeking behavior. Finally, a review of the parent study for Aims 2 and 3 of the 
thesis, i.e., the M-SIMU study is described in detail and a description of the study area is 
provided.  
 
2.2. Measles disease and global control efforts 
2.1.1 Measles virus and clinical features 
Measles is caused by a negative-strand RNA virus of the genus Morbillivirus, Family 
Paramyxoviridae. It primarily affects children and is transmitted when aerosolized measles virus 
(MV) is inhaled or introduced into the conjunctiva. After a 10-14 day incubation period, the 
initial symptoms of measles illness – fever, cough, runny nose and conjunctivitis – appear in the 
infected person and usually last up to three days. These unspecific symptoms are followed by the 
development of lesions on the inside lining of the cheeks, known as Koplik’s spots, which are 
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specific to measles. A maculopapular rash beginning in the facial area and eventually spreading 
to the rest of the body begins one to two days after the appearance of Koplik’s spots. Symptoms 
may be different in immunocompromised people.19–21 Measles is extremely infectious and can be 
transmitted to as many as 9 out 10 susceptible, exposed people.22 
 
Although measles virus infection is self-limiting in most people, infection with the virus can lead 
to secondary infections due to measles-induced immune suppression and to sequelae such as 
pneumonia, diarrhea, blindness, acute post-infection measles encephalitis, measles inclusion 
body encephalitis and subacute sclerosing panencephalitis (SSPE).19,23,24 Complications occur 
most frequently among children age <5 years, adults age >20 years, pregnant women and 
immunocompromised individuals such as persons infected with human immunodeficiency virus 
(HIV) and malnourished persons.23 The frequency of complications among measles cases can 
range from as high as 25% (diarrhea) to as low as 0.01% (SSPE)25. There is no measles-specific 
antiviral treatment though management of sequelae may include rehydration, vitamin A 
administration and antibiotic treatment of secondary bacterial infections.21 The case fatality ratio 
(CFR) for measles is typically 5% in endemic low-income settings21 but can be as high as 10%23 
or even higher during outbreaks or in emergency situations.26,27 Measles CFR is influenced by 
factors such as access to quality care, nutritional status and MCV coverage.21 Infection with 




2.2.2. Burden of disease 
Measles is a substantial cause of mortality and morbidity. In 2015, there were an estimated 7 
million (95% confidence interval [CI] 4.2 million – 28.7 million) measles cases and 89,780 (95% 
CI 45,700 – 269,600) measles deaths globally. The WHO regions contributing the largest 
proportion of measles deaths were South East Asia (43%) and Africa (42%) meaning that 85% of 
global measles deaths occurred in these two regions. Despite the substantial burden of measles 
disease, 2016 morbidity and mortality estimates represent a 76% and 84% decline, respectively, 
since 2000.1 Measles outbreaks occurred in at least six countries globally in 2016 i.e., Romania, 
Italy, Cambodia, Kenya, Nigeria and Sierra Leone.29,30  The quality of measles morbidity and 
mortality data is hampered by low rates of diagnosis and reporting,31 leading to reliance on 
modelled estimates. For example, in 2016, 132,137 measles cases were reported to the World 
Health Organization (WHO), compared to the model-estimated 7 million cases.  
 
No current data on age-specific measles morbidity could be found, but measles is known to be a 
major cause of childhood mortality. In 2015, measles was estimated to cause 74,000 of 3.4 
million global non-neonatal deaths among children age <5 years. Of note, childhood measles 
morbidity has declined by 85% since 2000 when it accounted for 485,000 of non-neonatal deaths 
among children age <5 years. A little over 50% of global measles deaths in 2015 occurred in 
sub-Saharan Africa (SSA) and together with South Asia, these two regions accounted for 91% of 




In addition to the individual burden of morbidity and mortality, measles can also impose a 
substantial economic burden on families and the health sector. The cost of measles treatment in 
six LMICs (Bangladesh, Brazil, Colombia, Ethiopia, Tajikistan and Uganda), for example, was 
estimated to range from $2.83 (Ethiopia) to $77.90 (Brazil) per case in 2015 US dollars (USD).32 
Though the estimated measles treatment costs in these LMICs pales in comparison to costs in 
high-income countries - $511 per case in 2015 USD – these costs represent a substantial 
proportion of total health expenditure (THE) per capita in LMICs. For example, 2014 THE per 
capita was $27 and $947 in Ethiopia and Brazil, respectively.33 Furthermore, the health sector 
and societal costs in the event of an outbreak are considerable. For example, the combined health 
sector and societal cost of a 2011-12 outbreak in Ethiopia resulting in 5,257 cases was $555,866 
(cost indexed to 2015 USD).34 In 2016, the Measles and Rubella (MR) Initiative spent $5.4 
million to support measles outbreak activities in four LMICs.29 
 
2.2.3. Measles vaccines 
Measles vaccines have been in use since 1963 when the first live attenuated vaccine and first 
inactivated vaccine were licensed in the US. In 1967 the formalin-inactivated measles vaccine 
was withdrawn because it increased the risk of atypical measles in recipients when they were 
infected with wild-type MV and was also poorly immunogenic. Live attenuated vaccines, which 
are developed by serial passage at varying temperatures in chick embryo, dog kidney and sheep 
kidney cells, among others, also have a history of safety concerns. In 1975 the first licensed live 
attenuated vaccine was withdrawn due to frequent reactogenicity events (fever and rash) among 
recipients. In 1992 a high-titer live attenuated measles vaccine was withdrawn following 
increased mortality in female child recipients. Despite this storied history, other live attenuated 
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measles vaccine strains developed since the late 1960s are safe, effective and continue to be used 
worldwide. Measles vaccine strains in use today are those derived from the first licensed live 
attenuated vaccine strain, e.g., AIK-C, Schwarz and Edmonston-Zagreb or non-Edmonston 
strains such as Leningrad-4, Shanghai-191 and CAM-70. There are no known significant 
differences in effectiveness or safety profile of these strains. Current measles vaccine can be 
found as stand-alone products or in combination with other vaccines such as rubella, mumps and 
varicella commonly designated as MR, MMR or MMR-V vaccines.21,22,35–38       
 
Measles vaccine induces protective antibody levels in approximately 85% of children vaccinated 
at age 9 months and in 90-95% of children vaccinated at age 12 months. Thus, age is an 
important predictor of antibody response; vaccine-induced antibodies increase with increasing 
age at time of vaccination up to approximately 15 months of age.39 MCV administration at age 
<9 months reduces the likelihood of developing vaccine-induced immunity because of 
interference from circulating maternal anti-measles antibodies and immune system immaturity. 
Nevertheless, vaccination recommendations typically take into account the age-specific risk of 
measles infection and expected immunogenicity to designate the recommended measles 
vaccination age. For example, a supplemental dose of MCV at age 6 months is recommended for 
HIV-infected or exposed infants, for refugee infants and during outbreaks.38 Of the 68 countries 
providing measles vaccination schedule information to the WHO, most recommend the first dose 
of measles vaccine at age 9 months; the range is 6 months (Malaysia) to 18 months (Ghana).40 
Vaccine-induced immunity against measles is long-lived, lasting “decades”.39 MCV is typically 
administered during routine immunization activities and may also be administered through 
supplemental immunization activities (SIAs) such as mass vaccination campaigns in LMICs. 
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SIAs are recommended to increase MCV coverage levels in settings with low coverage and to 
provide an opportunity for administration of a second measles dose.41 Measles vaccine is highly 
cost-effective. It costs roughly $1 per dose and every $1 invested in measles vaccination within 
LMICs is estimated to avert $58 in direct medical, direct non-medical and indirect costs.41,42 
Further, there is evidence that an ancillary benefit of measles vaccine is that it reduces all-cause 
mortality, beyond the effect expected against measles disease alone.43   
 
2.2.4. Global measles control 
Since 2001, global measles control efforts have been led by the Measles & Rubella Initiative 
(MR Initiative; formerly the Measles Initiative), a collaboration between WHO, the US Centers 
for Disease Control and Prevention (CDC), UNICEF, the American Red Cross and the United 
Nations Foundation. The MR Initiative is also supported by numerous other organziations.41 
Based on targets set by WHO regions and adopted by member states, the MR Initiative seeks to 
attain elimination of measles – defined as the interruption of endemic measles transmission for 
≥12 months in a setting with strong surveillance19,44 – in all six WHO regions by 2020, with 
elimination of the disease in at least four WHO regions (Americas, Western Pacific [WPRO], 
European [EUR] and Eastern Mediterranean [EMRO]) having been expected by 2015.41 
Additionally, the following interim targets towards measles elimination were endorsed by the 
World Health Assembly (WHA) in 2010 and were set to be achieved by 2015: attainment of  
≥90% national and ≥80% district-level coverage for one dose of MCV (MCV1), reduction of 
measles incidence to <5 cases per million population globally, and reduction of 2000 global 
measles mortality by 95%.41 Although measles is eradicable, 19,39 no global target for measles 




In its 2010-2020 plan, the MR Initiative lays out a five-component strategy for nations to attain 
measles elimination goals: 1) achieve high vaccination coverage for two doses of MCV, 2) 
implement strong disease surveillance coupled with program evaluation, 3) implement rapid 
outbreak response, 4) increase vaccination confidence and vaccine demand through public 
engagement and communication and 5) implement research to identify cost-effective processes, 
improved vaccination strategies and improved diagnostic tools.41 Importantly, successful measles 
control is integral for the realization of Sustainable Development Goal (SDG) 3 i.e., “Ensure 
healthy lives and promote well-being for all at all ages”. Specifically, measles control will 
facilitate achievement of two SDG targets, namely, riddance of “preventable” deaths in children 
age <5 years by 2030 and universal access to vaccines.45 
 
In the absence of other effective interventions, measles vaccine is a cornerstone for measles 
elimination efforts. Measles vaccine is expected to avert 14.1 million deaths between 2011 and 
2020.4 Of note, progress towards measles elimination targets is an indicator of success in the 
2011-2020 Global Vaccine Action Plan (GVAP), a strategic framework endorsed by the WHA in 
2012 to ensure achievement of global vaccination targets and the ensuing health and 
socioeconomic benefits.4  
 
Despite the availability of a highly effective vaccine and a global disease control program, 
measles elimination is not on track. All MR Initiative and WHA 2015 measles control targets 
were missed. By 2015, only 61% of 194 countries reporting immunization data to WHO attained 
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≥90% national MCV1 coverage and global measles incidence was 36 per million population. In 
fact, global MCV1 coverage, estimated at 85% in 2015, had been stagnant since 2009 and in the 
same year MCV2 coverage was 61% across the 160 countries that had introduced a routine 
second dose.46 The substantial decline in measles mortality mentioned previously (85%) fell 
short of the ≥95% measles mortality reduction target. Finally, while at least four WHO regions 
were expected to attain measles elimination by 2015, only the Americas region, which 
eliminated measles in 2002,41 met the target and was certified free of endemic measles in 2016.46 
Of note, whereas five of 37 WPRO countries/areas and 21 of 53 EUR countries had eliminated 
measles as of 2015, no country in the other WHO regions (AFRO, EMRO, SEARO) had 
eliminated measles.46    
 
Increasing MCV1 and MCV2 coverage levels is crucial for putting measles control back on track 
and for achieving the overall goal of measles elimination in WHO regions. High coverage with 
two doses of MCV is a prerequisite for measles elimination, a lesson learned from settings with 
successful measles control programs such as the US.47 Specifically, attainment of  ≥95% 
coverage for both MCV1 and second dose MCV (MCV2) at the national and district levels is 
required.41 In turn, these high levels of MCV1 and MCV2 coverage are necessary to establish the 
≥89-94% population immunity (herd protection) needed to interrupt measles virus 
transmission.19    
 
There are pronounced differences in measles vaccine coverage at the regional, national and sub-
national levels. In 2016, there was a ≥24% difference in MCV1 and MCV2 coverage between 
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WPRO, the WHO region with the highest coverage (MCV1, 96%; MCV2, 93%), and AFRO 
which had the lowest coverage (MCV1, 72%; MCV2, 24%). Similar to global coverage, MCV1 
coverage in AFRO was stagnant between 2011 and 2016, having increased by only one 
percentage point in those years.48 Within AFRO, 2016 MCV1 coverage ranged from 99% 
(Comoros) to 20% (South Sudan).49 More than half of the 21 million children not receiving 
measles vaccine worldwide in 2016 were in six countries in AFRO, SEARO and EMRO, i.e., 
Democratic Republic of Congo, Ethiopia, Nigeria, India, Indonesia and Pakistan.46  
 
At the sub-national level, measles vaccination uptake may vary by wealth and educational status. 
In one evaluation restricted to LMICs, 2010-2014 MCV coverage was higher by ≥20% in the 
richest vs. poorest quintile and among the most vs. least educated in, respectively, 21 of 68 and 
24 of 54 LMICs assessed. In the same evaluation, MCV coverage was higher in urban areas 
compared to rural areas in most (54%) of the 68 LMICs evaluated.50 Furthermore, MCV 
coverage at the sub-national level may also vary by geographic region or community. For 
example, in Nigeria MCV coverage is lower in the northern vs. the southern regions51 and other 
examples of regional variation can be found in other settings.52,53 MCV coverage also tends to be 
lower in refugee populations living in non-conflict settings as indicated by measles outbreaks 
among refugee communities in countries such as Ivory Coast54, Kenya,55 and Tanzania.56 
Encouragingly, MCV coverage across sexes seems equitable in LMICs.50 Nevertheless, 
interventions to improve MCV coverage should reach sub-groups who may have relatively low 




2.3. Barriers to measles vaccination in LMICs 
Barriers to childhood vaccination are generally grouped into supply-side factors – issues 
associated with availability of vaccine, access to and quality of health services – or demand-side 
factors i.e., factors related to parental knowledge, attitudes and beliefs about vaccination and 
vaccination services (Figure 2.1). Common barriers to vaccination in LMICs are well 
summarized in several reviews.5,6,8,9,57–59 Low MCV coverage and inequalities in MCV coverage 
could be attributed to both supply-side and demand-side factors; specific examples are provided 
in the following sections.  
 
2.3.1. Supply-side barriers 
Supply-side barriers may include inaccessible vaccination services due to cost, distance or 
difficult travel environments, unfriendly health facility staff, poor or incomplete communication 
by health staff, health facility staff’s poor vaccine knowledge, long wait times and vaccine stock-
outs.5,6,9,57–59  
 
Studies conducted in a number of settings have validated these common supply-side factors as 
barriers to MCV receipt. Long distance to health facilities and long wait times at health facilities 
has been identified as a barrier to measles vaccination in the Lao People’s Democratic Republic 
(PDR), Malawi, Pakistan and Papua New Guinea (PNG).60–63 Furthermore, longer distance to a 
health facility was associated with lower likelihood of timely measles vaccination in Kenya.64  
Additionally, difficulty accessing vaccination services in conflict settings is a generally 
recognized threat to measles control programs41,51 and even temporary insecurity can discourage 
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caregivers from seeking measles vaccinaton.62 Shortage of vaccine supplies has been identified 
as a reason for low measles vaccination uptake in Lao PDR and Nigeria.60,65 MCV stock-outs 
likely influence vaccination coverage in other settings as well. Between 2010 and 2015, MCV 
stock-outs occurred in 5-14% of countries globally and just between January and August 2017, 
MCV stock-outs had been reported in at least three countries, i.e., Ghana, Greece and 
Romania.66–69  Ironically, fear of wastage and stock-out may result in the refusal by health 
facility staff to open multi-dose MCV vials, which are used in Gavi-supported70 and other 
countries, unless a substantial number of children needing MCV are present. This refusal to open 
multi-dose vials leads to missed opportunities for administering MCV when children are turned 
away62,71and is thought to drive the high proportion of missed opportunities for multi-dose vial 
vaccines relative to other single-dose vaccines.72  In addition, health facility staff’s poor vaccine 
knowledge has been shown to result in the false contraindication for administration of MCV to 
children aged older than 12 months.5 Finally, caregivers’ apprehension of unfriendly treatment 
by health care workers have been reported as reasons for not vaccinating children against 
measles in Nigeria and PNG (Table 2.1).62,65    
 
2.3.2. Demand-side barriers 
Demand-side barriers may include caregivers’ negative beliefs about vaccination, concern about 
adverse events following immunization (AEFI), under-prioritization of vaccination relative to 
other competing activities, and lack of knowledge about the frequency of vaccination or location 
of vaccination services. Costs due to travel or other indirect costs associated with vaccination are 
another barrier to MCV-seeking.5,6,8,9,58–60 Outside demand-side barriers identified in reviews, 
forgetfulness has been cited as a reason for unintentional missed vaccinations in a variety of 
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LMICs73–77 by 5.5%76 to 26%75,77 of surveyed caregivers. Further, caregivers have cited failure to 
receive reminders as a reason for missed vaccinations.75 In most LMICs there is a substantial gap 
between the DTP primary series, typically given within the first four months of life, and MCVs 
which are typically administered at 9 months of age or later. This gap may contribute to higher 
likelihood of caregivers forgetting to seek MCV.   
 
Misapprehensions about the need for measles vaccine and concerns about vaccine side effects 
are generally recognized barriers to measles vaccine-seeking.41 Studies in Brazil, China, Lao 
PDR, PNG and Nigeria found that caregivers failed to vaccinate their children against measles at 
all or in a timely manner due to concerns about the number of vaccinations given to children,60,62 
fear of or miscomprehension about adverse events following vaccination,60,62,78–80 and beliefs 
that MCV was ineffective or unnecessary.60,65,78,79 Conversely, knowing that vaccines can 
prevent illness was associated with higher MCV uptake in Pakistan.61 Furthermore, potentially 
incorrect assessment of contraindications by caregivers79 and not knowing MCV due 
dates60,65,79,81 were identified as reasons for delaying or missing MCV in China, India, Lao PDR 
and Nigeria. Even when caregivers may initially know the MCV due date, the long interval 
between the time when early infancy vaccines are administered and the recommended age for 
MCV may result in caregivers forgetting, as hypothesized variously.82–84 Competing priorities, 
such as community/social events and domestic chores have also been documented to result in 
missed measles vaccinations in Lao PDR and PNG.60,62 Finally, at least one study documented 




2.3.3. Interplay of demand-side barriers with socio-demographic characteristics and with supply-
side barriers 
Caregiver attributes such as educational attainment, socioeconomic status, family size, age, 
residence (rural vs. urban), social networks and cultural practices determine vaccine-seeking for 
their children.5,9,58,59,85 These factors have been shown to specifically influence MCV-seeking in 
various settings. Older86,87 or younger64 maternal age (alternately), higher maternal or paternal 
education level,60,79,87–91 higher socioeconomic status,60,79,87,88,91 and urban residence92 have been 
associated with higher MCV1 uptake in diverse settings such as Brazil, China, Gambia, Kenya, 
Lao PDR, Pakistan and Uganda. At the same time, high educational attainment,63,64 urban93 or 
rural94 residence (alternately), higher socioeconomic status,90 small household size63,90,95 and 
younger maternal age64,95 have been associated with timely measles vaccination in Burkina Faso, 
Kenya, Guatemala, Malawi, Peru and Tanzania.  Also, as noted previously, a WHO assessment 
found substantial inequalities in MCV coverage in LMICs by socioeconomic status and 
educational attainment.50 Caregiver attributes may determine MCV status because they likely 
influence caregivers’ beliefs about, knowledge of, and attitudes towards vaccination and 
vaccination services (Figure 2.1). 
 
Aside from caregiver attributes, supply-side factors such as access to, quality of and availability 
of vaccination services influence demand-side factors (Figure 2.1). For example, poor 
communication by health facility staff could result in caregivers not knowing when upcoming 
vaccinations are due, caregivers’ low perception of vaccination benefits and caregivers’ 




2.4. Metrics used to measure vaccination uptake 
By far, the most commonly used metric to measure infant vaccination uptake is the proportion of 
children age 12-23 months who received a certain vaccine by age 12 months. Commonly 
referred to as vaccination coverage, this metric has been used since 1980 by leading public health 
organizations such as the WHO and the United Nations Children’s Fund (UNICEF). Global and 
national vaccination coverage estimates are pervasively used as indicators of the quality of 
preventive health services, to set global disease control targets for vaccine-preventable diseases 
(VPDs), to identify vaccination system improvement priorities and to assess suitability of 
vaccination systems for the introduction of new vaccines.96   
 
A less-often considered, but important metric is vaccination timeliness. Vaccination timeliness 
speaks to the assessment of the appropriateness of the timing of vaccination. As a metric, 
vaccination timeliness measures the proportion of children receiving a vaccine within a certain 
window of the recommended age of vaccination. The recommended age for a vaccine is 
designed to maximize its disease control potential in view of the local epidemiology and burden 
of the VPD while at the same time taking into account the vaccine’s safety and convenience of 
the recommended vaccination age given other regularly scheduled child health facility visits.97 
Thus, the timing of vaccination has implications for the safety and effectiveness of vaccines as 
well as disease control program costs. Early vaccination could reduce vaccine effectiveness as in 
the case of measles vaccine when administered before age 6-9 months (due to interference with 
the immune response from circulating maternal antibody). Additionally, children who are 
inappropriately vaccinated early would need an additional vaccine dose at the appropriate age to 
improve vaccine effectiveness, at additional cost. Delayed vaccination can increase the risk of 
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disease among those with delayed vaccination and importantly among children who are too 
young to be vaccinated or those with contraindications for a vaccine(s). For communicable VPD, 
a certain level of vaccination coverage within a community or population reduces the risk for 
disease transmission within that community/population i.e., “herd immunity” or “community 
immunity”. Given that communities typically have a certain proportion of susceptible people that 
cannot be vaccinated due to age or contraindications and the possibility of primary vaccination 
failure, delaying vaccination among eligible children increases the pool of susceptible persons 
and so increases the risk of disease transmission in the community as has been shown for 
pertussis, measles and Hemophilus influenzae type b (Hib) in high-income settings such as the 
US, New Zealand and Canada.98,99 Further, delaying vaccination can increase the risk of vaccine 
adverse events; for example, there is a theoretical increased risk of intussusception with 
administration of Rotateq or Rotarix at ages >32 weeks or ≥25 weeks, respectively.100 Finally, 
delayed vaccination can reduce the likelihood of receiving other vaccines and of achieving full 
immunization. A study in Kenya showed that delayed receipt of the first dose of pentavalent 
vaccine was a significant predictor for not receiving the third dose of pentavalent and measles 
vaccines as well as for not being fully vaccinated by age 12-23 months.64 Similarly, a US study 
showed that vaccination with delay significantly reduced the probability of full vaccination by 
24.7%.101     
 
Despite their pervasive use, vaccination coverage estimates are imperfect indicators of 
vaccination timeliness as demonstrated in several settings. For example, Nepal 2012 national 
estimates of vaccination coverage by age 12 months were: 96%, 90% and 90% for bacillus 
Calmette-Guerin (BCG), DTP3 and third dose polio (Polio3) vaccines, respectively. However, a 
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recent study found that 49%, 42% and 45% of a birth cohort had received no doses of BCG, 
DTP3 or Polio3, respectively, by age six months whereas BCG is recommended at birth and 
DTP3 and Polio3 are recommended for administration at age 14 weeks in Nepal. Thus, the 
proportions not vaccinated by age six months reflect a six month delay in BCG administration 
and a 10 week delay in DTP3 and Polio3 administration.102 In a different analysis of DHS 
vaccination data from 45 LMICs, the median proportion of children receiving not BCG by age 
four weeks (four week delay) was 51% and was 90% for DTP3 at age 4 months (two week 
delay). In contrast, median vaccination coverage by age 12 months was 89% and 65% for BCG 
and DTP3, respectively.103 In Kenya, vaccination timeliness estimates have been shown to be 
lower than vaccination coverage estimates by as much as 54 percentage points.64,104 Other 
additional LMIC studies found substantial delays in vaccination, leading to considerable 
discrepancies in vaccination coverage estimates compared to vaccination timeliness 
estimates.85,90,91,94,105–109 
 
2.5. Potential of mHealth interventions to improve MCV coverage and timeliness 
In the face of stagnated MCV coverage, innovative interventions have the potential to 
substantially increase vaccination coverage and timeliness to levels needed to meet existing 
targets and to eliminate measles. The MR Initiative’s strategic plan and the GVAP recommend 
implementation of demand-side interventions as one way to increase vaccine coverage.4,41 The 
GVAP further notes that novel interventions exploiting mobile phones may also have a positive 
impact on vaccine coverage and that mobile phone-based interventions may be used to increase 
public demand for vaccines.4 In the context of a supportive supply-side environment, mobile-
phone delivered demand-side interventions that reach caregivers across the different strata of 
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socioeconomic characteristics influencing vaccination uptake have the potential to significantly 
improve MCV coverage and timeliness.  
 
In LMICs, access to mobile phones has rapidly accelerated. In 2017, 96% of  people living in 
United Nations-classified developing countries110 owned a mobile phone, compared to 23% in 
2005. In Africa, 75% of inhabitants owned a mobile phone in 2017 compared to only 12% in 
2005.16  In Kenya, 86% of inhabitants own a mobile phone. Mobile phone access levels surpass 
mobile phone ownership estimates as mobile phone sharing is prevalent in these settings.17,18 
Beyond the traditional use of mobile phones to place phone calls and to send text messages, in 
some LMICs such as Kenya, mobile phones are also used to conduct financial transactions 
whereby money is transacted through mobile phones, i.e., mobile money (mMoney). In Kenya, 
the leading mobile network provider, Safaricom has operated the most widely used mMoney 
service, “M-PESA”, since 2007. In 2013, M-PESA deposits and withdrawals totaled $7.2 billion 
and $6.3 billion, respectively,111 and its widespread use has been documented in the academic 
literature.112–114  
 
Due to the reach of mobile phones, mHealth interventions are perceived to have great potential 
for improving the health of people in LMICs, including the potential to improve vaccination 
metrics. In particular, high mobile phone access can be leveraged to deliver short message 
service (SMS or text message) vaccination reminders and mMoney vaccination incentives to 
improve vaccination coverage and timeliness. SMS reminders have been shown to improve non-
vaccine related health outcomes in LMICs such as HIV testing uptake,115 HIV treatment,116–118 
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antenatal care-seeking119 and delivery by skilled attendants,120 among others. There is some 
suggestion that SMS reminders may improve vaccination coverage and timeliness in LMICs, 
though this evidence has not been quantitatively synthesized.104,121–126 At the same time, there is 
some evidence that incentives can improve non-vaccination health outcomes and health 
utilization in LMICs.15,127–130 Current evidence of the impact of incentives on vaccination uptake 
is mixed,15,127,131 and could benefit from generation of additional evidence. Mobile phone-based 
delivery of incentives may be more advantageous than manual delivery as it may save on costs 
associated with manual disbursement of the incentive and manual retrieval by the client. For 
example, a study in Niger showed that mMoney transfers in a social poverty alleviation program 
was associated with improved childhood nutrition compared to manual cash transfers.132 An 
added advantage of mMoney incentives over manually-delivered monetary incentives is that they 
may be more safely delivered in areas where robbery is a security concern. Despite several 
projects evaluating the direct impact of mMoney incentives on health promotion,133 only one 
study demonstrating a positive impact of mMoney incentives on vaccination coverage and 
timeliness could be found.104 Additional studies assessing SMS vaccination reminders and 
mMoney vaccination incentives would contribute to our understanding of their impact. 
 
2.6. Evidence for the use of vaccination reminders in LMICs 
Since as early as 1998, the use of reminders to improve childhood vaccination coverage has been 
recommended in high income settings such as the US.134–136 In high income settings, reminders 
with or without additional interventions have been shown to significantly improve the odds of 
childhood vaccination coverage, including MCV coverage.10,135 At least five and eight studies 
have explored the impact of non-text message and text message reminders, respectively, on 
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pediatric vaccination coverage in LMICs, with mixed results. Although systematic reviews of the 
impact of various interventions on childhood vaccination coverage in LMICs have been 
conducted,14,131 no stand-alone review of the effect of reminders is readily available in the 
published literature.   
 
2.6.1. Non-SMS reminders 
The impact of non-SMS reminders on DTP and full immunization uptake has been assessed 
previously. These studies assessed the impact of reminders such as modified vaccination cards 
and stickers and most found that non-text message reminders increased childhood vaccination 
coverage by 5% to 42%.137–141 Of interest, none of these studies evaluated the impact of non-text 
message reminders on MCV coverage either as a primary or secondary outcome. These studies 
are summarized in the following sections. 
 
2.6.1.1. DTP coverage  
In Pakistan, researchers evaluated the impact of a novel immunization card, designed to 
emphasize upcoming immunization appointments and intended to function as a reminder for 
urban caregivers, coupled with or without immunization education on coverage for the third dose 
DTP vaccine (DTP3). In relative terms, the likelihood of DTP3 vaccination was significantly 
higher by 25% (control coverage= 55%) among children whose caregivers were randomized to 
receive the redesigned immunization card and significantly higher by 31% (control coverage= 
55%) among children whose caregivers received the card coupled with education, both compared 
to caregivers who received neither.137 Another randomized controlled trial (RCT) evaluating the 
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same intervention but among rural caregivers in Pakistan demonstrated similar results with 70% 
higher risk of DTP3 vaccination (control coverage= 39%) among caregivers randomized the 
redesigned card group coupled with or without education, compared to caregivers receiving 
neither intervention (Table 2.3).138  
 
However, one study conducted in Kenya found a null effect of non-text message reminders on 
vaccination coverage. The study evaluated the impact of sticker reminders – one placed on the 
mother-child health (MCH) booklet and another placed in a visible area of the house – on 
coverage with the second and third infant doses of pentavalent vaccine (DTP, hepatitis B and Hib 
vaccines; [Penta]). In contrast to the other non-text message studies described, there was no 
significant difference in coverage for Penta3 among infants whose caregivers received the sticker 
reminders compared to infants whose caregivers received standard care (Table 2.3).125 
 
2.6.1.2. Full or age-appropriate vaccination  
In rural Guatemala, a randomized-controlled trial assessed the impact of targeted vaccination 
reminders delivered by community health workers (CHWs) on receipt of all age-appropriate 
recommended vaccinations; CHWs in the control group did not change their usual practices. 
Among children aged 10-23 and 48-53 months, CHW-delivered reminders resulted in 4.6% 
significantly higher age-appropriate childhood vaccination coverage compared to control 
children on the absolute scale.139 A study in urban/sub-urban Nigeria found that randomly-
assigned reminder and recall (for missed appointments) mobile phone calls to caregivers either 
with or without theoretical training for immunization providers significantly increased the 
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likelihood of receipt of all recommended vaccinations by age 12 months (RR 1.70; control 
coverage= 39%) in both groups relative to children whose caregivers did not receive 
reminder/recall phone calls (Table 2.3).140          
 
2.6.2. Text message reminders 
Text message (SMS) reminders have been shown to significantly improve healthcare 
appointment attendance142 and vaccination uptake10 in mostly high income settings. Various 
reviews have qualitatively described assessments of the impact of SMS vaccination reminders on 
vaccination uptake in LMICs though none have provided pooled quantitative estimates of their 
impact.143–145 Here, we provide a short description of these studies. In Chapter 3, we present 
results from a systematic review and meta-analysis of the impact of SMS vaccination reminders 
on vaccination coverage and timeliness in LMICs as presented in published research studies 
through April 2018.  
 
In the following sections, vaccination timeliness is defined as the proportion of children 
vaccinated within ≤4 weeks of the national vaccination program recommended age. Vaccination 
coverage as vaccination timeliness plus the proportion of children vaccinated >4 weeks after the 
recommended age up to a specified age, provided that there is no conflict between the definition 
of timeliness and coverage. For example, WHO defines MCV1 coverage as the proportion of 
children receiving MCV1 by age 12 months in countries where MCV1 is recommended before 
age 12 months96 but defines MCV2 coverage as the proportion of children vaccinated according 
to the national MCV2 vaccination guidelines.146 Therefore, for a country such as Kenya that 
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recommends MCV1 at age 9 months and MCV2 at age 18 months, MCV1 timely coverage 
would include children vaccinated at age ≤10 months, MCV1 overall coverage would include 
children receiving measles vaccine at age ≤12 months, and MCV2 coverage would include 
children receiving MCV2 at age 18 months. 
 
2.6.2.1. DTP3 overall coverage 
Five studies – three RCTs and two quasi-experimental studies - evaluating the impact of text 
message reminders on DTP3 overall coverage yielded mixed results. Compared to control 
children, the likelihood of receiving DTP3 in older infancy was significantly higher among SMS 
reminder recipients in one RCT conducted in Burkina Faso123 and one quasi-experimental study 
conducted in Bangladesh.126 But, SMS reminders had no impact of DTP3 overall coverage in the 
other studies conducted in China, Guatemala and Kenya.104,124,147 It should, however, be noted 
that in one of these studies, DTP3 overall coverage in the control arm was so high (98%)104 as to 
preclude meaningful improved uptake.   
 
2.6.2.2. DTP3 timely coverage 
Findings from evaluations of the impact of SMS reminders on DTP3 timely coverage were 
heterogeneous across six RCTs104,121–123,147,148 and two quasi-experimental studies.125,149 SMS 
reminders significantly improved DTP3 timely coverage in two RCTs conducted in Nigeria and 
Zimbabwe121,122 and in both quasi-experimental studies, one of which was conducted in Kenya 
and the other in Vietnam.125,149 However, four RCTs conducted in Burkina Faso, Guatemala, 
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Kenya and Pakistan did not find significant increases in DTP3 timely coverage after the use of 
SMS reminders .104,123,147,148  
 
2.6.2.3. MCV coverage 
One RCT104 and two quasi-experimental studies124,150 evaluated the effect of text message 
reminders on MCV coverage with variable results. One RCT conducted in Kenya and one quasi-
experimental study conducted in China assessed the effect of SMS reminders on MCV1. The 
RCT did not find a significant increase in MCV1 overall coverage with the use of SMS 
reminders whereas the quasi-experimental study found a significant increase.104,151  The other 
quasi-experimental study assessed the impact of SMS reminders on MCV2 uptake in the 
Philippines and found that SMS reminders did not significantly improve MCV2 coverage.150   
 
2.6.2.4. MCV timeliness 
SMS reminders may improve MCV1 timeliness. Two studies evaluating the impact of SMS 
reminders on MCV1 timeliness were found. In both studies, one a RCT conducted in Kenya and 
the other a quasi-experimental study conducted in Vietnam, SMS reminders significantly 
improved MCV1 timeliness.104,149 
 
2.6.2.5. Full immunization coverage (FIC) 
Based on current studies, there is limited evidence that SMS reminders significantly improve 
FIC. The four studies assessing the impact of SMS reminders on FIC defined full immunization 
as receipt of BCG, 3 doses each of DTP, polio and hepatitis B vaccines, one dose of MCV 
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with104,126,149 or without124 3 doses of Hib vaccine. SMS reminders did not significantly improve 
FIC in one RCT conducted in Kenya104 nor in a quasi-experimental study conducted in China.124 
In contrast, SMS reminders significantly improved FIC in two quasi-experimental studies 
conducted in Bangladesh and Vietnam.126,149   
 
2.6.2.6. Full immunization timeliness 
Similar to MCV timeliness, only one study – the RCT conducted in Kenya – assessed full 
immunization timeliness. In this study, full immunization timeliness was defined as receipt of 
BCG, three doses of DTP, polio, Hib and hepatitis B vaccines and MCV1 within two weeks of 
the MCV1 due date as MCV1 is recommended at the oldest date among the vaccines included in 
the definition. That study found that SMS reminders significantly improved full immunization 
timeliness.104  
 
2.6.2.7. Other vaccines 
Third dose polio vaccine (Polio3) coverage: The impact of SMS reminders on Polio3 coverage 
was assessed in two RCTs and one quasi-experimental studies with all finding no significant 
impact. SMS reminders did not significantly improve Polio3 coverage in two RCTs conducted in 
Guatemala and Kenya, respectively. Though it should be noted that in the Kenya RCT, control 
arm Polio3 coverage by age 12 months was 97%, leaving little room for meaningful 
improvement.104,147 Similarly, reminders did not significantly improve Polio3 coverage in one 




Polio3 timeliness: Polio3 timeliness was assessed in two RCTs and one quasi-experimental study 
with mixed results. One RCT conducted in Zimbabwe and a quasi-experimental study in 
Vietnam found that SMS reminders significantly improved Polio3 timeliness.121,149 In contrast,  
there was no significant increase in Polio3 timeliness among children whose caregivers received 
SMS reminders compared to control children in a Kenya RCT.104  
 
Primary series pneumococcal conjugate vaccine (PCV) coverage: Two RCTs assessing PCV 
coverage were conducted in Guatemala and Kenya. The primary PCV series consists of two 
doses in Guatemala and three doses in Kenya. These two RCTs did not find any significant 
increases in PCV primary series coverage among SMS reminder recipients compared to those 
who did not receive SMS reminders.104,147  
 
PCV timeliness: PCV primary series timeliness was assessed in one study conducted in 
Zimbabwe where the PCV primary series consists of three doses. This RCT found that SMS 
reminders significantly improved PCV primary series timeliness.121    
 
2.6.2.8. Summary of existing evidence  
Few studies in LMICs have assessed the impact of SMS reminders on vaccination coverage and 
timeliness. Heterogeneity in findings from these few studies makes it challenging to draw 
conclusions as to whether SMS reminders can be effectively used to improve vaccination 
coverage and timeliness. Importantly, at least one study demonstrated that mobile-phone based 
interventions, including reminders, have the potential to improve vaccination coverage even 
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among caregivers who do not own a mobile telephone and traditionally hard-to-reach groups 
such as rural-dwellers, low-income families, children of the least educated and families with 
poor access to health facilities due to distance.104 Additional studies evaluating the impact of text 
message reminders on vaccination coverage and timeliness could contribute to the current 
understanding of their impact, particularly effects on vaccination timeliness versus effects on 
vaccination coverage in later infancy. More studies would also provide more data points to allow 
stratified meta-analysis to identify factors that may influence the efficacy of text message 
reminders such as baseline vaccination coverage, the number of reminder messages sent, the 
frequency of reminders and the content of messages sent, among others. Further, additional 
studies would inform the reproducibility of findings from previous studies. Finally, more 
robustly designed studies with low risk of bias are needed. 
 
2.7. Use of incentives to improve childhood vaccination coverage in LMICs 
The impact of monetary and non-monetary incentives provided to health service clients on 
pediatric and adult health outcomes as well as health service utilization has been evaluated in 
several LMICs. These evaluations have included small research studies, small health programs as 
well as large social welfare programs. Whereas some large social welfare programs have 
specifically targeted health, any impacts on health have been ancillary for others. Outside 
vaccination, incentive programs in LMICs have demonstrated significant improvements in 
childhood nutritional status, reductions in childhood anemia prevalence, reductions in childhood 
illness episodes, increases in breastfeeding practices as well reductions in child mortality, among 
other health outcomes. Improvements in health outcomes have been shown even during 
humanitarian crises. In addition, incentives have been associated with increases in utilization of 
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health services such as HIV counseling, reproductive health and childhood preventive care, 
among others. These incentives have been either conditional, meaning that they are disbursed 
subject to health service clients’ compliance with the targeted health behavior, or unconditional, 
meaning that incentives are provided regardless of the compliance. In the literature reviewed, 
these programs provided incentives up to $336 per year per household. 15,127–129  
 
The association between the value of the incentive and the magnitude of impact observed is not 
clear. For example, a study in Malawi found that any incentive amount, from $0.10 to $3.00, 
significantly increased the proportion of adults retrieving HIV testing results, compared to no 
incentive. This finding suggests that the presence of an incentive, regardless of the value, had a 
positive effect.152 In contrast, a study in Kenya found that lower value incentives did not 
significantly increase voluntary circumcision whereas higher value incentives did.130 At the same 
time, behavioral economists caution that incentives can have no effect or a negative effect if the 
incentive amount is not high enough or even if it is too high.153,154 Social protection programs, 
which were observed to provide the largest amounts of incentives, may offer relatively large 
incentive amounts as they are intended to have broader economic effects outside of health. 
Focusing on pediatric vaccination, the following sections describe experience with conditional 
and unconditional monetary and non-monetary incentives on vaccination coverage in LMICs.  
 
2.7.1. Impact of large-value cash transfers on pediatric vaccination 
The impact of social welfare program conditional cash transfers (CCTs) and unconditional cash 
transfers (UCT) targeting health and non-health outcomes in Nicaragua, Honduras, Mexico, 
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Colombia and Zimbabwe have been assessed in various studies.127,155,156 Notably, these programs 
largely focused on general health and educational outcomes, involved relatively large amounts of 
cash transfers ranging from a maximum of $52 to $284 annually, and with the exception of one 
study,155 did not condition cash transfers on discrete vaccination outcomes. 
 
2.7.1.1. DTP  
CCTs significantly improved DTP coverage in Honduras, Colombia and Nicaragua though the 
impact in Nicaragua was not sustained. The proportion of children age 42-92 days receiving 
DTP1 whose families participated in a cluster-randomized CCT program in Honduras 
(Programa de Asignacion Familiar [PRAF]) significantly increased absolutely by 6.9% 
compared to control; the program provided  £2.53 to  £16.10 monthly ($4.74 to $30.17 in 2015 
USD) conditioned on school attendance, and attendance at monthly child and antenatal care 
(ANC) visits (Table 2.4).157  
In Colombia, families participating in Familias en Accion (FA) received approximately $15.38 
monthly ($20.28 in 2015 USD) conditioned on preventive healthcare visits for children age 0-6 
months, among other incentives. The proportion of children age <24 months with up-to-date 
DTP vaccination was 8.9% higher among FA program participants, after adjustment for changes 
in vaccination uptake in the pre- vs post-program period. This difference was statistically 
significant at the 10%, but not 5%, level. Up-to-date DTP vaccination among children age >24 
months was not statistically different among FA vs. control children (Table 2.4).158  
In Nicaragua the Red de Protection Social (RPS) provided cash transfers of up to $37.33 
bimonthly ($51.38 in 2015 USD) conditioned on parental health education, childhood preventive 
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healthcare visits and satisfactory weight gain. RPS significantly improved DTP3 coverage 
overall, among children age 12-23 months living >5km from a health facility and among children 
whose mothers had fewer than 4 years of education by 9%, 12% and 10% on the absolute scale, 
respectively. However, the significant increase in DTP3 occurred only in the first year of the 
program and was not sustained into the second year (Table 2.4).156  
 
2.7.1.2. MCV 
Measles vaccine coverage among children in families receiving CCTs significantly increased in 
Nicaragua but not in Mexico or Honduras. In contrast to the impact of CCTs on DTP coverage in 
Honduras, there was no significant difference in measles vaccine coverage among children 
participating vs. not participating in the PRAF program (program described previously; Table 
2.4).157  
The social welfare program Progresa in Mexico provided up to $25 bi-monthly ($37.43 in 2015 
USD) to families, conditioned on child health care appointment attendance, among others. There 
was a 3.0% absolute increase in the proportion of Progresa children receiving measles vaccine 
by age 12-23 months compared to control. Though this increase was significant 6 months after 
the start of Progresa, by 12 months after the program start date, the increase was no longer 
significant at the 5% level (Table 2.4).159  
Under the RPS program in Nicaragua described previously, MCV coverage among RPS children 
age 12-23 months was significantly higher compared to control children in the first year, but not 
in the second program year. In the first year of RPS, MCV absolute coverage was higher among 
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intervention children by 15% overall, 17% among those living >5km from a health facility and 
15% among children with mothers who had <4 years of education (Table 2.4).156   
 
2.7.1.3. FIC 
Overall FIC among children participating in Nicaragua’s RPS and aged 12-23 months was 
significantly higher by 23% and 15% in absolute terms during the first and second year of the 
program, respectively. RPS CCTs also improved FIC in the same age group among ‘hard-to-
reach’ children i.e., among children living >5km from a health facility by 27% in the first year of 
the program and by 23% and 14% on the absolute scale in the first and second year of the 
program, respectively, among children with mothers who had <4 years of education (Table 
2.4).156 
 
2.7.1.4. Other vaccination outcomes 
CCTs resulted in significant increases in BCG coverage in Mexico – though that effect was 
short-lived – and in Nicaragua, though the effect was short-lived in one sub-group. Under 
Progresa in Mexico there was a 5% significant absolute increase in the proportion of children 
receiving BCG by age 12 months compared to control, six months after initiation of the program. 
However, BCG coverage by 12 months of age after program initiation was not significantly 
different in Progresa vs. control children (Table 2.4).159 In Nicaragua, CCTs significantly 
increased BCG coverage by 9% and 6% on the absolute scale in the first and second years, 
respectively of RPS. Additionally, CCTs significantly increased absolute BCG coverage among 
children living >5km from a health facility in both RPS years by 13% and 7%. Among RPS 
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children born to mothers with <4 years of education, BCG coverage was significantly higher 
than control children’s BCG coverage in the first year by 9% on the absolute scale but not in the 
second year of RPS (Table 2.4).156  
A cluster-randomized controlled research study in Zimbabwe evaluated the impact of an up to 
$30 ($35.27 in 2015 USD) bi-monthly cash payment on infant birth registration, up-to-date 
vaccination (BCG, DTP, polio and MCV), growth monitoring, school attendance and parental 
skills training. In one study group payment was conditioned on the fulfillment of the outcomes of 
interest but in another, cash transfers were unconditional. No significant differences in 
appropriate vaccination for age were observed in either the CCT or UCT group compared to 
control (Table 2.4).155 
 
2.7.2. Impact of small-value incentives on pediatric vaccination 
At least four studies have evaluated the impact of monetary and non-monetary incentives, such 
as coupons and food, on vaccination in LMICs. Studies in India,160 Kenya,104,161 and Pakistan162 
suggest that monetary and non-monetary incentives have the potential to improve vaccination 
coverage and also suggest that incentive-based interventions have the potential to impact hard-to-
reach populations. Moreover, all of the identified studies provided a conditional incentive; where 
the caregiver was only given the incentive if the child was vaccinated.  No studies providing 





Conditional monetary and non-monetary incentives significantly improved the proportion of 
children receiving DTP3 within two weeks of the recommended age in Pakistan and in Kenya. In 
a quasi-experimental study conducted in Pakistan, coupons redeemable for food or medicine 
purchases and valued at $2.00 ($2.35 in 2015 USD) were offered at every vaccination visit 
through the DTP3 visit. The likelihood of DTP3 receipt by age 18 weeks among children in the 
coupon group was double (RR 2.20, 95% CI: 1.95–2.48, p<0.001) the likelihood among children 
in the control group (no coupons; Table 2.5).162  
In a cluster RCT conducted in Kenya, the likelihood of Penta3 coverage at age ≤18 weeks was 
significantly higher among children whose caregivers received text message reminders coupled 
with a monetary $2.35 in 2015 incentive for each vaccine received within two weeks of the 
recommended due date, compared to children whose caregivers received no intervention (RR 
1.12; 95% CI 1.03, 1.22). Notably, the likelihood of Penta3 receipt by age 18 weeks in the same 
study was not significantly different among children whose caregivers received text message 
reminders coupled with a smaller $0.88 (2015 USD) incentive compared to control (RR 1.07; 
95% 0.98, 1.17) and perhaps points to the effects of the value of the incentive as has been posited 
prior.130,154 Further, Penta3 coverage by age 12 months was not statistically significantly 
different among text message and incentive groups compared to control ($0.88 incentive RR 
1.00; 95% CI 0.98, 1.02 and $2.35 incentive RR 1.01; 95% CI 0.99, 1.02), but this may be 





Small incentives coupled with SMS reminders have been shown to improve measles vaccination 
timeliness and vaccination by age 12 months in one study. The same cluster RCT conducted in 
Kenya104 evaluated the impact of incentives, coupled with text message reminders on timely 
measles vaccination i.e., proportion vaccinated by age 9 months + 2 weeks as well as coverage 
by 12 months of age. The probability of timely measles vaccination was significantly higher in 
the group receiving text message reminders coupled with a conditional $0.88 incentive (RR 1.37; 
95%CI: 1.19–1.59) as well as in the group receiving reminders coupled with a conditional $2.35 
incentive (RR: 1.42; 95%CI: 1.23–1.63) compared to control. When coverage was assessed at 
age 12 months, measles vaccine coverage was significantly higher only in the group receiving 
text message reminders coupled with the $2.35 incentive (RR: 1·07; 95%CI 1.01–1.14), though 
the absolute difference in the proportion of intervention children vaccinated compared to the 
proportion of control children vaccinated (6% absolute difference) was lower than observed for 
timely measles vaccination (21% absolute difference; Table 2.5).104   
 
2.7.2.3. Age-appropriate and full vaccination 
There is mixed evidence on the impact of small incentives on age-appropriate and full 
vaccination. A different quasi-experimental study in Kenya evaluated the impact of distribution 
of a hygiene kit valued at $0.40 in 2009-2010 ($0.43 in 2015 USD) coupled with water treatment 
and hand hygiene education on vaccination coverage. Compared to baseline, age-appropriate 
vaccination among children age 2-13 months increased significantly by approximately 9% (p = 
0.04) in the intervention area. However, age-appropriate vaccination in the same age group 
increased significantly from baseline in the control area by 15.6% (p <0.001).161 Although, for 
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reasons unclear to the author of this dissertation, the study’s authors did not compare coverage in 
the intervention vs. control area, the difference-in-difference crude RR estimate calculated by the 
dissertation author suggests that children in the intervention area were significantly less-likely to 
have up-to-date vaccination compared to control area children (RR 0.93; 95% CI 0.87, 0.99; 
Table 2.5). 
In the cluster RCT evaluating the impact of a $0.88 or $2.35 incentive coupled with text message 
reminders on vaccination uptake in Kenya, intervention children were, respectively, 1.37 (95% 
CI 1.18, 1.59) or 1.42 (95% CI 1.23, 1.65) times more likely to be fully immunized (BCG, 
Penta3, Polio3 and MCV) by age 9 months and 2 weeks than control children. However, by age 
12 months, full immunization among children receiving the $0.88 incentive coupled with SMS 
reminders was not significantly different than control children (RR 1.04; 95% CI 0.96, 1.11). But 
FIC by age 12 months among children receiving the $2.35 incentive coupled with SMS 
reminders was significantly higher than FIC among control children (RR 1.09; 95 CI 1.02, 1.16; 
Table 2.5).104  
A cluster RCT in India showed a 6.66 fold (95% CI 4.53, 8.80) higher likelihood of full 
vaccination (BCG, DTP3, Polio3 and MCV) among children age 1-3 years who received lentils 
and a set of plates valued at $1.75 ($2.20 in 2015 USD), coupled with provision of a monthly 
vaccination camp, compared to control children (Table 2.5).160          
 
2.7.3. Summary impact of incentives on vaccination coverage and timeliness 
In summary, monetary and non-monetary incentives ranging in value from small to large have 
been shown to improve BCG, DTP, measles, age-appropriate and full vaccination coverage in a 
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variety of LMICs but have been ineffective in others. In some cases, incentives were coupled 
with additional interventions such as education161 and text message reminders.104 Incentives may 
overcome barriers to vaccination that are associated with travel costs, competing priorities and 
caregiver motivation. When coupled with other interventions that address other barriers to 
vaccination, incentives have the potential to substantially increase vaccination coverage, 
including improving vaccination uptake in hard-to-reach populations.   
49 
 
2.8. Theoretical role of reminders and incentives in improving pediatric vaccination uptake     
The intended effect of reminders and incentives is to increase caregivers’ demand for vaccines. 
Reminders and incentives may enable, reinforce or predispose caregivers to seek vaccination for 
their children. Together, the Health Behavior Model (HBM) and the PRECEDE/PROCEDE 
planning model, discussed in detail in the following sections, can be used to conceptualize how 
reminders and incentives for pediatric vaccinations may theoretically influence caregivers’ 
vaccine-seeking behavior.  
 
2.8.1. The Health Behavior Model 
The Health Behavior Model (HBM), developed to address low vaccination coverage,163,164 is 
particularly pertinent to an assessment of the role that reminders and incentives may play in 
improving vaccination coverage in LMICs. The HBM theoretical constructs posit that an 
individual’s likelihood of engaging in positive health behavior is influenced by: perceived 
susceptibility of the disease/condition, perceived severity of the disease/condition, perceived 
benefits of engaging in the positive health behavior, perceived barriers to engaging in the 
positive health behavior and cues to action (Figure 2.2).164,165 In the context of pediatric 
vaccination, perceived susceptibility, severity and benefits speak to a caregiver’s perceptions 
about the likelihood of the infant being infected with the VPD in question, the severity of the 
VPD if infected, and the extent to which vaccination can either prevent illness or reduce its 
severity. Perceived barriers speak to factors, believed or actual, that inhibit the caregiver’s ability 
to seek vaccination for the child, such as travel expenses. In the context of SMS reminders for 
vaccination, messages could include wording designed to heighten the caregiver’s perception of 
their child’s susceptibility to VPD, the severity of the VPD and the benefits of vaccination. SMS 
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vaccination reminders coupled with incentives could overcome barriers of forgetfulness and 
transport or other costs. Also if coordinated with the health system to ensure availability of 
vaccination services, SMS vaccination reminders could overcome caregivers’ concerns related to 
availability of those services. Finally, SMS reminders and incentives could function as cues to 
action by triggering motivated caregivers to undertake the actual act of vaccinated their 
children.164    
 
2.8.2. The PRECEDE/PROCEED planning model 
The PRECEDE/PROCEED planning framework can provide a structure for understanding how 
interventions may impact individual-level factors that influence behavior. Within 
PRECEDE/PROCEED, individual-level factors influencing behavior are organized into three 
categories: predisposing, reinforcing and enabling factors (Figure 2.3). Predisposing factors 
influence an individual’s motivation to engage in the behavior. Reinforcing factors encourage 
continued practice of the behavior and enabling factors facilitate motivated individuals’ 
engagement in the target behavior.166 The HBM theoretical constructs can be translated into 
predisposing, reinforcing or enabling factors and we can then map out how text message 
reminders and incentives may impact these constructs/factors to bring about vaccine-seeking 
behavior.  
 
Predisposing factors: The perception that an infant is susceptible to VPD, that VPD are severe 
and/or that vaccines are beneficial may predispose a caregiver to seek vaccination. Additionally, 
the perception of reduced barriers to vaccination such as the availability of transport funds, may 
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predispose a caregiver to seek vaccination. Reminders could predispose caregivers to seeking 
vaccination for their infants by influencing caregivers’ perception of the severity of VPDs and 
the benefits of vaccination (Figure 2.4). Studies in both high- and low-income settings have 
shown that in addition to information about vaccine due dates, reminder messages can include 
language conveying the risk and severity of VPDs as well as the benefits of vaccination. For 
example, in a RCT conducted in Australia, reminder postcards included language such as “The 
children who are most likely to catch measles are those who have not been 51mmunized”.167  In 
another RCT conducted in Kenya (M-SIMU study), the phrase “Vaccines save Kenyan babies’ 
lives”, was appended to text message reminders”.168 Monetary incentives may predispose 
caregivers – who were previously indisposed to seeking vaccines for their infants due to the 
perceived barrier of transportation costs – to seek vaccination (Figure 2.4).  
 
Reinforcing factors: For caregivers who are already motivated to vaccinate their infants and if 
applicable, have previously vaccinated their children, the continued perception that infants are 
susceptible to severe VPD may reinforce (continued) vaccine-seeking. Additionally, HBM ‘cues 
to action’ may encourage continued engagement in vaccine-seeking (Figure 2.4). Thus, 
reminders conveying the susceptibility and severity of VPD as described above may reinforce 
vaccine-seeking through perpetuating the perception of susceptibility and severity. Reminders 
and incentives may also continue to encourage (reinforce) caregiver vaccine-seeking through 
HBM ‘cues to action’ such as affirming vaccine due dates, incentivizing vaccination (in the case 
of conditional incentives) and perhaps through the Hawthorne effect whereby caregivers may 
modify vaccine-seeking behavior because they perceive that they are being monitored.169 As an 
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example, the Hawthorne effect was hypothesized to induce improved malaria case-management 
among healthcare workers in Kenya receiving SMS reminders.170    
 
Enabling factors: For caregivers already predisposed to vaccinating their children, vaccination 
reminders and incentives may facilitate vaccine-seeking by either prompting caregivers to seek 
vaccines (HBM ‘cues to action’) or by minimizing caregivers’ perceived barriers (Figure 2.4). 
Reminders may cue already motivated caregivers by providing them with actionable information 
such as the vaccine due date and venue. Incentives conditioned on timely vaccination could 
further spur caregivers into action by creating urgency for seeking vaccination. Finally, for 
caregivers who perceive expenses related to vaccine-seeking as a barrier but are otherwise 
motivated, incentives may facilitate vaccine-seeking.     
 
2.8.3. Motivation crowding theory: Social science perspectives on monetary incentives  
Economists and psychologists have considered the mechanisms through which monetary 
incentives modify behavior and the implications of their use. Social science theory about the 
mechanisms through which monetary incentives influence behavior change are relevant for 
public health interventions such as this dissertation’s aims looking at the short- and long-term 
impact of monetary incentives on caregivers’ vaccine-seeking behavior. Monetary incentives are 
thought to influence an individual’s extrinsic motivation i.e., the motivation induced by a desire 
to receive the incentive, as well as an individual’s intrinsic and social motivation to engage in the 
incentivized behavior i.e., motivation to engage in the behavior that is not driven by a desire to 
receive the incentive. By changing preferences (for intrinsic/social vs. extrinsic rewards) and 
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changing how an individual perceives the behavior in question, incentives can improve (“crowd-
in”), diminish (“crowd-out”) or have no effect on intrinsic and social motivation to engage in the 
incentivized behavior.171 Theoretical mechanisms about how incentives crowd-in or crowd-out 
intrinsic/social motivation can be explored using the example of incentives to improve caregiver 
vaccine-seeking.  
 
Incentives can crowd-in (improve) intrinsic/social motivation through a number of theoretical 
mechanisms. For a caregiver who would otherwise be only motivated to vaccinate their children 
by external rewards, the mere presence and/or value of incentives can signal to the caregiver that 
vaccination is important, thereby changing their preference from external rewards to 
intrinsic/social rewards. Furthermore, if incentives are unconditional rather than conditional, 
psychologists theorize that a caregiver may perceive incentives as supportive (rather than 
controlling), as promoting self-esteem and promoting autonomy over vaccine-seeking.171 Thus, 
unconditional incentives may provide an opportunity for a caregiver to engage in vaccination for 
self-determined intrinsic/social reasons (rather than for an extrinsic conditional reward), thereby 
53ignaling that intrinsic motivation is important.  Additionally, in the process of vaccinating the 
child, the caregiver may derive information about the importance of vaccination – for example, 
that vaccination protects the health of the child and of the community – which may function as 
intrinsic/social motivations to vaccinate the child or the child’s siblings in the future.  
 
On the other hand, theoretical mechanisms propose how the design and perceptions of monetary 
incentives can crowd-out intrinsic/social vaccine-seeking behavior. The presence and value of 
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the incentive could signal that vaccination is difficult, risky or, if the value of the incentive is 
perceived to be low, that vaccination is not important. In addition, the presence of the incentive 
could signal to the caregiver that their intrinsic/social motivation is unreliable or insufficient, 
thus the need for an external stimulus.154 If conditional, a caregiver may further perceive the 
incentive to be controlling, dismissive of their intrinsic/social motivation and reducing their 
autonomy over vaccine-seeking.171 Finally, vaccine-seeking in particular may have a substantial 
level of social motivation. A caregiver may seek vaccination to not only protect the health of 
their child but also that of the community. They may also vaccinate their child to promote their 
image as a good parent and a good community member. Incentivizing vaccine-seeking may 
diminish a caregiver’s social motivation by modifying their “decision frame from social to 
monetary” or by “diluting the signal”154 of their social motivation within themselves or to other 
community members.  
 
If priced correctly, monetary incentives can lead to a short-term improvement in the practice of 
the target behavior as a result of the impact of the incentives on extrinsic motivation. This impact 
on extrinsic motivation is usually larger relative to any motivation crowding-out effect that the 
incentives may have.154 However, once incentives are discontinued, practice of the target 
behavior may return to baseline levels, if incentives had no effect on intrinsic/social motivation, 
or diminish, if incentives crowded out intrinsic/social motivation.154,171 Several economic and 
psychology studies have demonstrated the crowding out effect. For example, one study evaluated 
the proportion of parents picking up children late from daycare before and after the imposition of 
a $3 dollar fine for late pick-up. Late pick-up increased after the $3 fine was imposed and 
continued even after the fine was discontinued. It is theorized that the fine enabled parents to 
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place a value (low penalty) on late pick-up and to replace what was previously a social decision 
frame with a monetary one, resulting in persistently lowered intrinsic/social motivation to pick 
up children on time.154,171  
 
In contrast, there is no evidence of crowding out in the health behavior literature. However, few 
studies, none of which were conducted in LMICs and none of which assessed vaccination 
impact, have assessed the long-term effects of monetary incentive interventions. From the few 
studies that have performed long-term impact assessments of incentive interventions, there is a 
suggestion that incentives may either not substantially impact or may crowd-in intrinsic/social 
motivation to engage in health behavior.172 Four US studies – two evaluating the impact of 
monetary incentives on smoking cessation, one on increased gym attendance and one on weight 
loss – found short-term increases in the target behavior for persons who received incentives 
compared to those that did not, but no significant long-term differences.173–176 These findings 
suggests that while monetary incentives increased extrinsic motivation to engage in the 
behaviors, they had no impact on intrinsic/social motivation. Three different studies, one each 
assessing the impact of monetary incentives on smoking cessation, gym attendance and weight 
loss, found both short-term and long-term increases in the target behaviors among incentivized 
individuals compared to controls.177–179 Findings from those studies suggest that incentives 
improved both extrinsic and intrinsic/social motivation to practice the target behaviors. 
Additional assessments of the long-term effects of incentive interventions on health behaviors, 
particularly from LMICs, would help build empirical evidence to inform our understanding of 
whether incentives crowd-in or crowd-out intrinsic/social motivation to engage in positive health 





2.9. The M-SIMU study 
2.9.1. Relevance and overview 
The M-SIMU study is a precursor of two studies included in this dissertation and that contribute 
to Aims 2 and 3 of this thesis. Aim 2, the evaluation of the impact of SMS reminders with or 
without unconditional incentives, follows up on seminal findings from the M-SIMU study by 
exploring scalable approaches to implementing vaccination reminders and incentives i.e., the M-
SIMI study.  Aim 3 will enroll M-SIMU caregivers with children born after completion of the 
M-SIMU study and will provide an assessment of differences in caregivers’ vaccine seeking 
after the M-SIMU study, i.e., the MSBC study. 
 
A seminal study, M-SIMU is the first known RCT to evaluate the impact of text message 
reminders, with or without small conditional mobile phone-delivered monetary incentives, on 
vaccination coverage in rural SSA. The M-SIMU study, as mentioned previously, was conducted 
in 2013-15 in Gem and Rarieda (Asembo) sub-counties, Siaya County, Kenya. The study was 
conducted within the Kenya Medical Research Institute (KEMRI) and CDC Health and 
Demographic Surveillance System (HDSS). The M-SIMU study is described in detail in two 




2.9.2. M-SIMU study design, procedures and outcomes 
The M-SIMU study was a cluster RCT in which 152 villages were randomly assigned to one of 
four study arms: control (no intervention); text message reminders only (SMS); text message 
reminders coupled with a KES 75 incentive (SMS+75KES; 1USD = 85KES at the time); text 
message reminders coupled with a KES 200 incentive (SMS+200KES). Like reminder messages, 
monetary incentives were delivered to mobile phones using mMoney transfer services.  
 
Children aged <5 weeks were identified by KEMRI-employed Village Reporters (VRs), who 
notified the study team of potentially eligible children. These children were screened for study 
eligibility criteria and eligible children enrolled by study-employed Community Interviewers 
(CIs) after caregivers provided informed consent. Caregiver-infant pairs were enrolled regardless 
of whether the caregiver owned a mobile phone or not. Caregivers not owning a mobile phone 
were asked to identify a mobile phone that they had access to, and one to which the study could 
send mMoney incentives and/or SMS reminders. Caregivers not owning a mobile phone 
commonly identified a shared phone in the household or compound. As a last resort, the 
enrolling CI’s phone could be used if the caregiver was unable to identify a shared phone. At 
enrollment, Cis collected sociodemographic information. Study-employed Health Facility 
Recorders (HFRs) stationed at designated health facilities recorded infants’ vaccinations and 
submitted vaccination notifications via text message to a study database. When infants reached 
age 12 months Cis performed household visits to record infants’ vaccination status and dates of 




Caregivers of infants in control villages only received a general health SMS message at the 
beginning of the study. Caregivers in intervention study villages received text message reminders 
for each of the three doses in the Penta series and for the first dose of MCV. One text message 
was sent three days and one day before the vaccine due date. Per the Kenya Expanded 
Programme on Immunisation (KEPI) the first, second and third doses of Penta are recommended 
at ages 6, 10 and 14 weeks, respectively, while first dose MCV is recommended at age 9 
months.180 Caregivers in the incentive villages received the applicable incentive if the infant was 
vaccinated within two weeks of the vaccine due date.      
 
The primary outcome assessed was full immunization coverage (FIC) i.e., receipt of BCG, 
DTP3, Polio3 and MCV1 at age 12 months in the intervention arms vs. the control arm. Other 
key outcomes assessed were DTP3 and MCV1 coverage by age 12 months. In addition, key 
vaccination timeliness outcomes assessed were DTP3 and MCV1 coverage within 2 weeks of the 
recommended vaccination age and FIC at age ≤9 months and 2 weeks.   
 
2.9.3. M-SIMU findings 
The primary M-SIMU analysis was restricted to 1600 children whose vaccination status was 
confirmed using MCH booklet, out of 2018 children enrolled total. Of the children included in 
the analysis, 360, 388, 446 and 406 were enrolled in the control, SMS, SMS+75KES and 
SMS+200KES arms, respectively. With the exception of MCV, vaccination coverage in the 
control arm for most vaccines at age 12 months was high, ranging from 97% (Polio3) to 98% 




Table 2 summarizes M-SIMU findings on vaccination coverage and vaccination timeliness for 
the vaccines assessed by study arm. In summary, compared to the control arm, the M-SIMU 
study found that the likelihood of: 
 FIC by age 12 months was 9% significantly higher in the SMS+200KES arm  
 MCV1 receipt by age 12 months was 7% significantly higher in the SMS+200 KES arm 
 FIC by age 9 months and 2 weeks was 18%, 37% and 42% significantly higher in the 
SMS, SMS+75KES and SMS+200KES arms, respectively 
 MCV1 receipt at age 9 months and 2 weeks was 18%, 37% and 42% significantly higher 
in the SMS, SMS+75KES and SMS+200KES arms, respectively 
 Penta3 receipt at age 16 weeks was 12% significantly higher in the SMS+200KES arm 
(Table 2.6).104 
 
Importantly, the M-SIMU study showed that text message reminders and incentives could 
increase vaccination coverage and timeliness in a rural setting with relatively high vaccination 
coverage. Further, the study found no significant differences in impact by mobile phone 




2.10. Research setting 
This dissertation analyzed prospectively collected as well as existing data from studies conducted 
in Gem and Rarieda (Asembo area) sub-counties located in Siaya County, Nyanza Region, 
Kenya. Kenya, a country in East Africa, falls under AFRO and has a population of 
approximately 46 million. Most of Kenya’s 46 million people are rural-dwellers; only 26% of 
Kenya’s population lives in urban areas. Though Kenya is a lower middle income country with a 
Gross National Income (GNI) per capita of $1290, roughly one-third of the population lives 
below the international poverty line i.e., access to <$1.90 per person, per day.181 Per capita health 
expenditure was $77.70 in 2014,182 translating to approximately $3 billion of health spending in 
total. In the same year, government entities contributed to 61% of the country’s health 
expenditure while 26% of spending on health was by households.183,184  
 
2.10.1. National-, County- and Sub-county-level basic indicators 
At 49 deaths per 1,000 live births, Kenya has the 46th highest under-5 mortality rate (U5MR) 
globally. The country’s infant mortality rate (IMR) is 36 deaths per 1,000 live births, which is 
slightly above the global IMR (32 deaths per 1,000 live births) and six-fold to nine-fold higher 
than the IMR in high income countries such as the United States, Canada and the United 
Kingdom.181 In 2015, there were an estimated 74,429 deaths in Kenyan children aged <5 years. 
Most (45.3%) of those deaths occurred in the first 28 days of life. Leading causes of neonatal 
mortality were intrapartum-related events (31.0%), preterm birth (26.0%), sepsis and meningitis 
(15.5%), congenital anomalies (13.2%) and pneumonia (6.2%). Among children age 1-59 
months, leading causes of death were pneumonia (20.3%), diarrhea (13.1%), injuries (11.6%), 
HIV/AIDS (10.2%) and malaria (9.3%). Other notable, vaccine-preventable causes of post-
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neonatal death were pertussis and measles, which caused 3.4% and 0.6% of deaths in children 
age 1-59 months, respectively.2 
 
One of 47 counties in Kenya, Siaya County is located in Nyanza Region in western Kenya. Lake 
Victoria forms the southern and partial western border of Siaya County. In 2011, Siaya County 
U5MR and IMR were 167 and 111 per 1,000 live births, respectively.185 Although these data are 
somewhat dated, they still underscore that child mortality in Nyanza County is higher than 
nationally; in 2010 national U5MR and IMR were 85 and 55 per 1,000 live births.186 Siaya 
County is classified as a “moderately marginalized” county based on its County Development 
Index (CDI) ranking. Developed by Kenya’s Commission on Revenue Allocation, the CDI is a 
composite measure of county-level development derived using county-level poverty, 
infrastructure, health and education indicators. Siaya County has the 27th largest CDI (0.5455) 
which is slightly higher than the average index across all counties (0.52044) but well below the 
CDI for the most developed County (Nairobi; CDI = 0.7663). Marginalization in Siaya County is 
primarily driven by poor infrastructure and education.187    
 
The study area, Gem sub-county and Asembo (within Rarieda sub-county), is part of the well-
established KEMRI and CDC HDSS (Figure 2.8). Households within the HDSS are enumerated 
and the HDSS collects sociodemographic, economic, vital status and health information on 
residents at least once every two years, but typically more frequently for vital status and health 
indicators. Various research studies are conducted in the HDSS including clinical trials, malaria 
prevention and treatment studies and tuberculosis (TB) treatment studies.188 The study area  is 
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rural with approximately 135,000 residents and covering roughly 500 square kilometers.189 The 
2008 combined U5MR and IMR for Gem and Asembo were 212 and 113 per 1,000 live births, 
respectively.188 These data suggest that IMR in the study area is comparable to County-level 
IMR but the study area U5MR is higher than Siaya County’s. Additionally, both the study area’s 
U5MR and IMR are markedly higher than the national U5MR and IMR described previously. 
High childhood mortality rates in the study area are in part attributed to malaria endemicity. The 
study area is also characterized by high HIV prevalence (15.4%) and high TB prevalence (6 
cases per 1,000 population).188 
 
2.10.2. Measles control in Kenya 
As a member of AFRO, Kenya is a party to the Region’s measles control targets. By 2020, the 
Region aims to achieve: 95% national- and district-level MCV1 coverage; ≥95% national- and 
district-level MCV coverage during SIAs; <1 confirmed case per 1,000,000 population measles 
incidence; annual identification of ≥1 measles case per 100,000 population in ≥80% districts; 
collection of adequate serum samples from ≥80% of suspected measles cases; and isolation of 
virus for confirmed chains of transmission. As noted previously, the region has set a target to 
eliminate measles by 2020. These targets are to be achieved through: establishment of a routine 
two-dose measles schedule; provision of SIAs every 2-4 years; case-based measles surveillance 





In 2016 Kenya national MCV1 coverage was 75%, appreciably lower than the 89% national-
level DTP3 coverage in the same year. Since 1984, the earliest year for which Kenya MCV1 
coverage data are available from WHO, MCV1 coverage has fluctuated with the lowest coverage 
being 55% in 1984 and the highest at 93% in 2012. Since 2013, MCV1 coverage has been at or 
below 79% (Figure 2.10).191 There is considerable variation in MCV1 coverage at the sub-
national level, with coverage in eight regions in 2014 ranging from 69.8% (North Eastern) to 
97.2% (Central).52 With specific regard to the research area, MCV1 coverage among children 
age 12-23 months in Nyanza Region was estimated at 85.3% in 2014 and this regional coverage 
was similar to the 84.8% MCV1 coverage estimate for Siaya County in the same year.52 A 2013 
vaccination coverage survey of 1,681 children age 12-23 months in the study area estimated 
MCV1 coverage at 83.0%,64 not markedly different from County- and Regional-level estimates 
(Table 2.7). MCV2 was introduced into the KEPI in 2013 and is recommended for 
administration at age 15-18 months.192 MCV2 coverage in 2016 was estimated at 32%.191 Thus, 
although Kenya has introduced a second routine dose of MCV, national- and administrative-level 
coverage for both doses is below the ≥95% coverage target required to interrupt measles 
transmission and lags behind coverage for vaccines given in early infancy such as DTP3. 
 
Since 2002, Kenya has instituted SIAs, though not always in a timely manner. For example, a 
one year delay in a SIA originally intended for 2005 is thought to have led to a 2006 measles 
outbreak in Kenya.193 The most recent SIA, for measles and rubella jointly, was conducted in 
May 2016 and was estimated to have a remarkable 95% coverage nationally, though only 77% of 




Though the number of confirmed measles cases in Kenya has declined steadily, from 215 cases 
in 2013 to 61 cases in 2016, measles incidence in 2016 remained at 1.3 per 1,000,000 population, 
which is above the WHO AFRO elimination target of <1 non-imported case per 1,000,000 
population by 2020. These data should be interpreted with caution as there is some suggestion of 
weaknesses in measles surveillance in Kenya. For example, Kenya did not meet one indicator of 
measles surveillance quality i.e., investigation of ≥2 cases of non-measles febrile rash per 
100,000 population.190,194 Measles control in Kenya is also challenged by the constant arrival of 
refugees from neighboring countries in conflict such as Somalia and South Sudan. These refugee 
populations often have low MCV coverage, leading to measles outbreaks among refugee 
populations in Kenya, which may spread to the general population as happened in 2011.195 More 
recently, a measles outbreak in a refugee camp in north-eastern Kenya was reported in April 
2017.196  
 
In summary, Kenya has made strides in measles control through introduction of a routine second 
dose of MCV, high MCV coverage through SIAs and reducing measles incidence. However, 
measles surveillance needs strengthening and MCV coverage levels are not on track to achieve 
2020 Regional targets.      
 
2.10.3. Measles vaccination in Kenya: Barriers and sociodemographic determinants 
Four studies were identified that specifically addressed barriers to measles vaccination in Kenya. 
With the exception of one which performed secondary data analysis of Demographic and Health 
Survey (DHS) data, all were cross-sectional surveys of caregivers, members of community-based 
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organizations, members of district health management teams or health facility staff. Barriers 
identified in these studies were similar to supply- and demand-side barriers identified in other 
settings. Supply-side factors included high cost or long distance to health facilities,64,197–199 
infrequent provision of measles vaccine at public health facilities,199 inconvenient schedule of  
vaccination services, hostile treatment by healthcare workers and health staff shortages.197 
Demand-side barriers identified by ≥5% of 400 community members and health staff in one 
study included competing priorities (29%), cultural beliefs (17%), fear of vaccination side effects 
(%), vaccine myths (6%) and incorrect assumption of contraindications by caregivers (5%).197   
 
Three studies, including two of the cross-sectional surveys above assessing barriers to 
vaccination and an additional secondary data analysis, assessed sociodemographic determinants 
of measles vaccination. Not receiving ANC, being a later born child, belonging to a lower wealth 
quintile and ethnic identity were identified as determinants of not receiving MCV or receiving 
MCV with delay.198,200 In addition, maternal age was identified as a determinant of not receiving 
MCV or receiving MCV with delay, though lower likelihood of receiving MCV was associated 
with younger maternal age in one study130 but with older maternal age in the other.64 Lower 
educational attainment and delayed receipt of the first dose of pentavalent vaccine were also 
identified as a determinants for not receiving MCV.64 
Two of the studies identifying barriers to, and sociodemographic determinants of, measles 
vaccination were conducted in Nyanza Region i.e., the same region encompassing the study area. 
The barriers to measles vaccination described previously were identified in these two studies as 
were all sociodemographic determinants with the exception of ANC, birth order, wealth quintile 
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and ethnicity.64,197 Therefore, in general, the barriers and sociodemographic determinants 
described are thought to be representative of those expected in the study area. 
 
2.10.4. Experience with SMS reminders and incentives for vaccination  
Kenya has considerable experience with mHealth interventions. An assessment of eHealth 
projects in Kenya identified at least 47 mHealth projects implemented in more than half of 
Kenya’s counties by 2016. mHealth projects leveraging SMS in Siaya County have included 
studies assessing HIV, malaria and maternal child health outcomes including vaccination.201 
Relatively few studies of monetary incentives to improve health outcomes in Kenya were found. 
Target outcomes in the studies identified included male circumcision for HIV prevention,130,202 
vaccination104,203 and pregnancy in adolescents and young adults,204 with four of these studies 
conducted within Nyanza region.  
 
Experience with text message reminders and small incentives for vaccination in the study area 
began with a 2011 pilot study which demonstrated that it was logistically possible and acceptable 
to deliver text message reminders and small incentives - in the form of mMoney and airtime – 
for the Penta vaccine series to caregivers in the study area. Although the study was not powered 
to evaluate the impact of the interventions on vaccination coverage, there was some suggestion 
that the interventions improved Penta2 coverage.203 As mentioned previously, the 2013-2015 M-
SIMU study showed that text message reminders with or without small, conditional monetary 
incentives could improve MCV1 overall and timely coverage, as well as timeliness and overall 




In summary, the research area was uniquely well-suited for the dissertation research. As briefly 
described previously, the dissertation research included two new data collection activities: 1) a 
RCT to evaluate the impact of text message reminders, with or without a small unconditional 
monetary incentive, on MCV coverage (M-SIMI study) and 2) a vaccination survey among 
children subsequently born to caregivers who participated in the M-SIMU study (MSBC study). 
The RCT and vaccination survey were conducted within a HDSS with the necessary 
infrastructure (community networks, human resources, supplies and equipment) and with an 
established research track record. Additionally, the target study population had previous 
experience with research studies in general and, specifically, with mobile phone delivered 
interventions to improve vaccination coverage. Finally, the research was conducted in an area 
with sub-optimal MCV uptake, allowing for assessment of the interventions, which if shown to 
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Chapter 2 Tables 
Table 2.1. Supply-side barriers to measles vaccination. Summary from studies conducted in LMICs 
 






























































































































Ambe 200165 Nigeria Cross-sectional survey Caregivers X   X    
Favin 20125 Not specified Review Not applicable       X 
Gibson 201564 Kenya Cross-sectional survey Caregivers  X      
Hutchins 199372 Multiple Review Not applicable      X  
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Mitchell 200961 Pakistan Cross-sectional survey Caregivers  X      
Mvula 201663 Malawi Prospective cohort study Caregivers  X      
Namuigi 200562 Papua New 
Guinea 
Cross-sectional survey Caregivers  X X X X X  
Phimmasane 
201060 
Lao PDR Qualitative survey and 
case-control study 
Public health physicians, 





Table 2.2. Demand-side barriers to measles vaccination. Summary from studies conducted in LMICs 
 

























































































Ambe 200165 Nigeria Cross-sectional survey Caregivers     
Deshpande 200181 India Cross-sectional survey Caregivers     
Hu 201379 China Cross-sectional survey Caregivers    X
King 201678 Nigeria Not applicable (correspondence) Not applicable    X
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Mitchell 200961 Pakistan Cross-sectional survey Caregivers X    
Namuigi 200562 Papua New 
Guinea 
Cross-sectional survey Caregivers  X X X
Phimmasane 
201060 
Lao PDR Qualitative survey and case-control 
study 
Public health physicians, nurses and 

















































































Ambe 200165 Nigeria Cross-sectional survey Caregivers X   X 
Deshpande 
200181 
India Cross-sectional survey Caregivers    X 
Hu 201379 China Cross-sectional survey Caregivers X  X X 
King 201678 Nigeria Not applicable (correspondence) Not applicable X    
Mitchell 200961 Pakistan Cross-sectional survey Caregivers     
Namuigi 200562 Papua New 
Guinea 
Cross-sectional survey Caregivers  X   
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Lao PDR Qualitative survey and case-
control study 
Public health physicians, nurses and 




















(95% CI) or 
(p-value) ‡ 












74 55 RR 1.31  
(1.18, 1.46) 
















Penta3 Kenya Stickers 84 83 OR§ 0.94  
(0.53, 1.67) 










53.5 49.4 RD 4.6 
(p <0.05) 
Brown, 2016140 RCT BCG, 
Polio0-3, 
Nigeria Mobile phone 
reminder/recall



























97 57 RR 1.70 
(1.47, 1.95) 
*RCT = randomized controlled trial 
† BCG = bacillus Calmette–Guérin vaccine; CCT = conditional cash transfer; DTP = diphtheria, pertussis and tetanus vaccine (suffix 
denotes the dose number); FIC = full immunization coverage; HepB = hepatitis B vaccine; MCV = measles containing vaccine (suffix 
denotes the dose number); Penta = DTP, Haemophilus influenzae type b (Hib) and hepatitis B combination vaccine (suffix denotes the 
dose number); Polio = Polio vaccine (suffix denotes the dose number); UCT = unconditional cash transfer; YF = yellow fever vaccine 
‡RR = Relative risk; RD = Risk difference; OR = Odds ratio; Effect sizes may be adjusted or unadjusted as represented in the cited 
research 





Table 2.4. Findings from studies evaluating the impact of large cash incentives on vaccination in LMICs, by vaccine type 
 






Incentive (value in 
2015 USD) 
Effect (95% CI) or (p-
value) ‡ 
DTP 




$4.74 – 30.17 
monthly 
RD 6.9% (1.0, 12.8)  
 








on preventive care 
visits 
RD 8.9% (0.05< p ≤0.10)  
Barham 2009156 Randomized, 
controlled 
DTP3 among 








care visits, and 
satisfactory weight 
gain 
Year 1: RD 9% (p ≤0.05) 
 
Year 2: RD 3% (p >0.10) 
 
See above DTP3 among 
children age 12-23 
months living >5 




See above Year 1: RD 12% (p ≤0.05) 
 
Year 2: RD 5% (p >0.10) 
See above DTP3 among 
children age 12-23 
months born to 
mothers with <4 
years of education 
Nicaragua 
(RPS) 
See above Year 1: RD 10% (p ≤0.05) 
 










Incentive (value in 
2015 USD) 
Effect (95% CI) or (p-
value) ‡ 




See above RD -0.2% (-9.4, 9.0)  
Barham 2005159 Randomized, 
controlled 








Month 6: RD 3% (p ≤0.05) 
 
Month 12: RD 3% (0.05< 
p ≤0.10)  
Barham 2009156 See above MCV1 among 




See above Year 1: RD 15% (p ≤0.01)  
 
Year 2: RD 6% (p >0.10) 
See above MCV1 among 
children age 12-23 
months living 




See above Year 1: RD 17% (p ≤0.01) 
 
Year 2: RD 2% (p >0.10)  
See above MCV1 among 
children age 12-23 
months born to 
mothers with <4 
years education  
Nicaragua 
(RPS) 
See above Year 1 RD: 15% (p ≤0.01) 
 
Year 2: RD 5% (p >0.10) 
FIC 
Barham 2009156 See above FIC among 




See above Year 1: RD 23% (p ≤0.01) 
 
Year 2: RD 15% (p ≤0.01) 
See above FIC among 
children age 12-23 
months living 
>5km away from 
a health facility 
Nicaragua 
(RPS) 
See above Year 1: RD 27% (p ≤0.01) 
 
Year 2: RD 13% (p ≤0.10) 
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Incentive (value in 
2015 USD) 
Effect (95% CI) or (p-
value) ‡ 
See above FIC among 
children age 12-23 
born to mothers 




See above Year 1: RD 23% (p ≤0.01) 
 
Year 2: RD 14% (p ≤0.05) 
OTHER OUTCOMES 




See above Month 6: RD 5% (p ≤0.05) 
 
Month 12: RD 1% (p 
>0.10) 
Barham 2009156 See above BCG among 




See above Year 1: RD 9% (p ≤0.01) 
 
Year 2: RD 6% (p ≤0.01) 
See above BCG among 
children age 12-23 
months living 
>5km away from 
a health facility 
Nicaragua 
(RPS) 
See above Year 1: RD 13% (p ≤0.01) 
 
Year 2: RD 7% (p ≤0.05) 
See above BCG among 
children age 12-23 
months born to 
mothers with <4 
years of education 
Nicaragua 
(RPS) 
See above Year 1: RD 9% (p ≤0.01) 
 
Year 2: RD 4% (p ≤0.10) 
95 
 






Incentive (value in 
2015 USD) 
Effect (95% CI) or (p-
value) ‡ 
Robertson 2013 RCT Up-to-date 
vaccination by age 





Up to $35.27 bi-
monthly 
conditioned on birth 
registration, 
appropriate 






RD 1.8% (-5.0, 8.7)   
See above Up-to-date 
vaccination by age 





See above RD 3.1% (-3.8, 9.9)  
*RCT = randomized controlled trial 
† BCG = bacillus Calmette–Guérin vaccine; DTP = diphtheria, pertussis and tetanus vaccine (suffix denotes the dose number); FIC = 
full immunization coverage; HepB = hepatitis B vaccine; MCV = measles containing vaccine (suffix denotes the dose number); UCT 
= unconditional cash transfer; YF = yellow fever vaccine; CCT = conditional cash transfer 






Table 2.5. Findings from studies evaluating the impact of small-value incentives on vaccination in LMICs, by vaccine type 
 




Country Incentive (value in 
2015 USD) 
RR‡ (95% CI) 
DTP 
Chandir 2010162 Observational DTP3 by age 18 
weeks 
Pakistan Coupons valued at 
$2.35 
2.20 (1.95, 2.48) 
Gibson 2017104 RCT Penta3 by age 18 
weeks 
Kenya $0.88 monetary 
incentive 
1.07 (0.98, 1.17) 
$2.35 monetary 
incentive 
1.12 (1.03, 1.22) 
See above Penta3 by age 12 
months 
Kenya $0.88 monetary 
incentive 
1.00 (0.98, 1.02) 
$2.35 monetary 
incentive 
1.01 (0.99, 1.02) 
MCV 
Gibson 2017104 See above MCV1 by age 9 
months and 2 
weeks 
Kenya $0.88 monetary 
incentive 
1.73 (1.19, 1.59) 
$2.35 monetary 
incentive 
1.42 (1.23, 1.63) 
See above MCV1 by age 12 
months 
Kenya $0.88 monetary 
incentive 
1.03 (0.97, 1.10) 
$2.35 monetary 
incentive 
1.07 (1.01, 1.14) 
AGE-APPROPRIATE AND FULL VACCINATION 
Briere 2012161 Observational Age-appropriate 
vaccination 
among children 
age 2-13 months 
Kenya Hygiene kit valued 
at $0.43 
0.93 (0.87, 0.99) 
Gibson 2017104 See above Kenya $0.88 monetary 
incentive 
1.37 (1.18, 1.59 
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Country Incentive (value in 
2015 USD) 
RR‡ (95% CI) 
Full immunization 
by age 9 months 
and 2 years 
$2.35 monetary 
incentive 
1.42 (1.23, 1.65) 
Full immunization 
by age 12 months 
Kenya $0.88 monetary 
incentive 
1.04 (0.96, 1.11) 
$2.35 monetary 
incentive 
1.09 (1.02, 1.16) 
Banerjee 2010160 RCT Full immunization 
among children 
age 1-3 years 
India Lentils and plate 
valued at $2.20 
6.66 (4.53, 8.80) 
 
*RCT = randomized controlled trial 
†DTP = diphtheria, pertussis and tetanus vaccine (suffix denotes the dose number); Penta = DTP, Haemophilus influenzae type b (Hib) 







Table 2.6. M-SIMU proportion vaccinated and RR of vaccination by age and vaccine type 
M-SIMU Study Arm 





N = 388 
SMS+75KES 
N = 446 
SMS+200KES








































































































Table 2.7. MCV coverage at the national, regional, county and study area level. Regions in 
Kenya and Counties in Nyanza Region with the highest and lowest coverage are included for 
context.  
 
Level of coverage MCV1 MCV2 
Kenya national 75% 32% 
Regions in Kenya   
 Central (Max.) 97% --* 
 North Eastern (Min.) 70% --* 
 Nyanza (Study Region) 85% --* 
Counties in Nyanza Region   
 Nyamira (Max.) 98% --* 
 Homa Bay (Min.) 80% --* 
 Siaya (Study County) 85% --* 
Study area in Siaya County   
 Gem and Asembo 83% --* 
MCV coverage estimates are from WHO/UNICEF,40 Kenya DHS 201452 and Gibson and colleagues.64 





Chapter 2 Figures 
 
Figure 2.1. Conceptual framework depicting supply- and demand-side factors that influence 








Figure 2.2. The Health Belief Model  
 
 






Figure 2.3. The PRECEDE/PROCEED model. Red oval highlights the constructs of focus.  
 
 






Figure 2.4. Conceptual framework: Theoretical mechanisms by which reminders and incentives 













Figure 2.5. Geographical context of the study area, Gem and Asembo, Siaya County, Nyanza 
Region, Kenya. Figure adapted from Odhiambo and colleagues.188 Red rectangles designate Gem 









Figure 2.6. Kenya national MCV1 coverage by age 12 months and MCV2 coverage at age 18 





























CHAPTER 3: TEXT MESSAGE REMINDERS TO IMPROVE 
VACCINATION UPTAKE IN LOW- AND MIDDLE-INCOME 
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1International Vaccine Access Center, Department of International Health, Johns Hopkins 




Objective: To assess the effect of short message service (SMS) reminders on vaccination 
coverage and timeliness in low- and middle-income countries. 
Methods: We searched PubMed, Scopus, Embase, Web of Science, Cochrane Library, and 
Global Health databases for studies assessing the impact of SMS reminders on vaccination 
uptake. We performed random-effects meta-analyses to estimate pooled relative risks (pRR) and 
risk differences (pRD) for vaccination timely coverage (generally the proportion vaccinated 
within ≤4 weeks of the recommended age) and vaccination overall coverage (generally 
proportion vaccinated >4 weeks after the recommended age). We performed random-effects 
meta-analyses to estimate pooled relative risks (pRR) and risk differences (pRD) for vaccination 
timeliness and coverage of third dose diphtheria, tetanus toxoid, pertussis vaccine (DTP3) and 
full immunization. The number of studies assessing first dose measles-containing vaccine 
(MCV1) overall coverage, MCV1 timely coverage, second dose MCV coverage and full 
immunization timely coverage was insufficient to perform meta-analyses.  
Findings: Seven randomized controlled trials (RCTs) and four quasi-experimental studies were 
included. Compared to no SMS reminders, SMS reminders did not significantly improve DTP3 
overall coverage across three RCTs (N= 1,641; pRR 1.11 [95% CI: 0.95, 1.31]; pRD 6.3% [95% 
CI: -5.2%, 17.8%]) but they significantly improved DTP3 overall coverage across two quasi-
experimental studies (N= 2,415; pRR 1.12 [95% CI: 1.04, 1.20]; pRD 9.0% [95% CI: 3.4%, 
14.6%]). SMS reminders significantly improved full immunization coverage (FIC) in a meta-
analysis of three quasi-experimental studies (N= 8,266; pRR 1.27 [95% CI: 1.16, 1.39]; pRD 
18.1% [95% CI: 8.5%, 27.6%]). SMS reminders significantly improved DTP3 timely coverage 
modestly across six RCTs (N= 2,846; pRR 1.12 [95% CI: 1.01, 1.25); pRD 7.0% [95% CI: 0.1%, 
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14.0%]) and more robustly across two quasi-experimental studies (N= 8,115; pRR 1.29 [95% CI: 
1.05, 1.60]; pRD 18.7% [95% CI: 8.8%, 28.6%]). The quality of evidence from meta-analyses 
was graded low or very low. Findings across studies included in meta-analyses were moderately 
or highly heterogeneous for DTP3 overall coverage across RCTs and DTP3 timely coverage.  
Conclusion: Current evidence suggests that SMS reminders improve DTP3 timely coverage 
though the effect may be modest. SMS reminders may improve DTP3 overall coverage and FIC 
though there is mixed evidence.  Drivers of heterogeneity in findings across different studies 
need to be determined. If vaccination SMS reminders are implemented, concurrent assessment of 




In 2016, approximately 5.6 million children below the age of 5 years died globally, with 80% of 
deaths occurring in sub-Saharan Africa and southern Asia.1 Annually, vaccines against diseases 
such as tetanus, pertussis and measles prevent approximately 2-3 million deaths, yet 1.5 million 
children die from vaccine-preventable diseases.2 In 2016, 62 of 136 World Bank-classified low- 
and middle-income countries (LMICs) did not achieve the national coverage target of 90% for 
third dose diphtheria-tetanus-pertussis (DTP3) by age 12 months set in the 2011-2020 Global 
Vaccine Action Plan (GVAP). Many LMICs are also not on track to achieve the GVAP 2020 
target of 90% coverage nationally for all other recommended vaccines.3–5 Increasing the 
proportion of children receiving recommended vaccines, nationally and within all sub-national 
populations, will reduce the number of childhood deaths.    
 
High levels of mobile phone access and ownership in LMICs – estimated at 98.7 mobile phone 
subscriptions per 100 people in 20176 – afford an opportunity to stimulate demand for 
vaccination through the use of short message service (SMS; or text message) reminders to 
caregivers of infants or to adults who are due for vaccination. Findings from predominantly high 
income settings suggest that SMS reminders significantly improve vaccination uptake.7 
However, the cumulative evidence of the impact of SMS reminders on vaccination uptake in 
LMICs and the quality of that evidence have not been well characterized. Some previously 
published reviews of the impact of interventions on vaccine uptake within LMICs did not 
disaggregate the impact of mobile phone based (mHealth) interventions such as SMS reminders 
from the impact of non-mHealth interventions.8,9 In addition, other reviews focusing on mHealth 
interventions did not perform meta-analysis.10–14 To date, only one scoping review has focused 
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on the impact of SMS reminders in LMICs; however, it did not include any quantitative 
synthesis.15 Furthermore, several planned reviews have not yet progressed to publication.16–18 In 
addition, reviews that excluded evidence from studies that are not randomized controlled trials 
(RCTs) could discard valuable information.17,18  
 
As some governments, donors, and other stakeholders begin to implement SMS vaccination 
reminders at scale19,20 and others consider introducing SMS vaccination reminders, it is 
important to understand their impact to date as well as the quality of evidence. This systematic 
review and meta-analysis aimed to assess whether SMS reminders significantly improve 
vaccination coverage and timeliness in LMICs, as compared to no SMS reminders, and whether 
their impact differs by vaccine antigen, the coverage outcome versus the timeliness outcome and 
by study design. The scope of this systematic review and meta-analysis covers both children and 
adults. However, in this paper, we present findings from the review and meta-analysis of the 
impact among only children.   
 
3.3. Methods 
3.3.1. Protocol and registration 
This systematic review and meta-analyses followed Preferred Reporting Items for Systematic 
Review and Meta-Analyses (PRISMA) guidelines (Checklist, Appendix pp 19-21).21 The review 




3.3.2. Information sources and search 
Initial searches of PubMed, Scopus, Embase, Web of Science, Cochrane Library, and Global 
Health databases were performed on March 30, 2016 and June 2, 2017. An additional search to 
find articles published through April 30, 2018 was conducted. Key search concepts were SMS 
reminders and vaccination; specific search terms are provided in Table 3.1. Search results were 
imported into RefWorks, which is a citation manager application, and automatically de-
duplicated using RefWorks. Search results were imported into Microsoft® Excel® (Microsoft 
Corporation, Redmond, Washington) after de-duplication.  
 
3.3.3. Study selection and eligibility criteria 
Search results were independently screened by two authors (EK, DG). An independent arbitrator 
provided a final decision in case of discordant conclusions. In primary screening, titles and 
abstracts were reviewed to identify search results potentially including data on the impact of 
SMS reminders on vaccination uptake. We retrieved the full-text of screened-in publications and 
reviewed these according to secondary screening inclusion criteria: (i) research article published 
in a peer-reviewed journal; (ii) randomized controlled or quasi-experimental study design; (iii) 
study evaluated the impact of SMS reminders on vaccination uptake; (iv) study conducted in a 
LMIC as defined by the World Bank;23 (v) study reported (or provided data needed to estimate) 
risk ratios or risk differences, and, (vi) written in English language or non-English language  




3.3.4. Data collection 
For all eligible studies, one author (EK) extracted information about participants, interventions, 
comparators, outcomes and study design (PICOS).21 Except in one instance, specified in Table 
3.4, the intervention and comparator data were as defined by the study. We contacted 
investigators for additional data on vaccination timeliness and to address any questions. Data 
were abstracted using pre-defined table shells; abstracted data were reviewed for accuracy by a 
different author (DG) than the one performing abstraction. 
 
3.3.5. Risk of bias and quality of evidence assessment 
Within-study risk of bias was assessed for all studies passing through secondary screening using 
the Cochrane Collaboration’s domain-based evaluation tool.24 We, however, excluded the 
performance bias domain from the Cochrane Collaboration’s tool as it is not possible to blind 
participants to the receipt of SMS vaccination reminders. Risk of bias figures were generated 
using RevMan Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration). 
 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working 
Group criteria were used to assess the quality of evidence for the pooled estimate of the impact 
of SMS vaccination reminders for each outcome and vaccine type. Using the GRADE scoring 
system, RCTs were assigned a score of 4 and non-RCTs were assigned a score of 2 at the 
beginning of the assessment. For each set of evidence from an outcome-vaccine type analysis, 
one point was deducted if: any of the included studies had high risk of bias in any of the 
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Cochrane Collaboration domains assessed; there was moderate to high statistical heterogeneity in 
meta-analysis; and if study populations were judged by the scorer as being not representative 
based on study selection criteria. Studies could receive an additional point if the summary 
estimate was greater than 2 and statistically significant.25,26  
 
3.3.6. Statistical analysis 
We used abstracted data to estimate the risk ratios (RR), differences in risk (RD) and associated 
95% confidence intervals (95% CI) for vaccination in SMS reminder (intervention) groups 
compared to non-intervention groups. We focused on review of DTP3, first dose measles 
containing vaccine (MCV1), second dose measles containing vaccine (MCV2) and full 
immunization because some are targets of the 2011-2020 GVAP, are used for monitoring routine 
immunization system performance and/or are used for monitoring Sustainable Development 
Goals (SDG 3.8).4,27 Full immunization included vaccines specified in the respective study. 
 
We performed DerSimonian and Laird random-effects meta-analysis to calculate pooled  RR 
(pRR), pooled RD (pRD) and estimated the heterogeneity statistic using the Mantel-Hanszel 
model.28  Separate meta-analyses were performed for DTP3 timely and overall coverage as well 
as full immunization coverage. We defined overall coverage as the proportion of children 
vaccinated >4 weeks after the recommended due date and timely coverage as the proportion of 
children vaccinated within four weeks of the recommended due date. Within each meta-analysis, 
we estimated separate pRR and pRD for RCTs and quasi-experimental studies. Statistical 





3.4.1. Study selection and participants 
The search terms identified 1,604 studies. After removal of duplicates, 731 abstracts underwent 
primary screening. From the primary screening, 138 full-text records were reviewed using 
secondary screening criteria. After application of secondary screening criteria, 11 articles were 
included in meta-analyses. Reasons for screening out are provided in Figure 3.1. Reasons for 
exclusion from secondary analysis by study are provided in Table 3.2. Of note, two studies that 
evaluated SMS reminders for adult vaccination were excluded because we focused on childhood 
vaccination in this analysis.29,30 We undertook a quantitative synthesis of 11 studies20,31–40  which 
examined the effect of SMS reminders to improve pediatric vaccination timeliness and coverage 
(Table 3.3). 
 
The 11 included studies were comprised of seven RCTs 31,33–38 and four quasi-experimental 
studies.20,32,39,40 Five studies were conducted in sub-Saharan Africa (Burkina Faso, Kenya [n=2], 
Nigeria, and Zimbabwe),31,34,35,37,40 five in Asia (Bangladesh, China, Pakistan, Philippines and 
Vietnam),20,32,36,38,39 and one study in Central America (Guatemala).33 All included studies were 
published between 2015 and 2018.  During analysis, one RCT38 was grouped with quasi-
experimental studies because only the study’s control arm was included in RR estimation; in that 
study, control households received SMS reminders and the study collected pre- and post-RCT 
vaccination coverage data (Table 3.4). Additionally, one of the studies was a cluster RCT with 
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no change in statistical significance when analyzing it as an individually randomized controlled 
trial.35 
 
3.4.2. Interventions and comparisons 
All included studies used SMS to either remind caregivers about infants’ scheduled vaccination 
dates31,33–40 or to notify caregivers about community vaccination sessions.20,32 The number of 
reminders ranged from one to four per scheduled vaccination visit. The timing of messages 
ranged from ten days prior39 to the scheduled day of vaccination.32,40 Three studies did not 
specify the reminder message schedule.20,37,38 One study sent additional recall messages to 
unvaccinated children.34 All comparator groups received no SMS reminders but some received 
health education,31 vaccination counseling36 or non-SMS reminders20,33,35,37,39,40 per 




The effect of SMS reminders on overall or timely coverage was the primary or secondary 
objective for all but one study.33 Studies evaluated the impact of SMS reminders on coverage for: 
first,20,31,32,35–38 second20,31,32,35–38,40 and third20,31–38,40 doses of diphtheria, tetanus and pertussis 
combination vaccine (DTP1 – DTP3) or pentavalent/ Quinvaxem (DTP, Haemophilus influenzae 
type B and hepatitis B combination) vaccine; first,20,31,35,37,38 second20,31,35,37,38 and 
third20,31,33,35,37,38 doses of polio vaccine (Polio1 – Polio3); pneumococcal conjugate vaccine 
(PCV) primary series;31,33,35,37 MCV1;20,35,38 second dose measles containing vaccine (MCV2);39 
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and full immunization.20,32,35,38 Studies assessing full immunization defined it as receipt of 
bacille Calmette-Guerin (BCG) vaccine, three doses of pentavalent/Quinvaxem vaccine and 
MCV120,32,35 or BCG, DTP3, three doses of hepatitis B vaccine and MCV1.38 
 
Vaccination status was ascertained using caregivers’ verbal report31,32,38, health facility 
vaccination records,31,33–35,37,39 child health cards,32,35,36,38 or a digital immunization registry.20 
For two studies that collected both verbal and written vaccination data, written records were 
included in the meta-analysis either because we abstracted only that data32 or because that 
study’s authors only analyzed written vaccination records.35 One study author provided 
additional vaccination timeliness data through correspondence.33 
 
3.4.3.1. DTP3 overall coverage 
Five studies32,33,35,37,38 – three RCTs (N= 1,641 participants) and two quasi-experimental studies 
(N= 2,415) – evaluated the impact of SMS reminders on DTP3 overall coverage. Comparison 
group DTP3 overall coverage ranged from 42%37 to 98%35 and was measured 3.5 months33 to 38 
weeks35 after the recommended due date (Table 3.4). Of the three RCTs,33,35,37 only one study 
found a significant effect of SMS reminders on DTP3 overall coverage.37  When pooled, data 
from the RCTs showed an 11% increase (pRR 1.11; 95% CI: 0.95, 1.31; p= 0.198) in the 
likelihood of DTP3 overall vaccination at older ages among SMS reminder infants compared to 
non-SMS reminder infants which equated to 6.3% higher (pRD 95% CI: -5.2%, 17.8%; p= 
0.285) DTP3 overall coverage, though these findings were not statistically significant. The 
findings across the studies were highly heterogeneous (I-squared 90.0%; Figures 3.4 & 3.5). A 
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sensitivity meta-analysis whereby we excluded one RCT that was unlikely to realize an increase 
in DTP3 overall coverage due to high baseline DTP3 overall coverage (98.1%)35 neither changed 
the interpretation of the meta-analysis nor the heterogeneity (Figures 3.6 & 3.7).  
 
Of the two quasi-experimental studies32,38, DTP3 overall coverage was significantly higher 
among SMS reminder recipients in one.32 Pooled estimates from the quasi-experimental studies 
showed a 12% (pRR 1.12, 95% CI: 1.04, 1.20; p= 0.002) statistically significant increase in the 
likelihood of DTP3 overall vaccination at older ages among infants receiving SMS reminders 
compared to control infants, translating to 9.0% (pRD 95% CI: 3.4%, 14.6%; p= 0.002) 
significantly higher DTP3 overall coverage  among SMS reminder infants. Findings were 
homogeneous across quasi-experimental studies (I-squared 0%; Figures 3.4 & 3.5). 
 
3.4.3.2. MCV1 overall coverage 
Two studies, one RCT35 (N= 748 participants) and one quasi-experimental study38 (N= 213), 
assessed the impact of SMS reminders on MCV1 overall coverage. Meta-analysis was not 
performed as there was only one RCT and one quasi-experimental study. Comparison group 
MCV1 overall overage was 81% in the quasi-experimental study38 and 84% in the RCT.35 In 
both studies, MCV1 coverage by age 12 months was assessed.  
 
In the RCT, SMS reminder infants had a 4% (RR 1.04; 95% CI: 0.98, 1.10; p= 0.210) 
statistically insignificant increase in the likelihood of receiving MCV1 by age 12 months 
compared to control infants, a 3.2% (RD 95% CI: -1.8%, 8.3%; p= 0.210) statistically 
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insignificant absolute increase. In the quasi-experimental study, SMS reminder infants had a 
12% (RR 1.12; 95% CI: 1.00, 1.25; p= 0.046) statistically significant increase in the likelihood 
of measles vaccination by age 12 months compared to control infants, which translated to a 9.7% 
(RD 95% CI: 0.3%, 19.0%; p= 0.046) absolute increase in MCV1 overall coverage among SMS 
reminder infants (Table 3.4, RRs and RDs not shown). 
 
3.4.3.3. MCV2 coverage 
One quasi-experimental study (N= 50) assessed the impact of SMS reminders on MCV2 
coverage.39 In this study, SMS reminders did not significantly increase the likelihood of second 
dose measles vaccination (RR 1.12; 95% CI: 0.79, 1.58; p= 0.529) or absolute coverage with 
MCV2 by age 17 months (RD 8.0%; 95% CI: -16.8%, 32.8%; p= 0.529) as compared to no SMS 
reminders (Table 3.4, RRs and RDs not shown). 
 
3.4.3.4. Full immunization coverage (FIC) 
Four studies, one RCT (N= 748 participants)35 and three quasi-experimental studies (N= 
8,266)20,32,38 evaluated the effect of SMS reminders on FIC.  Comparison group FIC ranged from 
53%32 to 82%35 (Table 3.4). No meta-analysis was performed for RCTs as there was only one 
RCT with a FIC outcome.35 In this RCT, the likelihood of full immunization as well as absolute 
FIC were slightly higher but not significantly so, among SMS reminder infants compared to 
control infants (RR 1.04; 95% CI: 0.98. 1.11; RD 3.3%; 95% CI: -1.9%, 8.6%; p= 0.213; 




Among the three quasi-experimental studies, two found that SMS reminders significantly 
increased FIC as compared to no reminders.20,32 The pooling of quasi-experimental studies found 
a 27% (pRR 1.27; 95% CI: 1.16, 1.39; p< 0.001) statistically significant increase in the 
likelihood of full immunization among SMS reminder infants compared to control infants, which 
translated to an 18.1% (pRD 18.1%; 95% CI: 8.5%, 27.6%; p< 0.001) absolute increase in FIC 
among SMS reminder infants. There was low to moderate heterogeneity in the findings across 
the three quasi-experimental studies (pRR I-squared= 41.2%; pRD I-squared= 69.4%; Figures 
3.8 & 3.9).    
 
3.4.3.5. DTP3 timely coverage 
The impact of SMS reminders on DTP3 timely coverage was assessed in six RCTs31,33–37 (N= 
2,847) and two quasi-experimental studies20,40 (N= 8,115). The proportion of comparison group 
achieving DTP3 timeliness ranged from 25%37 to 83%40 (Table 3.5).  
 
The likelihood of achieving DTP3 timeliness was significantly higher among SMS reminder 
infants compared to control infants in two31,34 of the six RCTs and insignificantly higher in 
three33,37,41 of the remaining four RCTs. When pooled, SMS reminder infants had a 12% (pRR 
1.12; 95% CI: 1.01, 1.25; p= 0.036) statistically significant increase in the likelihood of 
achieving DTP3 vaccination timeliness and 7.0% (pRD 95% CI: 0.1%, 14.0%; p= 0.047) higher 
DTP3 timely coverage compared to infants who did not receive SMS reminders. RCT findings 
were moderately heterogeneous (pRR I-squared= 69.7%; pRD I-squared= 76.8%; Figures 3.10 




Both quasi-experimental studies assessing DTP3 timely coverage found significant increases in 
DTP3 timely coverage among SMS reminder infants compared to control infants. When pooled, 
SMS reminder infants had a 29% (pRR 1.29; 95% CI: 1.05, 1.60; p= 0.016) statistically 
significant increase in the likelihood of achieving DTP3 timely coverage compared to control 
infants, translating to 18.7% (pRD 95% CI: 8.8%, 18.6%; p< 0.001) significantly higher DTP3 
timely coverage among SMS reminder infants. Findings across quasi-experimental studies were 
highly heterogeneous (I-squared 94.3%; Figures 3.10 & 3.11). 
 
3.4.3.6. MCV1 timely coverage 
MCV1 timely coverage was assessed in one RCT and one quasi-experimental study.20,35 In both 
studies, SMS reminder infants were significantly more likely to achieve MCV1 timeliness and 
had higher MCV1 timely coverage compared to control infants. MCV1 timely coverage was 
8.7% (RD 95% CI: 1.6%, 15.8%) higher among the RCT SMS reminder infants and 21.9% (RD 
95% CI: 20.2%, 23.6%) higher among the quasi-experimental SMS reminder infants, compared 
to the respective control infants (Table 3.5; RDs not shown). 
 
3.4.3.7. Full immunization timely coverage 
Only one study35 evaluated the impact of SMS reminders on full immunization timely coverage. 
This RCT found significantly full immunization timely coverage among children in the 
intervention group (58.8%) compared to comparison group (50.3%; Table 5.3). A pooled 




3.4.4. Risk of bias 
None of the included studies had low risk of bias across all of the five domains assessed. 
Four,31,35–37 three,31,33,34 two33,37 and one34 of the RCTs had high or unclear risk of detection bias, 
selection bias due to lack of allocation concealment, attrition bias and selection bias due to lack 
of random sequence generation, respectively. None of the RCTs had reporting bias (Figure 3.2).  
All five of the quasi-experimental studies had high or unclear risk of selection bias and detection 
bias. One quasi-experimental study each had unclear risk of attrition bias32 and reporting bias20 
(Figure 3.3). 
 
3.4.5. Quality of evidence 
Among RCTs, the evidence for the impact of SMS reminders on DTP3 overall and timely 
coverage was rated low. Evidence from RCTs received a low GRADE score due to issues with 
methodological quality i.e., high or unclear risk of bias, moderate to high heterogeneity in 
findings across studies and modest impact i.e., RR <2. Among quasi-experimental studies, the 
evidence for the impact of SMS reminders on DTP3 overall coverage, FIC and DTP3 timely 
coverage was deemed to be of very low quality, low quality and very low quality, respectively. 
Quasi-experimental study scores were downgraded because of high or unclear risk of bias in 






Based on current evidence, SMS reminders can significantly increase DTP3 timely coverage and 
may increase DTP3 and full immunization overall coverage. Previous reviews of the impact of 
SMS reminders have either used evidence predominantly from high-income settings7 or have not 
performed quantitative analyses to synthesize available data.10,11,15 This is the first analysis to 
pool evidence on the effect of SMS reminders on vaccination in LMICs. 
 
Pooled estimates from both RCTs (n= 6) and quasi-experimental studies (n= 2) showed 
significant increases in DTP3 timely coverage of 7% to 18% among infants whose caregivers 
received SMS reminders. The pooled estimate of the effect of SMS reminders on DTP3 overall 
coverage was 6.3% RCTs (n= 3) but was not statistically significant, while the summary increase 
from quasi-experimental studies (n= 2) was 9.0% and was statistically significant. Only one RCT 
assessed FIC and found a 3% statistically insignificant increase, whereas quasi-experimental 
studies (n= 3) found 18% significantly higher FIC among infants whose caregivers received 
SMS reminders. Taken together, the evidence from RCTs and quasi-experimental studies 
suggests that SMS reminders may improve DTP3 and full immunization overall coverage. Lack 
of studies prevented synthesis of evidence for the impact of SMS reminders on MCV1 overall 
coverage as well as MCV1 and full immunization timely coverage though 1 of 2, 2 of 2 and 1 of 
1 studies found significant increases in MCV1 overall coverage, MCV1 timely coverage and FIC 




The pooled estimates for the effect of SMS reminders on DTP3 uptake and FIC should be 
interpreted with caution. The number of studies included in each meta-analysis was few, with 
moderate to high heterogeneity in findings across studies, particularly for the RCTs. 
Furthermore, the evidence for the impact of SMS reminders on coverage and timeliness was 
assessed to be of low to very low quality per GRADE criteria.25,26 The quality determination was 
driven by high or unclear risk of bias within each study and the heterogeneity in findings for 
DTP3 overall and timely coverage outcomes. Moreover, the magnitude and direction of bias are 
unknown. Lastly, two studies20,32 included supply-side interventions in addition to SMS 
reminders and so the observed impact on DTP3 vaccination and full immunization may not be 
wholly attributable to the demand-side effect of SMS reminders.  
 
Still, decision-makers may be keen to implement SMS reminders for vaccination at scale given 
the relatively low delivery costs compared to those of other efficacious interventions like 
education, outreach campaigns, and incentives.8,9 In Zimbabwe, the marginal cost of 
significantly improving DTP3 timely coverage using SMS reminders was estimated at $0.99 per 
child.31 Additionally, with high levels of mobile phone access, and a shrinking digital divide 
where mobile phone access is increasingly available among traditionally ‘hard-to-reach’ sub-
groups,42 there is potential to inexpensively achieve equitable vaccine uptake compared to 
traditional health facility or community based interventions.   
 
Yet, current evidence, which has limited generalizability, may be insufficient to support scaled 
implementation of SMS reminders in all settings. Most studies recruited participants from health 
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facilities, rather than the community, an important selection bias. Thus, the findings may not 
accurately reflect the impact of SMS reminders for children who have had no contact with the 
immunization program (left-outs) and who, in some settings, make up a considerable proportion 
of under-vaccinated children.43 Furthermore, we found substantial unexplained heterogeneity in 
effect size across RCTs and quasi-experimental studies. The extent to which non-individual-level 
confounding or effect modifying factors such as SMS reminder delivery characteristics (e.g. 
frequency, timing, length, etc.), baseline vaccination uptake, or mobile phone ownership may 
have contributed to the heterogeneous impact in these LMIC studies is not well understood. The 
frequency and content of text messages have been shown to influence the uptake of HIV 
counseling and testing44 and one US-based study found higher influenza vaccination coverage 
among people receiving supplementary educational content along with SMS reminders.45   
 
Moreover, rather than utilize a single intervention, like SMS reminders, comprehensive mobile 
phone-based interventions may be more successful given that they can target different reasons 
for delayed or under-immunization. In one study, SMS reminders coupled with a mobile-money 
incentive significantly improved DTP3 timely coverage, MCV1 overall coverage and FIC 
whereas SMS reminders alone did not improve those outcomes.35  
 
Finally, it is unclear whether SMS reminders generate demand for vaccination among those who 
would otherwise not receive vaccination. One study, which conducted community-based 
recruitment, found that SMS reminders significantly improved MCV1 and full immunization 
uptake by age 9 months and 2 weeks (i.e., timeliness endpoint) but not by age 12 months, the 
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age-cutoff used in WHO vaccination coverage estimates.35,46 A plausible explanation for this 
observation could be that SMS reminders elicited more timely vaccination among caregivers 
already predisposed to vaccinate their children, but did not stimulate demand among vaccine-
hesitant caregivers. Thus, outside a strict definition of vaccination timeliness, similar proportions 
of children were vaccinated in the intervention and comparison groups. 
 
This systematic review has several limitations. We could not estimate the magnitude or direction 
of bias and its influence on the estimated RRs. One implication of the small number of included 
studies is that we could not perform stratified analyses, aside from those by vaccine and study 
design, to explain heterogeneity. Furthermore, there was inconsistency in the definition of timely 
uptake used across the studies. There is no consensus on a single definition for vaccination 
timeliness and our timeliness analysis included studies assessing DTP3 vaccination on,31,40 or 
within nine days,37 two weeks33,35 and four weeks34 of, the recommended vaccination age. We 
also did not search the grey literature and so will have missed findings from those sources if they 
exist. However, the risk of publication bias in this analysis may be low; two of 11 studies 
included in the systematic review did not find a significant impact of SMS reminders on any 
outcome.33,36 Finally, in estimating RR we were unable to adjust for any confounders as we did 
not have access to participant-level data for all except one study.35 Although evidence from 
meta-analysis was assessed to be of poor quality, the GRADE scoring rubric may not adequately 
assess interventions to improve vaccination coverage and timeliness. In the GRADE assessment, 
we were unable to assign an additional point to meta-analyses that found statistically significant 
increases in vaccination uptake of as much as 18% as GRADE guidelines stipulate a RR cut-off 
value of >2. This cut-off is likely inappropriate cut-off for several reasons: in settings with 
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vaccination coverage or timeliness of >50% it is impossible to obtain a RR >2; RR <2 can still 
represent substantial gains in vaccination coverage or timeliness; and, it is rare to observe RR 
effect sizes of >2 for demand-side vaccination interventions in LMICs.8,9 Still, the evidence may 
have been of moderate quality at best.   
 
To better understand the potential of SMS reminders to improve vaccination coverage and 
timeliness, additional well-designed studies with sufficient sample size in more diverse LMIC 
settings are needed. In addition, programs introducing SMS reminders at scale should consider 
conducting concurrent implementation research. Specific areas of interest for study and program 
research activities include assessment of the impact of SMS reminders on vaccination timeliness 
and coverage by age 12 months, evaluation of the influence of population characteristics, 
message attributes and other programmatic factors on observed effect sizes as well as 
optimization of reminder attributes. 
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Chapter 3 Tables 
Table 3.1. Database search terms 
 
Database Search terms 
PubMed (("text message" OR "text messaging" OR 
"short message service" OR "SMS" OR 
"information communication technology" OR 
"ICT" OR "text reminder")) AND 
((((((((immunization program[MeSH Terms]) 
OR vaccination[MeSH Terms]) OR 
immunization[MeSH Terms])) OR 
vaccination) OR vaccine) OR immunization) 
OR immunisation) 
 
Scopus and EmBase ("text message" OR "text messaging" OR 
"short message service" OR "SMS" OR 
"information communication technology" OR 
"ICT" OR "text reminder") AND 
(immunization OR vaccination OR 
immunisation OR vaccine) 
 
Web of Science and Global Health TOPIC (Web of Science) / KEYWORD 
(Global Health): (("text message" OR "text 
messaging" OR "short message service" OR 
"SMS" OR "information communication 
technology" OR "ICT" OR "text reminder") 
AND (immunization OR vaccination OR 
immunisation OR vaccine)) OR TITLE: 
 (("text message" OR "text messaging" OR 
"short message service" OR "SMS" OR 
"information communication technology" OR 
"ICT" OR "text reminder") AND 
(immunization OR vaccination OR 
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among low-income, urban children. J Pediatr. 2012;161(3):568-569. 
doi:10.1016/j.jpeds.2012.07.009. 
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a research article 
5 Ahlers-Schmidt CR, Chesser AK, Nguyen T, et al. Feasibility of a 
randomized controlled trial to evaluate Text Reminders for 




6 Ahlers-Schmidt CR, Chesser A, Hart T, Paschal A, Nguyen T, Wittler 
RR. Text messaging immunization reminders: feasibility of 
implementation with low-income parents. Prev Med (Baltim). 
2010;50(5-6):306-307. doi:10.1016/j.ypmed.2010.02.008. 
Letter to the editor 
7 Ashish K. Scope of leveraging mhealth for routine immunization 




8 Atnafu A, Otto K, Herbst CH. The role of mHealth intervention on 
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controlled field trial in rural Ethiopia. mHealth. 2017;3:39. 
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1 Atnafu A, Bisrat A, Kifle M, Taye B, Debebe T. Mobile health 
(mHealth) intervention in maternal and child health care: Evidence 
from resource-constrained settings: A review. Ethiop J Heal Dev. 
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1 Badawy SM, Kuhns LM. Texting and Mobile Phone App Interventions 
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 Citation Reason for 
exclusion 
2 Castano PM, Stockwell MS, Malbon KM. Using digital technologies to 
improve treatment adherence. Clin Obstet Gynecol. 2013;56(3):434-
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Review 
2 Chai SJ, Tan F, Ji Y, Wei X, Li R, Frost M. Community-level text 
messaging for 2009 H1N1 prevention in China. Am J Prev Med. 
2013;45(2):190-196. doi:10.1016/j.amepre.2013.03.014. 
RR could not be 
estimated; study is 
a pre-post design 
without enough 
data provided to 
adjust for 
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2 Crawford J, Larsen-Cooper E, Jezman Z, Cunningham SC, Bancroft E. 
SMS versus voice messaging to deliver MNCH communication in rural 
Malawi: assessment of delivery success and user experience. Glob 
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2 Creel L, Pandit-Rajani T, Devlin K, Khana L, Brady N. Community 
health workers as frontline health responders in complex environments: 
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Systematic review 
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Systematic review 
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Review 
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3 Dombkowski KJ, Harrington LB, Dong S, Clark SJ. Seasonal influenza 
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doi:10.1016/j.amepre.2011.09.028. 




 Citation Reason for 
exclusion 
3 Dombkowski KJ, Harrington L, Hanauer D, Kennedy A, Clark S. 
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doi:10.1177/0009922811420715. 
Review 
3 Fadda M, Galimberti E, Fiordelli M, Romanò L, Zanetti A, Schulz PJ. 
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Meta-analysis 
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and completion: A systematic review. Patient Educ Couns. 
2017;100(7):1280-1286. doi:10.1016/j.pec.2017.02.004. 
Systematic review 
3 Frew PM, Lutz CS. Interventions to increase pediatric vaccine uptake: 
An overview of recent findings. Hum Vaccines Immunother. 
2017;13(11):2503-2511. doi:10.1080/21645515.2017.1367069. 
Review 
3 Gatuha G, Jiang T. KenVACS: Improving vaccination of children 
through cellular network technology in developing countries. 




4 Ghadieh AS, Hamadeh GN, Mahmassani DM, Lakkis NA. The effect 
of various types of patients’ reminders on the uptake of 
pneumococcal  vaccine in adults: A randomized controlled trial. 
Vaccine. 2015;33(43):5868-5872. doi:10.1016/j.vaccine.2015.07.050. 
Adult study 
4 Ghazisaeedi M, Sheikhtaheri A, Allahverdi B, Azizi B. Design and 
implementation of a children vaccination reminder system based on 





unable to translate 
4 Goodman A, Bushar J, Kendrick S, Pierretti A, Grider T. Text4baby as 




4 Henrikson N, Zhu W, Nguyen M, Baba L, Berthoud H, Hofstetter A. 
Health system-based HPV vaccine reminders: Randomized trial results. 






 Citation Reason for 
exclusion 
4 Herrett E, van Staa T, Free C, Smeeth L. Text messaging reminders for 
influenza vaccine in primary care: protocol for a cluster randomised 
controlled trial (TXT4FLUJAB). BMJ Open. 2014;4(5):e004633 
Protocol 
4 Herrett E, Williamson E, van Staa T, et al. Text messaging reminders 
for influenza vaccine in primary care: a cluster randomised controlled 
trial (TXT4FLUJAB). BMJ Open. 2016;6(2):e010069. 
Non-LMIC setting 
(US) 
4 Hofstetter AM, Barrett A, Camargo S, Rosenthal SL, Stockwell MS. 
Text message reminders for vaccination of adolescents with chronic 
medical conditions: A randomized clinical trial. Vaccine. 2017;35(35 
Pt B):4554-4560. doi:S0264-410X(17)30920-9 [pii]. 
Non-LMIC setting 
(US) 
4 Hofstetter AM, Vargas CY, Camargo S, et al. Impacting delayed 
pediatric influenza vaccination: A randomized controlled trial of text 




4 Hofstetter AM, DuRivage N, Vargas CY, et al. Text message 
reminders for timely routine MMR vaccination: A randomized 
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Risk ratios and 
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Table 3.3. Key characteristics of included studies   
 
RANDOMIZED CONTROLLED TRIALS 





















Penta1, OPV1, PCV1 (6w) 
Penta2, OPV2, PCV2 (10w) 
Penta3, OPV3, PCV3 (14w)  
 
Frequency: 7 days, 3 days 
and 1 day before scheduled 
vaccination 
Usual care (health 
education) 








Penta2, Polio2, PCV2, 
Rota2 (4m) 
Penta3, Polio3 (6m)  
 








3. Eze 201534 Nigeria; Egor area 
in Edo State 
Health facility 
(N=8) 










Frequency:1 day before 
scheduled vaccination 













Frequency: 3 days and 1 day 
before scheduled vaccination
Usual care (next 
due date written 
in immunization 
card) 














Frequency: 4 reminders on 















Penta1, PCV1, Rota1, OPV1 
(2m) 
Penta2, PCV2, Rota2, OPV2 
(3m) 
Penta3, PCV3, Rota3, OPV3 
(4m) 




schedules in child 









Frequency: Not specified  
QUASI-EXPERIMENTAL STUDIES 












7. Chen 201638 China; Sichuan 
province 
Village (N=32) 
Upper middle No Vaccine/dose (scheduled 
age): 
BCG, HBV1 (birth) 
HBV2 (1m) 
Polio1 (2m) 
DTP1, Polio2 (3m) 





Frequency: Not specified  














MCV2/MMR (12-15m) § 
 
Frequency: One reminder 7-

























Frequency: 2 days before, 




10. Nguyen 201720 Vietnam; Ben Tre 
province 
 
Sub-sample of all 









Hepatitis b (birth) 
BCG (0-30 d) 
Quinvaxem1, Polio1 (2m) 
Quinvaxem2, Polio2 (3m) 
Quinvaxem3, Polio3 (4m) 
MCV1 (9-11m) 
 
Frequency: Not specified  
Paper-based 
reminders47 
11. Uddin 201632 Bangladesh; 
Sunamgonj district 
and Dhaka city 
Community 
clusters (N=40) 








Frequency:1 day before 
scheduled EPI vaccination 
session, opening time and 










*As classified by The World Bank.23 †Abbreviations: BCG = Bacille Calmette-Guerin; DTP2, DTP3 = Second and third dose 
diphtheria, tetanus & pertussis antigen-containing vaccine; m = months; MCV1 = First dose measles-containing vaccine; PCV1, 
PCV2, PCV3 = First, second and third dose pneumococcal conjugate vaccine; Penta1, Penta2, Penta3 = First, second and third dose 
pentavalent vaccine (DTP, Haemophilus influenzae type B and hepatitis B combination vaccine); Polio1, Polio2, Polio3 = First, 
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second and third dose polio vaccine; Quivaxem1, Quinvaxem2, Quivaxem3 = first, second and third dose of Quivaxem vaccine (DTP, 
Haemophilus influenzae type B and hepatitis B combination vaccine); Rota1, Rota2, Rota3 = First, second and third dose rotavirus 
vaccine; w = weeks; YF = Yellow fever vaccine. ‡ Participants who did not own a phone were not allocated to the intervention arm. 





Table 3.4. Vaccination coverage in intervention children compared to comparison children for key outcomes assessed 
 
RANDOMIZED CONTROL TRIALS 
Reference Key outcomes assessed Intervention Comparison 
  n % n % 
Domek 201633 DTP3 by age ~8-9.5 months† 160 84.4 161 80.7 
Gibson 201735 DTP3 by age 12 months 388 96.7 360 98.1 
 MCV1 by age 12 months 388 87.1 360 83.9 
 FIC by age 12 months 388 85.6 360 82.2 
Schlumberger 201537 DTP3 by unspecified ageǁ 274 60.3 298 42.3 
QUASI-EXPERIMENTAL STUDIES 
Reference Key outcomes assessed Intervention Comparison 
  n % n % 
Chen 201638  DTP3 by age 12 months 104‡ 89.4 109‡ 83.3 
 MCV1 by age 12 months 104 90.4 109 81.0 
 FIC by age 12 months 104 81.7 109 71.4 
Garcia-Dia 201739 MCV2/MMR by age 15-17 months 25 76.0 25 68.0 
Nguyen 201720 FIC by age 12 months 3,374 99.2 3,997 75.4 
Uddin 201632,§ BCG + DTP3 at age >18 weeks to 11 months 524/ 677 73.5/ 80.2 517/ 484 79.7/ 75.6 
 FIC at age > 9months and 28 days to 11 months 208/ 156 60.1/ 66.0 196/ 122 63.3/ 53.3 
 
*Abbreviations: BCG = bacille Calmette-Guerin; DTP3 = third dose diphtheria, tetanus & pertussis antigen-containing vaccine; FIC = 
Full immunization coverage (as defined by authors); MCV1 = First dose measles-containing vaccine; Penta3 = third dose pentavalent 
vaccine (DTP, Haemophilus influenzae type B and hepatitis B combination vaccine). †The range in age was due to enrollment at age 
8-14 weeks. All enrolled children were followed for six months. ‡Only data from the study’s control group were used because an 
additional intervention (smartphone app) was used in the study’s intervention group. To estimate the RR and RD, we used the study’s 
control group’s endline data as the “intervention” data and the study’s control group’s baseline data as the “comparison” data. 
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§Intervention and comparison numbers and percentages depict pre- and post-intervention data, respectively. RRs and RDs estimated 
using a difference-in-differences approach e.g., the RR represents the degree to which the relative change in vaccination uptake among 
SMS reminder recipients exceeds the relative change in vaccination uptake in the comparison group over the same period. ǁSpecific 
age could not be determined but included assessment of vaccination status among catch-up age children (M Schlumberger, personal 
communication); the same study assessed timeliness within 9 days of the recommended age therefore this measure indicates coverage 




Table 3.5. Vaccination timely coverage in intervention children compared to comparison children for key outcomes assessed 
 
RANDOMIZED CONTROL TRIALS 
Reference Key outcomes assessed* Intervention Comparison 
  n % n % 
Bangure 201531 DTP3 at age 14 weeks 152 95.0 152 75.0 
Domek 201633 DTP3 at age ≤6.5 months 160 60.6 161 59.6 
Eze 201534 DTP3 at age ≤18 weeks 452 69.0 453 60.3 
Gibson 201735 DTP3 at age ≤16 weeks 388 74.2 360 74.2 
 MCV1 at age ≤9 months + 2 weeks 388 59.5 360 50.8 
 Full immunization at age ≤9 months + 2 weeks 388 58.8 360 50.3 
Kazi 201836 DTP3 at age 14 weeks 150 31.3 150 26.0 
Schlumberger 201537 DTP3 by age 4 months + 10 days 154 29.2 114 25.4 
QUASI-EXPERIMENTAL STUDIES 
Reference Key outcomes assessed* Intervention Comparison 
  N % N % 
Haji 201640 Penta3 at age 14 weeks 372 96.5 372 83.1 
Nguyen 201720 Quinvaxem3 by age 5 months 3,997 53.6 3,374 77.2 
 MCV1 by age ~10.8 months 3,997 70.4 3,374 92.3 
 
*Abbreviations: BCG = bacille Calmette-Guerin; DTP3 = third dose diphtheria, tetanus & pertussis antigen-containing vaccine; FIC = 
Full immunization coverage (as defined by authors); MCV1 = First dose measles-containing vaccine; Penta3 or Quinvaxem3 = third 
dose pentavalent vaccine or Quinvaxem vaccine (DTP, Haemophilus influenzae type B and hepatitis B combination vaccine). †Only 
data from the study’s control group were used because an additional intervention (smartphone app) was used in the study’s 
intervention group. To estimate the RR and RD, we used the study’s control group’s endline data as the “intervention” data and the 




Table 3.6. Quality of evidence assessment using the Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) Working Group’s criteria 













-1 -1 0 0 RR: 1.11  
(0.95,1.31) 










Considerable heterogeneity (subgroup I-squared = 90.0%; Figure 3.4) 






















High risk of selection bias,32,38 unclear risk of detection bias32,38 and attrition bias32 (Figure 3.3) 













Score 8,266  
(3 studies) 








High risk of selection bias,20,32,38 high20 and unclear32,38 risk of detection bias, unclear risk of attrition 
bias32 and reporting bias20  (Figure 3.3) 













-1 -1 0 0 RR: 1.12  
(1.01, 1.25) 






High33,34 or unclear31 risk of selection bias, high35 or unclear31,36,37 risk of detection bias and high33 or 
unlear37 risk of attrition bias (Figure 3.2) 
Explanation - 
Consistency 
Moderate heterogeneity (I-squared=  69.7% - 76.8%; Figure 3.11) 



















Score= 0  
Explanation - 
Methodological quality 
High20 or unclear40 risk of selection bias, high risk of detection bias,20,40 and unclear risk of reporting 
bias20 (Figure 3.3) 
Explanation - 
Consistency 
High heterogeneity (I-squared= 94.3% - 97.9%; Figure 3.11) 
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Chapter 3 Figures 
Figure 3.1. PRISMA study selection flow diagram 
 
  
Records after duplicates 
removed  
(n= 731) 
Full-text articles excluded (n= 127) 
 Abstract /commentary /letter to the editor /op-ed 
/protocol /report (n= 36) 
 Not a RCT or quasi-experimental study (n= 24) 
 Non-SMS intervention or non-vaccination outcome 
(n= 9) 
 Non-LMIC setting (n= 41) 
 RR could not be estimated (n= 5) 
 Other (n= 10) 
 Adult study (n= 2)* 
Records identified through 
database searching  
(n= 1,604) 
Records excluded (n= 593) 
 No focus on SMS/SMS efficacy (n= 481) 
 SMS for other outcome (n= 54) 
 Opinions on SMS (n= 25) 
 Review/commentary/letter/erratum (n= 17) 
 Other (n= 16) 
Studies included in qualitative 
synthesis and meta-analysis  
(n=11) 
Full-text articles assessed for 
eligibility  
(n= 138) 
*Adult studies are excluded from this analysis focusing on vaccination coverage and timeliness among 
children, but they are not an exclusion criterion in the protocol 
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Figure 3.2. Risk of bias summary and risk of bias graph for included randomized controlled trials. The within-study risk of bias for 
each domain assessed is shown in the risk of bias summary. The risk of bias graph shows the proportion of studies with low, unclear 






Figure 3.3. Risk of bias summary and risk of bias graph for included quasi-experimental studies. The within-study risk of bias for 
each domain assessed is shown in the risk of bias summary. The risk of bias graph shows the proportion of studies with low, unclear 






Figure 3.4. Summary relative risk of DTP3 overall coverage among SMS reminder infants compared to non-SMS reminder infants, 




Study design and Author-Year
Subgroup (I-squared = 0.0%)
Uddin 2016
Chen 2016






























Figure 3.5. Summary difference in DTP3 overall coverage at older ages among SMS reminder infants compared to non-SMS 




Study design and Author-Year
Subgroup (I-squared = 0.0%)
Uddin 2016
Chen 2016






























Figure 3.6. Sensitivity analysis: Summary relative risk of DTP3 vaccination coverage among SMS reminder infants compared to non-
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Figure 3.7. Sensitivity analysis: Summary difference in DTP3 overall coverage among SMS reminder infants compared to non-SMS 




Study design and Author-Year
Subgroup (I-squared = 0.0%)
Uddin 2016
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Figure 3.8. Summary relative risk of achieving full immunization coverage among SMS reminder infants compared to non-SMS 




Study design and Author-Year



























Figure 3.9. Summary difference in full immunization coverage among SMS reminder infants compared to non-SMS reminder infants, 




Study design and Author-Year



























Figure 3.10. Summary relative risk of achieving DTP3 timeliness among SMS reminder infants compared to non-SMS reminder 
infants, by study design  
Quasi-experimental studies
Randomized controlled trials
Study design and Author-Year
Subgroup (I-squared = 97.9%)
Nguyen 2017
Haji 2016
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CHAPTER 4: A RANDOMIZED CONTROLLED TRIAL ASSESSING 
THE EFFICACY OF TEXT MESSAGE REMINDERS WITH OR 
WITHOUT UNCONDITIONAL MONETARY INCENTIVES TO 
IMPROVE MEASLES VACCINATION COVERAGE AND 





High levels of mobile phone ownership and access in low and middle income countries provide 
an opportunity to improve vaccination coverage through the use of mobile phone based 
interventions. A previous cluster randomized controlled trial that we conducted (the M-SIMU 
study) found that short message service (SMS, or text message) reminders coupled with or 
without conditional monetary incentives improved vaccination uptake in rural Kenya. Because 
conditional incentives require real-time monitoring of vaccination status, they are challenging to 
scale up. We conducted a different trial, the ‘Mobile and Scalable Innovations for Measles 
Immunization’ (M-SIMI) study, to evaluate the impact of SMS reminders with or without an 
unconditional monetary incentive - which may represent a more scalable approach - on first dose 
measles vaccination (MCV1) timeliness and coverage in rural western Kenya.   
Methods 
Infants age 6 to 8 months old were identified from the community by Community Health 
Volunteers. Infants meeting study eligibility criteria were enrolled into an individually-
randomized controlled trial and assigned to one of three study arms: Control; SMS reminders 
only (SMS only); and SMS plus 150 Kenya Shillings (KES) incentive (SMS+150KES). Infants 
randomized to the Control arm received no intervention. Those randomized to the SMS only arm 
were sent two SMS reminders for measles vaccination, three days and one day before the 
scheduled vaccination date. Infants randomized to the SMS +150 KES arm were sent two SMS 
reminders on the same schedule as SMS only arm infants as well as a KES 150 (~US $1.50 as of 
December 2016) incentive, sent three days before the scheduled measles vaccination date. At 
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enrollment, Community Interviewers (CIs) collected data on baseline characteristics. When 
infants reached age 12 months, CIs conducted a follow-up visit to ascertain vaccination status.  
The primary outcome was measles vaccination by age 10 months (timeliness endpoint).  MCV1 
receipt by age 12 months, time to measles vaccination, and the mean number of days 
undervaccinated for measles were secondary outcomes. Using log-binomial regression, the 
relative risk (RR) and 95% confidence interval (95% CI) of vaccination in each intervention arm 
compared to the control arm was computed for measles vaccination by age 10 months and by age 
12 months, separately. The risk difference (RD) and 95% CI for measles vaccination in each 
intervention arm compared to the control arm by age 10 months and age 12 months, separately, 
was also computed using binomial regression. Both the RR and RD were analyzed using 
intention-to-treat (ITT) and per-protocol (PP) principles. Regression models adjusted for any 
unequally distributed baseline characteristics that were also likely to influence vaccine-seeking. 
Stratified analysis for key demographic variables was performed to assess effect modification of 
the intervention on measles vaccination by age 10 months.  Time to measles vaccination by age 
12 months for each arm was plotted using the Kaplan-Meier method and the median, first 
quartile (Q1) and third quartile (Q3) obtained. Differences in the mean number of days 
undervaccinated were compared using the two-sample t-test with unequal variances. 
Results 
Of 639 infants assessed for eligibility, 537 met inclusion criteria and were randomized to each of 
the study arms (N= 179 in each arm). The analytic sample included 160 Control arm, 146 SMS 
only arm and 149 SMS+150KES arm infants. The proportion of infants receiving MCV1 by age 
10, i.e., MCV1 timely coverage, was 68.1% (N= 109), 78.1% (N= 114) and 77.9% (N= 116) in 
the Control arm, SMS only arm and SMS+150KES arm, respectively. The proportion of infants 
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receiving MCV1 by age 12 months, i.e., MCV1 overall coverage, was 78.1% (N= 125), 84.2% 
(N= 123) and 84.6% (N= 126) in the Control arm, SMS only arm and SMS+150KES arm, 
respectively.  
The likelihood of measles vaccination by age 10 months was not significantly higher in the SMS 
only arm compared to the Control arm (adjusted RR [aRR] 1.13; 95% CI: 0.99, 1.30; p= 0.070) 
but was significantly higher in the SMS+150KES arm compared the Control arm (aRR 1.16; 
95% CI: 1.01, 1.32; p= 0.035). Regression models were adjusted for maternal age which was 
unevenly distributed across study arms. The adjusted difference in timely vaccination coverage 
in the SMS only arm compared to the Control arm was 9.2%, though not significantly different 
(95% CI: -0.6, 19.0; p= 0.066) while timely coverage was significantly higher in the 
SMS+150KES arm compared to the Control arm (aRD 10.0; 95% CI: 0.8, 20.3; p= 0.034). 
Results from the ITT analysis were similar to those from the PP analysis with the exception that 
MCV1 timely coverage in the SMS only arm was significantly higher than that in the Control 
arm (per-protocol aRD 10.2; 95% CI: 0.1, 20.3; p= 0.048). Neither mobile phone ownership 
status, age at enrollment, birth order, travel time to a health facility or maternal educational level 
significantly modified the effect of the interventions (stratum-specific p-values >0.05 and overall 
interaction term p-values >0.05).  
The likelihood of measles vaccination by age 12 months was not significantly higher among 
intervention arm infants compared to Control arm infants (SMS only: aRR 1.07 95% CI: 0.96, 
1.19; p= 0.199; SMS+150KES: aRR 1.09; 95% CI: 0.97, 1.20; p= 0.156). Similarly, compared to 
the Control arm, MCV1 overall coverage was not significantly higher in the SMS only arm (aRD 
5.7; 95% CI: -3.0, 14.3; p= 0.199) or in the SMS+150KES arm (aRD 6.8; 95% CI: -1.8, 15.3; p= 
0.119). Inferences from the ITT analysis were the same as from the PP analysis.  
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There was no significant difference in time to measles vaccination across study arms (log-rank 
test p= 0.182) nor in the mean number of days undervaccinated. 
Conclusions 
SMS reminders coupled with an unconditional incentive may be used to improve measles 
vaccination timeliness in settings without substantial supply-side barriers to vaccination. There is 
some suggestion that, when implemented with fidelity, SMS reminders alone may also improve 
vaccination timeliness. Common determinants of vaccine-seeking behavior did not modify the 
effect of the interventions on measles vaccination timeliness. The analysis was underpowered to 
observe an effect of the interventions on vaccination coverage by age 12 months.  
Funding 




Vaccination is estimated to prevent up to 3 million deaths annually1 and is projected to avert as 
many as 426 million of cases of disease between 2011 and 2020.2 However, the full potential of 
vaccines to prevent morbidity and mortality, remains unrealized due to sub-optimal vaccine 
coverage and inequitable access to vaccines. Higher vaccination coverage and more equitable 
access to vaccines would increase by 1.5 million the number of deaths averted every year.3  
 
In 2016, there were an estimated 89,780 measles deaths and 186,811 reported measles cases 
globally. This reported number of measles cases likely underestimates the true burden of disease 
as 52% of reporting countries in 2016 were deemed to have weak measles surveillance, 4 
caregivers may not seek measles treatment and surveillance systems may under-report measles 
cases.5–7 According to the 2011-2020 Global Vaccine Action Plan (GVAP), measles was 
expected to be eliminated in four of six World Health Organization (WHO) regions by 2015,8 but 
had been eliminated in only the Americas region by 2016. Failure to achieve the elimination 
target is largely attributable to suboptimal measles vaccination coverage.4 In 2016, global 
coverage with the first and second dose measles-containing vaccines (MCV) was 86% and 64%, 
respectively,9 both levels falling below the 95% coverage with two vaccine doses needed for 
measles elimination.10 Beyond protecting against measles virus infection, MCVs are also thought 
to reduce all-cause mortality in children.11  
 
Inequalities in vaccination coverage are evident at the global level whereby, for example, 
coverage with the first dose of measles-containing vaccine (MCV1) is greater than 90% in the 
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Americas, Europe and Western Pacific WHO regions and 87%, 77% and 72% in the South-East 
Asia, Eastern Mediterranean and Africa WHO regions, respectively. Furthermore, and possibly 
correlated to disparities in vaccination coverage by WHO region, MCV1 overall coverage in 
low-income and lower-middle-income countries was 76% and 81% in 2016, respectively, 
compared to 94% in upper-middle-income and high-income countries.9 Moreover, inequalities in 
vaccine coverage by socioeconomic status and geographic residence are widely acknowledged.12  
 
At the national level in 2016, MCV1 overall coverage in Kenya was 75% with 61 reported 
measles cases, though this burden is likely an underestimate for similar reasons described 
previously for global estimates. For example, Kenya did not meet measles surveillance targets in 
2016, suggesting weak measles surveillance.13 In addition, there were an estimated 248 measles 
deaths among Kenyan children younger than 5 years old in 2015 suggesting a higher number of 
measles cases as measles case fatality ratio is typically 5% in non-outbreak and non-emergency 
situations.9,14 MCV1 overall coverage in Siaya County has been estimated at 83 to 84%,15,16 well 
below the 95% coverage target.  
 
Caregivers of children in low and middle-income countries (LMICs) attribute failure to vaccinate 
or delayed vaccination to supply-side factors – including inadequate vaccine supplies, difficult 
access to health facilities and unfriendly treatment by healthcare workers – and to demand-side 
factors including lack of knowledge about vaccination, competing priorities and concerns about 
vaccine safety.16–27 Demand-side interventions,  such as reminders, education and incentives 
have been shown to increase demand for childhood vaccination in a variety of LMICs.28–39 and 
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may be used to improve vaccination coverage in settings with limited supply-side barriers to 
vaccination. Given high levels of mobile phone ownership and access in LMICs – in 2017 there 
were 98.7 and 77.8 mobile phone subscribers per 100 inhabitants in developing and African 
countries, respectively40 – mobile phone based interventions (mHealth) to improve vaccination 
coverage may be particularly well-placed to reach a substantial number of caregivers. Studies 
evaluating the use of mobile phone call reminders in Nigeria and Kenya,19,33 text message 
reminders in Bangladesh, Burkina Faso, Kenya, Nigeria and Zimbabwe30–32,38,39 as well as text 
message reminders coupled with mobile money (mMoney; electronic funds transferred via 
mobile phone) and conditional incentives in Kenya,35 found that the interventions significantly 
improved vaccination timeliness and/or coverage. mMoney refers to funds transferred using 
mobile banking, which is ubiquitous in Kenya and can be described as conduct of financial 
transactions using mobile phones.41 
 
We sought to evaluate the impact of short message service (SMS or text message) reminders 
with or without an unconditional mMoney incentive on childhood measles vaccination timeliness 
and coverage in Gem sub-county, Siaya County, Kenya. Previously, we conducted the Mobile 
Solutions for Immunization (M-SIMU) cluster-randomized controlled trial in Gem and Rarieda 
sub-counties, Kenya.  The M-SIMU study showed that SMS reminders alone and SMS 
reminders coupled with a Kenya Shilling 75 (KES; ~US $0.75 as of December 2016) or KES 
200 (~US $2.00) mMoney incentive conditioned on receipt of vaccination within two weeks of 
the recommended date significantly improved the likelihood of timely MCV1 coverage i.e., 
vaccination within two weeks of the vaccine due date. Further, the M-SIMU study found that 
SMS reminders coupled with the conditional KES 200 mMoney incentive significantly improved 
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the likelihood of measles vaccination by age 12 months, raising coverage in the study sample 
from 84% to 90%.35  
 
In this low-resource setting, scaling up conditional incentives may not be feasible as they require 
real-time monitoring of vaccination receipt in order to determine if caregivers meet the 
conditions for receiving the incentive. In a setting without routinely collected electronic 
vaccination records, real-time monitoring of vaccination receipt would need to be performed by 
either already stretched health facility staff likely to under-prioritize monitoring, or by newly 
employed staff, creating new expenses. Thus, unconditional incentives which do not require 
monitoring of vaccination receipt, may be more feasibly delivered at scale. Unconditional 
incentives may also have the added benefit of being less likely to reduce caregivers’ intrinsic 
motivation to seek vaccination for their children compared to conditional incentives, which run 
the risk of reducing intrinsic vaccine-seeking behavior by appearing controlling.42 
 
The Mobile and Scalable Innovations for Measles Immunization (M-SIMI) individually 
randomized controlled trial aimed to evaluate the effect of SMS reminders, with or without an 
unconditional mMoney incentive, on first dose measles vaccination coverage by 10 months of 
age.  Secondary outcomes were first dose measles vaccination by age 12 months, time to measles 




4.3.1. Trial design and participants 
The M-SIMI study was a three-arm parallel individually randomized controlled trial, conducted 
in Gem sub-county, Siaya County, Kenya villages falling within the Kenya Medical Research 
Institute/ Centers for Disease Control and Prevention collaboration (KEMRI/CDC) Health and 
Demographic Surveillance System (HDSS). The Gem sub-county KEMRI/CDC HDSS is a 
predominantly rural setting with relatively high malaria, HIV and tuberculosis prevalence, high 
infant mortality and over 90% DTP3 coverage among infants.16,43 The study setting is described 
in more detail within Chapter 2.  
 
Community health workers – referred to as community health volunteers (CHVs) in the study 
setting – identified households with children age 6-8 months. Community Interviewers (CIs), 
hired by the study, visited CHV-identified households to provide general information about the 
study and to perform screening if the caregiver was willing. Eligible infants and their caregivers 
(infant-caregiver pair) were required to: be aged 6-8 months; be self-reported residents of the 
village, not have received a dose of routine measles vaccine; and not have plans to move within 
six months of enrollment (Appendix 7.1). Shortly after enrollment, the study team made a 
decision to confirm age eligibility using the date of birth as recorded in the maternal child health 
(MCH) booklet, thus MCH availability was a de facto eligibility criterion applied after study 
commencement. For infants meeting eligibility criteria, CIs provided detailed study information 
using an informed consent document written in the caregiver’s preferred language i.e., Dholuo, 
Kiswahili or English (Appendices 7.2 – 7.4). An impartial witness was involved in the informed 
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consent process in cases where the caregiver could not read. Eligible infants whose caregivers 
provided consent were enrolled into the study.     
 
CIs received training on research ethics and study procedures prior to study commencement. The 
study was approved by the KEMRI Scientific and Ethics Review Unit (SERU; 
KEMRI/SERU/CGHR/003/3311). The Johns Hopkins Bloomberg School of Public Health 
Institutional Review Board (JHSPH IRB) deferred ethical oversight to KEMRI SERU. The study 
was registered on ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT02904642).  
 
4.3.2. Interventions 
Enrolled infants were randomized to one of three study arms: Control, SMS reminders only 
(SMS only), or SMS reminders coupled with a KES 150 incentive (SMS+150 KES; where KES 
150 ≈ $1.50 USD as of December 2016). KES 150 was selected based on formative research 
previously conducted in the study area. At enrollment all participants received the following text 
message, which included some health-related motivational content: 
 
“Thank you for enrolling baby <<infant’s name>> in MSIMI Study. The greatest wealth is 
health. This study is sponsored by KEMRI.”  
 
Control arm participants received no interventions. SMS only arm participants received two 
SMS reminders; one sent three days before the scheduled measles vaccination date and the other 
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sent one day before the scheduled measles vaccination date. SMS+150KES arm participants 
received reminders on the same schedule as the SMS only arm participants and also received the 
KES 150 incentive three days before the scheduled measles vaccination date i.e., on the same 
day as the first, 3-day reminder.  
 
SMS reminders were sent in the caregiver’s preferred language i.e., Dholuo, Kiswahili or 
English; caregivers were queried as to their preferred language at enrollment.  The 3-day 
reminder comprised of a standard reminder portion, a phrase intended to motivate caregivers 
and, for SMS+150KES arm participants, a portion explaining that the study was sending the 
incentive to assist with travel expenses. The same motivational phrase was included in the 3-day 
reminder for all participants. The 1-day reminder was the same across participants and consisted 
of a reminder portion as well as a motivational phrase that was different from the 3-day reminder 
motivational phrase (Table 4.1). Caregivers in the Control arm were expected to receive one text 
message (a message welcoming them to the study that was not a reminder) total and those in the 
intervention arms were expected to receive three text messages total. 
 
SMS reminders were programmed to be sent out automatically using RapidSMS, an open-source 
platform.44 At enrollment, CIs submitted an SMS to the RapidSMS server containing the infant’s 
name, infant’s date of birth, and caregiver’s preferred phone number. Based on the information 
submitted, SMS reminders were sent from the RapidSMS server to the phone number provided 
by the caregiver on the schedule previously described i.e., three days and one day before the 
scheduled measles vaccination date. The Kenya Expanded Programme on Immunization (KEPI) 
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recommends MCV1 administration at age nine months.45 The study defined the recommended 
measles vaccination age as 274 days since birth i.e., assuming 30.42 days per month on average. 
Thus, the scheduled measles vaccination date was 274 days from the infant’s date of birth, if 
falling on a weekday. If falling on a Saturday or Sunday, the scheduled measles vaccination date 
was defined as the following Monday. 
 
RapidSMS was also programmed to automatically create a cumulative incentive payment list for 
infants enrolled in the SMS+150KES arm. The payment list included infants’ Study IDs, 
caregivers’ preferred phone numbers and payment dates i.e., three days before the scheduled 
vaccination date. Using the RapidSMS-generated payment list, study staff manually transmitted 
the KES 150 incentive from a smart phone using the M-PESA mobile money platform operated 
by Safaricom, one of Kenya’s mobile network providers.46     
 
4.3.3. Outcomes 
The primary outcome was the proportion of infants receiving MCV1 by age 10 months, i.e., 
MCV1 timely coverage. Age 10 months was defined as 304 days since the date of birth. The 
proportion receiving MCV1 by age 10 months was obtained using the formula below: 
 
	 	 	 	 1	 	 304	





Secondary outcomes were the proportion of infants receiving MCV1 by age 12 months, i.e., 
MCV1 overall coverage, time to measles vaccination by age 12 months and the number of days 
undervaccinated. Age 12 months was defined as 365 days from birth. The proportion receiving 
MCV1 by age 12 months was calculated using the following formula: 
 
	 	 	 	 1	 	 365	
	 	 	 	 	 	
 
 
Analytic approaches, including details on the time to measles vaccination and days 
undervaccinated analyses, are described in the statistical methods section. All outcomes were 
specified a priori.  
 
4.3.4. Procedures, data collection and cleaning 
At the screening/enrollment visit, CIs collected vaccination status, sociodemographic, economic, 
mobile phone access, mobile phone usage, healthcare utilization and other general health 
information from caregivers (Appendix 7.5). CIs conducted a follow-up visit when infants were 
aged ≥12 months to collect vaccination status as well as information on caregivers’ opinion of 
the interventions, reasons for delayed measles vaccination (i.e., not vaccinated by age 10 
months), incentive use and other general health information (Appendix 7.6). Vaccination status, 
used for the study’s primary and secondary outcomes, was collected at the enrollment and 
follow-up visits from either MCH booklet records or the caregiver’s verbal report if the MCH 
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booklet was not available. If the child’s vaccinations were not up-to-date at the 12 month follow-
up visit, the CI referred the caregiver to the nearest health facility for vaccinations.  
 
Electronic versions of the enrollment and follow-up questionnaires (Appendices 7.5 & 7.6) were 
created using Open Data Kit (ODK), an open-source platform for creating, collecting and storing 
aggregating data.47 CIs used smart mobile phones loaded with the ODK Collect app to access 
and complete the electronic versions of the questionnaires and to submit completed forms to the 
data server.   
 
On a regular basis, data were queried for inconsistencies e.g., vaccination date occurring after the 
respective visit date, vaccination date occurring before date of birth, inconsistent data between 
the enrollment and follow-up visit. Data queries were provided to the data manager and resolved 
by the Field Supervisor (FS) or CI by either re-visiting the household or reviewing health facility 
records to confirm data. To assure data quality, the Kenya site Principal Investigator (PI) 
conducted accompanied interviews in a fraction of households whereby the PI was present 
during study visits to assess whether the questionnaires and study procedures were administered 
as intended. In addition, following CI visits, the FS conducted repeat interviews in a random 
sample representing 5% of study households to enable comparison of data collected by the CI to 




4.3.5. Sample size 
The study aimed to measure a ≥15% increase in MCV1 timely coverage, in the intervention arms 
compared to the control arm. Data from the M-SIMU study estimated MCV1 timely coverage in 
the study area at approximately 70%.35 We presumed that a ≥15% increase in the proportion of 
children receiving MCV1 by age 10 months would represent a meaningful public health increase 
in MCV1 timeliness i.e., an increase to 85% of infants receiving MCV1 by age 10 months. 
Assuming 70% outcome in the M-SIMI control group, a 15% absolute difference in the primary 
outcome between control and intervention arms, a type 1 error (alpha) of 0.05, a power (1-beta) 
of 0.80 and applying a continuity correction, 134 infants would be required in each study arm. 
The sample size calculation used is shown in Figure 4.1. The sample size was adjusted to 
account for up to 25% loss-to-follow up i.e., assuming that up to 25% of infants would not be 
included in the analytic sample due to death, outmigration, verbal report of measles vaccination 
at 10 months of age, and other reasons. After accounting for potential losses to follow-up, the 
estimated sample size to assess the primary outcome was 537 infants total, translating to 179 
infants enrolled in each of the three study arms.  
 
4.3.6. Randomization and blinding 
Simple randomization with an allocation ratio of 1:1:1 to the Control, SMS only or SMS+150 
arm was performed using a list of computer-generated random numbers. A list of 537 
“Allocation IDs”, i.e., one unique ID for each study arm allocation, were generated. Allocation 
IDs were structured into five groups because five CIs were involved in screening and enrollment. 
Thus, the Allocation IDs were labelled #1A – #108A; #1B - #108B; #1C - #107C; #1D - #107D 
and #1E - #107E. The study group associated with each Allocation ID followed the random 
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sequence generated, thus, within each sequential Allocation ID group, the sequence of study 
group allocation was random. The Allocation ID and respective study arm i.e., Control arm, 
SMS only arm or SMS+150KES arm were printed on a card and placed into an opaque envelope 
which was labelled with the Allocation ID and sealed. Randomization and preparation of the 
allocation envelopes was performed by the Data Manager who had no contact with participants. 
 
During the enrollment period, the site PI provided CIs, who did not have access to the allocation 
sequence, with a pre-defined number of allocation envelopes on a weekly basis. After 
determining that an infant was eligible for the study, the CI opened the allocation envelope to 
identify the study arm allocation so as to provide the relevant information for the study arm 
assigned during the informed consent process. CIs opened each allocation envelope sequentially 
e.g., the allocation envelope labelled with Allocation ID #2A was opened after the allocation 
envelope labelled with Allocation ID #1A. If a caregiver refused participation after the allocation 
envelope had been unsealed, the CI returned the unsealed allocation envelope to the PI. The 
Allocation ID of the unsealed envelope was then switched with that of a yet unused, sealed, 
randomly picked allocation envelope such that the study arm associated with the Allocation ID 
of the previously unsealed envelope had a chance of being different from the original study arm. 
Switching was performed to try ensure that CIs continued to be blinded to the allocation 





Given the nature of the interventions, participants were not blinded to the study arm allocated. 
CIs, who assigned participants to the study interventions during the screening/enrollment visit 
and also assessed vaccination status at the follow-up visit, were also not blinded to the 
intervention assigned. However, given the 4-6 month lag time between enrollment and follow-up 
and the high number of enrollees (537) compared to the five CIs, it is unlikely that CIs would 
remember most participants’ allocation. In addition, follow-up interview questions that required 
the CI to identify the participants’ assigned study arm appeared after vaccination status data were 
collected (Appendix 7.6). The data analyst had access to participants’ study arm allocation 
during analysis as some of the analysis, e.g., vaccination risk factors among Control arm 
children, required knowledge of study arm allocation.       
 
4.3.7. Statistical methods 
4.3.7.1. Assessment of baseline characteristics 
The distribution of participant characteristics by study arm at baseline was assessed to evaluate 
whether any characteristics that are predictive of vaccination status were unequally distributed 
across groups; Table 4.2 summarizes variables that were included in the assessment and 
describes creation of derived variables. Derived variables were calculated using the entire study 
sample as opposed to only the analytic sample so as to be more representative. Only infants with 
an MCH booklet at the follow-up visit were included in endpoint analyses as MCH booklet 
vaccination data were considered to have better reliability and validity than caregiver verbal 
reports which can over- or under-estimate vaccination coverage.48–51 In order to evaluate possible 
selection bias of the analytical sample as compared to those who were lost to follow-up and/or 
were excluded because they did not have an MCH booklet at the follow-up visit, we compared 
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baseline participant characteristics of participants in the analytic sample to those excluded from 
the analytic sample. 
 
4.3.7.2. Analysis of MCV1 timely coverage and MCV1 overall coverage 
The primary endpoint – differences in the proportion of infants receiving MCV1 by age 10 
months in the intervention arms as compared to the control arm – was assessed using log-
binomial regression. To estimate the primary endpoint for each arm, children were censored at 
age 10 months, i.e., the numerator included all children who were alive by age 10 months and 
had received MCV1 when aged ≤304 days while the denominator included all children who were 
alive by age 10 months. Any predictive baseline characteristics determined to be unequally 
distributed at the 5% significance level were included in the log-binomial model to allow 
adjustment for potential confounders. The log-binomial model was used to estimate the risk ratio 
(RR) and 95% confidence interval (95% CI) of measles vaccination by age 10 months in each of 
the intervention arms compared to control. The model was specified as follows:  
 
Log	Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS150	 …	 	βpXp	
where:  
Pr(Y = 1) is the probability of receiving MCV1 by age 10 months;  
β0 is the constant i.e., the log risk of measles vaccination by age 10 months in the Control 
arm given a zero value for all other predictors; 
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β1 is the log risk ratio of measles vaccination by age 10 months in the SMS only arm 
compared to the control arm for otherwise similar infants; 
SMS is an indicator variable with a value of 1 if the infant was randomized to the SMS 
only arm and a value of 0 otherwise; 
β2 is the log risk ratio of measles vaccination by age 10 months in the SMS+150KES arm 
compared to the control arm for otherwise similar infants; 
SMS150 is an indicator variable with a value of 1 if the infant was randomized to the 
SMS+150KES arm and a value of 0 otherwise; 
βp is the log risk ratio of measles vaccination by age 10 months for a one unit increase in 
variable Xp among otherwise similar infants;  
and  
Xp is a potentially confounding variable(s). 
 
Additionally, to assess the absolute difference in timely vaccination coverage, risk differences 
(RD) along with 95% CIs were computed with the model specified as follows: 
Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS150	 …	 	βpXp	
where:  
Pr(Y = 1) is the probability of receiving MCV1 by age 10 months;  
β0 is the constant i.e., the probability of measles vaccination by age 10 months in the 
Control arm given a zero value for all other predictors; 
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β1 is the difference in the probability of measles vaccination by age 10 months in the 
SMS only arm compared to the Control arm for otherwise similar infants; 
SMS is an indicator variable with a value of 1 if the infant was randomized to the SMS 
only arm and a value of 0 otherwise; 
β2 is the difference in the probability of measles vaccination by age 10 months in the 
SMS+150KES arm compared to the control arm for otherwise similar infants; 
SMS150 is an indicator variable with a value of 1 if the infant was randomized to the 
SMS+150KES arm and a value of 0 otherwise; 
βp is the difference in probability of measles vaccination by age 10 months for a one unit 
increase in variable Xp among otherwise similar infants;  
and  
Xp is a potentially confounding variable(s). 
 
The primary endpoint was analyzed according to intention-to-treat (ITT) principles, meaning that 
all participants in the analytic sample were included in their respective study arm regardless of 
whether interventions were delivered per protocol. A primary endpoint modified per-protocol 
sensitivity analysis was conducted to evaluate how the primary endpoint was influenced by 
including only participants who received the interventions as intended. The modified per-
protocol was defined as having received two SMS reminders at the defined schedule i.e., 3 days 
and 1 day before the scheduled vaccination date. This modified per-protocol definition was 
selected for consistency with the definition used in the precursor M-SIMU study35 and also to 
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ensure sufficient sample size as barriers to sending incentives per-protocol were anticipated. 
Without modification, the per-protocol sample size was anticipated to be too small to assess the 
primary endpoint. The same analytic approach as for MCV1 timely coverage was used to assess 
whether the interventions significantly increases measles vaccination coverage by age 12 
months, a secondary outcome.   
 
4.3.7.3. Risk factor and sub-group analyses 
In order to evaluate whether the impact of interventions on measles vaccination by age 10 
months varied significantly for different levels of baseline participant characteristics, we 
performed stratified (sub-group) analysis. To identify independent variables to include in the 
sub-group analysis, a risk factor analysis of baseline participant characteristic variables 
associated with differential MCV1 timely coverage among only Control arm participants was 
conducted. A univariate log-binomial regression of MCV1 timely coverage on each baseline 
participant characteristic assessed was performed to obtain RR and 95% CI for measles 
vaccination by age 10 months in one or more levels of the categorical independent variable 
compared the reference level. The univariate log-binomial regression models were specified as 
follows: 
Risk factor analysis regression model 
Log	Pr Y 1|Control 	 	β0	 	β1.VARL1	 	βp.VARLP	
where:  
Pr(Y = 1) is the probability of receiving MCV1 by age 10 months, given enrollment in 
the Control arm; 
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β0 is the constant i.e., the log risk of measles vaccination by age 10 months among 
Control arm participants having the reference value (level 0; L0) of the variable in 
question; 
β1 is the log risk ratio of measles vaccination by age 10 months among Control arm 
participants falling into a different category of the variable in question, i.e. level 1 (L1), 
compared to those in the reference category L0; 
VARL1 is an indicator variable with a value of 1 for L1 of the categorical variable and has 
a value of 0 otherwise; 
βp is the log risk ratio of measles vaccination by age 10 months among Control arm 
participants falling into level P (LP) the categorical variable in question, compared to 
those in the reference category L0; 
VARp is an indicator variable with a value of 1 for LP of the categorical variable and has 
a value of 0 otherwise; 
 
Variables significant at the 10% level were included in sub-group analysis. Stratification by 
mobile phone ownership status and travel time to the health facility were pre-specified in the 
study protocol. Maternal education was included because there is some suggestion that it may 
modify the impact of SMS reminders with or without incentives on vaccination coverage. In the 
M-SIMU study, the stratum-specific relative risk of vaccination among less educated caregivers 
receiving SMS reminders with or without incentives compared to less educated caregivers 
receiving no interventions was found to be significantly higher than the stratum-specific relative 
risk of vaccination among more educated caregivers receiving interventions compared to more 
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educated Control arm caregivers, although the overall interaction term was not statistically 
significant.35 The analysis showing potential effect modification by maternal education status 
was published after completion of the M-SIMI study protocol, therefore maternal education was 
included post-hoc.  
 
In the sub-group analysis, regression models unadjusted for and adjusted for maternal age were 
run. Unadjusted regression was performed to detect any significant sub-group differences that 
might be missed in adjusted regression models due to small numbers of infants included in the 
respective strata. The significance level for sub-group analysis was 5%. Regression models for 
the sub-group analysis were defined as below:  
Sub-group analysis regression model 
Log	Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS150	 	β3.VAR	 	β4.SMS*VAR	 	β5.SMS150*VAR	 	
βp.Xp 	
where:  
Pr(Y = 1) is the probability of receiving MCV1 by age 10 months; 
β0 is the constant i.e., the log risk of measles vaccination by age 10 months in the Control 
arm given a zero value for all other predictors; 
β1 is the log risk ratio of measles vaccination by age 10 months in the SMS only arm 
compared to the control arm for otherwise similar infants; 
SMS is an indicator variable with a value of 1 if the infant was randomized to the SMS 
only arm and a value of 0 otherwise; 
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β2 is the log risk ratio of measles vaccination by age 10 months in the SMS+150KES arm 
compared to the control arm for otherwise similar infants; 
SMS150 is an indicator variable with a value of 1 if the infant was randomized to the 
SMS+150KES arm and a value of 0 otherwise; 
β3 is the log risk ratio of measles vaccination by age 10 months for a one unit increase in 
VAR among otherwise similar infants; 
VAR is the variable under assessment in the sub-group analysis; 
β4 is the log relative change in the risk of measles vaccination in the SMS only arm 
compared to the Control arm, for one level of VAR vs. a different level of VAR; 
SMS*VAR is an interaction term created by multiplying the values of SMS and VAR; 
Β5 is the log relative change in the risk of measles vaccination in the SMS+150KES arm 
compared to the Control arm, for one level of VAR vs. a different level of VAR; 
SMS150*VAR is an interaction term created by multiplying the values of SMS150 and 
VAR;  
βp is the log risk ratio of measles vaccination by age 10 months for a one unit increase in 
variable Xp among otherwise similar infants;  
and  




4.3.7.4. Analysis of time to measles vaccination 
Survival analysis was performed to assess whether time to measles vaccination differed 
significantly across the study arms. Time origin was defined as the point of enrollment and thus 
participants were considered at risk beginning from the time they enrolled in the RCT. The 
outcome assessed was time (in days) to measles vaccination by age 12 months, a two-state non-
recurrent event. Events were right-censored at age 365 days. The cumulative probability of 
measles vaccination was plotted using the failure functions estimated using the Kaplan-Meier 
method. The 25th, 50th and 75th percentile times to measles vaccination for each study outcome 
and study arm were obtained. Equality of the cumulative incidence functions were tested using 
the log-rank test. A sensitivity analysis of time to measles vaccination was performed whereby 
the time origin was defined as age 271 days, i.e., the intended start of intervention deployment, 
and infants who received MCV1 before age 271 days were left-censored.  
 
4.3.7.5. Estimation of number of days undervaccinated 
In the analysis of the number of days undervaccinated, observations were censored at age 12 
months. Infants were considered undervaccinated if they were vaccinated on or after age 10 
months (304 days) or if they were unvaccinated by age 12 months. For infants who were 
vaccinated after age 303 days, the number of days undervaccinated was calculated as the age of 
vaccination in days minus 303. For infants who were not vaccinated by age 12 months, the 
number of days undervaccinated was calculated as 364 minus 303. The mean, median, 25th 
percentile and 75th percentile of days undervaccinated were calculated for all infants and also for 
infants who were vaccinated on or after age 10 months. Mean days undervaccinated were 




4.3.7.6. Analysis of caregivers’ experiences, attitudes and opinions 
The frequency and percent of caregivers’ reasons for delayed vaccination, recollection of 
intervention receipt, use of the monetary incentive and opinions of the intervention were 
tabulated.  
 
With the exception of the risk difference and days undervaccinated analyses, the statistical 






CHVs identified 639 potentially eligible infants between December 6, 2016 and March 31, 2017. 
Of those, 102 infants were excluded for the following reasons: received routine measles vaccine 
(44 infants), not residents of the study area (20 infants), not aged between 6 and 8 months (13 
infants), did not have an MCH booklet (11 infants), caregivers refused participation (10 infants), 
planning to move (2 infants), MCH booklet date incongruences (1 infant) and inability to 
communicate with a deaf and mute caregiver (1 infant). A total of 537 infants – the target sample 
size - were randomized to the Control, SMS only and SMS+150KES arms (179 infants each; 
Figure 4.3).  
 
Follow-up visits when the infants achieved 12 months of age were conducted between April 19, 
2017 and October 8, 2017. Follow-up visits were completed for 170, 157 and 158 infants in the 
Control arm, SMS only arm and SMS+150KES arm, respectively. Nine infants enrolled in the 
Control arm could not be followed up as they had migrated out of the study area. Of 24 and 21 
infants not followed up in the SMS only and SMS+150KES arms, respectively, 19 in each arm 
out-migrated, caregivers of two infants in the SMS only arm refused to complete the follow-up 
visits, and three infants in the SMS only arm as well as two infants in the SMS+150KES died 
before the 12 month follow-up visit without collection of vaccination data post-enrollment. In 
addition, 10 Control arm infants as well as nine infants each in the SMS only arm and the 
SMS+150KES arm were excluded from analysis. Eight infants in each arm were excluded 
because they did not have an MCH booklet available at the follow-up visit although verbal 
vaccination reports were obtained from caregivers. Two pairs of twins (Control n= 2; SMS only 
n= 1; SMS+150KES n= 1) were also excluded from analysis because individual twins within 
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each pair were enrolled in different study arms; it was determined that the effects of the 
respective intervention could not be reliably isolated within these twin pairs. Thus, the analytic 
sample included 160 (89.4%), 146 (81.6%) and 149 (83.2%) out of all infants enrolled in the 
Control, SMS only and SMS+150KES arms, respectively (Figure 4.3).  
 
4.4.1. Baseline characteristics 
At enrollment, more than half of caregivers included in the analytic sample owned a mobile 
phone (68.6%; n= 312), a higher proportion compared to previous mobile phone ownership 
levels.35 The vast majority of caregivers (97.8%; n= 445) used the Safaricom network. Slightly 
more male infants (52.5%; n= 239) were enrolled than female infants and most infants (64.2%; 
n= 292) were enrolled when they were aged 6 months. Prior to enrollment, 95.8% (n= 436) of 
enrolled infants had received the third dose of pentavalent vaccine (Penta3; diphtheria, pertussis, 
tetanus, hepatitis B, Haemophilus influenzae type b). Approximately two-thirds (64.2%; n= 232) 
of participants lived within 30 minutes of a health facility and a similar proportion of mothers 
attained primary education or higher (65.7%; n= 299). Close to one-fifth (18.9%; n= 86) of 
infants were firstborn children and a little over 80% (n= 371) of infants were delivered at a 
health facility. Half (50.1%; n= 228) of mothers were aged 25 years or younger and almost one-
third (31.8%; n= 144) of mothers reported having attended more than four antenatal care (ANC) 
visits (Table 4.3).  
 
With the exception of maternal age, baseline characteristics were evenly distributed across study 
arms. In the Control arm, 50.0% (n= 80) of mothers were aged ≤25 years while the percentages 
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in the SMS only and SMS+150KES arm were 58.9% (n= 86) and 41.6% (n= 62), respectively 
(Table 4.1). The difference in the distribution of maternal age across study arms was statistically 
significant (p= 0.012). Because maternal age was unevenly distributed across study arms 
and because it has been shown to be a determinant of childhood vaccination status within 
the M-SIMI study area,16 maternal age was included as an independent variable in 
regression models. 
 
The 82 (Control arm n= 19; SMS only arm n= 33; SMS+150KES n= 30) participants who were 
excluded from the analytic sample were similar to participants in the analytic sample except for 
birth order and maternal age. The percentage of firstborn children was significantly higher 
among excluded participants than those the analytic sample (41.5% vs. 18.9%; p< 0.001) as was 
the percentage of mothers aged 25 years or younger (68.3% vs. 50.1%; p= 0.002; Table 4.4). 
Restricted to infants who were excluded, the proportion of firstborn infants was 31.6% in the 
Control arm compared to 48.5% and 40.0% in the SMS only arm and SMS+150KES arm, 
respectively. The proportion of mothers aged 25 years or less among excluded participants was 
57.9% in the Control arm, 60.6% in the SMS only arm and 83.3% in the SMS only arm (data not 
shown).  
 
4.4.2. Deployment of interventions 
 All intervention arm participants were sent at least one SMS reminder. Overall, per-protocol 
SMS reminders were sent to 252 (85.4%) intervention participants. Specifically, per-protocol 
reminders were sent to 126 participants each in the SMS only and SMS+150KES arms, 
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representing 86.3% and 84.6% of participants in each arm, respectively. Reminders for 20 
participants in the SMS only arm were not sent out per-protocol for the following reasons: two 
reminders sent but second reminder sent on scheduled vaccination date (8 participants); only one 
reminder sent (11 participants); and reminder sent after scheduled vaccination date (1 
participant). In the SMS+150KES arm, reasons for not sending out reminders per-protocol for 23 
participants were: three reminders sent (2 participants); two reminders sent but second reminder 
sent on vaccination date (6 participants); only one reminder sent (14 participants); and reminders 
sent after scheduled vaccination date (1 participant; Table 4.5).  
 
mMoney incentives were sent to all participants in the SMS+150KES arm. Ninety-one (61.1%) 
incentives were sent out three days before the scheduled vaccination date, as intended in the 
study protocol. All but four participants were sent incentives on or before the scheduled 
vaccination date. Incentives were sent out between one and 28 days after the scheduled 
vaccination date for the four participants (Table 4.9). By day of week, 14 (9.4%) incentives were 
intended to be paid on a Sunday, 30 (20.1%) on a Monday, 23 (15.4%) on a Tuesday, 64 (43.0%) 
on a Friday and 18 (12.1%) on a Saturday. None of the approximately 20% of payments intended 
to be sent on a Sunday or Saturday were sent on the intended date. Of payments intended to be 




4.4.3. MCV1 timely coverage 
4.4.3.1. Intent-to-treat analysis (ITT) 
The ITT analysis of MCV1 timely coverage included all Control (N= 160), SMS only (N= 146) 
and SMS+150KES (N= 149) participants in the analytic sample. Respectively, 109 (68.1%), 114 
(78.1%) and 116 (77.9%), of infants in the Control, SMS only and SMS+150KES arms received 
MCV1 by age 10 months. Compared to Control arm infants, those in the SMS only arm were not 
statistically significantly more likely to receive measles vaccine by age 10 months in the crude 
analysis (crude RR [cRR] 1.15; 95% CI: 1.00, 1.31; p= 0.050) or in the regression model 
adjusted for maternal age (adjusted RR [aRR] 1.13; 95% CI: 0.99, 1.30; p= 0.070). The 
likelihood of timely MCV1 was not significantly higher in the SMS+150KES arm compared to 
the Control arm in the unadjusted analysis (cRR 1.14; 95% CI: 1.00, 1.31; p= 0.055) but was 
after adjustment for maternal age (aRR 1.16; 95% CI: 1.01, 1.32; p= 0.036; Table 4.6). In 
multivariable risk difference analyses, approximately 10 additional infants per 100 received 
MCV1 by age 10 months in the SMS only arm; however, there was no statistically significant 
difference in MCV1 timely coverage compared to the Control arm (adjusted risk difference 
[aRD] 9.2; 95% CI: -0.6, 19.0; p= 0.066). MCV1 timely coverage was significantly higher in the 
SMS+150KES arm by 10.6% compared to the Control arm (aRD 10.6; 95% CI: 0.8, 20.3; p= 
0.034) compared to the Control arm (Table 4.7).  
 
4.4.3.2. Sub-group analysis 
The univariate risk factor analysis conducted among only Control arm infants included all 
baseline characteristics; age at enrollment was dichotomized i.e., age 6 months vs. age 7-8 
months owing to the small number of infants enrolled at age 8 months (Table 4.3). Phone 
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ownership and being aged 7-8 months at enrollment were associated with higher likelihood of 
measles vaccination by age 10 months at the 10% significance level cRR 1.28 (95% CI: 0.98, 
1.67; p= 0.073) and cRR 1.21 (95% CI: 0.99, 1.49; p= 0.068), respectively. Being a later-born 
child was associated with lower likelihood of timely measles vaccination (cRR 0.83; 95% CI: 
0.67, 1.03; p= 0.092). Time to health facility, which was pre-specified for inclusion in the sub-
group analysis was not significantly associated with timely measles vaccination (cRR 1.04; 95% 
CI: 0.83, 1.30; p= 0.727). Similarly, maternal educational level, specified post-hoc, was not 
significantly associated with measles vaccination status (cRR 1.19; 95% CI: 0.93, 1.53; p= 
0.166; Table 4.8).  Thus, phone ownership status, age at enrollment, birth order and time to 
health facility were included in sub-group analyses. Of note, there were no significant 
differences in MCV1 timely coverage among higher wealth households compared to less wealthy 
households (Table 4.8).   
 
The probability of timely measles vaccination arm in the SMS only arm and in the 
SMS+150KES did not differ significantly at the 5% level for different levels of phone 
ownership, age at enrollment, birth order and time to health facility in either the unadjusted (all 
stratum-specific p>0.05; Figures 4.4[A] & [B]) or adjusted (all stratum-specific and overall 
interaction term p>0.05 Figures 4.5[A] & [B]) regression models.     
 
4.4.3.3. Per-protocol analysis 
The per-protocol analysis included all Control arm participants (N= 160) and only those 
participants in the SMS only and SMS+150KES arms who were sent the 3-day and 1-day 
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reminder (N= 126 for each arm). Per-protocol MCV1 timely coverage in the intervention arms 
was similar to ITT timely coverage; 109 (68.1%), 100 (79.4%) and 99 (78.6%) infants in the 
Control, SMS only and SMS+150KES arms were vaccinated by age 10 months, respectively. In 
the unadjusted per-protocol regression model, infants in the SMS only arm were significantly 
more likely to receive timely measles vaccination compared to infants in the Control arm (cRR 
1.16; 95% CI: 1.01, 1.34; p= 0.031) but the likelihood of timely measles vaccination was not 
significantly different after adjustment for maternal age (aRR 1.15; 95% CI: 1.00, 1.32; p= 
0.052). The likelihood of timely measles vaccination in the SMS+150KES arm was significantly 
higher compared to the Control arm in both unadjusted (cRR 1.15; 95% CI: 1.00, 1.33; p= 0.046) 
and adjusted (aRR 1.17; 95% CI: 1.02, 1.35; p= 0.024) regression models (Table 4.11). The 
adjusted difference in MCV1 timely coverage between SMS only infants compared to Control 
infants with similarly aged mothers was 10.2% (95% CI: 0.1, 20.3; p= 0.048) and 11.6% (95% 
CI: 1.4, 21.7; p= 0.025) for SMS+150KES infants compared to Control infants (Table 4.12).  
 
4.4.4. MCV1 overall coverage 
4.4.4.1. ITT analysis 
All participants in the analytic sample were included in the ITT analysis of MCV1 overall 
coverage. Respectively, 125 (78.1%), 123 (84.2%) and 126 (84.6%) of Control, SMS only and 
SMS+150KES infants received MCV1 by age 12 months. The likelihood of measles vaccination 
by age 12 months among SMS only arm infants was 1.08 and 1.07 times that of infants in the 
Control arm in the crude and adjusted analysis, respectively, but this higher risk did not achieve 
statistical significance in the crude analysis (95% CI: 0.97, 1.20; p= 0.171) or in the analysis 
adjusted for maternal age (95% CI: 0.96, 1.19; p= 0.199). Infants in the SMS+150KES arm were 
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more likely to receive measles vaccine by age 12 months in the crude analysis (cRR 1.08; 95% 
CI: 0.97, 1.20; p= 0.147) and in the adjusted analysis (aRR 1.09, 95% CI: 0.98, 1.21; p= 0.124) 
though in neither case did the association achieve statistical significance (Table 4.13). 
Approximately, 6 additional infants per 100 and 7 additional infants per 100 in the SMS only 
arm and SMS+150 KES arm, respectively, received measles vaccination compared to the Control 
arm; this difference in risk was not statistically significant (aRD 5.7%; 95% CI: -3.0, 14.3%; p= 
0.199 [SMS only arm]; aRD 6.8%; 95% CI: -1.8, 15.3%; p= 0.119 [SMS+150KES arm]; Table 
4.14).  
 
4.4.4.2. Per-protocol analysis 
The per-protocol analysis of MCV1 overall coverage included 160 infants in the Control arm and 
126 infants each in the SMS only arm and SMS+150KES arm. By age 12 months, 125 (78.1%) 
infants in the Control arm had received MCV1 compared to 126 (84.9%) in the SMS only arm 
and 146 (84.1%) in the SMS+150KES arm. Coverage estimates in the intervention arms were 
similar to estimates in the ITT analysis. The likelihood of measles vaccination in the SMS only 
arm in the crude analysis was 1.09 times (95% CI: 0.97, 1.21; p= 0.138) that in the Control arm 
and 1.08 times (95% CI: 0.97, 1.20; p= 0.163) that in the Control arm in the adjusted analysis. 
Neither of these relative risks were statistically significant. Similarly, the likelihood of measles 
vaccination in the SMS+150KES arm was 1.08 times that in the Control arm but this higher 
likelihood was not statistically significant in both the crude analysis (95% CI: 0.96, 1.20; p= 
0.194) and the adjusted analysis (95% CI: 0.97, 1.21; p= 0.166; Table 4.15). Absolute MCV1 
overall coverage was not statistically significantly different in the SMS only arm compared to the 
Control arm in the crude analysis (cRD 6.8%; 95% CI: -2.2, 15.7%; p= 0.137) or in the adjusted 
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analysis (aRD 6.3%; 95% CI: -2.6, 15.2%; p= 0.165). Similar to the SMS only arm, 
approximately 6 additional infants per 100 were vaccinated in the SMS+150KES arm than in the 
Control arm, but this difference was not statistically significant in the crude analysis (cRD 6.0%; 
95% CI: -3.0, 15.0%; p= 0.193) or in the adjusted analysis (aRD 6.4%; 95% CI: -2.5, 15.3; p= 
0.161; Table 4.16). 
 
4.4.5. Time to measles vaccination 
In the time to measles vaccination including all participants in the analytic sample, three 
vaccination events occurring after age 365 days, one in the SMS only arm and two in the 
SMS+150KES arm, were excluded due to right-censoring. However, those infants contributed to 
analysis through age 365 days. Forty-two infants including 16 (11.4%) Control, 12 (8.2%) SMS 
only and 14 (9.4%) SMS+150KES infants who received measles vaccination prior to age 271 
days, the targeted intervention start date were included in the primary survival analysis. The 
median age of entry into the survival analysis was 204 days (Age 6 months and 20 days; Q1= 
195, Q3= 218 days) in the Control arm, 203 days (Q1= 193, Q2= 222 days) in the SMS only arm 
and 204 days (Q1= 193, Q2= 221) in the SMS+150KES arm. The cumulative probability of 
failure, i.e., measles vaccination by age 12 months was 78.3% in the Control arm, 84.3% in the 
SMS only arm and 84.6% in the SMS=150KES arm (Table 4.17). The median time to measles 
vaccination was age 286 days (Age 9 months and 12 days; Q1= 276, Q3= 324 days) in the 
Control arm, age 284 days (Q1= 276, Q3= 298 days) in the SMS only arm and 282 days (Q1= 
275, Q3= 302 days) in the SMS+150KES arm (Figure 4.6). There was no significant difference 
in time to measles vaccination across study arms (log-rank test p= 0.182) even after performing 
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testing stratified by maternal age (maternal age ≤25 years log-rank test p= 0.195, maternal age 
>25 years log-rank test p= 0.576, stratified log-rank test p= 0.158; Table 4.18).  
 
The sensitivity analysis of time to measles vaccination excluded the 42 previously described 
infants who received MCV1 before the targeted intervention start date i.e., infants who received 
MCV1 before 271 days of age. Thus, the sensitivity analysis included 146, 135 and 137 Control, 
SMS only and SMS+150 participants, respectively. The cumulative probability of measles 
vaccination by age 12 months was 75.7% in the Control arm, 82.8% in the SMS only arm and 
83.0% in the SMS+150KES arm (Table 4.19). The median time to measles vaccination in the 
Control arm was 288 days (age 9 months and 17 days; Q1= 279, Q3= 337 days), 286 days in the 
SMS only arm (Q1= 278, Q3= 302 days) and 284 days in the SMS+150KES arm (Q1= 277, Q3= 
303 days; Figure 4.7). There was no statistically significant difference in the time to measles 
vaccination across study arms in unstratified testing (log-rank test p= 0.118) or in testing 
adjusted for maternal age (stratified log-rank test p= 0.101; Table 4.20). 
 
4.4.6. Days undervaccinated 
Within the analytic sample, infants in the Control arm, SMS only arm and SMS+150KES arm 
were undervaccinated against measles for 14.9 days (standard error: 2.0), 10.5 days (1.8) and 
10.1 days (1.8) on average, respectively, by age 12 months. The mean number of days 
undervaccinated was not statistically significantly different in the SMS only arm compared to the 
Control arm (two-sample t-test p= 0.108) or in the SMS+150KES arm (p= 0.071). The median 
number of days undervaccinated was zero in all study arms, but this median value was driven by 
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the >50% MCV1 timely coverage in the study arms. The number of infants undervaccinated for 
one or more days was 51 (31.9%), 32 (21.9%) and 33 (22.1%) in the Control arm, SMS only arm 
and SMS+150KES arm, respectively (Table 4.21).  
 
In the analysis restricted to undervaccinated infants, the average number of days undervaccinated 
was 46.9, 48.2 and 45.5 in the Control arm, SMS only and SMS+150KES arm, respectively. 
There was no statistically significant difference in the mean number of days undervaccinated 
among Control infants who were not vaccinated by age 10 months compared to similar SMS 
only arm infants (p= 0.788) and to similar SMS only arm infants (p= 0.788). The median and 
75th percentile of days delayed was 61, the highest possible number of days undervaccinated due 
to right censoring at age 12 months. The 25th percentile of median days undervaccinated was 29 
in the Control and SMS only arm compared to 15 in the SMS+150KES arm.  
 
Infants not vaccinated by age 12 months (61 days undervaccinated) made up the highest number 
of undervaccinated infants in all study arms, 35 (68.6%) in the Control arm, 23 (71.9%) in the 
SMS only arm and 23 (69.7%) in the SMS+150 KES arm. Among infants vaccinated with delay, 
i.e., vaccination when aged 10 or 11 months, the number of days undervaccinated ranged from 2-
34 in the Control arm, 1-37 in the SMS only arms, and 2-19 in the SMS+150KES arm. Five 
(9.8%), two (6.3%) and five (15.2%) Control arm, SMS only arm and SMS+150KES arm infants 
were undervaccinated for 1-7 days. Three (5.8%) Control arm infants and two infants each in the 
SMS only arm (6.3%) and the SMS+150KES arm (6.1%) were undervaccinated for 8-14 days. 
Three (5.8%) Control arm, four (12.5%) SMS only arm and three (9.1%) SMS+150KES arm 
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infants were undervaccinated for 15-21 days. No SMS+150KES arm infants were 
undervaccinated for more than 19 days. Five (9.8%) Control arm infants and no SMS only arm 
infants were undervaccinated for 22-35 days. One (3.1%) SMS only arm infant was 
undervaccinated for 37 days (Table 4.21).  
 
4.4.7. Reasons for delayed vaccination 
The reason for delayed vaccination was obtained for 95 (81.9%) of the 116 infants that did not 
receive MCV1 by age 10 months. Caregivers of 10 Control arm, three SMS only arm and eight 
SMS+150KES arm infants were not queried about the reason for delayed measles vaccination as 
the interviewer did not identify them as having delayed vaccination. Of the 95 infants (41 
Control, 29 SMS only and 25 SMS+150KES) whose caregivers were queried, reasons for not 
receiving MCV1 by age 10 months included: an ongoing nurses strike (n= 34; 35.8%), vaccine 
stock-out (15; 15.8%), infant’s illness (8; 8.4%), being away on travel (7; 7.4%), vaccination not 
recorded in the MCH booklet per caregiver (6; 6.3%), not knowing the vaccination due date (5; 
5.3%), nurse’s refusal to open multi-dose vaccine vial given few infants presenting for measles 
vaccination (3; 3.2%), caregiver forgot (2; 2.1%) and competing priorities (2; 2.1%). In addition, 
one caregiver each reported that MCV1 was not given by age 10 months because of: far distance 
to the clinic, delay in the infant’s pentavalent vaccine series, the caregiver’s perception that 
measles vaccine is not important, the caregiver’s omission to carry the MCH booklet to the 
clinic, a recommendation by the caregiver’s friend to not vaccinate and the caregiver being ill. 
Seven caregivers (one Control arm, 4 SMS only arm, 2 SMS+150KES arm) were queried but did 
not provide a reason for not being vaccinated (Table 4.22). There was no significant difference 




4.4.8. Intervention receipt, use of incentive, opinions of interventions 
4.4.8.1. Reported receipt of SMS reminders 
Whereas at least one SMS reminder was sent out by the study team to participants, 98 (67.1%) 
and 120 (80.5%) of SMS only arm and SMS+150KES arm caregivers, respectively, reported that 
they received at least one SMS reminder. In addition, 47 (32.2%) and 27 (18%) of SMS only and 
SMS+150KES caregivers, respectively, reported that they did not receive reminders. One SMS 
only and SMS+150KES caregiver each did not remember whether they received a reminder and 
one SMS+150KES caregiver interviewed was different from the enrolled caregiver and so did 
not know. Due to the arrangement of the questionnaire, caregivers who reported not receiving 
any reminders were not queried as to whose phone the reminders were sent. But based on 
caregivers’ mobile phone ownership at the end of the study, 19 (40%) and 10 (37%) of SMS and 
SMS+150KES caregivers, respectively, who reported not receiving any SMS reminders also did 
not own a mobile phone at the end of the M-SIMI study.  
 
Of the 98 SMS only arm caregivers who reported receipt of at least one SMS reminder, 66 
(67.4%) owned the phone receiving reminders and 32 (32.7%) received reminders on a shared 
phone. Thirty (30.6%) of SMS only arm caregivers reported receiving one reminder, 62 (63.3%) 
reported two reminders, one (1.0%) reported three reminders and 5 (5.1%) reported receiving at 
least one reminder but did not know the exact number. The proportion of caregivers who 
reported receiving two reminders among caregivers who owned the phone to which reminders 
were sent was significantly larger than the proportion among caregivers who shared the phone to 
which reminders were sent (71.2% vs. 46.9%; p= 0.019). The proportion of caregivers who did 
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not know the number of reminders received was significantly higher among those sharing a 
phone compared to those who owned the phone receiving messages (15.6% vs. 0%; p= 0.001; 
Table 4.23).  
 
In the SMS+150KES arm, 82 (68.3%) of caregivers reporting receipt of at least one SMS 
reminder owned the phone receiving reminders while 38 (31.7%) shared the phone receiving 
reminders (Table 4.23). Twenty-one (17.5) of SMS+150KES arm caregivers reported receiving 
one reminder, 94 (78.3%) reported two reminders, two (1.7%) reported receiving three reminders 
and 3 (2.5%) did not know how many reminders were received. The proportion of caregivers 
who did not know the number of reminders received was significantly higher among 
SMS+150KES caregivers who shared a phone compared to those who owned the phone 
receiving reminders (7.9% vs. 0%; p= 0.010; Table 4.23). 
 
 
4.4.8.2. Caregiver opinions about SMS reminders 
Of the 98 SMS only arm caregivers who reported receiving at least one SMS reminder, 88 
(89.8%) opined that the reminders influenced the decision to vaccinate the infant; 80 (90.9%) of 
their infants were vaccinated by age 12 months. Most caregivers (n= 80; 81.6%) felt that two 
SMS reminders were adequate while eight (8.2%) of caregivers would have preferred more; 
other caregivers either shared a mobile phone or had no opinion. Close to 90% of caregivers 
were happy with the length of the SMS reminders, the rest either shared a mobile phone or had 




Among the 110 SMS+150KES arm caregivers reporting receipt of at least one SMS reminder, 
110 (91.7%) felt that the reminders influenced their decision to vaccinate their infant; 96 (87.3%) 
were vaccinated by age 12 months. Similar to caregivers in the SMS only arm, most caregivers 
(n= 94; 78.3%) felt two reminders were sufficient; 15 (12.5%) felt that the reminders were too 
few while the rest either shared a phone or had no opinion. With regard to the length of the SMS 
reminders, 106 (88.3%) of caregivers were satisfied with the length of the reminder used, one 
(0.8%) caregiver felt that the message was too short while 13 (10.8%) did not opine as they 
shared a phone (Table 4.24).      
 
4.4.8.3. Caregivers’ reported receipt of incentive, use of incentive and opinions 
Of 149 SMS+150KES arm caregivers, 105 (70.5%) reported that they received the mMoney 
incentive, of whom 76 (72.4%) owned the phone to which the mMoney incentive was sent. 
Receipt of the incentive influenced the decision of 88 of the 105 caregivers to vaccinate their 
infant; 78 infants of these 88 caregivers received MCV1 by age 12 months. Respectively, 16 
(15.2%), 67 (63.8%) and 20 (19.0%) of caregivers cashed out the incentive on the same day, 
within 1-3 days of receiving the incentive and more than three days after receiving the incentive. 
Two (1.9%) of the caregivers did not cash out the incentive. Approximately 95% reported a 
positive experience related to receiving the incentive while four (3.8%) had no opinion about the 
experience. One (1.0%) caregiver reported a very negative experience but further details were 
not recorded. Only one caregiver reported that they would be less likely to vaccinate their infant 
in the future in the absence of an incentive. Incentives were commonly used to cover transport 
costs (n= 59; 56.2%), for housing expenses (n= 21; 20.0%) and to purchase food (n= 16; 15.2%). 
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Other uses of the incentive included purchase of medicine, infants’ clothing and purchase of 
mobile phone airtime (via mMoney) by one of the two caregivers that did not cash out the 
incentive. The other caregiver that did not cash out the incentive had not used it as of the time of 




SMS reminders coupled with an unconditional KES 150 incentive significantly increased, as 
compared to control infants, the proportion of infants receiving measles vaccine by age 10 
months whereas SMS reminders alone did not. In the per-protocol analysis, timely measles 
coverage by age 10 months was significantly higher in the SMS only arm compared to the 
Control arm, suggesting that when delivered as intended, SMS reminders may significantly 
improve timely measles vaccination coverage. In addition, MCV1 timely coverage estimates for 
SMS only and SMS+150KES infants were comparable, suggesting no added benefit of 
unconditional incentives over SMS reminders only. The interventions did not differentially 
impact MCV1 timeliness significantly by strata of mobile phone ownership status, travel time to 
a health facility, age at enrollment, birth order or maternal educational level. The interventions 
did not significantly improve secondary outcomes of measles vaccination coverage by age 12 
months nor the time to vaccination. This study was novel in that it evaluated the impact of SMS 
reminders coupled with unconditional monetary incentives on vaccination timeliness and 
coverage. To our knowledge, it is only the second study, after the M-SIMU study,35 to evaluate 
the impact of SMS reminders coupled with monetary incentives on vaccination uptake and the 
first to evaluate the combined impact of SMS vaccination reminders coupled with unconditional 
incentives.  
 
The finding from this study that SMS reminders coupled with an incentive significantly increase 
measles vaccination timeliness is consistent with the M-SIMU study35 and reproduces a positive 
finding within the same study population; both studies included participants sampled from Gem 
sub-county. In the M-SIMU study, SMS reminders alone significantly increased MCV1 timely 
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coverage by 10% while SMS reminders coupled with conditional monetary incentives 
significantly improved MCV1 timely coverage by approximately 20%. Of note, the impact of 
SMS reminders coupled with unconditional monetary incentives on MCV1 timely coverage in 
the M-SIMI study was less than that observed for SMS reminders coupled with conditional 
incentives in the M-SIMU study, suggesting differential impact of unconditional versus 
conditional incentives. Of note also is that the impact of SMS reminders alone in the M-SIMI 
study was comparable to that observed in the M-SIMU study.35  
 
Despite their modest impact, the observation that SMS reminders with or without unconditional 
monetary increased timely measles coverage by approximately 10 percentage points in the M-
SIMI study is of public health significance. Delay in vaccination reduces herd immunity and can 
lead to accumulation of a susceptible pool of susceptible persons particularly in this setting with 
high HIV prevalence. Furthermore, measles vaccine fails to induce protection in about 15% of 
infants receiving a first dose at age 9 months,52 making it more important to improve population 
immunity by vaccinating as many infants as possible given that the number of secondary measles 
infections increases with decreasing vaccination coverage.53   
 
It is encouraging that there were no differential effects of the interventions on timely measles 
vaccination among caregivers who owned a mobile phone (a potential indicator of 
socioeconomic status) vs. those that did not, households with shorter vs. longer travel time to a 
clinic, firstborn vs. later-born infants or less educated vs. more educated caregivers. In part, the 
Sustainable Development Goals aspire for equitable access to vaccines (Target 3.8)54 yet 
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characteristics such as socioeconomic status, health facility access, birth order and education 
level can influence access to vaccination.55–58 The findings from this study suggest that the 
observed increases in timely vaccination coverage did not occur at the expense of already 
disadvantaged sub-groups. Previously, the M-SIMU study found that increases in full 
vaccination coverage among infants of less educated caregivers who received SMS reminders 
with or without a conditional monetary incentives, compared to similar control infants, were 
significantly higher than increases in vaccination coverage among infants of more educated 
caregivers who received the interventions, compared to similar control arm caregivers.35 This 
finding suggested that the interventions were more impactful for disadvantaged infants. Although 
this pattern was not observed in the M-SIMI study, the interventions did not appear to amplify 
inequitable access to vaccination.  
 
The interventions in the M-SIMI study did not significantly improve measles vaccination 
coverage by age 12 months or the time to measles vaccination, in contrast to the M-SIMU study 
in which SMS reminders coupled with a conditional 200 KES incentive significantly improved 
measles vaccination coverage by age 12 months and the time to vaccination.35 This discrepancy 
in findings could be due to several reasons.  
 
First, the M-SIMI study was underpowered to detect the level of difference observed in the 
study. For a study to detect a 6.1% or 6.5% absolute increase in vaccination coverage by age 12 
months, as observed in this study (Table 4.13), the analytic sample would need to include at 
least 677 or 593 participants, respectively, in each group which is greater than this study’s total 
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analytic sample of 455. One approach to increasing the power of an underpowered study is to 
combine similar study arms. When we combined data from the SMS only and SMS+150KES 
arms of the M-SIMI study and compared MCV1 overall coverage in the intervention arms to the 
Control arm, we found no statistically significant differences in the likelihood of measles 
vaccination by age 12 months (aRR 1.08; 95% CI: 0.98, 1.19; p= 0.114) or in the absolute 
difference in vaccination coverage (aRD 6.2%; 95% CI: -1.3, 13.8%; p= 0.106; Table 4.26). 
However, the combined sample size of the intervention arms (N= 295) was still underpowered to 
detect a 6.2% absolute difference in vaccination coverage.  
 
Second, the incentive amount and nature of the incentive differed in the M-SIMI study compared 
to the M-SIMU study. In the M-SIMI study, caregivers received a maximum monetary incentive 
of KES 150 (~US $1.87 in August 2015 after indexing to 2015 KES and applying exchange 
rate). In contrast, caregivers in the M-SIMI study received as much as KES 800 as this study 
incentivized the pentavalent vaccine primary dose in addition to MCV1 (KES 800 = ~US $9.41 
in August 2015.35 Formative research for the M-SIMU study whereby caregivers in the study 
area were asked what amount of money might motivate a caregiver to prioritize attending the 
vaccination visit rather over other activities found a larger proportion of caregivers (93%) felt 
that KES 200 would be motivational compared to 83% who felt that KES 150 would be 
motivational (D. G. Gibson, unpublished data, September 2014). Therefore, one could theorize 
that the KES 200 M-SIMU incentive offered for each of four vaccine doses elicited more 
extrinsic motivation for caregivers to seek vaccination compared to the KES 150 M-SIMI 
incentive as higher incentive amounts are thought to elicit higher impact.59 In addition, the 
incentive was delivered unconditionally in the M-SIMI study whereas in M-SIMU the incentive 
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was sent only if the infant was vaccinated within two weeks of the vaccine due date. There is 
mixed evidence on whether the impact of conditional incentives varies from that of 
unconditional incentives. Systematic reviews have found positive health effects of both 
conditional and unconditional incentives for outcomes such as HIV prevention and treatment and 
health care seeking.60–62 Only one systematic review and meta-analysis found that unconditional 
incentives improved return rates for mailed surveys whereas conditional incentives did not.63 
Furthermore, the role of monetary versus non-monetary nature of incentives on the impact of 
conditional versus unconditional incentives is not well understood. Even in the absence of 
conditions, it is theorized high levels of community interest in achieving the outcome could 
mimic the effects of conditions.64 In terms of vaccination outcomes, evaluations of large 
conditional and unconditional cash transfer programs in Central and South America found that 
the transfers significantly increased uptake for some vaccines but not for others, with neither 
type of cash transfer program having consistently significant findings across different 
vaccines.65–68 In the one cluster randomized controlled trial that simultaneously assessed the 
impact of both conditional and unconditional cash transfers on childhood health in Zimbabwe, 
neither intervention significantly improved the proportion of children who were up-to-date on 
their vaccinations even though families could receive as much as $212 (incentive value indexed 
to 2015 USD).69 In the behavioral economics literature, conditional incentives are theorized to 
have a negative impact whereby they may inhibit intrinsic motivation through reducing one’s 
perception of choice and agency.42 Thus, there is no clear evidence of differential impact of 
conditional versus unconditional incentives and it remains unclear if the different modality of the 
incentive in the M-SIMI study compared to the M-SIMU study may have influenced the different 




Finally, we may have observed differences in the impact of SMS reminders coupled with an 
incentive in the M-SIMI study compared to the impact observed in the M-SIMU study because, 
as mentioned previously, M-SIMU caregivers received reminders and incentives for four vaccine 
doses as opposed to only MCV1 in the M-SIMI study. The repeated vaccination prompts during 
the M-SIMU study may have induced greater vaccine seeking among caregivers as more 
frequent reminders may be associated with greater impact.70  
 
Nevertheless, we observed that the 78.1% MCV1 overall coverage estimate in the M-SIMI 
Control arm differed markedly from the expected 83-84% coverage based on previous estimates 
of coverage in the study area16,35 and in Siaya County.15 In particular, we expected similar 
MCV1 overall coverage in M-SIMU35 and M-SIMI studies as they were conducted in the same 
geographical area. The lower MCV1 overall coverage observed in the M-SIMI study suggested 
that there may have been procedural differences between the studies or secular changes affecting 
baseline measles vaccination coverage. One procedural difference between the studies is that 
while the M-SIMU study included infants who received measles at any age (infants were 
enrolled within one month of age), the M-SIMI study excluded 44 infants who had received 
measles vaccination before enrollment (Figure 4.3). To assess whether excluding these infants 
may have impacted the estimate of MCV1 overall coverage in the Control arm, we equitably 
distributed the 44 infants across study arms and designated them to have received measles 
vaccination by age 12 months. After including these infants who were excluded for having 
received measles vaccination before enrollment, Control arm MCV1 overall coverage was 79.9% 
but the likelihood of vaccination in the Control arm was not significantly lower than that in the 
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SMS only arm (aRR 1.07; 95% CI: 0.97, 1.18; p= 0.184) or the SMS+150KES arm (aRR 1.08; 
95% CI: 0.98, 1.19; p= 0.116; Table 4.27). Baseline MCV1 overall coverage in the M-SIMI 
study remained below that in the M-SIMU after including infants who had received measles 
vaccine before enrollment, so it seems unlikely that M-SIMI eligibility criteria influenced the 
lower Control arm MCV1 overall coverage in M-SIMI.  
 
Another possible explanation for lower MCV1 overall coverage in the M-SIMI Control arm 
compared to M-SIMU was a nurses’ strike that began on June 5, 201771 and was ongoing at the 
time of the M-SIMI study’s completion. Of the 455 infants in the analytic sample, 32.1% reached 
age 12 months after the strike began. MCV1 overall coverage was 88.4% among infants reaching 
age 12 months before the strike began and 79.3% among those reaching their first birthday after 
the strike launched. We found that the risk of receiving MCV1 by age 12 months was about 10% 
lower among infants who reached age 12 months after the strike began (RR 0.90; 95% CI: 0.83, 
0.97; p= 0.010, data not shown). However, MCV1 overall coverage was not significantly higher 
in the intervention infants who reached age 12 months before the strike compared to Control 
infants who also reached age 12 months before the strike nor among intervention compared to 
Control infants who reached age 12 months after the strike begun (data not shown). It is still 
plausible though that the nurses’ strike reduced the potential impact of interventions as 
caregivers seeking MCV1 in public health facilities would have been unable to get their infants 
vaccinated. Another supply-side factor that might have minimized MCV1 uptake is that few 




To leverage the information from the M-SIMI and M-SIMU studies, which were conducted in 
the same study area and assessed similar interventions with the exception of the value of the 
monetary incentive and conditional nature, we performed a post-hoc random-effects meta-
analysis to pool the data from the two studies. In this pooled analysis, SMS reminders alone 
improved measles vaccination timeliness (RR 1.15; 95% CI: 1.04, 1.28; p= 0.007; Figure 4.8) as 
did SMS reminders coupled with an unconditional KES 150 incentive or a conditional KES 200 
incentive (RR 1.28; 95% CI: 1.05, 1.56; p= 0.014; Figure 4.9). However, SMS reminders alone 
did not significantly improve MCV1 overall coverage (pooled RR 1.05; 95% CI: 0.99, 1.11; p= 
0.105; Figure 4.8) whereas SMS reminders coupled with an incentive significantly improved the 
likelihood of measles vaccination by age 12 months (pooled RR 1.07; 95% CI: 1.02, 1.13; p= 
0.007; Figure 4.9). This accumulated evidence suggests that SMS reminders alone can improve 
measles vaccination timeliness. But, reminders’ impact on the proportion of infants receiving 
MCV1 in this setting is less clear. In this setting where MCV1 overall coverage is typically 
>80%,15,16,35 reaching the additional 10-15% coverage needed for measles control is challenging 
as these remaining children represent those with the greatest barriers to vaccination. SMS 
reminders alone may not be sufficient to surmount the barriers faced by these children, whereas 
the addition of other interventions such as incentives, could overcome those barriers. Beyond the 
M-SIMI study area, a study conducted in the Philippines found no impact of SMS reminders on 
MCV2 coverage while another study conducted in China found a significant increase in MCV1 
overall coverage compared to baseline following the use of SMS reminders.72,73 Pooled evidence 
from the M-SIMI and M-SIMU studies strongly suggest that in a setting with limited supply-side 
barriers to vaccination, SMS reminders coupled with an incentive can significantly improve 
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MCV1 timeliness as well as the proportion of infants receiving MCV1 by age 12 months but the 
impact of SMS reminders alone is unclear.  
 
Caregivers’ opinions of the interventions and their experiences with them were generally positive 
(Tables 4.23 – 4.25). It appears that a smaller proportion of caregivers agreed with the number 
of SMS reminders compared to other modalities such as the length of the reminder. However, 
some caregivers were unable to respond since the phone was shared. In addition, not all 
reminders may have been relayed to caregivers who were sharing phones. This study sent the 
same number of reminders as the M-SIMU study, yet satisfaction with the number of reminders 
during the M-SIMU study was higher than we found in this study.35 More formative research 
into the optimal number of vaccination reminders in this setting may help finesse the intervention 
and perhaps influence outcomes. In the HIV literature, too frequent reminders have been linked 
to desensitization to reminders.74 Encouragingly, virtually all caregivers who reported receiving 
the incentive also reported increased or the same likelihood of vaccinating their children in the 
future. One criticism of incentives is that they may dampen intrinsic motivation to engage in 
positive behaviors, leading to reduced practice of the incentivized behavior once incentives are 
withdrawn.42,75,76 The most commonly reported use of the incentive was to cover transportation 
costs, which we theorized was a barrier to vaccination that the incentive could help overcome. 
Although incentives were also used to cover other costs such as housing expenses and food it 
still might have encouraged caregivers to vaccinate their infants by reframing their perceived 




Supply-side factors were more commonly cited as reasons for delayed vaccination than demand-
side factors. Of 88 caregivers who gave a reason for delayed measles vaccination, 60 cited 
supply-side factors including the nursing strike, vaccine stock-out, vaccination not recorded in 
MCH booklet or forgetting to carry the MCH booklet, nurse’s refusal to open the vial and far 
distance to the clinic. The high contribution of supply-side factors was likely driven by the 
nurses’ strike. Still, this setting with high DTP3 coverage highlights the use of multi-dose 
measles vaccine vials and measles vaccine stock-outs as barriers to vaccination. Multi-dose vials 
as a barrier to measles vaccine is widely discussed anecdotally and has been documented in some 
studies.21,24 Caregiver forgetfulness and not knowing the vaccine due date was cited by a few 
caregivers and more frequently by Control arm caregivers. Vaccine hesitancy does not appear to 
be common in this setting – only one caregiver expressed the feeling that vaccination was not 
important and one other caregiver was discouraged from vaccination by a friend – but caregivers 
may have been reluctant to express hesitancy to study staff, particularly among those caregivers 
who did not provide a reason for delayed vaccination. These findings underscore the need for 
supply-side as well as demand-side interventions to improve vaccination uptake.   
 
This study has several limitations. First, the analytic sample comprised 84.7% of enrolled 
participants. Excluded infants were more likely to be firstborn children and to have mothers aged 
25 years or less. Similar patterns were observed in the M-SIMU study and are attributed to 
cultural practices around pregnancy and birth whereby mothers return to their rural home to 
receive support caring for newly-born infants.35 The proportion of firstborn children and younger 
mothers among excluded participants was higher in the intervention arms compared to the 
Control arm. Firstborn infants and children of younger mothers are thought to be less at risk of 
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being unvaccinated or receiving vaccination with delay than later-born infants and children of 
older mothers, respectively.16,56–58,79 Thus, the effect estimates for the intervention arms may 
have been biased towards the null. Due to limited resources we were unable to mitigate the 
impact of losses to follow-up or missing MCH records. We had limited resources to track infants 
who were lost to follow-up or to attempt to ascertain vaccination status from clinic records. We 
were reluctant to include verbal report of vaccination status because evidence from other settings 
implies that they may under- or over-estimate actual vaccination coverage.48–51 We know little 
about the validity of verbal vaccination report in this setting, but preliminary analysis from a 
different study indicates that it has high sensitivity with less than perfect specificity (K. Hayford, 
unpublished data, February 2018), suggesting that verbal report could over-estimate vaccination 
coverage in this setting.  
 
Another limitation of this study is that only 85.4% of SMS reminders and 61.1% of mMoney 
incentives were sent out as intended i.e., three days and one day before the scheduled vaccination 
date for reminders and three days before the scheduled vaccination date for the incentive. 
Delivery of SMS reminders was hampered mainly by power outages during which the 
RapidSMS server would not send out reminders until power was restored and the server 
computer turned on. To a minimal extent, reminders were not sent out per-protocol because of 
inaccurate dates of birth submitted to the server by CIs via SMS, which in turn impacted the 
timing of the reminders. mMoney incentives were delayed because they were sent out manually 
by study staff during weekdays but on weekends when staff were not working. In the per-
protocol analysis, measles vaccination timeliness was borderline significant for the SMS only 
arm and the absolute increase in vaccination coverage was significantly higher in the SMS only 
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arm compared to the Control arm (Tables 4.11 and 4.12). These findings were not borne out in 
the intent-to-treat analysis, suggesting that efficacy in the SMS only arm might have been 
impacted by imperfect delivery of reminders. At the same time the difference in findings in the 
per-protocol versus intent-to-treat analyses may provide some insight into the real-world 
effectiveness of SMS reminders when delivered within a program setting which may experience 
similar or other challenges to sending out reminders strictly as intended. The per-protocol 
analysis did not take into account per-protocol delivery of the incentive for the SMS+150KES 
arm. Only 81 infants in the SMS+150KES arm received both reminders and the incentive per-
protocol. Measles vaccination coverage by age 10 months and age 12 months in this sub-sample, 
77.8% and 83.6%, respectively, was similar to coverage in the analytic per-protocol sample (data 
not shown). Given the small sub-sample size (81 infants) and the similarity of its vaccination 
coverage estimates to the per-protocol sample, regression to obtain RR and RD was not 
performed because the sample size may have been too small to detect any significant differences. 
Additional research is needed to determine whether the timing of the incentive may impact its 
effect.  
 
A related limitation is that only 67.1% and 80.5% of SMS only arm and SMS+150KES arm 
caregivers reported receiving at least one reminder. Further, only 70.5% of SMS+150KES arm 
caregivers reported receiving the incentive. If truly 20% or more participants did not receive the 
interventions, the observed effects would have been biased towards the null. A higher proportion 
of SMS+150KES arm participants receiving the interventions compared to SMS only arm 
participants could explain the differential impact of the interventions on MCV1 timeliness 
(Table 4.13). However, measurement of intervention receipt was susceptible to recall bias as we 
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asked caregivers whether they had received the interventions about three months after they had 
been sent. Beside recall bias, reported receipt of interventions may have been influenced by 
phone ownership, whereby caregivers who owned a phone may have been more likely to receive 
the interventions and to remember having received the intervention compared to who shared the 
phone to which interventions were sent. Because of how the questionnaire was structured, we do 
not know the proportion of caregivers who reported receiving one or more reminder, stratified by 
phone ownership type among all caregivers. But among only caregivers who reported receiving 
one or more reminders, a higher proportion of caregivers who owned a phone reported receiving 
two reminders compared to the proportion of caregivers sharing a phone who reported receiving 
two reminders (Table 4.23). We did not observe differential impact of interventions among 
caregivers who owned a phone versus those who shared a phone (Figures 4.4 and 4.5), 
suggesting that phone ownership impact did not impact receipt of the interventions, but the study 
was not powered to detect sub-group differences. Curiously, the proportion of SMS+150KES 
caregivers who reported receiving SMS reminders was higher than the proportion who reported 
receiving the incentive. This could perhaps be explained if SMS messages were more likely to be 
passed along than the incentive for SMS+150KES caregivers who shared a phone. Indeed, 10 
(27.0%) of 37 SMS+150KES caregivers who reported receiving SMS reminders via a shared 
phone also reported not receiving the incentive (data not shown). We did, however, verify that 
SMS reminders and incentives were sent as one study staff’s phone number was included with in 
all batches of SMS reminders and incentives sent out as a quality control measure;  as such we 




An additional limitation of this study is that CIs, who collected measles vaccination status at the 
follow-up visit, were responsible for assigning the study arm at enrollment and were therefore 
not blinded to study arm allocation. To minimize the risk of outcome ascertainment bias, the 
follow-up questionnaire was structured to collect vaccination data prior to any questions that 
identified the study arm allocation. For CIs to be biased when ascertaining vaccination status, 
they would have had to rely on their memory of the participant’s study arm allocation during the 
enrollment visit, which was conducted four to six months prior to the follow-up visit. Each CI 
enrolled approximately 107 participants and so we think it is unlikely. Nevertheless, the study’s 
Field Supervisor performed repeat interview for approximately 5% of enrolled infants and only 
one discrepancy was identified and resolved by a review of the child’s vaccination status. 
Therefore, we have no evidence of outcome ascertainment bias.  
 
Based on findings from the M-SIMU study, we do not recommend the use of small monetary 
unconditional vaccination incentives in settings with relatively high yet suboptimal MCV1 
vaccination timeliness and coverage. Although large unconditional monetary incentives in some 
social programs within LMICs have been observed to have positive a positive impact on 
vaccination uptake, in this study we found that they had no added benefit on MCV1 timeliness 
over SMS reminders alone and that their non-significant impact on MCV1 overall coverage was 
comparable to the impact of SMS reminders alone, yet the cost of their implementation was 
higher than the cost of SMS reminders alone. Given that SMS reminders are relatively 
inexpensive to implement, we recommend continued evaluation of the impact of SMS reminders, 
particularly in large studies that may be able to detect modest increases in vaccination uptake by 
12 months of age or later.  
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Chapter 4 Tables 
Table 4.1. Content for SMS reminder messages 
  
 3-day reminder 1-day reminder 
Study arm Content Characters Content Characters 
SMS only 
Tell Mama <<infant’s 
name>> that Measles 
vaccine is due this week. 
Most Gem babies get 
vaccinated, be one of 
them! 
114 including spaces; 
count includes up to 17 
characters for the child’s 
name 
Tell Mama <<infant’s 
name>> that Measles 
vaccine is due this week. 
Go to the clinic if you 
haven’t already. Vaccines 
save Kenyan babies lives. 
142 including spaces; 
count includes up to 17 
characters for the child’s 
name 
SMS+150KES 
Tell Mama <<infant’s 
name>> that Measles 
vaccine is due this week. 
We are sending 150ksh to 
assist with travel. Most 
Gem babies get 
vaccinated, be one of 
them! 
159 including spaces; 
count includes up to 17 




Table 4.2. Variables included in analysis of distribution of baseline characteristics across study arms 
 
Characteristic Existing or derived 
variable 
Description  
Mobile phone access Existing Binary: 0= Shares; 1= Owns 
Mobile phone network Derived Binary: 0= Other ; 1= Safaricom 
Participants were asked to select a mobile phone network operator from four 
options (Safaricom, Airtel, Orange, YU or DK). Other vs. Safaricom was used 
because Safaricom commands most of the mobile phone operator market share. 
For example, in the first quarter of 2017 and out of 6 mobile network operators, 
Safaricom operated 71.9% of mobile phone subscriptions and 77.3% of m-
Money transfers80 
Infant’s sex Existing Binary: 0= Female; 1= Male 
Infant’s age at 
enrollment 
Derived Categorical: 0= 6 months; 1= 7 months; 2= 8 months 
Infant’s age at enrollment was calculated by subtracting the infant’s date of 
birth from the date of enrollment. The number of days was divided by 30.42 (in 
the analysis one month = 30.42 days) so as to obtain the number of months. 
Infants whose calculated age was <7 months were categorized as being aged 6 
months at enrollment; those whose calculated age was ≥7 months but <8 
months categorized as being aged 7 months and those with calculated age  ≥8 
months as being aged 8 months.  
Penta3 received before 
enrollment  
Existing Binary: 0= Not vaccinated; 1= Vaccinated 
 
Travel time to health 
facility 
Derived Binary: 0= ≤30 minutes; 1= >30 minutes 
Travel time to health facility was collected as a categorical variable i.e., 0-15 
minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes and >60 minutes. The 
30 minute cutoff was selected because the median category was 16-30 minutes 
(Figure 4.2A). In addition, studies conducted in Uganda and South Africa have 
shown that patients within 30 minutes travel time to a health facility have 
higher levels of HIV care-seeking81 and higher levels of access to healthcare.82 
Maternal education Derived  Binary: 0= ≤7 years; 1= >7 years 
232 
 
Characteristic Existing or derived 
variable 
Description  
Maternal education level was collected in a series of two variables, one 
categorical (Primary, Secondary, Post-secondary or none) and the other 
continuous (Class or form completed). Caregivers selecting no education or 
primary education with class <8 were classified as having ≤7 years of 
education. The cutoff at 7 years was used because primary school education in 
Kenya is 8 years; this cutoff allows distinguishing caregivers with less than 
primary education vs. those with primary education or more. In addition, 7 
years was the median years of maternal education in this sample (Figure 4.2B) 
Birth order  Derived Binary: 0= Firstborn; 1= Later-born 
Birth order was collected as a categorical variable i.e., 1= 1st; 2= 2nd; 3= 3rd; 4= 
4th; 5= 5th; 6= 6th; 7= 7th; and 8= >7th born. Firstborn vs. later-born was used as 
studies in various settings have shown that, compared to later-born children, 
firstborn children are more likely to receive MCV,58 to receive MCV in a 
timely manner,79 as well as to be up-to-date for other vaccines.56,57,79   
Location of last delivery Derived Binary: 0= At home; 1= Health facility 
Location of last delivery was collected as a categorical variable 1= At home 
with no Skilled Birth Attendant (SBA)/ Midwife; 2= At home with 
SBA/Midwife; 3= Health Facility; 4= Don’t know. At home vs. health facility 
was selected because it might reflect caregivers’ health-seeking behavior.  
Maternal age  Derived Binary: 0= ≤25 years; 1= >25 years 
Maternal age was collected as a continuous variable. Age 25 years was selected 
as the cutoff because the median maternal age was 25 years (Figure 4.2C). 
Number of ANC visits 
for enrolled infant 
Derived Binary: 0= ≤4 visits; 1= >4 visits 
Number of ANC visits was collected as a continuous variable. Four visits was 
selected as the cutoff based on the 2002 recommendation from WHO for a 
minimum of four ANC visits.83 The new eight-visit minimum recommended by 
WHO in November 2016 was not used because M-SIMI mothers experienced 
pregnancy prior to issuance of the new guidelines.84 
Socioeconomic quintile  Derived  Binary: 0= Bottom 40%; 1= Upper 60% 
A series of variables to record asset ownership was collected i.e. the number of 
the following items owned by the household was collected: goats, cattle, sheep, 
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Characteristic Existing or derived 
variable 
Description  
poultry, donkey, pigs, plough, foam mattress, spring mattress, straw mattress, 
cell phone, radio, bicycle, sofa, lantern, TV. Using the same method used by the 
KEMRI HDSS to quantify SES, multiple correspondence analysis (MCA) was 
used to generate a SES index. The index was grouped into quintiles. The 
socioeconomic quintile variable was generated by coding the bottom two 
quintiles as being in the bottom 40% and the top three quintiles as being the 
upper 60% of the wealth distribution. The 40% cutoff was selected because 
socioeconomic status was calculated as a five-component index and a 40% 
cutoff was thought to be more likely capture inequitable health care access 
compared to a 20% cutoff. 
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Table 4.3. Baseline characteristics of infants in the analytic sample 
 
Control 
(N = 160) 
SMS only 
(N = 146) 
SMS+150KES 
(N = 149) 
Total 
(N=455) 
 No. (%) No. (%) No. (%) No. (%) 
Mobile phone access     
Shares 49 (30.6) 48 (32.9) 46 (30.9) 143 (31.4) 
Owns 111 (69.4) 98 (67.1) 103 (69.1) 312 (68.6) 
Mobile phone network     
Other 5 (3.1) 4 (2.7) 1 (0.7) 10 (2.2) 
Safaricom 155 (96.9) 142 (97.3) 148 (99.3) 445 (97.8) 
Infant’s sex     
Female 77 (48.1) 70 (47.9) 69 (46.3) 216 (47.5) 
Male 83 (51.9) 76 (52.1) 80 (53.7) 239 (52.5) 
Infant’s age at enrollment     
6m 104 (65.0) 92 (63.0) 96 (64.4) 292 (64.2) 
7m 53 (33.1) 52 (35.6) 51 (34.2) 156 (34.3) 
8m 3 (1.9) 2 (1.4) 2 (1.3) 7 (1.5) 
Penta3 before enrollment  
Not vaccinated 6 (3.8) 7 (4.8) 6 (4.0) 19 (4.2) 
Vaccinated 154 (96.3) 139 (95.2) 143 (96.0) 436 (95.8) 
Time to health facility     
≤30 minutes 110 (68.8) 85 (58.2) 97 (65.1) 292 (64.2) 
>30 minutes 50 (31.3) 61 (41.8) 52 (34.9) 163 (35.8) 
Maternal education     
≤7 years 53 (33.1) 54 (37.0) 49 (32.9) 156 (34.3) 
>7 years 107 (66.9) 92 (63.0) 100 (67.1) 299 (65.7) 
Birth order     
Firstborn 33 (20.6) 31 (21.2) 22 (14.8) 86 (18.9) 
Later-born 127 (79.4) 115 (78.8) 127 (85.2) 369 (81.1) 
Location of last delivery     
At home 30 (18.9) 28 (19.2) 25 (16.8) 83 (18.3) 
Health facility 129 (81.1) 118 (80.8) 124 (83.2) 371 (81.7) 
Maternal age     
≤25 years 80 (50.0) 86 (58.9) 62 (41.6) 228 (50.1) 
>25 years 80 (50.0) 60 (41.1) 87 (58.4) 227 (49.9) 
Number of ANC visits for enrolled infant
≤4 visits 114 (71.3) 99 (67.8) 96 (65.3) 309 (68.2) 
>4 visits 46 (28.7) 47 (32.2) 51 (34.7) 144 (31.8) 
Socioeconomic quintile     
Bottom 40% 72 (45.0) 55 (37.7) 52 (34.9) 179 (39.3) 




Table 4.4. Comparison of the distribution of baseline characteristics among infants in the 




















 No. (%) No. (%) No. (%)  No. (%)  
Mobile phone 
access    
   
Shares 143 (31.4) 7 (29.2) 19 (35.2) 0 26 (31.7) 0.960 
Owns 312 (68.6) 17 (70.8) 35 (64.8) 4 (100) 56 (68.3)  
Mobile phone 
network    
   
Other 10 (2.2) 2 (8.3) 0 0 2 (2.4) 0.892 
Safaricom 445 (97.8) 22 (91.7) 54 (100) 4 (100) 80 (97.6)  
Infant’s sex       
Female 216 (47.5) 9 (37.5) 31 (57.4) 
3 
(75.0) 
43 (52.4) 0.407 
Male 239 (52.5) 15 (62.5) 23 (42.6) 
1 
(25.0) 
39 (47.6)  
Infant’s age at 
enrollment    
   
6m 292 (64.2) 15 (62.5) 32 (59.3) 0 47 (57.3) 0.206 
7m 156 (34.3) 9 (37.5) 22 (40.7) 4 (100) 35 (42.7)  
8m 7 (1.5) 0 0 0 0  
Penta3 before 
enrollment (MCH 
card record only)    
   
Not vaccinated 18 (4.0) 3 (13.0) 3 (5.8) 0 6 (7.6) 0.150 
Vaccinated 437 (96.0) 20 (87.0) 49 (94.2) 4 (100) 73 (92.4)  
Penta3 before 
enrollment (MCH 
card and verbal 
record)    
 
  
Not vaccinated 18 (4.0) 3 (12.5) 3 (5.6) 0 6 (7.3) 0.175 
Vaccinated 437 (96.0) 21 (87.5) 51 (94.4) 4 (100) 76 (92.7)  
Time to health 
facility    
   
≤30 minutes 292 (64.2) 12 (50.0) 36 (66.7) 
2 
(50.0) 
50 (61.0) 0.579 
>30 minutes 163 (35.8) 12 (50.0) 18 (33.3) 
2 
(50.0) 
32 (39.0)  
Maternal education       
≤7 years 156 (34.3) 10 (41.7) 15 (27.8) 
2 
(50.0) 





















 No. (%) No. (%) No. (%)  No. (%)  
>7 years 299 (65.7) 14 (58.3) 39 (72.2) 
2 
(50.0) 
55 (67.1)  
Birth order       
Firstborn 86 (18.9) 7 (29.2) 27 (50.0) 0 34 (41.5) <0.001
Later-born 369 (81.1) 17 (70.8) 27 (50.0) 4 (100) 48 (58.5)  
Location of last 
delivery    
   
At home 83 (18.3) 3 (12.5) 10 (18.5) 0 13 (15.9) 0.598 
Health facility 371 (81.7) 21 (87.5) 44 (81.5) 4 (100) 69 (84.1)  
Maternal age       
≤25 years 228 (50.1) 12 (50.0) 42 (77.8) 
2 
(50.0) 
56 (68.3) 0.002 
>25 years 227 (49.9) 12 (50.0) 12 (22.2) 
2 
(50.0) 
26 (31.7)  
Number of ANC 
visits for enrolled 
infant    
 
  
≤4 visits 309 (68.2) 17 (73.9) 43 (79.6) 4 (100) 64 (79.0) 0.051 
>4 visits 144 (31.8) 6 (26.1) 11 (20.4) 0 17 (21.0)  
Socioeconomic 
quintile    
   
Bottom 40% 179 (39.3) 9 (37.5) 27 (50.0) 0 36 (43.9) 0.438 
Upper 60% 276 (60.7) 15 (62.5) 27 (50.0) 4 (100) 46 (56.1)  
 





Table 4.5. Number and timing of SMS reminders by intervention study arm and overall 
 
 SMS SMS+150KES Total 
SMS delivery N=146 N=149 N=295 
 n (%) n (%) n (%) 
Per-protocol* 126 (86.3) 126 (84.6) 252 (85.4) 
Not per-protocol 20 (13.7) 23 (15.4) 43 (14.6) 
3 reminders sent 0 (0) 2 (8.7) 2 (4.6) 
Reminder before day of appointment not sent 7 (35.0) 7 (30.4) 14 (32.5) 
Reminder three days before appointment not sent 4 (20.0) 7 (30.4) 11 (25.6) 
Second reminder sent on day of appointment 7 (35.0) 6 (26.1) 13 (30.2) 
Reminders sent 2 days before and on day of appointment 1 (5.0) 0 (0) 1 (2.3) 
Reminders sent after appointment date 1 (5.0) 1 (4.3) 2 (4.8) 
 
*Per-protocol SMS delivery = 2 reminders sent, one three days before and the other one day before scheduled vaccination date 
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Table 4.6. Intent-to-treat analysis: Crude and adjusted risk ratios for measles vaccination by age 10 months in intervention arms 
compared to the Control arm 
 





Control (N= 160) 109 (68.1) 
 
 
Ref -- Ref -- 



















Table 4.7. Intent-to-treat analysis: Crude and adjusted risk differences for measles vaccination by age 10 months in intervention arms 
compared to the Control arm 
 





Control (N= 160) 109 (68.1) 
 
 
Ref -- Ref -- 

















Table 4.8. Univariate risk factor analysis for not receiving MCV1 by age 10 months among 
Control children  
 
 MCV1 status   












Owns phone     
No 21 (42.9) 28 (57.1) Ref  
Yes 30 (27.0) 81 (73.0) 1.28 
(0.98, 1.67) 
0.073 
Infant’s sex     
Female 25 (32.5) 52 (67.5) Ref  
Male 26 (31.3) 57 (68.7) 1.02 
(0.82, 1.26) 
0.877 
Infant’s age at enrollment     
6m 38 (36.5) 66 (63.5) Ref  
7-8m 13 (23.2) 43 (76.8) 1.21 
(0.99, 1.49) 
0.068 
Penta3 before enrollment 
(MCH card record only) 
    
No 4 (80.0) 1 (20.0) Ref  
Yes 47 (30.3) 108 (69.7) 3.48 
(0.60, 20.17) 
0.164 
Time to health facility     
≤30 minutes 36 (32.7) 74 (67.3) Ref  
>30 minutes 15 (30.0) 35 (70.0) 1.04 
(0.83, 1.30) 
0.727 
Maternal education     
≤7 years 21 (39.6) 32 (60.4) Ref  
>7 years 30 (28.0) 77 (72.0) 1.19 
(0.93, 1.53) 
0.166 
Birth order     
Firstborn 7 (21.2) 26 (78.8) Ref  
Later-born 44 (34.6) 83 (65.4) 0.83 
(0.67, 1.03) 
0.092 
Location of last delivery     
At home 11 (36.7) 19 (63.3) Ref  
Health facility 40 (31.0) 89 (69.0) 1.09 
(0.81, 1.46) 
  0.571 
Maternal age     
≤25 years 23 (28.7) 57 (71.3) Ref  





 MCV1 status   












Number of ANC visits for 
enrolled infant 
    
≤4 visits 40 (35.1) 74 (64.9) Ref  
>4 visits 11 (23.9) 35 (76.1) 1.17 
(0.95, 1.45) 
0.140 
Socioeconomic quintile     
Bottom 40% 22 (30.6) 50 (69.4) Ref  







Table 4.9. Distribution of timing of incentive payments relative to the scheduled vaccination 
date for SMS+150KES arm participants 
 
When M-PESA sent* Number of participants (%) 
Day -3 91 (61.1)
Day -2 15 (10.1)
Day -1 21 (14.1)
Day 0 18 (12.1)
Day +1 1 (0.7)
Day +8 1 (0.7)
Day +10 1 (0.7)
Day +28 1 (0.7)
Total 149 (100)
 
*Reference point is scheduled vaccination date. For example, Day -3 is three days before 






Table 4.10. Distribution of timing of incentive payments by day of the week 
 
 Actual day when M-PESA sent, relative to the intended date  
Day of week when M-



















Sunday 0 (0) 11 (78.6) 3 (21.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 14 (9.4) 
Monday 29 (96.7) 1 (3.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 30 (20.1) 
Tuesday 17 (73.9) 3 (13.0) 1 (4.4) 0 (0) 0 (0) 0 (0) 1 (4.4) 1 (4.4) 23 (15.4) 
Friday 45 (70.3) 0 (0) 0 (0) 17 (26.6) 1 (1.6) 1 (1.6) 0 (0) 0 (0) 64 (43.0) 
Saturday 0 (0) 0 (0) 17 (94.4) 1 (5.6) 0 (0) 0 (0) 0 (0) 0 (0) 18 (12.1) 







Table 4.11. Per-protocol analysis: Crude and adjusted risk ratios for measles vaccination by age 10 months in intervention arms 
compared to the Control arm 
 





Control (N= 160) 109 (68.1) 
 
 
Ref -- Ref -- 




















Table 4.12. Per-protocol analysis: Crude and adjusted risk differences for measles vaccination by age 10 months in intervention arms 
compared to the Control arm 
 





Control (N= 160) 109 (68.1) 
 
 
Ref -- Ref -- 
SMS only (N= 126) 100 (79.4) 
 




















Table 4.13. Intent-to-treat analysis: Crude and adjusted risk ratios for measles vaccination by age 12 months in intervention arms 
compared to the Control arm  
  





Control (N= 160) 125 (78.1)  
  
Ref -- Ref -- 





















Table 4.14. Intent-to-treat analysis: Crude and adjusted risk differences for measles vaccination by age 12 months in intervention arms 
compared to the Control arm  
 





Control (N= 160) 125 (78.1) 
 
Ref -- Ref -- 





















Table 4.15. Per-protocol analysis: Crude and adjusted risk ratios for measles vaccination by age 12 months in intervention arms 
compared to the Control arm 
 





Control (N= 160) 125 (78.1) 
 
 
Ref -- Ref -- 





0.138   1.08 
(0.97,1.20) 
0.163 











Table 4.16. Per-protocol analysis: Crude and adjusted risk differences for measles vaccination by age 12 months in intervention arms 
compared to the Control arm 
  





Control (N= 160) 125 (78.1) 
 
 
Ref -- Ref -- 
SMS only (N= 126) 107 (84.9) 
 

















































182 0 0        
183 1 0     1 0  
184    0 0  2 0  
185 3 0  2 0     
186    4 0     
187 5 0  6 0  4 0  
188 7 0  11 0  8 0  
189 9 0  12 0  11 0  
190 12 0  15 0  22 0  
191 20 0  20 0  29 0  
192 22 0  28 0  32 0  
193 27 0  34 0  35 0  
194 30 0  41 0  38 0  
195 37 0  42 0  43 0  
196 43 0  44 0  48 0  
197 50 0  49 0  50 0  
198 53 0  52 0  52 0  
199 60 0  56 0  56 0  
200 64 0  60 0  61 0  
201 69 0  64 0  62 0  
202 73 0  69 0  63 0  
203 76 0  72 0  68 0  
































205 82 1 
0.012 
(0.002, 0.083) 74 0  77 0  
206 86 0 
0.012  
(0.002, 0.083) 78 0  81 0  
207 87 0 
0.012  
(0.002, 0.083) 81 0  85 0  
208 89 0 
0.012  
(0.002, 0.083) 84 0  89 0  
209 91 0 
0.012  
(0.002, 0.083) 89 0  91 0  
210 93 0 
0.012  
(0.002, 0.083)    92 0  
211 95 0 
0.012  
(0.002, 0.083)       
212 99 0 
0.012  
(0.002, 0.083) 90 0  94 0  
213 103 0 
0.012  
(0.002, 0.083) 92 0  96 0  
214 104 0 
0.012  
(0.002, 0.083) 94 0  97 0  
215 106 0 
0.012  
(0.002, 0.083)    98 0  
216 111 0 
0.012  
(0.002, 0.083) 98 0  103 0  
217 114 0 
0.012  
(0.002, 0.083) 100 0  105 0  
218 116 0 
0.012  
































219 122 0 
0.012  
(0.002, 0.083) 102 0  109 0  
220 123 0 
0.012  
(0.002, 0.083) 103 1 
0.010  
(0.001, 0.067) 110 0  
221 124 0 
0.012  
(0.002, 0.083) 106 1 
0.019 
 (0.005, 
0.074) 111 0  
222    107 0 
0.019  
(0.005, 0.074) 115 0  
223 125 0 
0.012  
(0.002, 0.083) 110 0 
0.019  
(0.005, 0.074) 117 0  
224 127 0 
0.012  
(0.002, 0.083) 111 0 
0.019 
 (0.005, 
0.074) 119 0  
225 129 0 
0.012  
(0.002, 0.083) 114 0 
0.019  
(0.005, 0.074) 120 0  
226    115 0 
0.019 
 (0.005, 
0.074) 122 0  
227    116 0 
0.019 
 (0.005, 
0.074) 126 0  
228 132 0 
0.012  
(0.002, 0.083) 118 0 
0.019  
(0.005, 0.074) 127 0  
229 134 0 
0.012  
(0.002, 0.083) 121 0 
0.019  
































230 137 0 
0.012  
(0.002, 0.083) 122 0 
0.019 
 (0.005, 
0.074) 135 0  
231 138 0 
0.012  
(0.002, 0.083) 123 0 
0.019 
 (0.005, 
0.074)    
232    127 0 
0.019  
(0.005, 0.074) 136 0  
233 140 0 
0.012  
(0.002, 0.083) 130 0 
0.019  
(0.005, 0.074) 137 0  
234 142 0 
0.012 
 (0.002, 
0.083) 132 0 
0.019  
(0.005, 0.074) 138 0  
235 143 0 
0.012 
 (0.002, 
0.083)       
236 146 0 
0.012  
(0.002, 0.083) 137 0 
0.019  
(0.005, 0.074)    
237 147 0 
0.012  
(0.002, 0.083) 139 0 
0.019  
(0.005, 0.074) 139 0  
238 150 0 
0.012 
 (0.002, 
0.083)       
239 152 0 
0.012 (0.002, 
0.083)    141 0  
240       143 0  
241 153 0 
0.012  
































242       144 0  
243 154 0 
0.012 
(0.002, 0.083)    146 0  
244 156 0 
0.012  
(0.002, 0.083) 142 0 
0.019  
(0.005, 0.074) 147 0  
245 157 0 
0.012  
(0.002, 0.083)       
247       149 1 
0.007  
(0.001, 0.047)
248       148 1 
0.013  
(0.003, 0.053)
251 159 1 
0.018  
(0.004, 0.077)       
253    144 1 
0.026 
 (0.008, 
0.079)    
255    143 1 
0.033  
(0.012, 0.086)    
257    142 1 
0.039  
(0.016, 0.093) 147 2 
0.027  
(0.010, 0.070)




259    141 1 
0.046  
(0.021, 0.101)    
260    140 1 
0.053  


































261 158 1 
0.025  
(0.008, 0.079)       
262 157 1 
0.031  
(0.011, 0.084) 139 1 
0.060  
(0.030, 0.117)    
263 156 2 
0.043  
(0.019, 0.097)    143 1 
0.047  
(0.023, 0.096)
264    138 2 
0.074  
(0.040, 0.133)    
265 154 1 
0.049  
(0.023, 0.104) 136 1 
0.080  
(0.045, 0.141) 142 1 
0.054  
(0.027, 0.104)
266 153 1 
0.056  
(0.028, 0.111)       
267       141 1 
0.060  
(0.032, 0.113)
268 152 1 
0.062  
(0.032, 0.118)    140 1 
0.067  
(0.037, 0.121)
269 151 5 
0.093 
 (0.056, 
0.154)    139 2 
0.081  
(0.047, 0.137)
270 146 2 
0.105 
 (0.065, 
0.168) 135 1 
0.087  
(0.050, 0.149) 137 2 
0.094  
(0.057, 0.153)
271 144 3 
0.124 
 (0.080, 
0.189)    135 3 
0.114  
(0.073, 0.177)
272 141 2 
0.136 
 (0.091, 
0.203) 134 3 
0.108  


































273 139 5 
0.168 
 (0.117, 
0.237) 131 3 
0.128  
(0.083, 0.196) 129 3 
0.154  
(0.105, 0.223)
274 134 8 
0.217  
(0.160, 0.291) 128 10 
0.196  
(0.140, 0.271) 126 9 
0.215  
(0.157, 0.290)
275 126 2 
0.230 
(0.171, 0.304) 118 5 
0.230  




276 124 4 
0.254  
(0.193, 0.331) 113 6 
0.271  




277 120 8 
0.304  
(0.239, 0.383) 107 3 
0.292  




278 112 3 
0.323  
(0.256, 0.402) 104 7 
0.339  
(0.268, 0.423) 97 7 
0.396  
(0.323, 0.479)
279 109 6 
0.360  
(0.291, 0.440) 97 3 
0.360 
 (0.287, 
0.444) 90 2 
0.409  
(0.335, 0.493)
280 103 3 
0.379  
(0.308, 0.459) 94 8 
0.414  
(0.339, 0.499) 88 7 
0.456  
(0.380, 0.540)
281 100 3 
0.397 
 (0.326, 
0.478) 86 4 
0.441  
(0.365, 0.526) 81 6 
0.497  
(0.420, 0.579)
282 97 5 
0.428 
 (0.356, 
0.509) 82 4 
0.469  


































283 92 1 
0.435 
 (0.362, 
0.515) 78 4 
0.496  
(0.418, 0.580) 72 3 
0.537  
(0.459, 0.619)
284 91 6 
0.472  
(0.398, 0.552) 74 3 
0.516  
(0.438, 0.600) 69 2 
0.550  
(0.473, 0.631)
285 85 3 
0.491 
 (0.416, 
0.571) 71 3 
0.537  
(0.458, 0.619) 67 3 
0.570  
(0.493, 0.651)
286 82 7 
0.534  
(0.459, 0.613) 68 2 
0.550  
(0.472, 0.632) 64 2 
0.584  
(0.506, 0.664)
287 75 2 
0.546  
(0.471, 0.625) 66 1 
0.557  
(0.479, 0.639) 62 2 
0.597  
(0.520, 0.676)
288 73 1 
0.553 
 (0.478, 
0.631) 65 2 
0.571  
(0.492, 0.652) 60 2 
0.611  
(0.533, 0.689)
289 72 2 
0.565  
(0.490, 0.643) 63 9 
0.632  
(0.555, 0.710) 58 1 
0.617  
(0.540, 0.695)
290 70 2 
0.578  
(0.502, 0.655) 54 4 
0.659  
(0.583, 0.735) 57 3 
0.638  
(0.561, 0.714)
291 68 1 
0.584 (0.509, 
0.661) 50 2 
0.673  
(0.597, 0.747) 54 2 
0.651  
(0.575, 0.727)
292 67 1 
0.590  
(0.515, 0.667) 48 3 
0.693 
(0.618, 0.766) 52 4 
0.678  
(0.602, 0.751)
293       48 1 
0.685 (0.609, 
0.757) 
294 66 1 
0.596  
(0.521, 0.672) 45 1 
0.700  
































295 65 1 
0.602  
(0.528, 0.678) 44 2 
0.714 
 (0.639, 
0.785) 47 1 
0.691  
(0.616, 0.764)
296 64 4 
0.627 
 (0.553, 
0.702)    46 2 
0.705  
(0.630, 0.776)
297    42 4 
0.741 
 (0.668, 
0.809) 44 2 
0.718  
(0.645, 0.788)
298 60 2 
0.640  
(0.566, 0.713) 38 2 
0.755  
(0.683, 0.821) 42 2 
0.732  
(0.659, 0.800)
299 58 1 
0.646  
(0.572, 0.719) 36 1 
0.762  
(0.690, 0.827) 40 2 
0.745  
(0.673, 0.812)
300 57 2 
0.658 
 (0.585, 
0.731) 35 1 
0.768  
(0.697, 0.833)    
301 55 2 
0.671  
(0.598, 0.742)       
302 53 2 
0.683  
(0.611, 0.754) 34 2 
0.782  
(0.712, 0.845) 38 4 
0.772  
(0.702, 0.835)
303       34 1 
0.779  
(0.709, 0.841)
304    32 1 
0.789  
(0.720, 0.851)    
305 51 1 
0.689  


































306 50 3 
0.708 
 (0.637, 
0.776)       
307    31 1 
0.796  
(0.727, 0.857) 32 2 
0.799  
(0.731, 0.859)
308       30 1 
0.805  
(0.738, 0.864)
309 47 1 
0.714 
 (0.643, 
0.782)    29 1 
0.812  
(0.746, 0.870)
312 46 1 
0.720 
 (0.650, 
0.788)       
313    30 1 
0.802  
(0.735, 0.862)    
315 45 2 
0.733  
(0.663, 0.799)       
316       28 1 
0.819  
(0.753, 0.876)
317    29 1 
0.809  
(0.742, 0.868) 27 1 
0.826  
(0.761, 0.881)
318       26 2 
0.839  
(0.776, 0.893)
319 43 2 
0.745  
(0.676, 0.810) 28 2 
0.823  
(0.757, 0.880)    


































323    26 1 
0.830  
(0.765, 0.885)    
324 41 1 
0.751 
 (0.683, 
0.815) 25 1 
0.837  
(0.772, 0.891)    
325 40 1 
0.758  
(0.689, 0.821)       
332 39 1 
0.764 
 (0.696, 
0.826)       
336 38 1 
0.770 
 (0.703, 
0.832)       
337 37 2 
0.783 
 (0.716, 
0.843)       
340    24 1 
0.843  
(0.780, 0.897)    
364 35 0 
0.783 
 (0.716, 
0.843) 23 0 
0.843  








Table 4.18. Results from unstratified and stratified log-rank tests assessing the equality of failure functions across study arms 
 
Arm Unstratified test, all 
participants 
Maternal age ≤25y 
stratum test 
Maternal age >25y  
stratum test 


















Control 124 141.69 65 75.06 60 66.68 125 141.74 
SMS only 123 117.14 75 73.86 48 45.03 123 118.89 
SMS+150KES 126 115.17 54 45.08 72 68.29 126 113.37 






Table 4.19. Sensitivity analysis: Cumulative failure functions for measles vaccination by age 12 months. Time origin is intervention 































271 144 3 
0.021 
(0.007, 0.063)    135 3 
0.022 
(0.007, 0.067)
272 141 2 
0.035  
(0.015, 0.081) 134 3 
0.022  
(0.007, 0.068) 132 3 
0.044  
(0.020, 0.096)
273 139 5 
0.069  
(0.038, 0.125) 131 3 
0.045  
(0.020, 0.097) 129 3 
0.067  
(0.035, 0.124)
274 134 8 
0.125  
(0.081, 0.191) 128 10 
0.119  
(0.075, 0.187) 126 9 
0.133  
(0.086, 0.203)
275 126 2 
0.139  
(0.092, 0.207) 118 5 
0.157  
(0.105, 0.230) 117 7 
0.185  
(0.129, 0.262)
276 124 4 
0.167  
(0.115, 0.238) 113 6 
0.201  
(0.143, 0.280) 110 6 
0.230  
(0.167, 0.310)
277 120 8 
0.222  
(0.163, 0.299) 107 3 
0.224  
(0.162, 0.304) 104 7 
0.281  
(0.214, 0.366)
278 112 3 
0.243  
(0.181, 0.322) 104 7 
0.276  
(0.208, 0.360) 97 7 
0.333  
(0.261, 0.420)
279 109 6 
0.285  
(0.218, 0.366) 97 3 
0.299 
 (0.229, 
0.384) 90 2 
0.348  
(0.274, 0.435)
280 103 3 
0.306  
(0.237, 0.388) 94 8 
0.358  
(0.284, 0.446) 88 7 
0.400  
(0.323, 0.488)
281 100 3 
0.326  
(0.256, 0.410) 86 4 
0.388  
(0.311, 0.476) 81 6 
0.444  
(0.365, 0.532)
282 97 5 
0.361  
(0.289, 0.445) 82 4 
0.418  


































283 92 1 
0.368  
(0.295, 0.452) 78 4 
0.448  
(0.368, 0.536) 72 3 
0.489  
(0.408, 0.576)
284 91 6 
0.410  
(0.335, 0.495) 74 3 
0.470  
(0.390, 0.558) 69 2 
0.504  
(0.423, 0.591)
285 85 3 
0.431  
(0.354, 0.515) 71 3 
0.493  
(0.412, 0.580) 67 3 
0.526  
(0.445, 0.612)
286 82 7 
0.479  
(0.401, 0.564) 68 2 
0.507  
(0.426, 0.595) 64 2 
0.541  
(0.459, 0.626)
287 75 2 
0.493 
 (0.415, 
0.577) 66 1 
0.515  
(0.434, 0.602) 62 2 
0.556  
(0.474, 0.641)
288 73 1 
0.500  
(0.422, 0.584) 65 2 
0.530  
(0.448, 0.616) 60 2 
0.570  
(0.489, 0.655)
289 72 2 
0.514  
(0.435, 0.598) 63 9 
0.597  
(0.515, 0.680) 58 1 
0.578  
(0.496, 0.662)
290 70 2 
0.528  
(0.449, 0.611) 54 4 
0.627  
(0.546, 0.708) 57 3 
0.600  
(0.519, 0.683)
291 68 1 
0.535  
(0.456, 0.618) 50 2 
0.642  
(0.561, 0.722) 54 2 
0.615  
(0.534, 0.697)
292 67 1 
0.542  
(0.463, 0.625) 48 3 
0.664  
(0.584, 0.743) 52 4 
0.644  
(0.564, 0.724)
293       48 1 
0.652 (0.572, 
0.731) 
294 66 1 
0.549  
(0.470, 0.631) 45 1 
0.672  
(0.592, 0.749)    
295 65 1 
0.556  
(0.477, 0.638) 44 2 
0.687  


































296 64 4 
0.583  
(0.504, 0.664)    46 2 
0.674  
(0.595, 0.751)
297    42 4 
0.716  
(0.639, 0.790) 44 2 
0.689  
(0.610, 0.765)
298 60 2 
0.597  
(0.518, 0.678) 38 2 
0.731  
(0.654, 0.803) 42 2 
0.704  
(0.626, 0.778)
299 58 1 
0.604  
(0.525, 0.684) 36 1 
0.739  
(0.662, 0.810) 40 2 
0.719  
(0.641, 0.792)
300 57 2 
0.618  
(0.540, 0.697) 35 1 
0.746  
(0.670, 0.816)    
301 55 2 
0.632  
(0.554, 0.710)       
302 53 2 
0.646  
(0.568, 0.723) 34 2 
0.761  
(0.686, 0.829) 38 4 
0.748  
(0.673, 0.818)
303       34 1 
0.756  
(0.681, 0.824)
304    32 1 
0.769  
(0.694, 0.836)    
305 51 1 
0.653  
(0.575, 0.729)    33 1 
0.763  
(0.689, 0.831)
306 50 3 
0.674 (0.597, 
0.749)       
307    31 1 
0.776  
(0.703, 0.842) 32 2 
0.778  
(0.705, 0.844)
308       30 1 
0.785 (0.713, 
0.850) 
309 47 1 
0.681  


































312 46 1 
0.688  
(0.611, 0.761)       
313    30 1 
0.784  
(0.711, 0.849)    
315 45 2 
0.701  
(0.626, 0.774)       
316       28 1 
0.800  
(0.729, 0.863)
317    29 1 
0.791  
(0.719, 0.855) 27 1 
0.807  
(0.737, 0.869)
318       26 2 
0.822  
(0.753, 0.881)
319 43 2 
0.715  
(0.640, 0.786) 28 2 
0.806  
(0.735, 0.868)    
322       24 1 
0.830  
(0.762, 0.887)
323    26 1 
0.813  
(0.743, 0.874)    
324 41 1 
0.722  
(0.648, 0.793) 25 1 
0.821  
(0.752, 0.880)    
325 40 1 
0.729  
(0.655, 0.799)       
332 39 1 
0.736  
(0.662, 0.805)       
336 38 1 
0.743  
(0.670, 0.811)       
337 37 2 
0.757  
































340    24 1 
0.828  
(0.760, 0.887)    
364 35 0 
0.757  
(0.685, 0.824) 23 0 
0.828  








Table 4.20. Sensitivity analysis: Results from unstratified and stratified log-rank tests assessing the equality of failure functions across 
study arms 
 
Arm Unstratified test, all 
participants 
Maternal age ≤25y 
stratum test 
Maternal age >25y  
stratum test 


















Control 109 126.78 58 68.71 51 58.10 109 126.81 
SMS only 111 103.80 70 67.15 41 38.78 111 105.94 
SMS+150KES 112 101.42 48 40.13 64 59.12 112 99.25 





Table 4.21. Number of days undervaccinated by study arm for all infants and only undervaccinated infants 
 
All infants






Mean (SE) 14.9 (2.0) 10.5 (1.8) 0.108 10.1 (1.8) 0.071 
Median (Q1, Q3) 0 (0, 21.5) 0 (0, 0) N/A 0 (0, 0) N/A 
Undervaccinated infants only 
Days undervaccinated Control  (N= 51) 
SMS only  
(N= 32) 
p-value* SMS+150KES  
(N= 33) 
p-value* 
Mean (SE) 46.9 (3.1) 48.2 (3.8) 0.788 45.5 (4.2) 0.788 
Median (Q1, Q3) 61 (29, 61) 61 (29, 61) N/A 61 (15, 61) N/A 
1-7 days, n infants (%) 5 (9.8) 2 (6.3) N/A 5 (15.2) N/A 
8-14 days, n infants (%) 3 (5.8) 2 (6.3) N/A 2 (6.1) N/A 
15-21 days, n infants (%) 3 (5.8) 4 (12.5) N/A 3 (9.1) N/A 
22-35 days, n infants (%) 5 (9.8) 0 N/A 0 N/A 
37 days, n infants (%) 0 1 (3.1) N/A 0 N/A 
61 days, n infants (%) 35 (68.6) 23 (71.9) N/A 23 (69.7) N/A 
 
Abbreviations: SE = standard error; Q1 = first quartile; Q3= third quartile; N/A = not applicable 
*p-value from two-sided t-test 
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Not vaccinated by age 10 
months 
51 (31.9%) 32 (21.9%) 33 (22.2%) 116 (25.5%) 
Reason for delay queried 41 (80.4%) 29 (90.6%) 25 (75.8%) 95 (81.9%)
Reason for delay Control  
(N = 41) 
n (%) 









Nurses' strike 12 (29.3) 13 (44.8) 9 (36.0) 34 (35.8) 
Vaccine not in stock 6 (14.6) 4 (13.8) 5 (20.0) 15 (15.8) 
Child was ill 4 (9.8) 2 (6.9) 2 (8.0) 8 (8.4) 
Reason not given 1 (2.4) 4 (13.8) 2 (8.0) 7 (7.4) 
Travelling 4 (9.8) 2 (6.9) 1 (4.0) 7 (7.4) 
Not recorded in MCH 
booklet 5 (12.2) 0 (0) 1 (4.0) 6 (6.3) 
Didn't know date 3 (7.3) 0 (0) 2 (8.0) 5 (5.3) 
Nurse refused to open vial 2 (4.9) 0 (0) 1 (4.0) 3 (3.2) 
Forgot 1 (2.4) 1 (3.4) 0 (0) 2 (2.1) 
Competing priorities 1 (2.4) 1 (3.4) 0 (0) 2 (2.1) 
Clinic too far 0 (0) 0 (0) 1 (4.0) 1 (1.1) 
Previous vaccine delayed 1 (2.4) 0 (0) 0 (0) 1 (1.1) 
Vaccine not important 0 (0) 0 (0) 1 (4.0) 1 (1.1) 
Forgot MCH booklet 0 (0) 1 (3.4) 0 (0) 1 (1.1) 
Discouraged by friend 1 (2.4) 0 (0) 0 (0) 1 (1.1) 




Table 4.23. Caregivers’ reported receipt of SMS reminders 
 













n (%) p-value 
Received ≥1 SMS reminder 98 (67.1) 66 (67.4) 32 (32.7) -* 120 (80.5) 82 (68.3) 38 (31.7) -* 














Received three reminders 1 (l.0) 1 (1.5) 0 (0) 0.484 2 (1.7) 2 (2.4) 0 (0) 0.332
Don’t know 5 (5.1) 0 (0) 5 (15.6) 0.001 3 (2.5) 0 (0) 3 (7.9) 0.010
 
*p-value not calculated as ownership of phone number to which reminder was sent was only collected for participants who reported 
that they received a reminder; there is no corresponding data on phone ownership for participants who reported that they did not 
receive any reminders 
271 
 







 n (%) n (%) 
SMS influenced decision to 
vaccinate 88 (89.8) 110 (91.7) 
Received MCV1 by age 12 months 80 (90.9) 96 (87.3) 
Number of SMS reminders   
Too few 8 (8.2) 15 (12.5) 
Just right 80 (81.6) 94 (78.3) 
Shared mobile phone 7 (7.1) 9 (7.5) 
Don't know 3 (3.1) 2 (1.7) 
Length of SMS reminders   
Too short 0 (0) 1 (0.8) 
Right length 88 (89.8) 106 (88.3) 
Shared mobile phone 8 (8.2) 13 (10.8) 









 n (%) 
Received MCV1 incentive 105 (70.5) 
Owned phone 76 (72.4) 
Incentive influenced decision to vaccinate 88 (83.8) 
Received MCV1 by age 12 months 78 (88.6) 
Mobile money cashed out  
Day when received 16 (15.2) 
Within 1-3 days of receipt 67 (63.8) 
More than 3 days after receipt 20 (19.0) 
Not cashed out 2 (1.9) 
Experience receiving incentive  
Very positive 98 (93.3) 
Somewhat positive 2 (1.9) 
Neutral 4 (3.8) 
Very negative 1 (1.0) 
Likelihood of future vaccination in the absence of incentive  
More likely 95 (90.5) 
Less likely 1 (1.0) 
The same 8 (7.6) 
Don't know 1 (1.0) 
M-PESA use  
Transport cost 59 (56.2) 
Housing expenses 21 (20.0) 
Food 16 (15.2) 
Airtime 1 (1.0) 
Medicine 5 (4.8) 
Infant's clothing 2 (1.9) 




Table 4.26. Adjusted risk ratio and risk difference for measles vaccination by age 12 months in the interventions (combined) 
compared to the Control arm  
  





Control (N= 160) 125 (78.1) 
 
Ref -- Ref -- 
SMS only & 
SMS+150KES (N= 295) 












Chapter 4 Figures 






Formula component Calculation or value 
n* Continuity-corrected sample size. Formula as above 
 
















Proportion in control group = 0.70 
P2 
 









Figure 4.2A. Distribution of travel time to the nearest clinic in M-SIMI households 
 
Minimum 0-15 minutes 
Maximum >60 minutes 
25th percentile 0-15 minutes 
Median 16-30 minutes 






























Figure 4.2B. Distribution of maternal education in years* 
 
Minimum 1 year 
Maximum 12 years 
25th percentile 5 years 
Median 7 years 
75th percentile 8 years 
 















































 Figure 4.3. Screening, enrollment and follow-up flow diagram for the M-SIMI study 
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Figure 4.4 Sub-group analysis of the impact of SMS reminders with or without KES 
150incentive on MCV1 timely coverage, by study arm, without adjustment for maternal age 
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4.4[B]. SMS+150KES vs. Control 
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Figure 4.5. Sub-group analysis of the impact of SMS reminders with or without KES 150 
incentive on MCV1 timely coverage, by study arm, adjusted for maternal age 
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4.5[B]. SMS+150KES vs. Control 
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Figure 4.6. Cumulative incidence of measles vaccination by age 12m since enrollment. Time 


































Figure 4.7. Sensitivity analysis: Cumulative incidence of measles vaccination by age 12m since 













































Figure 4.8. Pooled relative risk of measles vaccination comparing the effect of SMS reminders compared to no SMS reminders in the 





MCV1 by age 10m
M-SIMU, Gibson 2017
M-SIMI, Unpublished 2018
Subtotal  (I-squared = 0.0%, p = 0.682)
MCV1 by age 12m
M-SIMU, Gibson 2017
M-SIMI, Unpublished 2018
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Figure 4.9. Pooled relative risk of measles vaccination comparing the effect of SMS reminders coupled with an unconditional KES 





MCV1 by age 10m
M-SIMU, Gibson 2017
M-SIMI, Unpublished 2018
Subtotal  (I-squared = 76.0%, p = 0.041)
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M-SIMI, Unpublished 2018
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CHAPTER 5: A POST-TRIAL FOLLOW-UP STUDY TO EVALUATE 
THE IMPACT OF SHORT-TERM TEXT MESSAGE REMINDERS 
WITH OR WITHOUT CONDITIONAL MONETARY INCENTIVES 






In the context of stagnant measles vaccination coverage in low- and middle-income settings, 
short message service (SMS or text message) reminders and monetary incentives have the 
potential to generate more demand for vaccination. The M-SIMU study, a cluster randomized 
controlled study conducted in Kenya showed that SMS vaccination reminders alone or when 
coupled with small monetary incentives significantly improved first dose measles vaccination 
timeliness. In addition, SMS vaccination reminders coupled with the higher of two incentive 
amounts significantly improved measles vaccination coverage. SMS vaccination reminders and 
incentives were withdrawn were withdrawn subsequent to study completion. The long-term 
impact of short-term SMS vaccination reminders and incentives has not been previously studied. 
We conducted an evaluation to assess caregivers’ vaccine-seeking practices after withdrawal of 
M-SIMU interventions.  
Methods 
We conducted an observational post-trial follow-up study – The M-SIMU Subsequent Born 
Child study (MSBC) – to collect data on vaccination among children born to M-SIMU 
caregivers after the M-SIMU study (i.e., subsequent children; SC) and also second-dose measles-
containing vaccine (MCV2) status among M-SIMU children. Because we followed-up M-SIMU 
families, the study setting for the MSBC study was the same as that of the M-SIMU study i.e., 
the Kenya Medical Research Institute Health and Demographic Surveillance System in Gem and 
Rarieda (Asembo area) sub-counties, Siaya County. Study Community Interviewers (CIs) visited 
M-SIMU households and performed screening to ascertain eligibility criteria. We collected 
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sociodemographic status, vaccination status of the SC, and MCV2 status of the M-SIMU child 
from enrolled infant-caregiver pairs. During the M-SIMU study caregivers were randomized to 
receive either SMS vaccination reminders plus 200 Kenya Shillings (KES) incentives (SMS+200 
KES), SMS reminders plus 75 KES incentives (SMS+75KES), SMS reminders only (SMS only) 
or no interventions (Control). The primary objective was to assess whether first dose measles-
containing vaccine (MCV1) timely coverage, i.e., the proportion of children vaccinated at or 
before age 9 months and 2 weeks (9m+2w) was significantly different among SC of 
SMS+200KES caregivers compared to SC of Control caregivers. As a secondary objective, the 
difference in MCV1 timely coverage among SMS+75KES SC and SMS only SC compared to 
Control SC was assessed. Additional secondary objectives were to assess differences in MCV1 
uptake by age 12 months (MCV1 overall coverage) and third dose pentavalent vaccine 
(diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b; pentavalent 3) 
coverage at age 16 weeks or earlier (pentavalent 3 timely coverage) among SMS+200KES SC, 
SMS+75KES SC, and SMS only SC compared to Control SC. A final secondary objective was to 
compare MCV2 coverage by age 24 months among intervention M-SIMU children compared to 
Control M-SIMU children. Binomial regression with generalized estimating equations and robust 
error variance were performed to estimate risk differences (RD) and associated 95% confidence 
intervals (95% CI) with accounting for clustering. Poisson regression was used where binomial 
models failed to converge. Regression models adjusted for unequally distributed characteristics 
at MSBC enrollment or at M-SIMU baseline. Regression models included an interaction term 
between time (during M-SIMU vs. after M-SIMU) and the caregiver’s M-SIMU study arm to 
allow for estimation of risk difference-in-differences (DIDs). DIDs represented the absolute 
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effect of the removal of M-SIMU interventions on vaccination uptake after accounting for 
secular trends.  
Results 
Of 1,599 M-SIMU households, 1,467 were contacted of which 218 were eligible for enrollment 
in the MSBC study, i.e., 44, 60, 56 and 58 Control, SMS only, SMS+75KES and SMS+200KES 
households, respectively. MCV1 timely coverage was, 58.1% (25/43), 49.2% (29/59), 38.2% 
(21/55) and 40.7% (24/59) among Control SC, SMS only SC, SMS+75KES SC and 
SMS+200KES SC, respectively. During the M-SIMU study, MCV1 timely coverage was 60.5% 
(26/43), 61.0% (36/59), 60.0% (33/55) and 67.2% (39/58) among Control, SMS only, 
SMS+75KES and SMS+200KES M-SIMU children, respectively.  
MCV1 timely coverage among children of SMS+200KES caregivers was non-significantly lower 
by 25.2% after withdrawal of M-SIMU interventions compared to during the M-SIMU study, 
i.e., MCV1 timely coverage in SMS+200KES SC compared to SMS+200KES M-SIMU children 
(DID 95% CI: -55.3%, 4.8%; p= 0.099) resulting in 18.1% lower MCV1 timely coverage among 
SMS+200KES SC compared to Control SC though this difference was not statistically 
significant (adjusted RD [aRD] 95% CI: -39.3%, 3.1%; p= 0.095). After withdrawal of M-SIMU 
interventions, MCV1 timely coverage was non-significantly lower by 21.3% among children of 
SMS+75KES caregivers (DID 95% CI: -47.4%, 4.8%; p= 0.110) and by 11.2% among children 
of SMS only caregivers (DID 95% CI: -36.1%, 13.7%; p= 0.376) compared to during the M-
SIMU study. These decreases translated to significantly lower MCV1 timely coverage among 
SMS+75KES SC (aRD -21.7%; 95% CI: -41.9%, -1.6%; p= 0.035) and non-significantly lower 
MCV1 timely coverage among SMS SC (aRD -11.5%; 95% CI: -32.8%, 9.8%; p= 0.290) as 
compared to Control SC.     
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MCV1 overall coverage among Control SC, SMS only SC, SMS+75KES SC and SMS+200KES 
SC was 84.4% (27/32), 76.9% (40/52), 63.6% (28/44) and 60.9% (28/46), respectively, 
compared to 84.4% (27/32), 90.4% (47/52), 75.0% ( 33/44) and 87.0% (40/46) among Control, 
SMS only, SMS+75KES and SMS+200KES M-SIMU children. MCV1 overall coverage was not 
significantly lower among children of SMS+200KES caregivers (DID -24.5%; 95% CI: -50.9%, 
2.0%; p= 0.070), SMS+75KES (DID -8.6%; 95% CI: -32.0%, 14.9%; p= 0.473) caregivers or 
SMS only caregivers (DID -10.4%; 95% CI: -29.8%, 9.0%: p= 0.295) after the M-SIMU study 
compared to during the M-SIMU study. Compared to Control SC, MCV1 overall coverage was 
20.8% lower and 6.2% lower among SMS+200KES SC and SMS only SC, respectively, 
however these differences were not significant (SMS+200KES aRD 95% CI: -42.1%, 0.6%; p= 
0.057 and SMS only aRD 95% CI: -22.2%, 9.8%: p= 0.451). MCV1 overall coverage was 
significantly lower by 18.4% among SMS+75KES SC compared to Control SC (aRD 95% CI: -
36.2%, -0.5%; p= 0.044).  
Pentavalent 3 timely coverage among Control SC, SMS only SC, SMS+75KES SC and 
SMS+200KES SC was 70.5% (31/44), 70.0% (42/60), 62.5% (35/56) and 56.9% (33/58), 
respectively; this was not statistically significantly lower among intervention SC compared to 
Control SC nor after the M-SIMU study compared to during the M-SIMU study (all p> 0.05). 
MCV2 coverage by age 24 months was 52.8% (19/36), 31.1% (14/45), 20.5% (8/39) and 25.6% 
(11/43) among Control, SMS only, SMS+75KES and SMS+200KES M-SIMU children 
respectively. The likelihood of receiving MCV2 by age 24 months was significantly lower 
among SMS+200KES M-SIMU children compared to Control M-SIMU children (adjusted RR 
0.53; 95% CI: 0.30, 0.96; p= 0.035) as was the likelihood among SMS+75KES M-SIMU 
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children compared to M-SIMU Control children (adjusted RR 0.42; 95% CI: 0.20, 0.86; p= 
0.019).  
Conclusions 
These findings suggest lower MCV-seeking after withdrawal of SMS reminders alone or coupled 
with incentives among caregivers who previously received these interventions. Despite 
differences in MCV1 timely and overall coverage being significant only among subsequent 
children of SMS+75KES caregivers compared to those of Control caregivers, these results point 
to decreased MCV-seeking after withdrawal of SMS reminders alone or coupled with small 
monetary incentives. There were substantial reductions in MCV1 timely and overall coverage 
after the M-SIMU study, substantial differences in MCV1 timely and overall coverage in 
SMS+200KES SC and SMS only SC compared to Control SC as well as significant reductions in 
MCV2 coverage among SMS plus incentive children. However, these findings should not be 
generalized to the entire M-SIMU sample as MSBC households may not be representative. 
Follow-up of more M-SIMU households is recommended to clarify M-SIMU caregivers’ 
vaccine-seeking practices after withdrawal of M-SIMU interventions. Long-term follow-up for 
other health-related interventions, particularly those including monetary incentives, is 
recommended.  
Funding 





Measles is a leading global cause of child morbidity and mortality, yet first and second dose 
measles-containing vaccine (MCV1; MCV2) coverage levels at the global level and in most low- 
and middle-income countries (LMICs), including Kenya, remain stagnant and are below 90-95%, 
the coverage required to interrupt measles transmission.1,2 Innovative demand-side solutions to 
improve measles vaccination uptake in LMICs can jump-start stagnant vaccination uptake and 
assist in achievement of Sustainable Development Goal (SDG) 3, among other SDGs.3–5  
 
The M-SIMU study, a cluster randomized controlled study conducted in Kenya, evaluated the 
impact of two innovative demand-side interventions, short message service (SMS) vaccination 
reminders and small monetary incentives on vaccination timeliness and coverage.6 Although not 
the first study to assess the impact of SMS reminders or incentives on vaccination uptake in a 
LMIC,7–19 the M-SIMU trial was the first to examine the combined effect of SMS reminders and 
monetary incentives. The M-SIMU study found that: SMS reminders coupled with the higher of 
two incentive amounts significantly improved the proportion of infants receiving third dose 
pentavalent vaccine (diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type 
b;  pentavalent 3) at age ≤16 weeks (i.e., pentavalent 3 timely coverage); SMS reminders with or 
without incentives significantly improved the proportion of infants receiving MCV1 at age ≤9 
months and 2 weeks (MCV1 timely coverage); and that SMS reminders coupled with the higher 
of two incentive amounts significantly improved MCV1 coverage by age 12 months (MCV1 




M-SIMU interventions were intended to act as nudges to encourage caregivers to seek 
vaccination for their children. We expected that vaccine-seeking among caregivers who 
participated in the M-SIMU study would be sustained at M-SIMU levels in the period after the 
M-SIMU study, or that if vaccine-seeking declined in the absence of M-SIMU interventions it 
would not fall below pre-M-SIMU levels. However, some stakeholders expressed concern that 
exposing caregivers to M-SIMU interventions would result in decreased coverage once the 
incentives were withdrawn.  
 
The use of monetary incentives to promote behavior change, as was explored for vaccine-seeking 
in the M-SIMU study, is contentious. At the community level, some feel that incentives reward 
negative health behaviors.20–22 At the same time, behavioral economists have theorized that 
incentives, which are extrinsic motivators, may “crowd-out” intrinsic motivation to practice the 
behavior that is being incentivized. As such, in the absence of incentives, practice of the target 
behavior falls below pre-incentive levels. Crowding-out has been demonstrated for some non-
health behaviors whereby the incentivized behavior is not practiced at pre-incentive levels after 
the incentive is withdrawn.23–25 With regard to incentives for health-related behaviors no studies 
have demonstrated that incentives crowd-out intrinsic motivation.26 Despite the absence of 
evidence that incentives crowd-out intrinsic motivation to engage in positive health behaviors, 
and the relatively high vaccination coverage levels in the study area and in the control arm, we 
took seriously stakeholders’ concern that exposing caregivers to the M-SIMU interventions 




To evaluate vaccine seeking after withdrawal of M-SIMU interventions, we conducted a post-
trial follow-up study (The M-SIMU Subsequent Born Child study; MSBC) of vaccination uptake 
in the period after the M-SIMU study among subsequent children born to caregivers previously 
enrolled in the M-SIMU study as well among M-SIMU children. To our knowledge, there is no 





5.3.1. Study design and setting 
The MBSC study was an observational post-trial follow-up study of parental vaccine-seeking 
behavior after participation in the M-SIMU study. The M-SIMU study was a cluster-randomized 
controlled trial conducted in Gem and Rarieda sub-counties, Siaya County, Kenya in 2013-2015. 
The M-SIMU study evaluated the impact SMS reminders alone or coupled with KES 75 (~US 
$0.88 in August 2015) or KES 200 (~US $2.35 in August 2015) mobile phone-delivered 
incentives on vaccination coverage and timeliness. The M-SIMU study enrolled caregivers and 
infants aged 0-4 weeks from 152 within the Kenya Medical Research Institute (KEMRI) Health 
and Demographic Surveillance System (HDSS).27  Participants were randomized at the village 
level to either the Control arm, SMS only arm, SMS plus 75KES arm (SMS+75KES) or SMS 
plus 200KES (SMS+200KES) arm. Caregivers received two SMS reminders and one incentive 
for each of the following vaccine doses: first to third dose pentavalent (diphtheria, tetanus, 
pertussis, hepatitis B and Haemophilus type b) vaccines and first dose measles-containing 
vaccine (MCV1). The M-SIMU study and results have been described in detail elsewhere.6,28  
 
Because we followed-up M-SIMU families, the study setting for the MSBC study was the same 
as that of the M-SIMU study i.e., the KEMRI HDSS in Gem and Rarieda (Asembo area) sub-
counties, Siaya County.6 The study setting has been described in detail in Chapter 2. In short, 
Gem and Rarieda sub-counties are mainly rural areas characterized by high infant mortality, high 
prevalence of HIV, tuberculosis and malaria and contrastingly, high coverage with the 
Pentavalent vaccine series.6,27,29 The MSBC study leveraged the M-SIMU randomized controlled 
trial design to compare measles vaccination timeliness and coverage among children born to M-
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SIMU intervention arm caregivers after the M-SIMU study to vaccination coverage and 
timeliness among children subsequently born to M-SIMU Control arm caregivers.   
 
The study is reported following ‘Strengthening the Reporting of Observational Studies in 
Epidemiology’ (STROBE) guidelines.30 
 
5.3.2. Participants and procedures 
The 1,599 M-SIMU caregivers included in the M-SIMU primary analysis6 were identified from 
M-SIMU study records. Using the caregiver’s last known contact information, study-employed 
Community Interviewers (CIs) located M-SIMU caregivers and conducted a household visit. At 
the household visit, CIs explained the MSBC study and evaluated eligibility for caregivers 
willing to undergo screening. M-SIMU caregivers were eligible to enroll in the MSBC study if: 
the vaccination status of the child enrolled in the M-SIMU (M-SIMU child) study was verified 
using the maternal and child health (MCH) booklet at age 12 months; the M-SIMU child had an 
immediate younger sibling (i.e., subsequent born child) aged at least 10 months old; and the 
vaccination status of the subsequent child (SC) could be verified via MCH booklet. Enrollment 
was restricted to caregivers whose SC had MCH booklets because as in the M-SIMU study, 
vaccination status as recorded in the MCH booklet was considered more reliable than caregivers’ 
verbal report only.6 In addition, caregivers were excluded from the MSBC study if they were 
currently or previously enrolled in the M-SIMI study. The M-SIMI study was a randomized 
controlled trial investigating the impact of SMS reminders with or without unconditional 
incentives on first dose measles vaccine uptake. This study is described in detail in Chapter 3 
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and it coincided with the MSBC study. Caregivers enrolled in the M-SIMI study were excluded 
from the MSBC study as the MSBC study sought to evaluate vaccine-seeking behavior of 
caregivers who had not been exposed to SMS reminders or incentives for vaccination since the 
M-SIMU study. Caregivers meeting eligibility criteria were enrolled into the MSBC study after 
providing informed consent. In the event that a SC had not reached age 10 months, CIs requested 
to revisit the household when the SC achieved 10 months of age.  
 
CIs administered a questionnaire to enrolled caregivers to collect demographic data on the SC 
including, sex, date of birth and birth order, as well as the caregiver’s demographic information 
such as date of birth and educational attainment. CIs also collected the vaccination history of the 
SC, second-dose measles vaccination status of the M-SIMU child and health-seeking behavior of 
the caregiver including the number of antenatal care (ANC) visits undertaken for the SC and 
whether the SC was delivered in a health facility. Finally, caregivers were asked about other 
potential influences of vaccine-seeking behavior such as whether they received vaccination 
reminders or participated in studies evaluating interventions to improve vaccination uptake after 
their participation in the M-SIMU study. SC’s vaccination status and dates of birth were 
recorded from the MCH booklet, otherwise all other data were self-reported. CIs collected these 
data using smartphones which had the electronic study questionnaire loaded through the Open 
Data Kit open-source platform.31 The MSBC screening form, questionnaire and consent forms 




The MSBC received ethical approval from the Kenya Medical Research Institute (KEMRI) 
Scientific and Ethics Review Unit (KEMRI/SERU/CGHR/092/3456). The study was not 
reviewed by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board 
as it was determined to be under the jurisdiction of KEMRI SERU. 
   
5.3.3. Variables and data sources 
5.3.3.1. Outcomes 
The primary objective of the study was to determine if timely measles vaccination coverage 
differed significantly among SC of M-SIMU SMS+200KES arm caregivers compared to SC of 
M-SIMU Control arm caregivers. Thus, the primary outcome was the proportion of SC who had 
received first dose measles-containing vaccine (MCV1) at age 9 months and 2 weeks (9m+2w) 
or younger. Secondary outcomes included the proportion of SC receiving MCV1 by age 12 
months, the proportion of SC receiving the third dose of pentavalent vaccine (pentavalent 3) at 
age 16 weeks or younger, and the proportion of M-SIMU children receiving the second dose of 
measles-containing vaccine (MCV2) at or before age 24 months.  
 
Children were determined to be vaccinated if a vaccination date was entered in the MCH 
booklet. The age of vaccination was calculated as the documented vaccination date minus the 
child’s date of birth as documented in the MCH booklet. In calculations, one month was 
equivalent to 30.42 days and to assess if children met the time cutoff, the age in days was 
rounded off to the nearest integer. For all proportions, the denominator was the number of infants 




SC met the primary outcome definition if they received measles vaccination at or before age 288 
days and so the proportion of SC receiving MCV1 by age 9m+2w was calculated as follows: 
 
	 	 	 288	 	 	 	 	 	 	 	 288	
	 	 	 288	
 
 
SC were considered to have received measles vaccination by age 12 months if measles vaccine 
was received at ≤364 days of age, thus the secondary outcome, proportion of SC receiving 
measles vaccine by age 12 months was calculated as below: 
 	
	 	 	 364	 	 	 	 	 	 	 	 364	
	 	 	 364	
 
 
For the secondary outcome, proportion of SC receiving Penta3 at age ≤16 weeks, SC were 
considered to have achieved the outcome if they were age ≤112 days at the time of Penta3 
vaccination. Therefore, this secondary outcome was calculated as:  
 
	 	 	 112	 	 	 	 3	 	 	 112	





Finally, M-SIMU infants who received MCV2 before age 730 days were considered to have 
received MCV2 by age 24 months. As such the secondary outcome, proportion of M-SIMU 
infants receiving MCV2 by age 24 months was calculated using the formula below: 
 
	 	 	 	 730	 	 	 	 2	 	 730	




The exposure assessed was experience receiving SMS vaccination reminders with or without 
monetary incentives. Caregivers who were randomized to the SMS only arm in the M-SIMU 
study were considered to have been exposed to SMS vaccination reminders while those in the 
SMS+75KES or SMS+200KES arms were considered to have been exposed to SMS reminders 
and monetary incentives. Caregivers allocated to the M-SIMU Control arm were considered 
unexposed to the M-SIMU interventions. M-SIMU study allocation was obtained from M-SIMU 
records. Exposure in the M-SIMU study was defined according to intention-to-treat principles 
meaning that the analysis assumed exposure to the interventions for caregivers randomized to the 
M-SIMU study arms without consideration of whether the SMS only arm caregivers actually 
received the SMS reminders or whether SMS+incentive arm caregivers received SMS reminders 




5.3.3.3. Potential confounders 
We considered that uneven distribution of caregiver characteristics that may determine access to 
healthcare or health- or vaccine-seeking behavior could potentially confound the analysis. We 
assessed in the sub-sample of M-SIMU households included in the MSBC study, the distribution 
of sociodemographic characteristics across M-SIMU caregiver study arms comparing separately, 
the distribution of characteristics at the time of enrollment in to the MSBC study and at the time 
of enrollment in the M-SIMU study. For the MSBC study, distribution of the following 
characteristics was assessed: SC’s sex, history of receipt of any vaccination, sibship, location 
where the SC was delivered, mobile phone access type (owned vs. shared), maternal age, number 
of ANC visits attended during pregnancy with the SC, age of the SC and M-SIMU child at the 
time of the MSBC study and the birth interval between the M-SIMU child and the SC. 
Distribution of the following characteristics at the time of enrollment into the M-SIMU study 
was also assessed: M-SIMU child’s sex, location of deliver of the M-SIMU child, mobile phone 
access type (owned vs. shared), maternal educational attainment, travel time to the preferred 
health facility, region of residence (Asembo or Gem) and socioeconomic wealth quintile. To 
mitigate the risk of obtaining confounded results, any unequally distributed variables were 
included in regression models so as to adjust for potential confounders.  
 
Data for these variables were obtained from caregiver self-report during the MSBC or M-SIMU 
enrollment visit. Some characteristics were collected at the M-SIMU enrollment visit but not at 
the MSBC enrollment visit (maternal educational attainment, travel tie to health facility, region 
of residence and household assets) because we hypothesized that these characteristics would not 
have changed substantially between the time of the M-SIMU study and the MSBC study. Except 
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for mean age at enrollment in to the MSBC study and the mean birth interval, characteristics 
were coded into categorical variables as described in Table 5.1. Significance of differences in 
the distribution of characteristics at the 5% significance level was assessed using the Chi-squared 
test for binary variables and one way analysis of variance (ANOVA) with Bonferroni adjustment 
for multiple testing.  
 
5.3.3.4. Effect modifiers 
Because this study sought to evaluate whether there were significant differences in the 
proportion of children vaccinated in the presence of SMS vaccination reminders with or without 
monetary incentives, i.e., the proportion of M-SIMU children vaccinated, compared to the 
proportion of children vaccinated in the absence of these interventions, i.e., the proportion of SC 
vaccinated, we included an interaction term between the caregiver’s study arm and the child’s 
birth order to assess statistical interaction. Details of the model and the variables included in the 
difference in differences analysis are included below.  
 
In addition, we also performed sub-group analyses to evaluate whether differences in vaccine 
coverage among SC and M-SIMU children of caregivers enrolled in the M-SIMU intervention 
arms compared to children of M-SIMU control arm caregivers varied across strata of 
sociodemographic characteristics at the time when caregivers received the interventions, i.e., at 
the time of enrollment into the M-SIMU study. Characteristics included in the sub-group 
analyses were: M-SIMU child’s sex, location of M-SIMU child’s delivery, mobile phone access 
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type, maternal educational attainment, maternal age, travel time to a health facility, region of 
residence and socioeconomic wealth quintile. 
 
5.3.4. Bias 
The M-SIMU study was a randomized controlled trial and it found no difference in baseline 
characteristics among participants included in the analytic sample.6 Differential selection of M-
SIMU caregivers to participate in the MSBC study by study arm would bias the effect estimate 
towards or away from the null, depending on whether the selection bias differentially impacted 
vaccination coverage estimates of SC born to M-SIMU intervention arm caregivers or SC born to 
M-SIMU Control arm caregivers. To minimize the risk of selection bias, we planned to screen all 
caregivers included in the M-SIMU analytic sample for eligibility to enroll in the MSBC. 
Moreover, we compared M-SIMU baseline characteristics (M-SIMU child’s sex, location of M-
SIMU child’s delivery, mobile phone access type, maternal education attainment, maternal age, 
SES quintile and residence in Gem vs. Rarieda sub-counties) of caregivers who were followed 
up in MSBC to those who did not participate in the MSBC study to evaluate any statistically 
significant differences in their characteristics.  
 
In addition, M-SIMU intervention arm caregivers may have been more likely than Control arm 
caregivers, who received no intervention, to incorrectly recall their study arm either because of 
trouble remembering whether they were randomized to receive the KES 75 or KES 200 
incentive, or because they were among 3-7% of M-SIMU intervention arm caregivers who 
reported not receiving interventions during the M-SIMU study.6 To minimize information bias 
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related to misclassification of the exposure, we used M-SIMU records to identify caregivers’’ M-
SIMU study arm, rather than using caregivers’ self-report of M-SIMU study arm allocation.  
 
Furthermore, differential misclassification of vaccination status could have occurred if 
vaccination history was collected verbally. M-SIMU intervention arm caregivers may have been 
more likely to report vaccination of their children out of a desire to be regarded favorably by 
study staff as they were aware that the M-SIMU study interventions sought to encourage 
vaccination of their children. Thus, we collected vaccination history as recorded in the MCH 
booklet to minimize the risk of differential outcome misclassification. 
 
5.3.5. Study size 
Study sample size calculations were centered on the expected fertility of M-SIMU mothers. On 
average, M-SIMU mothers reported having 1.9 children under age 5 years living in their 
respective households (D.G. Gibson, unpublished data, May 2017). Total fertility rate in the 
study area was estimated at 5.3 children per woman in 2008.27 Thus, we assumed that all mothers 
enrolled in M-SIMU were at risk of having at least one child born after the child that was 
enrolled in the M-SIMU study. A previous analysis that included mothers from the study area 
estimated the mean birth interval (i.e., time between two subsequent births) in the study area at 
27.1 ± 10.1 months.32 The M-SIMU study enrolled mothers of children born between October 
2013 and October 2014. We assumed that the MSBC study would be conducted through 
December 2017 i.e., that the MSBC study would enroll SC born on or before February 2017. For 
M-SIMU mothers to have borne children on or before February 2017, the birth interval between 
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the M-SIMU child and the SC would range from 9 months (the minimum birth interval in the 
study area32) to 40 months (the number of months between October 2013 and February 2017). 
Assuming a similar distribution of birth intervals as observed prior (mean 27.1 ± 10.1 months),32 
we estimated that up to 89.9% of 1,599 M-SIMU mothers included in the primary analysis6 
would have a subsequent born child by February 2017. We further assumed that we would fail to 
enroll 10% of potentially eligible caregivers due to outmigration, ineligibility, refusals, death of 
the SC and other reasons. Thus, we anticipated enrolling up to 1,278 SC into the MSBC study. 
Specifically, by M-SIMU caregiver study arm, we anticipated enrolling up to: 288 Control arm 
SC, 310 SMS only SC, 356 SMS+75KES SC; and 324 SMS+200KES SC. 
 
We also estimated the effect size able to be detected with a sample size of 1,278. In the effect 
size estimation we assumed: a type 1 error (alpha) of 5%; power (1-beta) of 80%; 50.8% measles 
coverage among SC of M-SIMU Control arm caregivers at age 9m+2w (data from M-SIMU); at 
least 157 SC enrolled per M-SIMU caregiver study arm; 38 clusters (villages) per M-SIMU 
caregiver study arm; an average cluster size of four SC; and a coefficient of variation (CV) equal 
to 0.089 which was the CV observed in the M-SIMU study.6 Based on these assumptions and 
accounting for clustering, the study was powered to detect an absolute difference of ≥18% in the 
proportion of SC born to M-SIMU SMS+200KES arm caregivers receiving MCV1 by age 
9m+2w (the primary objective’s time cutoff) compared to those of M-SIMU Control arm 
caregivers. We felt that a difference of ≥18% in MCV1 timely coverage would represent a 
meaningful enhancement effect or inhibitory effect (depending on the direction of the difference) 




5.3.6. Statistical analysis and bias 
5.3.6.1. MCV1 timely coverage 
Log-binomial regression, or log-Poisson regression with robust error variance (modified 
Poisson) where log-binomial models failed to converge, was used to estimate the difference in 
risk (RD) of the primary outcome, receipt of MCV1 at age ≤9m+2w, among children of 
caregivers who were enrolled in the M-SIMU study intervention arms (separately) compared to 
children of M-SIMU Control arm caregivers. Associated 95% confidence intervals (95% CI) for 
RDs were also estimated. Generalized estimating equations (GEE) were used to account for 
spatial clustering; although there was two-way nested clustering (household and village), the 
models defined village as the clustering variable, as recommended previously.33 The working 
correlation structure specified in regression models was exchangeable and variance was 
estimated using the Huber/White/sandwich estimator. In addition, regression models included a 
variable indicating time i.e., after M-SIMU (SC) versus during M-SIMU (M-SIMU child) so as 
to adjust for secular trends. Furthermore, to allow for difference in differences estimation, an 
interaction term between the caregiver’s M-SIMU study arm and the time variable was also 
included in the model.  
 
In the RD model, the difference in differences estimate was calculated on the normal scale and 
represented the difference in risk differences i.e., the difference in risk of vaccination among SC 
of M-SIMU intervention arm caregivers compared to SC of M-SIMU Control arm caregivers 
minus the difference in risk of vaccination among M-SIMU intervention arm children compared 
to M-SIMU Control arm children. The RD model was specified as follows: 
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Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS75	 	β3.SMS200	 	β4.time	 	β5.SMS*time	 	
β6.SMS75*time	 	β7.SMS200*time	
where:  
Pr(Y = 1) is the probability of receiving MCV1 at age 9m+2w or earlier 2w;    
β0 is the constant i.e., the risk of receiving MCV1 at age 9m+2w or earlier in M-SIMU 
Control arm children given a zero value for all other predictors; 
β1 is the difference in the risk of receiving MCV1 at age 9m+2w or earlier among M-
SIMU children whose caregivers were randomized to the SMS only arm compared to 
those whose caregivers were randomized to the Control arm; 
SMS is an indicator variable with a value of 1 if the caregiver was randomized to the M-
SIMU SMS only arm and a value of 0 otherwise; 
β2 is the difference in the risk of receiving MCV1 at age 9m+2w or earlier among M-
SIMU children whose caregivers were randomized to the SMS+75KES arm compared to 
those whose caregivers were randomized to the Control arm; 
SMS75 is an indicator variable with a value of 1 if the caregiver was randomized to the 
M-SIMU SMS+75KES arm and a value of 0 otherwise; 
β3 is the difference in the risk of receiving MCV1 at age 9m+2w or earlier among M-
SIMU children whose caregivers were randomized to the SMS+200KES arm compared 
to those whose caregivers were randomized to the Control arm; 
SMS200 is an indicator variable with a value of 1 if the caregiver was randomized to the 
M-SIMU SMS+200KES arm and a value of 0 otherwise;  
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β4 is the difference in the risk of receiving MCV1 at age 9m+2w or earlier among SC of 
M-SIMU Control arm caregivers compared to their older M-SIMU siblings; 
time is an indicator variable with a value of 1 if the child is the younger sibling (SC) of 
the M-SIMU child and a value of 0 if the child was enrolled in M-SIMU;  
β5 is the difference in: the difference in the risk of receiving MCV1 at age 9m+2w or 
earlier among M-SIMU children whose caregivers were randomized to the SMS only 
arm compared to those whose caregivers were randomized to the Control arm, minus the 
difference in the risk of receiving MCV1 at age 9m+2w or earlier among SC whose 
caregivers were randomized to the SMS only arm compared to those whose caregivers 
were randomized to the Control arm; 
SMS*time is an interaction term with a value of 1 if the caregiver was randomized to the 
M-SIMU SMS only arm and if the infant is the younger sibling of an M-SIMU child and 
a value of zero otherwise;   
Β6 is the difference in: the difference in the risk of receiving MCV1 at age 9m+2w or 
earlier among M-SIMU children whose caregivers were randomized to the 
SMS+75KES arm compared to those whose caregivers were randomized to the Control 
arm, minus the difference in the risk of receiving MCV1 at age 9m+2w or earlier among 
SC whose caregivers were randomized to the SMS+75KES arm compared to those whose 
caregivers were randomized to the Control arm; 
SMS75*time is an interaction term with a value of 1 if the caregiver was randomized to 
the M-SIMU SMS+75KES arm and if the infant is the younger sibling of an M-SIMU 
child and a value of zero otherwise;   
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Β7 is the difference in: the difference in the risk of receiving MCV1 at age 9m+2w or 
earlier among M-SIMU children whose caregivers were randomized to the 
SMS+200KES arm compared to those whose caregivers were randomized to the Control 
arm, minus the difference in the risk of receiving MCV1 at age 9m+2w or earlier among 
SC whose caregivers were randomized to the SMS+200KES arm compared to those 
whose caregivers were randomized to the Control arm; 
and, 
SMS200*time is an interaction term with a value of 1 if the caregiver was randomized to 
the M-SIMU SMS+200KES arm and if the infant is the younger sibling of an M-SIMU 
child and a value of zero otherwise. 
 
5.3.6.2. MCV1 overall coverage and pentavalent 3 timely coverage 
Similar to the primary outcome analysis, log-binomial regression, or log-Poisson regression with 
robust error variance (modified Poisson) where log-binomial models failed to converge, was 
used to estimate the difference in risk (RD) of receiving MCV1 by age 12 months and 
pentavalent 3 at age ≤16 weeks, separately. Vaccination risk among children of caregivers 
enrolled in the individual M-SIMU study intervention arms was compared to the risk among 
children of M-SIMU Control arm caregivers. Associated 95% CI for RDs were also estimated. 
As previously, GEE were used to account for clustering at the village level, the exchangeable 
working correlation structure was specified and variance was estimated using the 
Huber/White/sandwich estimator. Regression models were the same as those used for assessment 
of the primary outcome, with the difference being in that the outcome was, first, MCV1 by age 
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12 months and second, pentavalent 3 at age ≤16 weeks. As previously, regression models 
included a variable indicating time i.e., after M-SIMU (SC) versus during M-SIMU (M-SIMU 
child) so as to adjust for secular trends. Furthermore, to allow for difference in differences 
estimation, an interaction term between the caregiver’s M-SIMU study arm and the time variable 
was also included in the model. Significance was assessed at the 5% level.  
 
5.3.6.3. MCV2 by age 24 months among M-SIMU children 
Log-binomial regression was used to estimate the RR, RD and associated 95% CIs of receiving 
MCV2 among M-SIMU children. GEE were used to account for clustering. Similar to the 
previously described regression models, these models defined village as the clustering variable, 
specified exchangeable correlation and estimated variance using the Huber/White/sandwich 
estimator. Significance was assessed at the 5% level. The RR model was specified as follows and 
included any variables assessed to be unequally distributed at M-SIMU baseline or at MSBC 
enrollment: 
 
Log	Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS75	 	β3.SMS200	 	βp.Xp	
where:  
Pr(Y = 1) is the probability of receiving MCV2 by age 24 months;   
β0 is the constant i.e., the log risk of MCV2 receipt by age 24 months among children 




β1 is the log risk ratio of MCV2 receipt by age 24 months among children previously 
enrolled in the M-SIMU SMS only arm compared to those previously enrolled in the M-
SIMU Control arm for otherwise similar children; 
SMS is an indicator variable with a value of 1 if the child was previously enrolled in the 
M-SIMU SMS only arm and a value of 0 otherwise; 
β2 is the log risk ratio of MCV2 receipt by age 24 months among children previously 
enrolled in the M-SIMU SMS+75KES arm compared to those previously enrolled in the 
M-SIMU Control arm for otherwise similar children; 
SMS75 is an indicator variable with a value of 1 if the child was previously enrolled in 
the M-SIMU SMS+75KES arm and a value of 0 otherwise; 
β3 is the log risk ratio of MCV2 receipt by age 24 months among children previously 
enrolled in the M-SIMU SMS+200KES arm compared to those previously enrolled in the 
M-SIMU Control arm for otherwise similar children; 
SMS200 is an indicator variable with a value of 1 if the child was previously enrolled in 
the M-SIMU SMS+200KES arm and a value of 0 otherwise. 
βp is the log risk ratio of MCV2 receipt by age 24 months for a one unit increase in 
variable Xp among otherwise similar infants; 
and, 
Xp is a potentially confounding variable(s). 
 
In addition, the following model was used to estimate RDs: 
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Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS75	 	β3.SMS200	 	βp.Xp	
where: 
Pr(Y = 1) is the probability of receiving MCV2 by age 24 months; 
β0 is the constant i.e., the probability of receiving MCV2 by age 24 months in the Control 
arm given a zero value for all other predictors; 
 β1 is the difference in the probability of receiving MCV2 by age 24 months among 
children previously enrolled in M-SIMU SMS only arm compared those previously 
enrolled in the Control arm for otherwise similar infants for otherwise similar children; 
SMS is an indicator variable with a value of 1 if the child was previously enrolled in the 
M-SIMU SMS only arm and a value of 0 otherwise; 
Β2 is the difference in the probability of receiving MCV2 by age 24 months among 
children previously enrolled in M-SIMU SMS+75KES arm compared those previously 
enrolled in the Control arm for otherwise similar infants for otherwise similar children; 
SMS+75KES is an indicator variable with a value of 1 if the child was previously 
enrolled in the M-SIMU SMS+75KES arm and a value of 0 otherwise; 
Β3 is the difference in the probability of receiving MCV2 by age 24 months among 
 children previously enrolled in M-SIMU SMS+200KES arm compared those previously 
 enrolled in the Control arm for otherwise similar infants for otherwise similar children; 
SMS+200KES is an indicator variable with a value of 1 if the child was previously 
enrolled in the M-SIMU SMS+200KES arm and a value of 0 otherwise; 
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βp is the difference in the risk of MCV2 receipt by age 24 months for a one unit increase 
 in variable Xp among otherwise similar infants; 
and,  
Xp is a potentially confounding variable(s). 
 
5.3.6.4. Sub-group analysis 
No sub-group analysis was performed.  
 
5.3.6.5. Sensitivity analysis 
To test the robustness of the primary outcome results and also to increase the sample size, we 
combined data from the SMS+75KES and the SMS+200KES arms so as to compare measles 
vaccination coverage at age 9m+2w or earlier among children of M-SIMU SMS only arm 
caregivers and children of SMS plus incentive arm caregivers to coverage among children of M-
SIMU Control arm caregivers.  
 
As with previous analysis, log-binomial regression, or log-Poisson regression when the log-
binomial model failed to converge, was used to estimate the RR, RD and associated 95% CIs of 
receiving MCV1 at age 9m+2w or earlier in children of caregivers who were allocated to receive 
M-SIMU interventions compared to Control arm caregivers. GEE was used to account for 
clustering and clustering and variance modeled similarly to the previously described models. The 
models were also adjusted for birth order and, to allow for estimation of the ratio of risk ratios 
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and the difference in risk differences, an interaction term between the caregiver’s M-SIMU study 
arm and child’s birth order was also included in the model. Aside from caregiver’s study arm, no 
other variables were included in the regression models. The RR model was specified as follows: 
	
Log	Pr Y 1 	 	β0	 	β1.SMS	 	β2.SMS incentive	 	β3.SC	 	β4.SMS*SC	 	
β5.SMS incentive*SC		
where:  
Pr(Y = 1) is the probability of receiving MCV1 at age 9m+2w or earlier 
β0 is the constant i.e., the log risk of receiving MCV1 at age 9m+2w or earlier among M-
SIMU Control arm children; 
β1 is the log risk ratio of receiving MCV1 at age 9m+2w or earlier among M-SIMU 
children whose caregivers were randomized to the SMS only arm compared to those 
whose caregivers were randomized to the Control arm; 
SMS is an indicator variable with a value of 1 if the caregiver was randomized to the M-
SIMU SMS only arm and a value of 0 otherwise; 
β2 is the log risk ratio of receiving MCV1 at age 9m+2w or earlier among M-SIMU 
children whose caregivers were randomized to the SMS+75KES or SMS+200KES arm 
compared to those whose caregivers were randomized to the Control arm; 
SMS+incentive is an indicator variable with a value of 1 if the caregiver was randomized 
to the M-SIMU SMS+75KES or SMS+200KES arm and a value of 0 otherwise; 
316 
 
β3 is the log risk ratio of the vaccination outcome among SC of M-SIMU Control arm 
caregivers compared to their older M-SIMU siblings; 
SC is an indicator variable with a value of 1 if the child is the younger sibling (SC) of the 
M-SIMU child and a value of 0 if the child was enrolled in M-SIMU;  
β4 is the log ratio of: the risk ratio of the vaccination outcome among M-SIMU children 
whose caregivers were randomized to the SMS only arm compared to those whose 
caregivers were randomized to the Control arm, divided by the risk ratio of the 
vaccination outcome among SC whose caregivers were randomized to the SMS only arm 
compared to those whose caregivers were randomized to the Control arm; 
SMS*SC is an interaction term with a value of 1 if the caregiver was randomized to the 
M-SIMU SMS only arm and the infant is the younger sibling of an M-SIMU child and a 
value of zero otherwise;   
Β5 is the log ratio of: the risk ratio of the vaccination outcome among M-SIMU children 
whose caregivers were randomized to the SMS+75KES or SMS+200KES arm compared 
to those whose caregivers were randomized to the Control arm, divided by the risk ratio 
of the vaccination outcome among SC whose caregivers were randomized to the 
SMS+75KES or SMS+200KES arm compared to those whose caregivers were 
randomized to the Control arm; 
and, 
SMS+incentive*SC is an interaction term with a value of 1 if the caregiver was 
randomized to the M-SIMU SMS+75KES or SMS+200KES arm and the infant is the 




In addition, to assess if trends in MCV2 coverage were similar to trends in MCV2 timely 
coverage (i.e., receipt of MCV2 by age 19 months),  a sensitivity analysis of the relative risk and 
differences in risk of MCV2 coverage by age 19 months across previous M-SIMU randomization 
arm was performed. The regression model for this sensitivity analysis was the same as that used 
for the MCV2 coverage by age 24 months outcome. Significance was assessed at the 5% level. 
 





Post-trial follow-up visits were conducted between August 4, 2018 and November 30, 2018. CIs 
visited 1,467 of 1,599 M-SIMU households (91.7%); 132 M-SIMU households were not visited 
as funding for the study ended before the households could be visited. Of the households visited, 
218 (14.9%) follow-up visits were completed. Follow-up visits were not conducted for the 
remaining households either because they did not meet MSBC eligibility criteria (n= 1,000; 
68.2%) or were lost to follow-up (n= 249; 17.0%). Of 1,000 caregivers not meeting MSBC 
eligibility criteria, 711 (71.1%) did not have a child born after M-SIMU, 203 (20.3%) had a SC 
younger than age 10 months, 62 (6.2%) had a SC but were enrolled in the M-SIMI study and 24 
(2.4%) did not have an MCH booklet for the SC. Among the 249 households lost to follow-up, 
223 (89.6%) moved away from the study area after the M-SIMU study, 22 (8.8%) were not at 
home at the time of the visit and four (1.6%) SC died prior to the screening visit. The 218 
participants followed up in the MSBC study included: 44, 60, 56 and 58 households previously 
randomized to the M-SIMU Control arm, SMS only arm, SMS+75KES arm and SMS+200KES 
arm, respectively. The total M-SIMU sub-sample included in the MSBC study represented 
13.6% (218/1599) of the entire M-SIMU sample and 12.2% (44/360), 15.5% (60/388) 12.6% 
(56/445) and 14.3% (58/406) of households enrolled in the M-SIMU Control arm, SMS only 
arm, SMS+75KES arm and SMS+200KES arm, respectively (Figure 5.1).  
 
5.4.2. Descriptive data 
At enrollment into the MSBC study, SC were approximately 18 months old on average (mean 
17.9 months, SD 6.0) and were born approximately 25 months after their older M-SIMU siblings 
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(mean 25.2 months, SD 6.1). A little over half of the SC were female (n= 119; 54.3%). All SC 
had received at least one vaccination at enrollment into the MSBC study. Most SC had 1-3 
siblings (n= 130; 59.4%) and close to three-quarters of SC were born at a health facility (n= 162; 
74.0%). In terms of caregiver characteristics, about 70% of caregivers owned a phone (n= 151; 
68.9%) and nearly half of mothers were aged ≤28 years (n= 107; 48.9%). Roughly 25% of 
mothers attended more than four ANC visits during pregnancy with the SC (n= 51; 23.3%). 
There were no statistically significant differences in characteristics of SC and their caregivers at 
the time of the MSBC interview. At the time follow-up in the MSBC study, M-SIMU children 
were approximately 3.5 years old on average (mean 43.2, SD 3.5). M-SIMU children of 
SMS+200KES arm caregivers (mean age 41.8 months, SD 3.2) were significantly younger than 
those of SMS only arm caregivers (mean age 43.8 months, SD 3.7; p= 0.010) and significantly 
younger than M-SIMU children of SMS+75KES arm caregivers (mean age 43.5 months, SD 3.5; 
p= 0.046; Table 5.2). Because children were left-censored at the respective age cut-off for 
analysis of the various outcomes, the age of M-SIMU children at the time of the MSBC 
interview was not controlled for in regression models.  
 
Characteristics of M-SIMU participants (n=1,599) at the time of enrollment into the M-SIMU 
study were similar across the four study arms and have been described previously. In short, half 
of the M-SIMU children were female, 72% of M-SIMU children were delivered at a health 
facility, slightly less than half of the caregivers owned a mobile phone and approximately 74% of 
mothers had more than seven years of education. A little over half of caregivers were 25 years 
old or younger, about 60% of households were within 30 minutes of travel time to a clinic and 




At the time of participation in the M-SIMU study, the sub-sample of M-SIMU participants later 
followed up in the MSBC study had statistically significant differences in sociodemographic 
characteristics compared to those who were not followed up. The M-SIMU sub-sample included 
in the MSBC study had lower levels of phone ownership at entry into the M-SIMU study 
compared to M-SIMU participants not followed-up in MSBC (38.8% [n= 85] vs. 51.0% [n= 
704]; p= 0.001). In addition, compared to M-SIMU participants not followed up in MBSC, a 
larger proportion of those followed had longer travel times to a health facility (46.1% [n= 101] 
vs. 38.0% [n= 524]; p= 0.022) and lived in Rarieda sub-county, i.e., in Asembo (28.3% [n= 62] 
vs. 19.8% [n= 273]; p= 0.004; Table 5.3). Specifically by study arm, compared to M-SIMU 
SMS+75KES arm households excluded from the MSBC study, a lower proportion of M-SIMU 
SMS+75KES households included in the MSBC study owned a mobile phone (26.8% [n= 15] vs. 
49.9% (n= 194); p= 0.001) and a higher proportion lived more than 30 minutes away from a 
health facility (48.2% [n= 27] vs. 32.4% [n= 126]; p= 0.020). In addition, compared to M-SIMU 
SMS+200KES arm households excluded from the MSBC study, a lower proportion of 
SMS+200KES included in MSBC owned a mobile phone at the start of the M-SIMU study 
(33.9% [n= 20] vs. 49.9% [n= 173]; p= 0.023; Table 5.4).   
 
In comparing M-SIMU baseline characteristics across M-SIMU study arm of the sub-sample 
included in the MSBC study, there were no statistically significant differences in the distribution 
of M-SIMU child’s sex, location of delivery for the M-SIMU child, maternal education, maternal 
age, travel time to a health facility, region of residence or socioeconomic quintile. However, 
phone ownership at the start of the M-SIMU study was not equally distributed in this sub-
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sample; 52.3% (n= 23) of Control arm caregivers owned a phone at the beginning of the M-
SIMU study compared to 45.0% (n= 27) of SMS only arm caregivers, 26.8% (n= 15) of 
SMS+75KES arm caregivers and 33.9% (n= 20) of SMS+200KES arm caregivers (p= 0.040; 
Table 5.5). Because of this imbalance, regression analyses were adjusted for mobile phone 
ownership status at the start of M-SIMU.  
 
In addition, because the previously described imbalances suggested that Control MSBC 
households were not comparable to intervention MSBC households, a post-hoc sensitivity 
analysis was performed whereby forward selection was used to create a model including 
additional characteristics that may have confounded the analysis. Additional characteristics 
assessed were: travel time to the nearest health facility, region of residence, maternal educational 
attainment as measured at the beginning of the M-SIMU study and the number of ANC visits 
attended for the subsequent child.  
 
5.4.3. Outcome data and main results 
5.4.3.1. MCV1 timely coverage 
MCV1 timely coverage was, 58.1% (25/43), 49.2% (29/59), 38.2% (21/55) and 40.7% (24/59) 
among Control SC, SMS only SC, SMS+75KES SC and SMS+200KES SC, respectively. Three 
SC who were enrolled before reaching age 9 months and 2 weeks, as well as their M-SIMU 
siblings, were excluded from the MCV1 timely coverage analysis. Among the sub-sample of 
Control arm, SMS only arm, SMS+75KES arm and SMS+200KES arm M-SIMU children 
followed-up in the MSBC study, MCV1 timely coverage during the M-SIMU study was 
respectively, 60.5% (26/43), 61.0% (36/59), 60.0% (33/55) and 67.2% (39/58; Table 5.6). Table 
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5.6 also includes MCV1 timely coverage for the entire M-SIMU sample6 for ease of reference by 
the reader. 
 
Children of SMS+200KES caregivers (primary outcome) 
In the primary objective analysis, there was a 25.2% absolute decrease in MCV1 timely coverage 
after the M-SIMU study compared to during the M-SIMU study among children of 
SMS+200KES caregivers, though this reduction in timely coverage was not statistically 
significant (adjusted risk difference-in-differences [DID] 95% CI: -55.3%, 4.8%; p= 0.099). This 
translated to 18.1% lower MCV1 timely coverage among SMS+200KES SC compared to 
Control SC that was not statistically significant (95% CI: -39.3%, 3.1%; p= 0.095). There were 
no substantial differences in crude estimates compared to estimates adjusted for M-SIMU 
baseline phone ownership status (Figure 5.2). Results for secondary analyses are described in 
the following sections 
 
Children of SMS+75KES arm caregivers 
MCV1 timely coverage was lower after the M-SIMU compared to during the M-SIMU study 
among children of SMS+75KES caregivers by 21.3% but this decrease was not statistically 
significant (adjusted DID 95% CI: -47.4%, 4.8%; p= 0.110). However, in the period after the M-
SIMU study, MCV1 timely coverage was significantly lower by 21.7% among children whose 
caregivers were previously enrolled in the M-SIMU SMS+75KES arm compared to those whose 
caregivers were in the M-SIMU Control arm (95% CI: -41.9%, -1.6%; p= 0.035). Crude and 




Children of SMS only arm caregivers 
MCV1 timely coverage was 11.2% lower among children of SMS only caregivers after the M-
SIMU study compared to during the M-SIMU study, although this difference did not achieve 
statistical significance (adjusted DID -11.2%; 95% CI: -36.1%, 13.7%; p= 0.376). This decrease 
translated to a statistically insignificant difference of 11.5% in MCV1 timely coverage among 
SMS only SC compared to Control SC (95% CI: -32.8%, 9.8%; p= 0.290). Crude and adjusted 
RR and RD estimates did not differ markedly (Figure 5.4). 
 
Sensitivity analyses of primary outcome 
In the sensitivity analysis that combined data from the SMS+200KES and SMS+75KES arms, 
SMS+incentive SC had 23.3% lower MCV1 timely coverage than their older M-SIMU siblings 
but this difference in timely coverage was not statistically significant (adjusted DID 95% CI: -
48.1%, 1.5%, p= 0.065). In the period after the M-SIMU study, MCV1 timely coverage was 
significantly lower by 19.8% among SMS+incentive SC compared to Control SC (aRD 95% CI: 
-38.1%, -1.5%; p= 0.034). Crude and adjusted estimates were comparable (Figure 5.5).   
 
In the post-hoc sensitivity analysis, mobile phone ownership at the start of the M-SIMU study, 
region of residence (Gem vs. Asembo), travel time to the nearest health facility, maternal 
educational attainment at the start of the M-SIMU study as well as the number of ANC visits 
attended for the SC were included as covariates. There were small changes towards the null for 
most RRs for all intervention households. Of note, the difference in MCV1 timely coverage 
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comparing SMS+75KES SC to Control SC borderline statistically significant (RD p= 0.050) 
compared to a p-value of 0.035 in the main secondary outcome analysis (Table 5.7). 
 
5.4.3.2. MCV1 overall coverage 
Among SC of Control arm, SMS only arm, SMS+75KES arm and SMS+200KES arm 
caregivers, MCV1 overall coverage was 84.4% (27/32), 76.9% (40/52), 63.6% (28/44) and 
60.9% (28/46), respectively. In the sub-sample of M-SIMU children surveyed in the MSBC 
study, MCV1 overall coverage was 84.4% (27/32), 90.4% (47/52), 75.0% (33/44) and 87.0% 
(40/46) for Control arm, SMS only arm, SMS+75KES arm and SMS+200KES arm participants 
(Table 5.6). Estimation of MCV1 overall coverage excluded 44 SC (12 Control, 8 SMS only, 12 
SMS+75KES and 12 SMS+200KES) who had not reached age 12 months, as well as their M-
SIMU siblings. MCV1 overall coverage estimates for the entire M-SIMU sample are also 
presented in Table 5.6. In the following results, RRs and associated 95% CIs for the MCV1 
overall coverage outcome were estimated using Poisson regression as binomial models failed to 
converge.  
 
Children of SMS+200KES caregivers 
Compared to during the M-SIMU study, MCV1 overall coverage among children of 
SMS+200KES caregivers after the M-SIMU study was lower by 24.5% though this decrease was 
not statistically significant (adjusted DID 95% CI: -50.9%, 2.0%; p= 0.070). The absolute 
decrease in MCV1 overall coverage among SMS+200KES arm SC compared to Control SC was 
20.8% and was not statistically significant (aRD 95% CI: -42.1%, 0.6%; p= 0.057). Crude point 
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estimates diverged somewhat from adjusted estimates and the p-value for the comparison of 
MCV1 overall coverage among SMS+200KES SC and Control SC indicated significantly lower 
coverage among SMS+200KES SC (Figure 5.6) 
 
Children of SMS+75KES caregivers 
After the M-SIMU study, MCV1 overall coverage was lower by 8.6% among SMS+75KES 
children compared to during the M-SIMU study but this difference was statistically insignificant 
(adjusted DID 95% CI: -32.0%, 14.9%; p= 0.473). But SMS+75KES SC had significantly lower 
MCV1 overall coverage than Control SC in the period after the M-SIMU study (aRD 18.4%, 
95% CI: -36.2%, -0.5%, p= 0.044). There were some small differences in the point estimates 
derived from the crude model compared to the adjusted model, but these differences did not 
impact the interpretation of the results (Figure 5.7).  
 
Children of SMS only caregivers 
Children of caregivers previously enrolled in the M-SIMU SMS only arm had 10.4% non-
significant lower MCV1 overall coverage after the M-SIMU study compared to during the M-
SIMU study (adjusted DID 95% CI: -29.8%, 9.0%; p= 0.295). This reduction resulted in 6.2% 
statistically insignificant lower coverage among SMS only SC compared to Control SC (95% CI: 
-22.2%, 9.8%; p= 0.451). Crude estimates of RDs were slightly larger than adjusted estimates, 




5.4.3.3. Pentavalent 3 timely coverage 
Pentavalent 3 timely coverage among SC born to M-SIMU Control arm, SMS only arm, 
SMS+75KES arm and SMS+200KES arm caregivers was 70.5% (31/44), 70.0% (42/60), 62.5% 
(35/56) and 56.9% (33/58), respectively. Among M-SIMU children followed up in the MSBC 
study, 72.7% (32/44), 71.7% (43/60), 76.8% (43/56) and 69.0% (40/58) Control arm, SMS only 
arm, SMS+75KES arm and SMS+200KES arm children received pentavalent 3 by age 16 weeks 
or younger (Table 5.8). Entire M-SIMU sample pentavalent 3 timely coverage is also presented 
in Table 5.8. 
 
SMS+200KES arm children 
Pentavalent 3 timely coverage was lower among SMS+200KES children after withdrawal of M-
SIMU interventions compared to during the M-SIMU study, but not significantly so (adjusted 
DID -9.9%; 95% CI: -30.7, 10.8; p= 0.348). SMS+200KES SC had statistically insignificant 
lower pentavalent 3 timely coverage compared to Control SC (aRD -13.1%; 95% CI: -31.8, 5.5; 
p= 0.167). Results from the crude and adjusted analyses were comparable (Figure 5.9). 
 
SMS+75KES arm children 
After the M-SIMU study, pentavalent 3 timely coverage was 12.9% lower in SMS+75KES SC 
compared to coverage during the M-SIMU study in SMS+75KES M-SIMU children but this 
difference did not achieve statistical significance (95% CI: -35.2, 9.5; p= 0.259). Pentavalent 3 
timely coverage was lower by 10.3% among SMS+75KES SC compared to Control SC in the 
period after the M-SIMU study though this difference was statistically insignificant (95% CI: -
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31.4%, 10.7%; p= 0.336). Estimates from the crude and adjusted analyses were comparable 
(Figure 5.10).  
 
SMS only arm children 
There were no notable differences in pentavalent 3 timely coverage among children of SMS only 
caregivers after the M-SIMU study as compared to timely coverage during the M-SIMU study 
(adjusted DID 0.4%; 95% CI: -17.1%, 17.9%; p= 0.964) or timely coverage among Control SC 
(aRD -1.2%; 95% CI: -19.4%, 17.0%; p= 0.897). Crude and adjusted estimates were comparable 
(Figure 5.11).  
 
5.4.3.4. MCV2 coverage by age 24 months among M-SIMU children 
MCV2 coverage by age 24 months was estimated among only M-SIMU children. Of 218 M-
SIMU children assessed, 163 (74.8%) had an MCH booklet that could be used to verify second 
dose measles vaccination status. Thus, MCV2 coverage by age 24 months was assessed in 163 
M-SIMU children. The proportion of M-SIMU Control arm, SMS only arm, SMS+75KES and 
SMS+200KES arm M-SIMU children receiving MCV2 by age 24 months was 52.8% (19/36), 
31.1% (14/45), 20.5% (8/39) and 25.6% (11/43), respectively (Table 5.9).  
 
MCV2 coverage among SMS+200KES M-SIMU children was significantly lower than coverage 
among Control M-SIMU children by 27.0% (95% CI: -49.0%, -5.0%; p= 0.016).  Similarly, 
MCV2 coverage among SMS+75KES M-SIMU children significantly lower by 29.2 percentage 
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points compared to coverage among Control M-SIMU children (95% CI: -52.1%, -6.2%; p= 
0.013). MCV2 coverage by age 24 months among SMS only M-SIMU children was 22.0% lower 
than coverage among Control M-SIMU children, but this difference was not statistically 
significant (95% CI: -45.2; 1.1; p= 0.062). For all comparisons, results from crude models 
differed slightly from the results from the adjusted model but the differences were not substantial 
and did not affect interpretation of the results (Table 5.9).  
 
Sensitivity analysis: MCV2 by age 19 months among M-SIMU children 
In this sensitivity analysis, the likelihood of receiving MCV2 by age 19 months among M-SIMU 
intervention children was lower compared to the likelihood among M-SIMU Control children. 
However, none of these reduced likelihoods achieved statistical significance. Similarly MCV2 
timely coverage was statistically insignificantly lower among M-SIMU intervention arm children 





This study is novel in being the first to assess the impact of withdrawal of SMS vaccination 
reminders and incentives on vaccine-seeking behavior among caregivers who previously 
received these interventions. Our findings indicate that withdrawal of SMS vaccination 
reminders alone, or SMS vaccination reminders coupled with incentives, may result in decreased 
vaccine-seeking for MCV.  
 
In the period after withdrawal of these interventions, MCV1 timely coverage, our primary 
outcome, and coverage by age 12 months were lower among subsequent children whose 
caregivers previously received the interventions, compared to subsequent children whose 
caregivers did not previously receive these interventions. These reductions could not be 
attributed to secular changes as difference-in-difference estimates accounted for secular trends, 
nor could the reductions be attributed to baseline differences in vaccine- or health-seeking 
among households that previously received M-SIMU interventions compared to Control 
households; inclusion of potentially confounding characteristics associated with vaccine- or 
health-seeking in sensitivity regression models had minimal impact on the findings. Although the 
decreases in MCV1 timely coverage and coverage by age 12 months were statistically significant 
only in the case of SMS+75KES SC compared to Control SC, the point estimates for other 
comparisons were in the same direction. Taken together this suggests that reductions in coverage 




When compared to MCV1 timely and overall coverage among Control SC in the period after 
withdrawal of M-SIMU interventions, the largest reduction was observed among SMS+200KES 
SC, followed by SMS+75KES SC and lastly by SMS only SC, suggesting a dose-response 
relationship whereby the magnitude of reductions lessened with decreasing intensity of the 
interventions. Second, the primary outcome sensitivity analysis whereby SMS+200KES and 
SMS+75KES households were combined showed that: MCV1 vaccine-seeking among 
SMS+incentive caregivers declined significantly after withdrawal of M-SIMU interventions, i.e., 
SMS+incentive SC timely coverage was significantly lower than SMS+incentive timely 
coverage among M-SIMU children, and that MCV1 timely coverage among SMS+incentive SC 
declined to below baseline levels, i.e., MCV1 timely coverage among SMS+incentive SC was 
significantly lower compared to Control SC. Moreover, and perhaps most concerning, we found 
that MCV2 coverage by age 24 months among children who were previously enrolled in the M-
SIMU study was lower among children who were randomized to M-SIMU intervention arms 
compared to Control M-SIMU children, and significantly lower among SMS+75KES and 
SMS+200KES children. This finding on MCV2 coverage by age 24 months among M-SIMU 
children is noteworthy because these were the very children previously enrolled in the M-SIMU 
study. Therefore, differences in MCV2-seeking among M-SIMU children can be more 
confidently associated with withdrawal of interventions compared to changes among SC who are 
temporally distal to the M-SIMU study and withdrawal of M-SIMU interventions. Finally, we 
observed small though statistically insignificant decreases in pentavalent 3-seeking among 




Reduced vaccine-seeking after withdrawal of M-SIMU interventions among caregivers who 
previously received them may be linked to a decrease in intrinsic vaccine-seeking motivation 
either because the presence and/or value of monetary incentives crowded-out caregivers’ 
intrinsic vaccine-seeking motivation or because withdrawal of M-SIMU interventions relayed a 
negative signal to caregivers. The theory that incentives crowd-out intrinsic motivation to 
perform the incentivized behavior in the absence of incentives is well established.24,34,35 As 
mentioned previously, to date, no studies have demonstrated that incentives to promote health-
related behaviors crowd-out intrinsic motivation. Previous studies have shown that after 
withdrawal of incentives practice of incentivized behaviors, such as exercising, weight loss and 
smoking cessation, is maintained or that it decreases but not to below pre-incentive levels.26,36–42 
Thus, this study is novel not only in being the first to assess the impact of withdrawal of SMS 
reminders and incentives on vaccine-seeking, but also in being the first to suggest that incentives 
may have crowded-out intrinsic motivation for a health-related behavior. This study’s findings 
are in contrast to caregivers’ attitudes at the end of the M-SIMU study whereby all but one of 
747 caregivers interviewed said that they were as or more likely to vaccinate their child in the 
absence of incentives.6  
 
A variety of mechanisms through which incentives may inhibit intrinsic motivation have been 
proposed and these seem plausible in the context of incentives for vaccination. Namely, the 
presence of incentives may have changed prosocially-motivated caregivers’ decision frame from 
social to monetary, may have signaled to caregivers that their vaccine-seeking was inadequate or 
that vaccination is risky (hence its incentivization). Additionally, if the incentives were priced 
too low, caregivers may have perceived that vaccination was not important. The incentive 
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amount in the M-SIMU study was selected based on feedback from mothers living close to the 
study area, but a ceiling amount of 200 KES was set by the study due to financial considerations. 
Perhaps a larger incentive value would have been identified had options above 200 KES been 
offered. Finally, the conditionality of incentives – M-SIMU caregivers received incentives only 
if their children were vaccinated with the recommended vaccination age – may have inhibited 
caregivers’ intrinsic motivation if they felt the conditions encroached on their free choice to 
vaccinate their child after the two week deadline. 6,34,35 We posit that caregivers on the vaccine-
hesitancy spectrum would have been most susceptible to inhibition of intrinsic motivation by 
incentives and that the mechanism through which incentives may have inhibited intrinsic 
motivation may have been different by caregiver. The mechanism by which withdrawal of SMS 
reminders may have reduced caregiver’s intrinsic vaccine-seeking motivation is not clear. 
However, one could speculate that the act of withdrawing M-SIMU interventions and, not the 
presence of the interventions themselves, may have inhibited caregivers’ intrinsic motivation by 
signaling that increasing vaccination uptake is not important i.e., if important the study would 
have continued providing incentives. 
 
In a post-hoc analysis, we investigated characteristics associated with not seeking MCV1 for SC 
among caregivers whose M-SIMU children previously received MCV1. Respectively, 22.7% (n= 
10), 23.3% (n= 14), 35.7% (n= 20) and 41.4% (n= 24) Control, SMS only, SMS+75KES and 
SMS+200KES caregivers who vaccinated their M-SIMU children at age ≤9m+2w did not do so 
for their SC. In addition, 9.1% (n= 4), 13.3% (n= 8), 21.4% (n= 12) and 27.6% (n= 16) of 
Control, SMS only, SMS+75KES and SMS+200KES caregivers who previously vaccinated their 
M-SIMU children against measles by age 12 months did not do the same for their SC. 
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Altogether, the data suggested that compared to Control caregivers, caregivers who previously 
received SMS reminders and incentives were more likely to lapse in MCV1-seeking for SC if 
they resided in Gem sub-county, were in the bottom two socioeconomic quintiles or were 
younger mothers (i.e., age ≤25 years). These characteristics may inform the mechanism 
responsible for reduced vaccine-seeking or perhaps inform future efforts to mitigate the patterns 
of long-term vaccine-seeking we observed. 
 
However, the results from this analysis do not present conclusive evidence on the impact of 
short-term SMS vaccination reminders with or without incentives on long-term vaccine-seeking 
as there are several important limitations. First, we included only 13.3% (213 of 1,599) of M-
SIMU caregivers in the MCV1 and pentavalent 3 coverage analyses and only 10.2% (163 of 
1,599) of M-SIMU children in the MCV2 coverage analysis. With these participants distributed 
across four M-SIMU study arms, small differences in individual children’s vaccination status 
had the potential to substantially influence interpretation of the results. Due to these small 
sample sizes, the magnitude of the effect of the withdrawal of M-SIMU interventions and 
associated significance levels may not reflect true patterns in MCV1-seeking after withdrawal of 
M-SIMU interventions. 
 
Second, there was some suggestion that MSBC Control households were different from MSBC 
intervention households at the start of the M-SIMU study. In comparing M-SIMU baseline 
characteristics, MSBC intervention households had significantly lower levels of mobile phone 
ownership compared to MSBC Control households. There was also some suggestion that SMS 
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plus incentive households enrolled in the MSBC study were less likely to reside in Asembo and 
more likely to have long travel times to a health facility at the start of the M-SIMU study, though 
there were no significant differences in these characteristics within the MSBC sample (Tables 
5.2 – 5.5).  Taken together, these differences could suggest that MSBC SMS plus incentive 
households were more likely to have characteristics that predict lower vaccine-seeking. Lower 
mobile phone ownership among MSBC caregivers previously enrolled in M-SIMU intervention 
arms suggests that they may have had lower vaccine-seeking at baseline as compared to MSBC 
Control caregivers as mobile phone ownership may be indirectly associated with vaccine-seeking 
through other direct determinants of vaccine-seeking such as wealth, literacy and educational 
attainment.43 Residence in Asembo has been associated lower child mortality, better knowledge 
of malaria treatment and higher obstetric health-seeking compared to residence in Gem.27,44,45 In 
addition, longer travel time to a health facility can be associated with decreased vaccine- or 
health-seeking.46–53 Further, the previously described differences suggest bias of effect estimates 
away from the null when they are not accounted for. Indeed, we observed small changes in RD 
and DID estimates after including region as a covariate in one of the sensitivity regression 
models whereby estimates shifted slightly towards the null and no reductions were statistically 
significant. Still, there may be other unknown confounders that we did not account for and that 
may challenge the internal validity of the MSBC results.  
 
In addition, we observed that MCV1 timely coverage in the sub-sample of M-SIMU Control 
children included in the MSBC study was substantially greater than coverage among all Control 
M-SIMU children and that MCV1 timely and overall coverage in the sub-sample of 
SMS+75KES M-SIMU children included in the MSBC study were substantially lower than 
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among all SMS+75KES M-SIMU children. Relatedly, in the sub-sample of M-SIMU children 
followed-up in the MSBC study, vaccination timeliness and coverage were not higher in any of 
the intervention arm children compared to Control M-SIMU children.6 Moreover there were 
significant differences in the distribution of baseline characteristics among MSBC households 
compared to M-SIMU households not included in MSBC. Thus, the sub-sample of M-SIMU 
households included in the MSBC study does not seem to be representative of the entire M-
SIMU sample and so the results of the MSBC study cannot be generalized to the entire M-SIMU 
sample.  
 
Furthermore, we cannot definitively establish a causal relationship between withdrawal of M-
SIMU interventions and reduced MCV-seeking for several reasons. First, 3% - 13% of M-SIMU 
caregivers interviewed at the end of the M-SIMU study reported that they either did not receive 
SMS reminders or incentives. The M-SIMU study had no way of establishing whether caregivers 
actually received the interventions and so with incomplete information about the level of 
exposure in MSBC intervention households we cannot fully infer causality. Second, the analysis 
assumed that Control SC were representative of intervention SC in the counterfactual where 
intervention households were never enrolled in the M-SIMU study, but this may not have been 
accurate. Third, reduction in intrinsic motivation after withdrawal of incentives has not 
previously replicated for health outcomes. Fourth, we did not directly measure intrinsic 
motivation prior to, during or after the M-SIMU study and therefore we cannot make direct 
linkages between changes in vaccine-seeking and intrinsic motivation. Finally, we are not 
confident in the mechanisms by withdrawal of M-SIMU interventions could have reduced 




We do not think that supply-side constraints influence the study findings. Although there was an 
ongoing nurses’ strike in Kenya that began two months before the start of the MSBC study and 
ended shortly before completion of the MSBC study,54,55 we do not think that this strike would 
have differentially affected vaccine-seeking among caregivers previously enrolled in the M-
SIMU study by M-SIMU study arm. One way that the strike could have differentially affected 
children was if there were substantial differences in the age of the children at the time of the 
MSBC follow-up survey; younger children reaching vaccination age at the time of the strike 
would have had less likelihood of being vaccinated. But we found no significant differences in 
age at the MSBC survey among SC and among M-SIMU children SMS only and SMS+75KES 
M-SIMU children were older than SMS+200KES, biasing them towards higher likelihood of 
vaccination (Table 5.2). However, the results from this analysis suggest that there was no effect 
of age on MCV2 coverage among SMS only and SMS+75KES M-SIMU children. 
 
Despite the limitations outlined above, our study had several strengths. First, we attempted to 
follow each M-SIMU caregiver, minimizing the risk of selection bias. Second, the MSBC study 
was built on the backbone of a cluster randomized controlled trial, which by design minimizes 
selection bias. Although we found some differences in characteristics across M-SIMU study 
arms, we adjusted for possible confounders in regression models. Another strength of this study 
is the difference-in-differences analytic approach used. This approach allowed us to adjust for 
secular trends in comparisons of coverage among intervention SC and their M-SIMU siblings as 
it included an adjustment for the trend seen among Control children across birth cohorts. In 
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addition, we had data on SC from all study arms, i.e., we did not use M-SIMU Control children 
as historical controls, allowing us to observe secular trends among Control children.  
 
The findings from this analysis are concerning in that they suggest that withdrawal of SMS 
reminders with or without incentives resulted in reduced vaccine-seeking. However, given the 
previously described limitations of the MSBC sample, it is essential for more M-SIMU 
households to be followed up so as to increase the post-trial follow-up sample size and to 
increase the likelihood that post-trial follow-up households are representative of the entire M-
SIMU sample. A larger, more representative MSBC sample would produce more robust results 
and allow more confident interpretation of the results.  
 
To conclude, we recommend evaluations of the impact of withdrawing short-term health 
interventions, particularly for studies assessing the impact of monetary incentives and other 
demand-generation interventions in LMICs. In addition, we recommend studies that assess the 
impact of behavioral interventions to generate demand for health service on intrinsic motivation 
among health service clients in LMICs. If confirmed through other studies, the findings from this 
analysis should signal to stakeholders the importance of sustaining behavioral health 
interventions, particularly those involving incentives, and the possible negative effects of 
withdrawing them. They should also encourage the evaluation of group incentives over 
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Chapter 5 Tables 
Table 5.1. Categorization of potential confounders assessed  
 
Characteristic Existing or derived 
variable 
Description  
Mobile phone access Existing Binary: 0= Shares; 1= Owns 
Caregivers reported whether they owned or shared a mobile phone 
Infant’s sex Existing Binary: 0= Female; 1= Male 
Caregivers reported the sex of the SC 
Any vaccination 
received  
Existing Binary: 0= Not vaccinated; 1= Vaccinated 
Caregivers reported whether the SC had ever received any vaccine 
Maternal education Derived in the M-
SIMU study 
Binary: 0= ≤7 years; 1= >7 years 
Maternal education level was collected in a series of two variables, one 
categorical (Primary, Secondary, Post-secondary or none) and the other 
continuous (Class or form completed). Caregivers selecting no education or 
primary education with class <8 were classified as having ≤7 years of 
education. The cutoff at 7 years was used because primary school education in 
Kenya is 8 years; this cutoff allows distinguishing caregivers with less than 
primary education vs. those with primary education or more.  
Sibship  Derived Binary: 0= 1-3 siblings; 1= >3 siblings 
Birth order was collected as a categorical variable i.e., 2nd, 3rd, 4th, 5th, 6th, 7th or 
>7th. Birth order has previously been shown to predict vaccination status.56–59 
Because none of the SC could be firstborn children we created a binary variable 
with a cut-off at 3 siblings  as a previous study in Israel showed higher varicella 
vaccination coverage for children with ≤3 siblings compared to those with more 
siblings.60 
Location of last delivery Derived Binary: 0= At home; 1= Health facility 
Location of last delivery was collected as a categorical variable 1= At home 
with no Skilled Birth Attendant (SBA)/ Midwife; 2= At home with 
SBA/Midwife; 3= Health Facility; 4= Don’t know. At home vs. health facility 
was selected because it might reflect caregivers’ health-seeking behavior.  
Maternal age  Derived Binary: 0= ≤28 years; 1= >28 years 
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Characteristic Existing or derived 
variable 
Description  
Maternal age was collected as a continuous variable. Age 28 years was selected 
because it was the median maternal age of SC. 
Number of ANC visits 
for SC 
Derived Binary: 0= ≤4 visits; 1= >4 visits 
Number of ANC visits was collected as a continuous variable. Four visits was 
selected as the cutoff based on the 2002 recommendation from WHO for a 
minimum of four ANC visits.61 The new eight-visit minimum recommended by 
WHO in November 2016 was not used because M-SIMI mothers experienced 
pregnancy prior to issuance of the new guidelines.62 
Socioeconomic quintile  Derived in the M-
SIMU study 
Binary: 0= Bottom 40%; 1= Upper 60% 
A series of variables to record asset ownership was collected i.e. the number of 
the following items owned by the household was collected: goats, cattle, sheep, 
poultry, donkey, pigs, plough, foam mattress, spring mattress, straw mattress, 
cell phone, radio, bicycle, sofa, lantern, TV. Using the same method used by the 
KEMRI HDSS to quantify SES, multiple correspondence analysis (MCA) was 
used to generate a SES index. The index was grouped into quintiles. The 
socioeconomic quintile variable was generated by coding the bottom two 
quintiles as being in the bottom 40% and the top three quintiles as being the 
upper 60% of the wealth distribution. The 40% cutoff was selected because 
socioeconomic status was calculated as a five-component index and a 40% 
cutoff was thought to be more likely capture inequitable health care access 
compared to a 20% cutoff. 
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(N = 56) 
SMS+200KES 
(N = 58) 
Total 
(N= 218) 
 No. (%) No. (%) No. (%) No. (%) No. (%) 
Sex      
Female 27 (61.4) 30 (50.0) 29 (51.8) 32 (55.2) 118 (54.1) 




     
Not vaccinated 0 0 0 0 0 
Vaccinated 44 (100) 60 (100) 56 (100) 58 (100) 218 (100) 
Sibship      
1-3 siblings 28 (63.6) 37 (61.7) 27 (48.2) 37 (63.8) 129 (59.2) 
>3 siblings 16 (36.4) 23 (38.3) 29 (51.8) 21 (36.2) 89 (40.8) 
Location of last 
delivery      
At home 12 (27.3) 16 (26.7) 16 (28.6) 13 (22.4) 57 (26.1) 
Health facility 32 (72.7) 44 (73.3) 40 (71.4) 45 (77.6) 161 (73.9) 
Mobile phone 
access      
Shares 14 (31.8) 17 (28.3) 19 (33.9) 18 (31) 68 (31.2) 
Owns 30 (68.2) 43 (71.7) 37 (66.1) 40 (69) 150 (68.8) 
Maternal age      
≤28 years 18 (40.9) 30 (50.0) 24 (42.9) 35 (60.3) 107 (49.1) 
>28 years 26 (59.1) 30 (50.0) 32 (57.1) 23 (39.7) 111 (50.9) 
Number of ANC 
visits in MSBC 
pregnancy 
     
≤4 visits 31 (70.5) 44 (73.3) 45 (80.4) 44 (75.9) 164 (75.2) 
>4 visits 11 (25.0) 16 (26.7) 11 (19.6) 12 (20.7) 50 (22.9) 







(N = 56) 
SMS+200KES 








Mean (SD) Mean (SD) Mean 
(SD) 
SC age in months 
at MSBC follow-
up 
     
 18.1 (6.7) 18.9 (6.3) 17.1 (5.2) 17.3 (5.6) 17.8 (5.9) 
Birth interval      









(N = 56) 
SMS+200KES 
(N = 58) 
Total 
(N= 218) 
 No. (%) No. (%) No. (%) No. (%) No. (%) 
M-SIMU 
children’s age in 
months at MSBC 
follow-up 
     





Table 5.3. Comparison of baseline M-SIMU characteristics among participants enrolled in the 
MSBC study compared to M-SIMU participants not included in the MSBC study 
 
 
Included in MSBC 
(N= 218) 





 No. (%) No. (%) No. (%)  
M-SIMU child's sex     
Female 109 (50.0) 691 (50.0) 800 (50.0) 0.992
Male 109 (50.0) 690 (50.0) 799 (50.0)  
Last delivery     
At home 71 (32.6) 374 (27.1) 445 (27.8) 0.093
At a health facility 147 (67.4) 1007 (72.9) 1154 (72.2)  
Mobile phone access      
Shares 133 (61.0) 677 (49.0) 810 (50.7) 0.001
Owns 85 (39.0) 704 (51.0) 789 (49.3)  
Maternal education     
≤7 years 64 (29.4) 347 (25.1) 411 (25.7) 0.184
>7 years 154 (70.6) 1034 (74.9) 1188 (74.3)  
Maternal age     
≤25 years 123 (57.2) 701 (50.9) 824 (51.7) 0.084
>25 years 92 (42.8) 677 (49.1) 769 (48.3)  
Time to clinic     
≤30 minutes 118 (54.1) 856 (62.0) 974 (60.9) 0.027
>30 minutes 100 (45.9) 525 (38.0) 625 (39.1)  
Region     
Asembo 62 (28.4) 273 (19.8) 335 (21.0) 0.003
Gem 156 (71.6) 1108 (80.2) 1264 (79.0)  
SES quintile     
Lower 40% 88 (40.4) 541 (39.2) 629 (39.3) 0.738





Table 5.4. Comparison of baseline M-SIMU characteristics of participants enrolled in the MSBC 




Included in MSBC 
(N= 44) 





 No. (%) No. (%) No. (%)  
M-SIMU child's sex     
Female 24 (54.5) 162 (51.3) 186 (51.7) 0.683
Male 20 (45.5) 154 (48.7) 174 (48.3)  
Last delivery     
At home 13 (29.5) 70 (22.2) 83 (23.1) 0.275
At a health facility 31 (70.5) 246 (77.8) 277 (76.9)  
Mobile phone access      
Shares 21 (47.7) 157 (49.7) 178 (49.4) 0.808
Owns 23 (52.3) 159 (50.3) 182 (50.6)  
Maternal education     
≤7 years 33 (75.0) 244 (77.2) 277 (76.9) 0.744
>7 years 11 (25.0) 72 (22.8) 83 (23.1)  
Maternal age     
≤25 years 25 (59.5) 149 (47.2) 174 (48.6) 0.132
>25 years 17 (40.5) 167 (52.8) 184 (51.4)  
Time to clinic     
≤30 minutes 23 (52.3) 179 (56.6) 202 (56.1) 0.584
>30 minutes 21 (47.7) 137 (43.4) 158 (43.9)  
Region     
Asembo 13 (29.5) 62 (19.6) 75 (20.8) 0.129
Gem 31 (70.5) 254 (80.4) 285 (79.2)  
SES quintile     
Lower 40% 15 (34.1) 117 (37.0) 132 (36.7) 0.705
Upper 60% 29 (65.9) 199 (63.0) 228 (63.3)  
SMS ONLY ARM 
 
Included in MSBC 
(N= 60) 





 No. (%) No. (%) No. (%)  
M-SIMU child's sex     
Female 31 (51.7) 148 (45.1) 179 (46.1) 0.350
Male 29 (48.3) 180 (54.9) 209 (53.9)  
Last delivery     
At home 19 (31.7) 91 (27.7) 110 (28.4) 0.535
At a health facility 41 (68.3) 237 (72.3) 278 (71.6)  
Mobile phone access      
Shares 33 (55.0) 150 (45.7) 183 (47.2) 0.186
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Owns 27 (45.0) 178 (54.3) 205 (52.8)  
Maternal education     
≤7 years 42 (70.0) 249 (75.9) 291 (75.0) 0.331
>7 years 18 (30.0) 79 (24.1) 97 (25.0)  
Maternal age     
≤25 years 34 (56.7) 169 (51.8) 203 (52.6) 0.491
>25 years 26 (43.3) 157 (48.2) 183 (47.4)  
Time to clinic     
≤30 minutes 30 (50.0) 195 (59.5) 225 (58.0) 0.173
>30 minutes 30 (50.0) 133 (40.5) 163 (42.0)  
Region     
Asembo 17 (28.3) 70 (21.3) 87 (22.4) 0.233
Gem 43 (71.7) 258 (78.7) 301 (77.6)  
SES quintile     
Lower 40% 22 (36.7) 122 (37.2) 144 (37.1) 0.938
Upper 60% 38 (63.3) 206 (62.8) 244 (62.9)  
SMS+75KES ARM 
 
Included in MSBC 
(N= 56) 





 No. (%) No. (%) No. (%)  
M-SIMU child's sex     
Female 27 (48.2) 201 (51.7) 228 (51.2) 0.628
Male 29 (51.8) 188 (48.3) 217 (48.8)  
Last delivery     
At home 18 (32.1) 121 (31.1) 139 (31.2) 0.876
At a health facility 38 (67.9) 268 (68.9) 306 (68.8)  
Mobile phone access      
Shares 41 (73.2) 195 (50.1) 236 (53) 0.001
Owns 15 (26.8) 194 (49.9) 209 (47)  
Maternal education     
≤7 years 35 (62.5) 286 (73.5) 321 (72.1) 0.085
>7 years 21 (37.5) 103 (26.5) 124 (27.9)  
Maternal age     
≤25 years 26 (47.3) 194 (50) 220 (49.7) 0.705
>25 years 29 (52.7) 194 (50) 223 (50.3)  
Time to clinic     
≤30 minutes 29 (51.8) 263 (67.6) 292 (65.6) 0.020
>30 minutes 27 (48.2) 126 (32.4) 153 (34.4)  
Region     
Asembo 17 (30.4) 75 (19.3) 92 (20.7) 0.056
Gem 39 (69.6) 314 (80.7) 353 (79.3)  
SES quintile     
Lower 40% 25 (44.6) 156 (40.1) 181 (40.7) 0.518
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Upper 60% 31 (55.4) 233 (59.9) 264 (59.3)  
SMS+200KES ARM 
 
Included in MSBC 
(N= 58) 





 No. (%) No. (%) No. (%)  
M-SIMU child's sex     
Female 27 (46.6) 180 (51.7) 207 (51.0) 0.466
Male 31 (53.4) 168 (48.3) 199 (49.0)  
Last delivery     
At home 21 (36.2) 92 (26.4) 113 (27.8) 0.124
At a health facility 37 (63.8) 256 (73.6) 293 (72.2)  
Mobile phone access      
Shares 38 (65.5) 175 (50.3) 213 (52.5) 0.032
Owns 20 (34.5) 173 (49.7) 193 (47.5)  
Maternal education     
≤7 years 14 (24.1) 93 (26.7) 107 (26.4) 0.679
>7 years 44 (75.9) 255 (73.3) 299 (73.6)  
Maternal age     
≤25 years 38 (65.5) 189 (54.3) 227 (55.9) 0.111
>25 years 20 (34.5) 159 (45.7) 179 (44.1)  
Time to clinic     
≤30 minutes 36 (62.1) 219 (62.9) 255 (62.8) 0.900
>30 minutes 22 (37.9) 129 (37.1) 151 (37.2)  
Region     
Asembo 15 (25.9) 66 (19.0) 81 (20.0) 0.224
Gem 43 (74.1) 282 (81.0) 325 (80.0)  
SES quintile     
Lower 40% 26 (44.8) 146 (42.0) 172 (42.4) 0.682













(N = 56) 
SMS+200KES




 No. (%) No. (%) No. (%) No. (%) No. (%)  
M-SIMU child's sex       
Female 24 (54.5) 31 (51.7) 27 (48.2) 27 (46.6) 109 (50.0) 0.855 
Male 20 (45.5) 29 (48.3) 29 (51.8) 31 (53.4) 109 (50.0)  
Last delivery       
At home 13 (29.5) 19 (31.7) 18 (32.1) 21 (36.2) 71 (32.6) 0.906 
At a health facility 31 (70.5) 41 (68.3) 38 (67.9) 37 (63.8) 147 (67.4)  
Mobile phone access        
Shares 21 (47.7) 33 (55.0) 41 (73.2) 38 (65.5) 133 (61.0) 0.043 
Owns 23 (52.3) 27 (45.0) 15 (26.8) 20 (34.5) 85 (39.0)  
Maternal education       
≤7 years 11 (25.0) 18 (30.0) 21 (37.5) 14 (24.1) 64 (29.4) 0.397 
>7 years 33 (75.0) 42 (70.0) 35 (62.5) 44 (75.9) 154 (70.6)  
Maternal age       
≤25 years 25 (59.5) 34 (56.7) 26 (47.3) 38 (65.5) 123 (57.2) 0.267 
>25 years 17 (40.5) 26 (43.3) 29 (52.7) 20 (34.5) 92 (42.8)  
Time to clinic       
≤30 minutes 23 (52.3) 30 (50.0) 29 (51.8) 36 (62.1) 118 (54.1) 0.558 
>30 minutes 21 (47.7) 30 (50.0) 27 (48.2) 22 (37.9) 100 (45.9)  
Region       
Asembo 13 (29.5) 17 (28.3) 17 (30.4) 15 (25.9) 62 (28.4) 0.957 
Gem 31 (70.5) 43 (71.7) 39 (69.6) 43 (74.1) 156 (71.6)  
SES quintile       
Lower 40% 15 (34.1) 22 (36.7) 25 (44.6) 26 (44.8) 88 (40.4) 0.579 
Upper 60% 29 (65.9) 38 (63.3) 31 (55.4) 32 (55.2) 130 (59.6)  
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Table 5.6. MCV1 timely coverage and MCV1 overall coverage among subsequent children (SC) and M-SIMU children, by study arm 
and overall 
 
Outcome assessed in Control SMS only SMS+75KES SMS+200KES Total 
 n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) 
MCV1 by at age 9m+2w or younger 
SC, 2017  
(N= 215) 25/43 (58.1) 28/59 (47.5) 20/55 (36.4) 23/58 (39.7) 96/215 (44.7)
* 
M-SIMU children in MSBC, 2014-2015
(N=215) 26/43 (60.5) 36/59 (61.0) 33/55 (60.0) 39/58 (67.2) 134/215 (62.3) 
All M-SIMU children, 2014-2015 
(N= 1,599) 183/360 (50.8) 231/388 (59.5) 315/445 (70.8) 292/406 (71.9) 1021/1599 (63.9) 
MCV1 by age 12 months 
SC, 2017 
(N= 174) 27/32 (84.4) 40/52 (76.9) 28/44 (63.6) 28/46 (60.9) 123/174 (70.7) 
† 
M-SIMU children in MSBC, 2014-2015
(N= 174) 27/32 (84.4) 47/52 (90.4) 33/44 (75.0) 40/46 (87.0) 147/174 (84.5) 
All M-SIMU children, 2014-2015  
(N= 1,598) 302/360 (83.9) 338/388 (87.1) 387/444 (87.2) 365/406 (89.9) 1392/1598 (87.1) 
 
*MCV1 timely coverage estimates among SC exclude three infants, one each born to a Control arm, SMS only arm and SMS+75KES 
arm caregiver, who were enrolled into MSBC before reaching age 9 months and 2 weeks 
†Estimation of MCV1 coverage by age 12 months in SC excluded 46 SC – eight, nine, 13 and 12 born to M-SIMU Control arm, SMS 
only arm, SMS+75KES and SMS+200KES arm caregivers, respectively - who had not reached age 12 months at the MSBC visit.  
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Table 5.7. Sensitivity analysis of MCV1 timely coverage: Risk differences during and after the M-SIMU study among children of 
intervention arm caregivers compared to those of Control caregivers. RDs are adjusted for the following M-SIMU baseline 
characteristics: mobile phone ownership status, travel time to nearest health facility, region of residence and maternal educational 
attainment. 
 
 Control SMS+200KES SMS+75KES SMS only 
  aRD* (95%CI) p aRD* (95%CI) p aRD* (95%CI) p 
After M-SIMU Ref -17.8 







During M-SIMU Ref 6.7 







Risk difference in 
differences (DID) 
Ref -24.4 








*aRD = Adjusted risk difference  
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Table 5.8. Pentavalent 3 timely coverage among subsequent children (SC) and M-SIMU children, by study arm and overall 
 
Outcome assessed in Control SMS only SMS+75KES SMS+200KES Total 
 n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) 
SC, 2017  
(N= 218) 31/44 (70.5) 42/60 (70.0) 35/56 (62.5) 33/58 (56.9) 141/218 (64.7) 
M-SIMU children in MSBC, 2014-2015 
(N=218) 32/44 (72.7) 43/60 (71.7) 43/56 (76.8) 40/58 (69.0) 158/218 (72.5) 
All M-SIMU children, 2014-2015 
(N= 1,599) 
267/360 




Table 5.9. MCV2 coverage by age 24 months, by M-SIMU study arm, risk ratios and differences in MCV2 vaccination among 
children previously enrolled in M-SIMU intervention arms compared to M-SIMU Control children. Adjusted RR and RD control for 
M-SIMU baseline mobile phone ownership. 
 











Control (N= 36) 19/36 (52.8) ref ref -- ref ref -- 



























Total (N= 163) 52/163 (31.9) -- -- -- -- -- -- 
 




Table 5.10. Sensitivity analysis: Relative risks and differences in the risk of receiving MCV2 by age 19 months among intervention 
arm M-SIMU children compared to Control M-SIMU children. Adjusted RRs and RDs control for M-SIMU baseline mobile phone 
ownership. 
 
Study arm MCV2 coverage 
n/N (%) 
cRR* aRR* p %cRD* %aRD* p 
Control (N= 36) 14/36 (38.9) ref ref -- ref ref -- 



























Total (N= 163) 41/163 (25.2) -- -- -- -- -- -- 
 
*cRR = crude risk ratio; aRR = adjusted risk ratio; cRD = crude risk difference; aRD= adjusted risk difference 
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Chapter 5 Figures 




Figure 5.2. MCV1 timely coverage: Crude and adjusted risk differences during and after the M-SIMU study among children of 
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Figure 5.3. MCV1 timely coverage: Crude and adjusted risk differences during and after the M-SIMU study comparing children of 
SMS+75KES and Control arm caregivers. Adjusted risk differences control for M-SIMU baseline phone ownership status. 
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Figure 5.4. MCV1 timely coverage: Crude and adjusted risk differences during and after the M-SIMU study comparing children of 
SMS only and Control arm caregivers. Adjusted risk differences control for M-SIMU baseline phone ownership status. 
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Figure 5.5. Sensitivity analysis of MCV1 timely coverage: Crude and adjusted risk differences during and after the M-SIMU study 
among children of SMS+incentive caregivers compared to those of Control caregivers. Adjusted risk differences control for M-SIMU 
baseline phone ownership status. 
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Figure 5.6. MCV1 overall coverage: Crude and adjusted risk differences during and after the M-SIMU study among children of 
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Figure 5.7. MCV1 overall coverage: Crude and adjusted risk differences during and after the M-SIMU study among children of 
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Figure 5.8. MCV1 overall coverage: Crude and adjusted differences risk differences during and after the M-SIMU study among 
children of SMS only caregivers compared to those of Control caregivers. Adjusted risk differences control for M-SIMU baseline 
phone ownership status. 
Risk difference-in-differences (DID)
During M-SIMU: SMS only vs. Control
After M-SIMU: SMS only vs. Control
Adjusted
Risk difference-in-differences (DID)
During M-SIMU: SMS only vs. Control
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Figure 5.9. Pentavalent 3 timely coverage: Crude and adjusted risk differences during and after the M-SIMU study among children of 
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Figure 5.10. Pentavalent 3 timely coverage: Crude and adjusted differences in the risk of receiving pentavalent 3 at age ≤16 weeks 
during and after the M-SIMU study among children of SMS+75KES caregivers compared to those of Control caregivers. Adjusted risk 
differences control for M-SIMU baseline phone ownership status. 
 
Risk difference-in-differences (DID)
During M-SIMU: SMS+75KES vs. Control
After M-SIMU: SMS+75KES vs. Control
Adjusted
Risk difference-in-differences (DID)
During M-SIMU: SMS+75KES vs. Control
After M-SIMU: SMS+75KES vs. Control
Crude




















Figure 5.11. Pentavalent 3 timely coverage: Crude and adjusted risk differences during and after the M-SIMU study among children 
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CHAPTER 6: CONCLUSION 
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6.1. Overview of thesis 
Health interventions delivered via mobile phone (mHealth) have the potential to increase demand 
for vaccination in low- and middle-income countries (LMICs) where predominantly low 
vaccination coverage intersects with high mobile phone access. Targeted client communications 
such as short message service (SMS or text message) vaccination reminders and incentives 
transmitted via mobile phone may generate demand for vaccination, thereby helping to achieve 
global measles elimination and equitable access to vaccines as envisioned in the 2011-2020 
Global Vaccine Action Plan (GVAP) and Sustainable Development Goals (SDGs).1,2 In most 
LMICs, first dose measles-containing vaccine (MCV1) coverage continues to fall below 90%. 
Some countries had not introduced second dose measles-containing vaccine (MCV2) as of 2016 
and those that recently introduced it struggle reach a large population of children. Yet 90%-95% 
coverage with two doses of MCV are required to eliminate measles. At the same time, 
vaccination timeliness is a metric that is not often used to assess vaccination program 
performance. The findings from this thesis may be informative for measles control programs and 
vaccination systems in LMICs.  
 
6.2. Aim I: Impact of SMS reminders on pediatric vaccination coverage and timeliness in 
LMICs 
In this aim we conducted a systematic review and meta-analysis to evaluate the impact of SMS 
reminders on pediatric vaccination uptake in LMICs. We identified 11 research articles that met 
inclusion criteria. Using data from those studies, we performed meta-analyses to estimate the 
pooled effect of SMS reminders on third dose diphtheria, tetanus and pertussis (DTP3) overall 
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vaccination coverage, full immunization coverage (FIC) and DTP3 timely coverage. Meta-
analyses to assess the impact of SMS reminders on MCV1 uptake could not be performed due to 
an inadequate number of studies. Based on pooled estimates, SMS reminders significantly 
increased the likelihood of achieving DTP3 timely vaccination in data from RCTs (pooled risk 
ratio [pRR] 1.12; 95% CI: 1.01, 1.25; p= 0.036) and from quasi-experimental studies (pRR 1.29; 
95% CI: 1.05, 1.60; p= 0.016). The magnitude absolute effect of SMS reminders on DTP3 timely 
coverage was moderate based on evidence in RCTs (pooled risk difference [pRD] 7.0%; 95% CI: 
0.1%, 14.0%; p= 0.047) and more substantial based on evidence from quasi-experimental studies 
(pRD 18.7%; 95% CI: 8.8%, 28.6%; p= 0.001). SMS reminders may also improve DTP3 overall 
coverage and FIC, but the evidence for impact on these vaccination outcomes came from only 
quasi-experimental studies (DTP3 overall coverage pRD 9.0%; 95% CI: 3.4%, 14.6%; p= 0.002 
and FIC pRD 18.1%; 95% CI: 8.5%, 27.6%; p< 0.001). This is the first meta-analysis of the 
impact of SMS reminders on vaccination uptake in LMICs.   
 
6.2. Aim 2: Impact of SMS reminders with or without unconditional monetary incentives 
on MCV1 coverage and timeliness 
To assess this aim, we conducted a parallel randomized controlled trial in rural Siaya County, 
Kenya, whereby infants were allocated to receive no interventions, SMS reminders only or SMS 
reminders coupled with a small, unconditional ~US $1.50 mobile-money (mMoney) incentive. 
We found that SMS reminders coupled with the unconditional monetary incentive significantly 
improved MCV1 timely coverage, i.e., the proportion of children vaccinated within two weeks of 
the recommended date, by 10.6% as compared to control (adjusted RD [aRD] 95% CI: 0.8%, 
20.3%; p= 0.034). Although the effect of SMS reminders on MCV1 timely coverage was not 
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statistically significant (aRD 9.2%; 95% CI: -0.6%, 19.0%; p= 0.066), we observed that the 
magnitude of its impact on timely coverage was similar to the impact of SMS reminders coupled 
with an incentive, and that the impact of SMS reminders alone likely did not achieve significance 
due to inadequate sample size. Neither one of the two interventions significantly improved 
MCV1 overall coverage, i.e., the proportion of children vaccinated by age 12 months, (SMS plus 
incentive aRD 6.8%; 95% CI: -1.8%, 15.3%; p= 0.119 and SMS only aRD 5.7%; 95% CI: -
3.0%, 14.3%; p= 0.199). However, the M-SIMI study was not powered to detect the magnitude 
of effect that we measured. In addition, the added effect of the unconditional incentive over SMS 
reminders alone was negligible. The Mobile and Scalable Innovations for Measles Immunization 
(M-SIMI) study is the first study to assess the combined impact of SMS reminders and 
unconditional incentives. 
 
6.3. Aim 3: Vaccine-seeking after withdrawal of temporary SMS reminders and incentives 
In this aim we sought to assess vaccine-seeking after withdrawal of SMS reminders and small 
conditional monetary incentives that were previously provided to caregivers in rural Western 
Kenya as part of a cluster randomized controlled trial (the Mobile Solutions for Immunization; 
M-SIMU study). The M-SIMU study sought to evaluate the impact of SMS reminders and small, 
conditional monetary incentives on vaccination coverage and timeliness. We conducted a post-
trial follow-up survey that found an indication of reduced vaccine-seeking among caregivers who 




Specifically, children who were born after the M-SIMU study to caregivers who previously 
received SMS reminders alone (SMS only), or combined with either a ~US $0.88 (SMS+75KES) 
or ~US $2.35 (SMS+200KES) incentive, had lower MCV1 timely coverage than their older 
siblings who were enrolled in the M-SIMU study. Decreases in MCV1 timely coverage ranged 
from 11.2% among subsequent children (SC) of SMS only caregivers (risk difference-in-
differences [DID] 95% CI: -36.1%, 13.7%; p= 0.376) to 25.2% among children of 
SMS+200KES caregivers (DID 95% CI: -55.3%, 4.8%; p= 0.099). Despite these decreases, 
MCV1 timely coverage was not significantly lower among SC of SMS only and SMS+200KES 
caregivers, compared to SC of caregivers who did not receive M-SIMU interventions (Control). 
However, the decrease in MCV1 timely coverage among children of SMS+75KES caregivers 
after withdrawal of M-SIMU interventions translated to 21.7% lower coverage than would be 
expected among children whose caregivers never received SMS vaccination reminders or 
incentives (RD 95% CI: -41.9, -1.6%; p= 0.035).  
 
Similarly, MCV1 overall coverage was also substantially lower among children born after the M-
SIMU study to caregivers who previously received M-SIMU interventions compared to MCV1 
overall coverage in their older siblings that were enrolled in the M-SIMU study. These decreases 
in MCV1 overall coverage ranged from 10.4% in SC of SMS only caregivers (DID 95% CI: -
29.8%, 9.0%; p= 0.295) to 24.5% among SC of SMS+200KES caregivers (DID 95% CI: -50.9, 
2.0%; p= 0.070). In the period after the M-SIMU study, MCV1 overall coverage was lower, 
though not significantly, among SC of SMS only and SMS+200KES compared to Control SC 
but significantly lower by 18.4% among SMS+75KES SC compared to Control SC (RD 95% CI: 




Also of note, MCV2 coverage by age 24 months among SMS+75KES and SMS+200KES 
children who were previously enrolled in the M-SIMU study was significantly lower compared 
to coverage among Control M-SIMU children by 29.2% (95% CI: -52.1%, -6.2%; p= 0.013) and 
by 27.0% (95% CI: -49.0%, -5.0%; p= 0.016), respectively. This is remarkable because MCV2 is 
recommended at age 15-18 months, which is after these children were discontinued from the M-
SIMU study and MCV2 coverage was assessed in the very same children previously enrolled in 
the M-SIMU study, i.e., not in SC. 
 
Taken together, we determined that these findings indicated decreased measles vaccine-seeking 
after withdrawal of SMS vaccination reminders and small, conditional monetary incentives. The 
M-SIMU Subsequent Born Child (MSBC) study is the first study to assess the impact of 
withdrawal of SMS reminders and incentives on vaccine-seeking. 
 
6.4. Strengths and limitations 
This dissertation work has some strengths and limitations. By pooling together studies in the 
meta-analysis of the impact of SMS reminders on vaccination uptake, we were able to obtain 
large sample sizes that were used to assess reminders’ impact on DTP3 overall and timely 
coverage as well as full immunization coverage. However, the studies included were at risk of 
bias as assessed using Cochrane risk of bias domains.3 In addition there was substantial 
heterogeneity in meta-analyses that we were unable to mediate by stratification due to the small 
number of studies. Furthermore, the quality of evidence from meta-analyses was poor owing to 
374 
 
the risk of bias and heterogeneity in findings. However, we are not in complete agreement that 
the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 
Working Group rubric used to score the quality of evidence from the meta-analysis was wholly 
appropriate but were confined to using that tool as we did not find a more appropriate scoring 
system.  
 
The assessment of the impact of SMS reminders with or without unconditional incentives on 
MCV1 timely and complete coverage in the M-SIMI study was strengthened by the randomized 
controlled design which reduced the risk of bias and confounding. An additional strength of this 
study is that we enrolled from the community. Studies that enroll from health facilities are 
limited because they do not capture children who have no contact with the health system, i.e., 
left-outs. A limitation of this study is that a substantial number of participants (82 of 537; 15.3%) 
were lost to follow-up. However, in sample size calculations we inflated the target sample size 
by 25% in anticipation of losses to follow-up. Consequently, the analytic sample size was within 
the sample size needed to assess a ≥15% increase in MCV1 timely coverage. In addition, we 
were not able to verify if the interventions reached caregivers. Although we asked participants at 
the final visit if they received the interventions, those data are subject to recall bias. We did, 
however, verify that SMS reminders and incentives were sent as one study staff’s phone number 
was included with in all batches of SMS reminders and incentives sent out as a quality control 
measure. Furthermore, study staff who conducted follow-up visits were not blinded to study arm 
allocation. But we believe that the risk of bias from unblinded allocation to be low as: each study 
Community Interviewer enrolled more than 100 participants; there was a 4-6 month lag between 
conducting the enrollment visit and the follow-up visit; and we found only one discrepancy in 
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outcome ascertainment (which was later clarified) comparing outcome data collected 
independently by Community Interviewers and the Field Supervisor within a 5% random sample 
of participants.  Future studies with similar procedures to the M-SIMI study could mitigate the 
risk of outcome ascertainment bias by assigning staff to collect vaccination status at homes 
different from those where they performed enrollment. 
 
The MSBC study had several strengths. First, we attempted to contact all M-SIMU households 
thus minimizing the risk of selection bias. Second, we followed up households that were 
previously enrolled in a randomized controlled trial and so had access to a Control group. In 
addition, we had information about baseline characteristics of the MSBC participants which 
allowed to assess if Control households were exchangeable with intervention households. This is 
particularly important because we conducted difference-in-differences (DID) analysis in the 
absence of information about baseline characteristics of participants in the period before the M-
SIMU study. Related to this, an additional strength is that we adjusted for temporal trends in 
using the DID approach to assess the magnitude of the difference in vaccine seeking after the M-
SIMU study compared to during the M-SIMU study in intervention households. However, the 
MSBC study had several limitations. We followed up only 14% of the entire M-SIMU sample 
size and this sample may not have been representative of the entire M-SIMU sample. In addition, 
while crowding theory could account for why vaccine-seeking decreased among intervention 
arm caregivers after withdrawal of SMS reminders and incentives, we did not specifically 
measure intrinsic behavior. Finally, the decreased vaccine-seeking we measured might be 




Despite the limitations described above, we believe that the strengths of this dissertation work 
engender confidence in the findings and that these findings have some implications for public 
health policy and future research. 
 
6.5. Implications for policy and future research  
The findings from this thesis work may be informative for governments, donors, public health 
researchers and other stakeholders. The findings from the systematic review and meta-analysis 
show that although the evidence for the impact of SMS reminders on vaccination coverage and 
timeliness is mixed, there is neither overwhelming evidence that SMS vaccination reminders 
significantly improve vaccination impact nor that they have a deleterious impact. Therefore, 
stakeholders considering implementation of SMS vaccination reminders at scale or to evaluate 
their impact in research studies should feel encouraged but should also consider two important 
findings from this thesis work. First, we found that the quality of evidence from meta-analyses 
was poor as judged using GRADE criteria4,5 as all included studies had high risk of bias in at 
least one of the Cochrane domains3 assessed. Thus, future RCTs or quasi-experimental studies 
assessing SMS impact on vaccination uptake should be well designed so as to avoid bias and 
should communicate methods thoroughly and clearly so as to avoid erroneous grading by quality 
assessors. In addition, we found only 11 assessments that met review inclusion criteria. More 
high quality assessments of the impact of SMS reminders on vaccination uptake in LMICs are 
needed and those that assess impact of MCV1 coverage and timeliness, MCV2 coverage and full 
immunization would be particularly informative. Additional studies would allow for stratified 
analyses and meta-regression that may inform modalities of SMS reminders and population 
characteristics that influence impact. Furthermore, future assessments need to include large 
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sample sizes as there is some suggestion from the meta-analysis that SMS reminders may have a 
modest but meaningful public health impact, which may not achieve statistical significance in 
small studies. Moreover, any programs implementing SMS vaccination reminders at scale, as in 
Ivory Coast,6 should perform impact assessments. Finally, future assessments of the impact of 
SMS reminders on vaccination uptake should assess the impact of SMS modalities such as 
content, wording and frequency of reminders. The impact of these modalities on the magnitude 
of effect has not been assessed for vaccination but they have been shown to influence the effect 
of SMS reminders for other outcomes.7,8  
 
Findings from the M-SIMI study contribute to the understanding of the impact of SMS reminders 
on MCV1 timeliness. Although M-SIMI findings were not included in the systematic review and 
meta-analysis (Aim 1) because they are not yet published, they support previous findings that 
SMS reminders improve MCV1 timely coverage.9 The M-SIMI study was underpowered to 
detect a 6% increase in MCV1 overall coverage, but if statistically significant in a larger study, 
this magnitude represents a meaningful impact in an area with typically 84% MCV1 overall 
coverage. Increasing vaccination coverage in a setting with high yet suboptimal coverage, in the 
‘last mile’ can be challenging as the remaining unvaccinated proportion may be children of 
caregivers who refuse vaccination or are on the extreme end of the vaccine hesitancy spectrum.10 
Vaccine refusal in ‘last mile’ households could be influenced by low levels of disease as well as 
mistrust of government as these ‘last mile’ households in LMICs are usually also the most 
marginalized.11,12 An additional important finding from the M-SIMI study is that unconditional 
incentives are unlikely to improve vaccination coverage. In the M-SIMI study we found that 
MCV1 timely and overall coverage estimates were similar among children whose caregivers 
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received SMS reminders only and those whose caregivers received SMS reminders coupled with 
an unconditional monetary incentive. Previously, the M-SIMU study which was conducted in the 
same study setting at the M-SIMI study, found that SMS reminders coupled with conditional 
monetary incentives significantly improved MCV1 coverage and timeliness and the magnitude 
of their effect was superior to the effect of SMS reminders alone.9 The M-SIMI study, in 
conjunction with M-SIMU, adds additional evidence in the ongoing debate about whether 
conditionality is needed for incentive and cash transfer. 
 
Results from the analysis of vaccine-seeking behavior after withdrawal of SMS vaccination 
reminders and incentives in the MSBC study point to the importance of sustaining interventions 
with demonstrated impact. However, the MSBC sample size was small and participants may not 
have been representative of the M-SIMU sample; follow-up of additional M-SIMU households is 
recommended. Taken together with findings from the M-SIMI and M-SIMU9 studies, findings 
from the MSBC have several implications. First, we recommend that incentives should only be 
introduced if they are intended to be sustained as we observed reductions in vaccine-seeking 
after withdrawal of SMS vaccination reminders and incentives among caregivers who previously 
received these interventions. As part of planning for research studies evaluating the impact of 
incentives, researchers should establish with donors, governments and other stakeholders, plans 
for sustaining incentives should they be shown to be impactful. However, findings from this 
dissertation research do not provide clarity on the merits of conditional versus unconditional 
incentives. On the one hand, the results from the M-SIMU study compared to those from the M-
SIMI study suggest that conditional incentives have superior impact. On the other hand, 
reductions in vaccine-seeking after withdrawal of M-SIMU interventions may be linked to the 
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conditionality of M-SIMU interventions as conditional incentives in particular are thought to 
reduce agency.13 In addition, outside the M-SIMU and M-SIMI studies, other studies in LMICs 
have shown a positive impact of both conditional14,15 and unconditional16 incentives while one 
study found no impact for either one.17 Even when shown to have impact, the duration of effect 
and consistency in impact of incentives across vaccine types within studies has varied.9,14,16 This 
points to the need for more studies assessing the impact of monetary incentives on vaccination 
uptake and also assessing the impact of the number and value of incentives. For example, a 
possible explanation for the increase in MCV1 overall coverage in the M-SIMU study but not in 
the M-SIMI study may not lie in the conditionality of the incentive but may have been linked to 
the frequency of incentives; the M-SIMU study delivered incentives for four vaccine doses while 
the M-SIMI study delivered one incentive total. In addition, studies evaluating behavioral 
interventions should assess the impact of their withdrawal on the behavior under study as 
findings from the MSBC study suggest that unintended consequences of removing M-SIMU 
interventions did not apply only to caregivers who previously received incentives, as posited in 
crowding theory,13,18 but also in caregivers who received SMS reminders alone. In that vein, 
follow-up of M-SIMI caregivers so as to assess the impact of withdrawal of SMS reminders and 
unconditional incentives is recommended. Finally, during research study development, donors, 
researchers and governments should articulate plans for sustaining behavioral interventions that 
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Appendix 7.2. M-SIMI consent form in Dholuo 
KEMRI/CDC AND JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
 
INFORMED CONSENT DOCUMENT 
Nying Nonro: Randomized Controlled Trial of the Impact of Mobile Phone Delivered 
Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and 
Timeliness in western Kenya 
 
Jotim Nonro: Dustin Gibson, Principal Investigator, Johns Hopkins School of Public Health 
(JHSPH); Benard Ochieng, Co-Principal Investigaor, KEMRI/CGHR; Joyce Were, 
KEMRI/CGHR; David Obor, KEMRI/CGHR; Daniel Feikin, CDC/Division of Viral Diseases; 
Eunice W. Kagucia, JHSPH; Katherine O’Brien, JHSPH; Kyla Hayford, JHSPH 
 
Gwenge mag nonro: Gem kod Asembo 
PI Version Date: 22May 2016 
Flesch-Kincaid readability level: 7.2 
Luo version  
 
CHAKRUOK 
Nyinga en ……………………….. to atiyo gi jotim nonro ma owuok KEMRI/CGHR kod Johns 
Hopkins kar tiegruok mar weche mag ngima manitie America. Wan kae mondo wang’e  kabende 
diher donjo e nonro matemo chanjo nyithindo mang’eny. Adhi wachoni mang’eny kuom gima 
watimo to kanitie gima ok odonjoni to inyisa mondo alerni matut. Wabiro bedo gi saa mar penjo 
bang’e kawasetieko. Ka aseduoko penjoni to abiro penji ka bende diher donjo e nonroni. 
Gima omiyo itimo nonroni 
Watimo nonroni nikech ei Kenya nyithindo mang’eny yudo chanjo molewo to moko ok yudi 
chanjo moro amora. Watimo nonroni mondo wang’e kawanyalo tiyo gi ong’we yamo (simu) 
mondo wajiw mine mondo oter nyithindgi e chanjo mar anyiew e kinde ma chanjono onego 
ochiwe. Nonroni ber nikech chanjo nyalo geng’o touche kod tho ne nyithindo. Wadwaro mondo 
wafweny  yore manyithindo mang’eny nyalo yudogo chanjo. 
Ang’o ma omiyo ikwayi mondo idonji e nonroni? 
Wakwayi ni mondo idonji e nonroni nikech in gi nyathi manitie e kind dweche auchiel kod aboro 
to kendo idak e gweng’ mawatime nonroni. Wageno ni mine gi nyithindo 600 ma owuok e 
gwengegi biro donjo e nonroni. 
Chenro mar nonro 
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 Ka iyie donjo e nonroni to ibiro keti e achiel kuom kidienje adek manene oyier ka itiyo gi 
yo ma ng’ato ang’ata ok nyal ng’eyo kidieny ma miyo man gi nyathi nyalo lware. Kuom 
ranyisi, inyalo dir siling to ka onyiso wich to iketo miyo e kidieny mar wich. Bende ka 
siling onyiso simba to ikete e kidieny mar simba.  Ibiro ti kod ong’we yamo e yore ma 
opogore opogore kuom jiwo mine mondo oter nyithindo e chanjo e kidieny ka kidieny. 
Wadwaro mondo wafweny ni kuom yore ma watiyogo e kidienje adek, ere manyalo miyo 
mine ter nyithindo e chanjo e saa ma owinjore? 
Magi e gik mabiro timore ka idonjo e nonroni: 
 Kawuono, ibiro nyisowa nying nyathini gi tarik mane onyuole. 
 Kawuono, wabiro kwayi nambani mar simu kata mar ng’at machiegni kodi ma inyalo 
tiyogo. 
 Kawuono, ibiro yudo ote machuok mapwoyi kuom donjo e nonroni. 
 Wabobiro e odi ka nyathini oseromo dweche 12. Ekindeno, wabiro penjo kuom chanjo 
mar nyathini, ngimane, jo odi, ewi ote machuok to gi kaka nineno nonroni. Magi duto 
biro kawo seche madirom dakika 30. 
 Ka gweng’u en achiel kuom gwenge ma jotich KEMRI/CGHR time limbe bang’ dweche 
ang’wen ka dweche ang’wen, to weche ma wakawo kuomi ibiro ket kanyakla gi weche 
ma jotich KEMRI/CGHR kawoga. 
 
(Som weche mabirogi isomo ne kidieny ka kidieny kaka owinjore) 
 Gweng’i nitie e kidieny mokwongo (1), e chakruok mar nonro ibiro yudo ote machuok 
achiel ewi weche mag ngima.  Inyalo tero nyathini e klinik mora mora ma ihero. 
 Gweng’i nitie e kidieny mar ariyo (2), wabiro oro ni ote machuok ariyo mondo oparni 
kapok ibiro e chanjo mar anyiew. Wabiro oro ote machuok mokwongo ndalo adek kapok 
chieng’ chanjo ochopo to mar ariyo chieng’ ma onindo ni chieng’ chanjo. Inyalo kelo 
nyathini e klinik  moro amora ma ihero. 
 Gweng’i nitie e kidieny mar adek (3), wabiro oroni ote machuok ariyo mondo oparni 
kapok ibiro e chanjo adek mokwongo. Wabiro oro ote ma okuongo ndalo adek kapok 
chieng’ chanjo ochopo to mar ariyo chieng’ ma onindo ni chieng’ chanjo.  Bende wabiro 
oroni shillings 150 ka chieng’ chanjo pok ochopo. 
Rach kata hinyruok ma dibedie 
Maricho manyalo timore ne ng’at ma nitiere  e nonroni tin. Jomoko nyalo neno ni penjo 
mipenjogi kawo sechegi mang’eny. Kaka pile, nyathi nyalo winjo malit e seche ma ichanje. Kata 
kamano, onge chanjo ma itemo manyien ma ibiro mi nyithindo e nonroni ka oweyo ma imiyoga 
nyithindo gi migao mar sirikal ma otelo ni weche mag ngima. Nyalore ni weche ma imiyowa 
nyalo chopo ni joma moko maok gin jotich nonroni. Wabiro temo matek mondo kik mano timre. 
Ber madibedie 
Moko kuom mabeyo manyalo timore ni nyathini en yudo chanjo e saa ma owinjore. Chanjo 
nyalo geng’o tuo kod tho. Wabiro ori e klinik machiegni kodi ka nyathini pok oyudo chanjo te 
ma onego omiye e kinde ma orwako dweche auchiel chakre nyuolne. Ok wabi chiwo pes wuoth 
kata chudo moro amora ma idwaro e klinik. Wabiro miyo migao mar ngima dwoko mar nonroni 
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mondo  okony e chanjo mar nyithindo ei Kenya. Dwokogi bende nyalo konyo nyithindo moko 
mag Africa mondo oyud chanjo e saa ma owinjore. 
Keto wechegi ma kiling’ling’ 
Wabiro temo mondo waket wechegi ma kiling’ling’ kaka nyalore. Ka iyiero donjo e nonroni to 
ibiro miyi namba mar nonro. Nambani ibiro keti e gik nonro duto makar nyingi. Gik mitiyogo e 
nonro ibiro kan ei kabat molor kod kiful kata e kompyuta man gi passwad manitie e senta 
KEMRI/CGHR, Kisian. Ok wabi tiyo gi nyingi e gano kata e oboke moro amora ewi nonroni. 
Wabiro keto nyingi gi nambani mar simu ma’opondo ma ng’ato ang’ata ma ok en jatich mar 
nonroni ok nyal nwang’o. 
Chiwruok e nonroni 
Ok ochuno ni nyaka idonji e nonroni. Bende inyalo yiero mondo iwuogi e nonroni  e saa moro 
amora bang’ ka isedonjo. Ok ochuno ni nyaka idwok penjo moro amora ma ok idwar dwoko. 
Yiero ni mondo idonji kata kik idonji e nonroni ok bimoni yudo thieth kata mono nyathini yudo 
chanjo e klinik machiegni kodi. Kapok iyiero mar donjo e nonroni, bed thuolo mar penjo ewi 
gimoro amora. 
Ng’ano ma anyalo tudora godo ka an gi penjo kata ywagruok? 
Ka in gi  penjo kata ywagruok kaluore gi yiero mari mar donjo e nonroni  to tudri kod Benard 
Omondi Ochieng’ , jachung’ mar nonroni KEMRI/CGHR Kisian , Kisumu-Busia Highway, P.O. 
Box 1578, 40100  katago ne simu e namba 0722245636/ 057-2022929 EXT 413.Ka iparo ni 
iyudo hinyruok e nonroni e yo moro amora, kata ka in gi penjo ewi ratiro mari kaka jachiwre e 
nonroni to idwaro tudori gi nga’t ma ok en achiel kuom jotich nonroni, tudri kod: Jagoro, 
KEMRI Ethics Review Committee, P.O. Box 54840 00200, Nairobi; Namba simu: 020-
2722541,0722205901, 0733400003; Email: erc@kemri.org. 
 
Bende in gi penjo moro amora ma inyalo penja? 
 
Bende diher mar donjo e nonroni? 
 
 
 Seyi mari (kata alama) mantiere piny mar oboke ni nyiso ni: 
 Osenyisa gima omiyo itimo nonroni, chenro, mabeyo madibedie kod maricho. 
 Osemiya thuolo mar penjo ka pok aketo seyi. 
 En yierona donjo e nonroni. 
 
Nying nyathi:        Tarik mar nyuol: ______________                                   
 
Nying mar Janyuol/Jarit:       
       
Seyi mar Janyuol/Jarit:     Tarik:__________  





Nying mar jakaw ayie: __________________________________________ 
 
Seyi mar jakaw ayie: _____________________    Tarik: _______________ 
 
(Kuom joma oknyal somo, janeno maok en achiel kuom anyuola kata jatich nonroni, nyaka ket 
seyi) 
Asesomo ma alero oboke mar ayie ne ng’at ma nyinge ondik malo kanyo ma aneno ka oyie gi keto 
alama.  
Nying janeno: _________________________________________  
 
Seyi mar janeno: _____________________    Tarik: _______________ 
 Give one copy to the participant and keep one copy in study records 
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Appendix 7.3. M-SIMI consent form in Kiswahili 
KEMRI/CDC NA SHULE YA AFYA YA UMMA YA JOHN HOPKINS 
WARAKA WA IDHINI 
 
Kichwa cha Utafiti: Majaribio ya kuthibitisha athari ya vikubusho vya rununu  na ruzuku ya 
usafiri kwa  kuboresha viwango vya uenezaji wa kinga na kalenda ya matukio magharibi mwa 
Kenya. 
Wapelelezi: Dustin Gibson, Principal Investigator, Johns Hopkins School of Public Health 
(JHSPH); Benard Ochieng, Co-Principal Investigaor, KEMRI/CGHR; Joyce Were, 
KEMRI/CGHR; David Obor, KEMRI/CGHR; Daniel Feikin, CDC/Division of Viral Diseases; 
Eunice W. Kagucia, JHSPH; Katherine O’Brien, JHSPH; Kyla Hayford, JHSPH 
Eneo ya utafiti: Kaunti ya Siaya 
Tarehe ya makala ya Mpelelezi mkuu: 22 May 2016 
Flesch-Kincaid readability level 7.6 
Toleo la Kiswahili 
Utangulizi  
Jina langu ni ___________________ ninafanya kazi na watafiti kutoka KEMRI/CGHR na shule 
ya umma ya Johns Hopkins iliyo kule Marekani. Tuko hapa kujua ikiwa ungependa 
kujumuishwa katika utafiti unaolenga kuwezesha watoto wengi kupata chanjo. Nitakuelezea kwa 
kina kuhusu utafiti huu. Ikiwa kuna jambo lolote hauelewi, tafadhali niulize ili nikueleze zaidi. 
Mwishowe, utakuwa na nafasi ya kuuliza maswali. Baada ya kujibu maswali yako, nitakuuliza 
ikiwa unataka kujumuishwa katika utafiti huu.  
Kusudi la utafiti 
Tunafanya utafiti huu kwa sababu watoto wengi nchini Kenya huchelewa kupata chanjo au 
hukosa kupata kabisa. Tunafanya utafiti kubaini ikiwa tunaweza kutumia simu ya rununu 
kuhimiza akina mama kuleta watoto wao ili wapate chanjo ya ukambi wakati unaofaa. Utafiti 
huu ni muhimu kwa sababu chanjo zinaweza kukinga watoto dhidi ya ugonjwa na hatimaye kifo. 
Tunataka kutafuta mbinu ya kuwezesha watoto wengi kupata chanjo. 
Kwa nini unaulizwa kushiriki? 
Tunakuuliza kushiriki katika utafiti huu kwa sababu una mtoto wa kati ya miezi sita na nane  na 
pia unaishi katika moja ya vijiji vinavyo husika katika utafiti huu. Tunatarajia akina mama na 
watoto 600 kushiriki katika utafiti huu kutoka eneo hii.  
Utaratibu wa utafiti 
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 Utachaguliwa kwa moja ya vikundi tatu kwa mbinu ya kubahitisha. Utakuwa na nafasi sawa 
ya kuwa katika moja ya vikundi hivyo tatu. Kila kikundi kitakuwa na mbinu tofauti ya 
kutumia simu ya rununu kuhimiza chanjo. Tunataka kulinganisha vikundi hivi tatu ili 
tubainishe njia bora zaidi ya kuhakikisha watoto wengi wanapata chanjo wakati unaofaa. 
Ukijijumuisha katika utafiti huu, yafuatayo yatafanyika: 
 Leo, utapeana jina na tarehe ya kuzaliwa ya mtoto wako. 
 Leo, tutakuulizia nambari yako ya simu au ya mtu unayoweza kufikia kwa urahisi. 
 Leo, utapata ujumbe fupi ya kukupongeza kwa kujiunga na utafiti huu. 
 Mtoto wako akifikisha umri wa miezi 12, tutakuja nyumbani kwako kuulizia kuhusu chanjo. 
Pia tutaangalia kitabu cha kliniki cha mama na mtoto. Hii inatarajiwa kuchukua takriban 
dakika 30. 
(Sehemu inayofuata ina aya ambayo yafaa kusomwa kulingana na kikundi ambacho mhusika 
alichaguliwa. Aya inayohusika pekee ndiyo itakayosomwa kwa kila mama) 
 Kijiji chako kiko katika kikundi cha kwanza. Hapo mwanzo wa utafiti, utapokea ujumbe fupi 
moja inayoangaza mambo ya afya. Unaweza kupeleka mtoto wako kwa kliniki  yoyote 
unayopenda. 
 Kijiji chako kiko katika kikundi cha pili. Tutakutumia ujumbe fupi mbili za kukukumbusha 
juu ya chanjo ya ukambi. Tutatuma ujumbe fupi ya kwanza siku 3 kabla siku ya chanjo na ya 
pili siku moja kabla siku ya chanjo. Unaweza kupeleka mtoto wako kwa kliniki  yoyote 
unayopenda. 
 Kijiji chako kiko katika kikundi cha tatu. Tutakutumia ujumbe fupi mbili za kukukumbusha 
kabla ya kuendea chanjo ya ukambi. Tutatuma ujumbe fupi ya kwanza siku 3 kabla siku ya 
chanjo na ya pili siku moja kabla ya siku ya chanjo.  Tutakutumia shilingi 150 siku mbili 
kabla siku ya chanjo kufika.   
Mabaya au madhara yanayoweza kutokea 
Madhara yanayoweza kutokea kwa sababu ya utafiti huu ni haba. Wengine wanaweza kuhisi 
maswali yanayouulizwa yanachukua muda wao mwingi. Kama kawaida, chanjo ya sindano 
inaweza kusababisha maumivu madogo kwa mtoto wako. Lakini hakuna chanjo yoyote ya 
majaribio itakayotumiwa katika utafiti huu isipokuwa chanjo ya kawaida inayotolewa na Wizara 
ya Afya. Inawezekana kwamba habari zako zitaweza kufikiwa na mtu ambaye sio mmoja ya 
watafiti. Hata hivyo tutajaribu tuwezavyo ili tuzuie habari zako kufikiwa na watu ambao 
hawahusiki. 
Mazuri yanayoweza kutokea 
Jambo nzuri ambalo linaweza kutendeka kwa mtoto wako ni kupata chanjo kwa wakati 
mwafaka. Chanjo zinaweza kuzuia magonjwa  na hatimaye kifo. Ikiwa mtoto wako hatakuwa 
amepata chanjo zinazofaa katika umri wa miezi kumi, tutakukuelekeza kwa kliniki kilicho karibu 
nawe lakini hatuta gharamia malipo yoyote. Tutapea matokeo ya utafiti huu Wizara ya Afya ili 
isaidie kuboresha kupatikana kwa chanjo nchini Kenya. Pia, matokeo hayo yataweza kusaidia 




Tutajaribu kuweka yale utakayotueleza kwa siri ipasavyo. Baada ya uamuzi wako wa kushiriki 
katika utafiti huu, utapewa nambari ya utafiti ambayo itatumika kwa vifaa vyote vya utafiti 
badala ya kutumia jina lako. Vifaa vyote vitawekwa ndani ya kabati inayofungwa na kifuli au 
kwenye tarakilishi iliyo na nambari ya siri ya KEMRI/ CGHR. Jina lako au chochote kile 
kinachoweza kukutambulisha hakitatumiwa katika ripoti za utafiti huu. Hatutafichua jina lako au 
nambari yako ya simu kwa mtu yeyote asiye mfanyikazi wa KEMRI/ CGHR anayehusika na 
utafiti huu. 
Kushiriki katika utafiti huu 
Sio lazima ushiriki katika utafiti huu. Unaweza kujiondoa katika utafiti huu wakati wowote licha 
ya kuanza. Pia, sio lazima ujibu swali lolote usilotaka kujibu. Huduma yoyote ya afya unayopata 
katika kliniki ikiwemo chanjo kwa mtoto wako haitaathiriwa kwa sababu ya uamuzi wako wa 
kushiriki au kutoshiriki katika utafiti huu. Kabla ya kufanya uamuzi wa kushiriki au kutoshiriki 
katika utafiti huu, kuwa huru kuuliza swali lolote. 
Ni nani ambaye nitawasiliana naye ikiwa nina maswali au malalamishi? 
Ikiwa una maswali au malalamishi juu ya kushiriki katika utafiti huu, wasiliana na Benard 
Omondi Ochieng’, msimamizi wa utafiti huu wa KEMRI/ CGHR, Kisumu-Busia Higway 
sanduku la posta 1578 40100 au nambari ya simu 0722245636/057-2022929 EXT 413. Ukiumia 
kwa njia yoyote ile au ukiwa na maswali kuhusu haki yako kama mshiriki katika utafiti na 
unataka kuzungumza na mtu asiyehusika moja kwa moja na utafiti huu, tafadhali wasiliana na 
katibu, KEMRI National Ethical Review Committee, sanduku la posta 54840 00200, Nairobi, 
nambari ya simu: 020 2722541, 0722 205901, 0733 400003; barua pepe: erc@kemri.org 
Je, una swali lolote?Je, ungependa kushiriki katika utafiti huu? 
 
Kutia sahihi (au alama) kwenye fomu hii inamaanisha: 
 Nimefahamishwa juu ya kusudi, taratibu, faida na madhara ya utafiti huu. 
 Nimepewa nafasi ya kuuliza maswali kabla ya kutia sahihi. 
 Nimekubali kushiriki katika utafiti huu kwa uamuzi wangu. 
Jina la mtoto:      Siku ya kuzaliwa: ______________ 
Jina la Mzazi/Msimamizi:           
Sahihi ya Mzazi/Msimamizi:__________________   Tarehe: __________________ 
(Weka “X” kama huwezi kuandika) 
--------------------------------------------------------------------------------------------------------------------- 
Jina la anayechukua makubaliano: ______________________________  
Sahihi ya anaye chukua makubaliano: _____________________     Tarehe: _______________ 
(Kwa wale wasioweza kusoma, msimamizi lazima akague na kuweka sahihi hapo chini) 
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Nimesoma na kuelezea kuhusu fomu ya makubaliano kwa aliyetajwa hapo juu na kutazama 
anapoweka alama ya kukubaliana.  
Jina la Msimamizi:_____________________________________________ 
Sahihi ya Msimamizi: _____________________Tarehe: ________________  




Appendix 7.4. M-SIMI consent form in English 
KEMRI/CDC AND JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
INFORMED CONSENT DOCUMENT 
Study Title: Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders 
and Unconditional Travel Subsidies on Measles Vaccination in Western Kenya  
Investigators: Dustin Gibson, Principal Investigator, Johns Hopkins School of Public Health 
(JHSPH); Benard Ochieng, Co-Principal Investigator, KEMRI/CGHR; Joyce Were, 
KEMRI/CGHR;David Obor, KEMRI/CGHR;Daniel Feikin, CDC/Division of Viral Diseases; 
Eunice W. Kagucia, JHSPH; Katherine O’Brien, JHSPH; Kyla Hayford, JHSPH 
Study Location: Siaya County and neighboring villages 
PI Version Date: 22May 2016 
Flesch-Kincaid readability level: 7.2 
English version (Local language version will be made available) 
Introduction 
My name is <insert name> and I am working with researchers from KEMRI/CGHR andJohns 
Hopkins School of Public Health; USA.We are here to find out if you would like to be in a 
research study that tries to get more infants vaccinated.  I am going to give you some information 
about what we are doing. If there is anything you don’t understand please ask me to stop and I 
will take time to explain. There will be time at the end for you to ask questions.  After answering 
your questions, I will ask you if you want to join the study.  
Purpose of study 
We are doing this study because many Kenyan infants get their vaccines late or not at all.  We 
are studying if we can use mobile phones to encourage mothers to bring children on time for 
measles vaccine.  This study is important because vaccines can protect infants from getting sick 
and dying.We want to explore ways to get more children vaccinated. 
Why you are being asked to take part 
We are asking you to join this study because you have a child who is six to eight months old and 
hasn’t received measles vaccine. We anticipate about 600 mothers and infants to join this study 
from this area. 
Study Procedures 
 You will be randomized to one of three groups. Randomization means it will be selected 
by chance, like using a coin flip. You will have an equal chance of being in each of the 
three groups.  Each group will have a different way of using mobile phones to encourage 
immunization. We want to compare the three groups to see which is the best way to get 
children vaccinated. 
If you join this study, this is what will happen during the next two to four months: 
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 Today, you will provide your child’s name and date of birth. We will ask you some 
questions about your child’s previous vaccines.  We will also ask you questions about 
you and your family.  This will take up to one hour. 
 Today, we will ask for your mobile phone number or that of someone who has a phone 
that you have easy access to. 
 When you bring your child to the clinic for measles vaccine at nine months, you should 
bring your MCH booklet with you.  
 When your child is 12 months old, we will come to your house.  We will ask questions 
about your child’s vaccinations, health, your household, SMS messages, and how you 
liked this study.  We will look at your maternal and child health card. This should 
take about 1 hour.   
 When your child is 24 months old, we might come to your house. If we come, we will 
ask questions about your child’s vaccinations and how you liked the study.  We will look 
at your maternal and child health card. This should take about 1 hour. 
 If your household is part of the HDSS, we will link these data to the HDSS data.  
 
 (The following section has different paragraphs to be read depending on which group the 
village has been assigned to.  Only the relevant paragraph will be read to each mother.) 
 
 You are in Group 1.   Today, you will get a SMS message congratulating you for joining 
our study. You will not receive any other SMS from us.   
 Youare in Group 2. Today, you will get a SMS message congratulating you for joining 
our study.We will send you two SMS reminders before measles vaccine visit.  This 
visit is due when your baby is nine months old.  We will send the first SMS three days 
before the vaccine is due.  We will send the second SMS on the day before the vaccine 
is due. We will not send you any other SMS other than those I just described to you. 
 You are in Group 3.Today, you will get a SMS message congratulating you for joining 
our study.We will send you two SMS reminders before measles vaccine visit.  This 
visit is due when your baby is nine months old.  We will send the first SMS three days 
before the vaccine is due.  We will send the second SMS on the day before the vaccine 
is due.  We will not send you any other SMS other than those I just described to you.  
Three days before your child turns nine months old, we will send you 150 KES.  This 
money will be sent to the phone number you provided us today. 
Potential Harms, Injuries, Discomforts, Inconveniences or Risks 
The risks from being in this study are small.  Some people might find the questions asked of 
them take too much time out of their day. Vaccine jabs might cause brief pain to your child, as 
usual.  But no new or experimental vaccines will be given in this study – only the regular, safe 
vaccines usually given by the Ministry of Health.  With any research study, there is a small 
chance your personal information may be revealed to people not in the study. We will do our 
best to prevent this. 
 
Potential Benefits 
Possible benefits to your child include getting him/her vaccinated on time.  Vaccines can prevent 
disease and death.  We will refer you to nearest clinic if your child does not have all vaccines by 
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12 months of age, but will not provide transportation or pay for any healthcare costs. We will 
give the results of the study to Ministry of Health to help improve child vaccinations in Kenya.  
The results might also help other African children to get their vaccines on time. 
 
Confidentiality 
We will try to keep your personal information as private as possible.  After you decide to take 
part, you will receive a study number.  This number will be used to label all study materials, 
rather than using your name.  All study materials will be kept in a locked cabinet or password 
protected computer at the KEMRI/CDC center in Kisian. Your name and identity will not be 
shown in any reports about this study.  We will not share your name or mobile phone number to 
anyone else besides the KEMRI/CGHR staff involved in this study. 
 
Participation 
You do not have to take part in this study.  You can decide to stop being part of this study at any 
time after you start.   You don’t have to answer any questions you don’t want to.  The health care 
you receive at area clinics, including the vaccines your child gets, will not be affected by your 
decision to take part, or not take part, in this study today.  Before deciding whether you want to 
take part, please feel free to ask any questions.  
 
Who do I call if I have questions or complaints? 
If you have questions or complaints as a result of being in this study please contact Mr. Benard 
Ochieng, Co-Principal Investigator at KEMRI/CGHR Kisian, off of Kisumu-Busia Highway, 
P.O. Box 1578 40100 or call 0722245636/057-2022929 EXT 413057-2022929 EXT 413.If you 
feel you have been harmed in any way, or if you have questions about your rights as a research 
subject, and want to talk about the study with someone who is not directly involved in this 
research project, please contact The Secretary, KEMRI Ethics Review Committee, P.O. Box 
54840-00200, Nairobi; Tel: 020-2722541, 0722205901, 0733400003; Email address: 
erc@kemri.org 
 
Do you have any questions for me?Do you want to take part in this research study? 
 
Your signature (or mark) on this form means: 
 I have been informed about the study’s purpose, procedures, possible benefits, and risks. 
 I have been given the chance to ask questions before I sign. 
 I have agreed to be in this study of my own free choice. 
 
Name of child:      Date of birth: ______________                                  
Name of Parent/Guardian:         
Signature of Parent/Guardian: ____________________  Date:__________  
(Put “X” if cannot sign name) 
--------------------------------------------------------------------------------------------------------------------- 




Signature of person administering consent: _____________________     Date: _______________ 
(For those who are not able to read, a witness, who is not a family member or study staff, must 
verify and sign below.) 
I have read and explained the consent form to the person named above and watched them indicate 
consent with a mark.  
Name of Interpreter/Witness: ________________________ 
Signature of Interpreter/Witness: _____________________Date ________________ 
Give one copy to the participant and keep one copy in study records
396 
 












































































  FROM CARD  VERBAL  




BCG      weeks   
Polio‐Birth      weeks   
Polio1      weeks   
Polio2      weeks   
Polio3      weeks   
Penta1      weeks   
Penta2      weeks   
Penta3      weeks   
PCV1      weeks   
PCV2      weeks   




























































Level of edu= highest level attempted 








































  FROM CARD  VERBAL  
Vaccine  Given: Yes/No  Date Received Given:Yes/No/DK Age at vaccination   Health Facility 
where vacc. given 
BCG      weeks   
Polio‐Birth      weeks   
Polio1      weeks   
Polio2      weeks   
Polio3      weeks   
Penta1      weeks   
Penta2      weeks   
Penta3      weeks   
PCV1      weeks   
PCV2      weeks   
PCV3      weeks   









































































































































Appendix 7.7. M-SIMI randomization Standard Operating Procedure (SOP) 
Purpose:	Describe	procedures	for	random	allocation	to	M‐SIMI	study	arms	
Step	 Equipment/materials	 Responsible	
1. Generate 1:1:1 random allocations to the M-SIMI study arms 
(control, SMS only, SMS+incentive) for 537 IDs 
	
Computer	 Data	analyst	
2. Divide the 537 random allocations into 5 blocks; 2 blocks will 
have 108 allocations and 3 blocks will have 107 allocations.  
Create allocation IDs by numbering each allocation within a 
block as follows: 
 Block 1: 1A – 108A 
 Block 2: 1B – 108B 
 Block 3: 1C – 107C 
 Block 4: 1D – 107D 





‐ Spreadsheet or other program to 
document groups 
Data	Analyst	
3. For each allocation, prepare allocation envelopes as follows: 
 Print the allocation ID and study arm on a card 
 Place the card in an opaque envelope 
 Seal the envelope and stamp the seal (to document when 
the seal is broken) 
 Write the allocation ID corresponding to the allocation (e.g. 





‐ Study arm allocations 




4. Preliminarily assign each CI to randomize participants using 
allocation envelopes from a particular Block e.g., CI#1 = Block 








5. Provide each CI with 10 allocation envelopes per week 
(assuming 2 enrollments/day) 
 
Sealed,	stamped	allocation	envelopes	 Field	Supervisor	
6. After determining eligibility, obtaining verbal consent and 
before obtaining written consent: 
 Open the sealed, stamped allocation 
 Allocations should be opened in sequence i.e., allocation 
1A should be opened before allocation 2A 
 Take note of which arm the participant is allocated 
 Write “ENROLLED” at the participant’s study ID on the 
allocation card 
 During consent, describe the procedures for the applicable 
study arm 
		
‐ Sealed, stamped allocation envelopes 
‐ Informed consent form 
‐ Pen 
CI	




8. Return the allocation cards for participants who have been 




9. Safely store allocation cards for enrolled participants. These 
may be destroyed once enrollment is complete 
 
Enrolled	participants’	allocation	cards	 Data	Analyst	
10. If the allocation envelope is opened but the participant is not 






11. Allocations for envelopes that have been opened but no 
participant was enrolled should be returned into the pool as 
follows: 
 Randomly select a sealed allocation envelope from the 
remaining pool of sealed allocation envelopes 
 Unseal this envelope 
 Switch the allocation IDs of the two cards. Ensure that the 
allocation IDs are changed on the card 
 Place the revised allocations into sealed envelopes and 
stamp the envelopes. Ensure that the correct allocation ID 
is recorded on the outside of the allocation envelope 
 Return the revised allocation envelope into circulation or to 





12. If a CI exhausts the allocation envelopes from the assigned 






Appendix 7.8. MSBC screening form 
Interviewer: ______________________  Date of Interview: DD/MM/YYYY 
Compound name: __________________ Village #____________ Compound#___________ 
EXCLUSION CRITERIA 
 
For mother/caregiver: IF YES FOR Q1…CHILD IS NOT ELIGIBLE 
1. Is the mother/infant enrolled in the M-SIMI study (KEMRI/SERU/CGHR/003/3311)? 
.......YES…………………….NO 





For mother/caregiver: IF NO FOR Q2, Q3 or Q4…CHILD IS NOT ELIGIBLE 
2. Were you enrolled in the MSIMU study? …………………YES…………………….NO 
If NO, caregiver is ineligible to enroll. Please stop the interview here. SKIP TO LAST 
Q AND SUBMIT 
3. Are you the caregiver of an infant aged 10 months or older and who was born after you 
joined the MSIMU study (MSB child)? …………………YES…………………….NO 
If NO, caregiver is ineligible to enroll. Please stop the interview here. SKIP TO LAST 
Q AND SUBMIT 
4. Can the vaccination status of that child be verified using the MCH booklet? 
.......YES…………………….NO 
 If NO, child is ineligible to enroll. Please stop the interview here. SKIP TO LAST Q 
AND SUBMIT 
 
For CI: IF NO FOR Q5 or Q6…CHILD IS NOT ELIGIBLE 
5. Was the vaccination status of MSIMU child verified using MCH booklet? 
…………YES…………………….NO 
If NO, caregiver is ineligible to enroll. Please stop the interview here. SKIP TO LAST 
Q AND SUBMIT 
 
IF MOTHER IS ELIGIBLE, TAKE INFORMED CONSENT IN APPROPRIATE 
LANGUAGE 
 




If NO, caregiver is ineligible to enroll. Please stop the interview here.SKIP TO LAST Q 
AND SUBMIT 
 
OTHERWISE, CI SHOULD CONGRATULATE MOTHER ON BEING ELIGIBLE FOR 















6. Child’s DOB according to Mother/caretaker [__][__] / [__][__] / [__][__][__][__]   
7. Is DOB in MCH book the same as the mother reports….YES…NO…..MCH BOOKLET NOT 
PRESENT 
7.1. If NO…what is the child DOB according to the MCH?[__][__] / [__][__] / 
[__][__][__][__] 
8. Child’s Location ID: [__][__][__]---[__][__][__][__]---[__][__]---[__][__][__] 
9. Caregiver First Name: [__][__][__][__][__][__][__][__][__][__][__][__] 
10. Caregiver Last Name: [__][__][__][__][__][__][__][__][__][__][__][__] 
11. Caregiver DOB:  [__][__] / [__][__] / [__][__][__][__] 
12. Is the caregiver of the MSIMU subsequent born child the same as the caregiver of the 






GPS Coordinates: _____________________________________________ 
Child's First Name: ____________________________________________ 
Child's middle Name: _________________________________________ 








FOR ALL PARTICIPANTS, COMPLETE THE REST OF THE QUESTIONNAIRE 
13. Do you own a mobile phone? ….YES……..NO…If YES, SKIP to Q14  
13.1. If no, whose mobile phone do you use to receive SMS and MPESA? (CAN 
CIRCLE MORE THAN ONE)................ HUSBAND….....OTHER PERSON IN 




Fill the "FROM CARD" column using the information from the card, in the table below. Fill HF 
using codes below 
 FROM CARD  
Vaccine Given: 
Yes/No 
Date Received  
BCG    
Polio-Birth    
Polio1    
Polio2    
Polio3    
Penta1    
Penta2    
Penta3    












PCV2    
PCV3    




22. Did anybody, such as a CHW, remind you about any of [NAME’S] immunization or do 
anything to encourage you to take [NAME] for vaccination? …..YES ……NO 
 22.1. If YES, who reminded or encouraged you? ____________ 
23. Apart from the MSIMU study, did you participate in any other studies that try to improve the 
number of children receiving vaccines? …..YES ……NO  
 23.1. If YES, name of study? ____________ 
24. How many CHILDREN UNDER 5 YRS of AGE, slept in this house last night? [___] [___] 
24.1. What is the birth order of the MSB child (2=second born)? 
….2nd….3rd….4th….5th….6th…..7th….>7 
26. How many persons are sleeping in the household regularly? This includes children under 5 
[__] [___] 
27. How many ANC visits did you make in your last pregnancy? [___] [___]  or NA 






28. Number of tetanus toxoid immunizations mother received in last pregnancy?  [___] [___] or 
DK 
29. Where was the MSB child born?....AT HOME WITH NO SBA………AT HOME WITH 




QUESTIONS ABOUT THE CHILD WHO WAS ENROLLED IN MSIMU 
THE FOLLOWING FOUR QUESTIONS ARE TO BE COMPLETED BY THE CI: 
32. In which MSIMU arm was the mother enrolled? …..ARM 1 (Control) …..ARM 2 (SMS) 
…..ARM 3 (SMS+75KES) …..ARM 4 (SMS+200KES) 
33. What was the study ID for the infant enrolled in MSIMU? (Please type)  
34. What was the DOB for the infant enrolled in MSIMU? …..MM/DD/YYYY 
35. What is the first name of the child who was enrolled in MSIMU? (Please type) 
QUESTIONS TO BE ANSWERED BY THE MOTHER 
36. Do you have a card where [NAME’S] vaccinations are recorded? …..YES…..NO 
36.1. IF YES, CI please answer: did the child receive a second dose of measles vaccine 
(MCV2)? …..YES….NO 
36.1.1. IF YES, CI please record the date of vaccine. (Please type) 
36.2. IF NO, did the child receive a second dose of measles vaccine?......YES…..NO 
36.2.1. IF YES, what was the age of the child (in months) when they received 













Appendix 7.10. MSBC consent form in Dholuo 
KEMRI/CDC AND JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
 
INFORMED CONSENT DOCUMENT 
Nying Nonro: Evaluation of the impact of short-term incentives and text message reminders on 
long-term parental vaccine-seeking practices: A vaccination coverage survey among MSIMU 
subsequent born children (The MSBC study) 
 
Jotim Nonro: Dustin Gibson, Principal Investigator, Johns Hopkins School of Public Health 
(JHSPH); Benard Ochieng, Co-Principal Investigaor, KEMRI/CGHR; Joyce Were, 
KEMRI/CGHR; David Obor, KEMRI/CGHR; Eunice W. Kagucia, JHSPH; Katherine O’Brien, 
JHSPH; Kyla Hayford, JHSPH 
 
Gwenge mag nonro: Gem kod Rarieda, sub-counties ei Kaunti ma Siaya 
PI Version Date: 12th May 2017 
Flesch-Kincaid readability level: 7.5 
Luo version  
 
CHAKRUOK 
Nyinga en …………………....…….. to atiyo gi jotim nonro ma owuok KEMRI/CGHR kod 
Johns Hopkins kar tiegruok mar weche mag ngima manitie America. Wan kae mondo wang’e  
kabende diher donjo e nonro mang'iyo kaka jonyuol manene jokanyo e nonro mar MSIMU tero 
nyithindgi e chanjo. Wabiro iri nikech na in achiel kuom  jogo mana gin jokanyo mar MSIMU.  
Bende iyiena mondo awach kodi ewi nonro maluo MSIMU ni?  Ka iyie, ahi wachoni mang’eny 
kuom gima watimo . Inyalo yiero donjo kata tamori. 
Bende iyiena mondo awach kodi ewi nonroni?  
Ka iyie: 
 




Watimo nonroni mondo wang'e kaka jonyuol tero nyithindgi e chanjo tok bedo e nonro mar 
MSIMU. Wadwaro ng'eyo ka timbe motenore gi tero nyithindo e chanjo lokore bang' bedo 
jakanyo e nonro machalo gi MSIMU, matiyo gi simu, ote machuok kod pesa matin mondo ojiw 
jonyuol oter nyithindo e chanjo e seche ma owinjore. Nonroni ber nikech chanjo nyalo geng’o 
tuoche kod tho ne nyithindo, to inyalo ti kod simu mondo nyithindo mang'eny oyudi chanjo. 
Nonroni biro konyowa duoko penjo manene openji bang' kanewachiwo duoko mar MSIMU ni 
jotim nonro mamoko kaachiel gi jotelo mag thieth. 
Ang’o ma omiyo ikwayi mondo idonji e nonroni? 
Wakwayi ni mondo idonji e nonroni nikech nene in achiel kuom jogo manene odonjo e nonro 
mar MSIMU to in gi nyathi madirom ja dweche 12. Wageno ni mine 1440 manene odonjo e 
nonro mar MSIMU biro donjo e nonroni. 
Chenro mar nonro 
 Ka iyie donjo e nonroni, wabiro kwayi mondo ikonwa nying nyathi kod tarik mar 
nyuolne. Wabiro penji penjo ma otenore kodi, ewi chanjo mar nyathini, ngimane, joodu 
kod pachi e weche mag chanjo. Wabiro kwayo mondo wane bug nyathi mar klinik. Magi 
duto biro kao saa achiel. 
 Wabiro ng'iyo bug klinik mar nyathi manene en jakanyo mar MSIMU kendo wapenji ewi 
chanjo mane nyathino oyudo bang' MSIMU. 
 Wabiro keto kanyakla weche ma imiyowa gi weche moko manene imiyowa e kinde 
manene watimo nonro mar MSIMU. 
Rach kata hinyruok ma dibedie 
Maricho manyalo timore ne ng’at ma nitiere  e nonroni tin. Jomoko nyalo neno ni penjo 
mipenjogi kawo sechegi mang’eny. E nonro mathoth, seche moko  weche ma jachiwre ochiwo 
nyalo chopo ni joma ok gin jotich nonro. Wabiro temo matek mondo kik mano timre e nonroni. 
Ber madibedie 
Wabiro ori e klinik machiegni kodi ka nyathini pok oyudo chanjo te ma onego omiye e kinde ma 
orwako dweche apar gi ariyo. Ok wabi chiwo pes wuoth kata chudo moro amora ma idwaro e 




mondo  okony e chanjo mar nyithindo ei Kenya. Dwokogi bende nyalo konyo nyithindo moko 
mag Africa mondo oyud chanjo e saa ma owinjore. 
Keto wechegi ma kiling’ling’ 
Wabiro temo mondo waket wechegi ma kiling’ling’ kaka nyalore. Ka iyiero donjo e nonroni to 
ibiro miyi namba mar nonro. Nambani ibiro keti e gik nonro duto makar nyingi. Gik mitiyogo e 
nonro ibiro kan ei kabat molor kod kiful kata e kompyuta man gi passwad manitie e senta 
KEMRI/CGHR, Kisian. Ok wabi tiyo gi nyingi kata nambani mar nonro e gano kata e oboke 
moro amora ewi nonroni. Wabiro keto nyingima opondo ma ng’ato ang’ata ma ok en jatich mar 
nonroni ok nyal nwang’o. 
Chiwruok e nonroni 
Donjo e nonroni en yiero mari, omiyo ok ochuno ni nyaka idonji e nonroni. Bende inyalo yiero 
mondo iwuogi e nonroni  e saa moro amora bang’ ka isedonjo. Ok ochuno ni nyaka idwok penjo 
moro amora ma ok idwar dwoko. Yiero ni mondo idonji kata kik idonji e nonroni ok bimoni 
yudo thieth kata mono nyathini yudo chanjo e klinik machiegni kodi. Kapok iyiero mar donjo e 
nonroni, bed thuolo mar penjo ewi gimoro amora. 
Ng’ano ma anyalo tudora godo ka an gi penjo kata ywagruok? 
Ka in gi  penjo kata ywagruok kaluore gi yiero mari mar donjo e nonroni  to tudri kod Benard 
Omondi Ochieng’ , jachung’ mar nonroni KEMRI/CGHR Kisian , Kisumu-Busia Highway, P.O. 
Box 1578, 40100. Kata go ne simu e namba 0722245636/ 057-2022929 EXT 413. Ka iparo ni 
iyudo hinyruok e nonroni e yo moro amora, kata ka in gi penjo ewi ratiro mari kaka jachiwre e 
nonroni to idwaro tudori gi nga’t ma ok en achiel kuom jotich nonroni, tudri kod: Jagoro, 
KEMRI Ethics Review Committee, P.O. Box 54840 00200, Nairobi; Namba simu: 020-
2722541,0722205901, 0733400003; Email: seru@kemri.org. 
 
Bende in gi penjo moro amora ma inyalo penja? Bende diher mar donjo e nonroni? 
 
 
 Seyi mari (kata alama) mantiere piny mar oboke ni nyiso ni: 
 Osenyisa gima omiyo itimo nonroni, chenro, mabeyo madibedie kod maricho. 
 Osemiya thuolo mar penjo ka pok aketo seyi. 
 En yierona donjo e nonroni. 
 





Nying mar Janyuol/Jarit:    _________________   
       
Seyi mar Janyuol/Jarit:   _________  Tarik:____________________  
(Ket “X” ka okinyal keto seyi) 
 
 
(Ket alama mar lith lwedo maduong'ka ok inyal ndiko "X") 
--------------------------------------------------------------------------------------------------------------- 
 
Nying mar jakaw ayie: _________________________________________________ 
 
Seyi mar jakaw ayie: ________________________    Tarik: _____________________ 
 
(Kuom joma oknyal somo, janeno maok en achiel kuom anyuola kata jatich nonroni, nyaka ket 
seyi) 
Osesom kendo olerne ng’at ma nyinge ondik malo kanyo oboke mar ayie, aneno ka oyie gi keto 
alama.  
 
Nying janeno: _________________________________________  
 
Seyi mar janeno: ____________________________    Tarik: _____________________ 





Appendix 7.11. MSBC consent form in Kiswahili 
KEMRI/CDC NA SHULE YA AFYA YA UMMA YA JOHNS HOPKINS 
 
WARAKA WA IDHINI 
 
Kichwa cha Utafiti: Majaribio ya kuthibitisha athari ya vikumbusho vya rununu na ruzuku kwa 
taratibu za wazazi kuwapeleka watoto kupata chanjo: Dodoso la viwango vya uenezaji wa kinga 
baadhi ya watoto waliozaliwa kufuata utafiti wa MSIMU (The MSBC Study) 
Wapelelezi: Dustin Gibson, Principal Investigator, Johns Hopkins School of Public Health 
(JHSPH); Benard Ochieng, Co-Principal Investigaor, KEMRI/CGHR; Joyce Were, 
KEMRI/CGHR; David Obor, KEMRI/CGHR; Daniel Feikin, CDC/Division of Viral Diseases; 
Eunice W. Kagucia, JHSPH; Katherine O’Brien, JHSPH; Kyla Hayford, JHSPH 
Eneo ya utafiti: Kaunti ndogo za Gem na Rarieda, Kaunti ya Siaya 
Tarehe ya makala ya Mpelelezi mkuu: 12 Mei 2017 
Flesch-Kincaid readability level 7.5 
Toleo la Kiswahili 
Utangulizi  
Jina langu ni ___________________ ninafanya kazi na watafiti kutoka KEMRI/CGHR na shule 
ya afya ya umma ya Johns Hopkins iliyo kule Marekani. Tuko hapa kwa sababu ulijijumuisha 
na utafiti wa “mobile solutions for immunization” yaani MSIMU. Je, tuna ruhusa yako ili 
kukueleza kuhusu utafiti unaofuatilia utafiti wa MSIMU? Ukikubali, tutakueleza kuhusu 
utafiti huo kisha utaamua kama ungependa kujijumuisha. 
Je, umenipa ruhusu ili kukueleza kuhusu utafiti unaofuatilia utafiti wa MSIMU? 
Kama ndio: 
Tuko hapa kujua ikiwa ungependa kujumuishwa katika utafiti unaolenga taratibu za wazazi 
kuwapeleka watoto kupata chanjo. Nitakuelezea kwa kina kuhusu utafiti huu. Ikiwa kuna jambo 
lolote hauelewi, tafadhali niulize ili nikuelezee zaidi. Mwishowe, utakuwa na nafasi ya kuuliza 
maswali. Baada ya kujibu maswali yako, nitakuuliza ikiwa unataka kujumuishwa katika utafiti 
huu.  
Kusudi la utafiti 
Tunafanya utafiti huu ili kuelewa taratibu za wazazi kupeleka watoto kupata chanjo baada ya 
kujiunga na utafiti wa MSIMU. Tungependa kuchunguza kama taratibu za wazazi kupeleka 




ambazo hutumia rununu, vikumbusho vya rununu, na ruzuku kuhimiza wazazi kuwapatia watoto 
wao chanjo wakati unaofaa. Utafiti huu ni muhimu kwa sababu chanjo zinaweza kukinga watoto 
dhidi ya ugonjwa na hatimaye kifo, na rununu zinaweza kusaidia watoto wengi kupata chanjo. 
Utafiti huu utatusaidia katika kujibu maswali ambayo yamejitokeza kutoka wanasayansi 
na maafisa wa afya baada ya kuwasilisha matokeo ya utafiti wa MSIMU. 
Kwa nini unaulizwa kushiriki? 
Tunakuuliza kushiriki katika utafiti huu kwa sababu ulijijumuisha na utafiti wa MSIMU na pia 
ulipata mtoto baada ya kushiriki katika utafiti wa MSIMU na mtoto huyo ana umri wa miezi 12 
au zaidi kwa wakati huu. Tunatarajia wazazi na watoto 1440 waliojishirikisha na MSIMU 
kushiriki katika utafiti huu. 
 
Utaratibu wa utafiti 
 Ukijijumuisha katika utafiti huu, tutakuuliza jina la mtoto na tarehe ya kuzaliwa. 
Tutauliza maswali kukuhusu. Pia tutauliza maswali kuhusu chanjo ambazo mtoto 
amepewa, afya ya mtoto, jamii yako na maoni yako kuhusu chanjo. Tutaangalia kitabu 
cha kliniki cha mama na mtoto. Shughuli hizi zitachukua takriban lisaa limoja.  
 
 Tutaangalia kitabu cha kliniki cha mama na mtoto kilichotumiwa kwenye mtoto 
uliyejumuisha katika utafiti wa MSIMU na pia tutauliza maswali kuhusu chanjo 
zozote alizopata baada ya utafiti wa MSIMU kuisha. 
 
 Tutajumuisha taarifa zako, taarifa za mtoto aliyehusishwa katika utafiti waMSIMU na 
taarifa za jamii yako kutoka rekodi za utafiti wa MSIMU.   
 
Mabaya au madhara yanayoweza kutokea 
Madhara yanayoweza kutokea kwa sababu ya utafiti huu ni haba. Wengine wanaweza kuhisi 
maswali yanayouulizwa yanachukua muda wao mwingi. Inawezekana kwamba habari zako 
zitaweza kufikiwa na mtu ambaye sio mmoja ya watafiti. Hata hivyo tutajaribu tuwezavyo ili 
tuzuie habari zako kufikiwa na watu ambao hawahusiki. 
 
Mazuri yanayoweza kutokea 
Ikiwa mtoto wako hatakuwa amepata chanjo zinazofaa katika umri wa miezi 12, tutakukuelekeza 
kwa kliniki kilicho karibu nawe lakini hatutagharamia malipo yoyote. Tutapea matokeo ya utafiti 
huu Wizara ya Afya ili isaidie kuboresha kupatikana kwa chanjo nchini Kenya. Pia, matokeo 
hayo yataweza kusaidia watoto wengi barani Afrika kupata chanjo wakati mwafaka. 
 
Usiri 
Tutajaribu kuweka yale utakayotueleza kwa siri ipasavyo. Baada ya uamuzi wako wa kushiriki 




badala ya kutumia jina lako. Vifaa vyote vitawekwa ndani ya kabati inayofungwa na kifuli au 
kwenye tarakilishi iliyo na nambari ya siri ya KEMRI/ CGHR. Jina lako au chochote kile 
kinachoweza kukutambulisha hakitatumiwa katika ripoti za utafiti huu. Hatutafichua jina lako 
kwa mtu yeyote asiye mfanyikazi wa KEMRI/ CGHR anayehusika na utafiti huu. 
 
Kushiriki katika utafiti huu 
Kushiriki katika utafitu huu ni kwa hiari yako, kwa hivyo sio lazima ushiriki katika utafiti huu. 
Unaweza kujiondoa katika utafiti huu wakati wowote licha ya kuanza. Pia, sio lazima ujibu swali 
lolote usilotaka kujibu. Huduma yoyote ya afya unayopata katika kliniki ikiwemo chanjo kwa 
mtoto wako haitaathiriwa kwa sababu ya uamuzi wako wa kushiriki au kutoshiriki katika utafiti 
huu. Kabla ya kufanya uamuzi wa kushiriki au kutoshiriki katika utafiti huu, kuwa huru kuuliza 
swali lolote. 
 
Ni nani ambaye nitawasiliana naye ikiwa nina maswali au malalamishi? 
Ikiwa una maswali au malalamishi juu ya kushiriki katika utafiti huu, wasiliana na Benard 
Omondi Ochieng’, msimamizi wa utafiti huu wa KEMRI/ CGHR, Kisumu-Busia Higway 
sanduku la posta 1578 40100 au nambari ya simu 0722245636/057-2022929 EXT 413. Ukiumia 
kwa njia yoyote ile au ukiwa na maswali kuhusu haki yako kama mshiriki katika utafiti na 
unataka kuzungumza na mtu asiyehusika moja kwa moja na utafiti huu, tafadhali wasiliana na 
katibu, KEMRI Ethics Review Committee, sanduku la posta 54840 00200, Nairobi, nambari ya 
simu: 020 2722541, 0722 205901, 0733 400003; barua pepe: seru@kemri.org 
Je, una swali lolote?Je, ungependa kushiriki katika utafiti huu? 
 
Kutia sahihi (au alama) kwenye fomu hii inamaanisha: 
 Nimefahamishwa juu ya kusudi, taratibu, faida na madhara ya utafiti huu. 
 Nimepewa nafasi ya kuuliza maswali kabla ya kutia sahihi. 
 Nimekubali kushiriki katika utafiti huu kwa uamuzi wangu. 
Jina la mtoto:      Siku ya kuzaliwa: ______________ 
Jina la Mzazi/Msimamizi:           
Sahihi ya Mzazi/Msimamizi:__________________   Tarehe: __________________ 
(Weka “X” kama huwezi kuandika) 
 
 





Jina la anayechukua makubaliano: ______________________________  
Sahihi ya anaye chukua makubaliano: _____________________     Tarehe: _______________ 
(Kwa wale wasioweza kusoma, msimamizi lazima akague na kuweka sahihi hapo chini) 
Fomu ya makubaliano imesomwa na kuelezwa kwa aliyetajwa hapo juu na nimetazama 
anapoweka alama ya kukubaliana.  
Jina la Shahidi:_____________________________________________ 
Sahihi ya Shahidi: _____________________Tarehe: ________________  





Appendix 7.12. MSBC consent form in English 
KEMRI/CDC AND JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
INFORMED CONSENT DOCUMENT 
Study Title: Evaluation of the impact of short-term incentives and text message reminders on 
long-term parental vaccine-seeking practices: A vaccination coverage survey among MSIMU 
subsequent born children (The MSBC study) 
Investigators: Dustin Gibson, Principal Investigator, Johns Hopkins School of Public Health 
(JHSPH); Benard Ochieng, Co-Principal Investigator, KEMRI/CGHR; Joyce Were, 
KEMRI/CGHR;David Obor, KEMRI/CGHR; Eunice W. Kagucia, JHSPH; Katherine O’Brien, 
JHSPH; Kyla Hayford, JHSPH 
Study Location: Gem and Rarieda sub-counties, Siaya County 
PI Version Date: 12th May 2017 




My name is .................................................................and I am working with researchers from 
KEMRI/CGHR and Johns Hopkins School of Public Health; USA. We are approaching you 
because you took part in the mobile solutions for immunization(MSIMU) study. Do we 
have permission to talk to you about a follow-up survey to the MSIMU study? If you say 
yes, we will describe the follow-up survey and you can choose to take part or not to take 
part in the survey.  
Do I have permission to talk to you about the follow-up survey?  
If yes: 
We are here to find out if you would like to be in a research study looking at vaccination 
practices of caregivers after participation in the mobile solutions for immunization (MSIMU 
study).  I am going to give you some information about what we are doing. If there is anything 
you don’t understand please ask me to stop and I will take time to explain. There will be time at 
the end for you to ask questions.  After answering your questions, I will ask you if you want to 
join the study.  
Purpose of study 
The purpose of this study is to understand caregivers’ vaccination practices after participating in 
the MSIMU study. We want to see if vaccination practices change after participation in studies 
like MSIMU which use mobile phones, reminders and small incentives to encourage mothers to 
vaccinate their children on time. This study is important because vaccines can protect infants 




study will help us address questions that have come up after we shared results of the 
MSIMU study with scientists and health officials. 
Why you are being asked to take part 
We are asking you to join this study because you participated in the MSIMU study and you gave 
birth to a child after the MSIMU study who is now aged 12 months or older. We think about 
1440 mothers from the MSIMU study will take part in this study. 
Study Procedures 
 
 If you join this study, we will request you to provide your child’s name and date of birth. 
We will ask questions about you. We will also ask questions about your child’s 
vaccinations, health, your household, and your thoughts about vaccination. We will look 
at your maternal and child health card. This should take about 1 hour. 
 
 We will look at the maternal and child health card of the child that participated in 
the MSIMU study and ask you questions about vaccinations that the child received after 
the MSIMU study. 
 
 We will link information about you, the child that participated in the MSIMU study and 
your household from the MSIMU study. 
Potential Harms, Injuries, Discomforts, Inconveniences or Risks 
The risks from being in this study are small.  Some people might find the questions asked of 
them take too much time out of their day. With any research study, there is a small chance your 




We will refer you to nearest clinic if your child does not have all vaccines by 12 months of age, 
but will not provide transportation or pay for any healthcare costs. Vaccines can prevent disease 
and death.  We will give the results of the study to Ministry of Health to help improve child 




We will try to keep your personal information as private as possible.  After you decide to take 
part, you will receive a study number.  This number will be used to label all study materials, 
rather than using your name.  All study materials will be kept in a locked cabinet or password 
protected computer at the KEMRI/CGHR center in Kisian. Your name and identity will not be 
shown in any reports about this study.  We will not share your name with anyone else besides the 
KEMRI/CGHR staff involved in this study. 
 
Participation 
Your choice to participate in this study is voluntary, therefore, you do not have to take part in 
this study.  You can decide to stop being part of this study at any time after you start.   You don’t 




including the vaccines your child gets, will not be affected by your decision to take part, or not 
take part, in this study today.  Before deciding whether you want to take part, please feel free to 
ask any questions.  
 
Who do I call if I have questions or complaints? 
If you have questions or complaints as a result of being in this study please contact Mr. Benard 
Ochieng, Co-Principal Investigator at KEMRI/CGHR Kisian, off Kisumu-Busia Highway, P.O. 
Box 1578 40100 or call 0722245636/057-2022929 EXT 413057-2022929 EXT 413. If you feel 
you have been harmed in any way, or if you have questions about your rights as a research 
subject, and want to talk about the study with someone who is not directly involved in this 
research project, please contact The Secretary, KEMRI Ethics Review Committee, P.O. Box 
54840-00200, Nairobi; Tel: 020-2722541, 0722205901, 0733400003; Email address: 
seru@kemri.org 
 
Do you have any questions for me? Do you want to take part in this research study? 
 
Your signature (or mark) on this form means: 
 I have been informed about the study’s purpose, procedures, possible benefits, and risks. 
 I have been given the chance to ask questions before I sign. 
 I have agreed to be in this study of my own free choice. 
 
Name of child:      Date of birth: ______________                                  
Name of Parent/Guardian:         
Signature of Parent/Guardian: ____________________  Date:__________  
(Put “X” if cannot sign name) 
 
 
(Put a thumb print  if cannot put "X") 
--------------------------------------------------------------------------------------------------------------------- 
Name of Person administering the consent: ______________ 
 





(For those who are not able to read, a witness, who is not a family member or study staff, must 
verify and sign below.) 
The consent form has been read and explained to the person named above and I watched him/her 
indicate consent with a mark.  
Name of Witness: _____________________________________________________ 
Signature of Witness: ______________________________Date _________________________ 






Appendix 7.13. Curriculum vitae 
CURRICULUM VITAE 




International Vaccine Access Center 
415 N Washington St. 
Baltimore, MD 21231 
Phone: 617-281-4853 
Email: ekagucia@jhu.edu  
 
EDUCATION AND TRAINING 
PhD/ Expected 2018 Johns Hopkins Bloomberg School of Public Health (JHSPH). Baltimore, MD 
Department of International Health. Division of Global Disease Control & 
Epidemiology 
Thesis title: mHealth interventions to improve measles vaccination coverage and 
timeliness: an assessment of the immediate and long-term impact on vaccine-seeking 
in rural Kenya 
Thesis co-advisors: Laura Hammitt, MD and Dustin Gibson, PhD 
 
MHS/ 2007 Johns Hopkins Bloomberg School of Public Health (JHSPH). Baltimore, MD 
Department of International Health. Division of Disease Prevention & Control 
 
Certificate/ 2006 Johns Hopkins Bloomberg School of Public Health (JHSPH). Baltimore, MD 
Vaccine Sciences and Policy Certificate 
 
BA/ 2005 Wellesley College. Wellesley, MA 
Double major in Biological Sciences and Africana Studies 
 
Study abroad/ 2004 University of Cape Town, Cape Town, South Africa 
Coursework in statistics, history and African studies 
 
PROFESSIONAL EXPERIENCE 
Sep 2014 – Present 
May 2011 – Aug 2014 
Feb 2011 – May 2011 
Graduate Research Assistant 
Research Associate 
Senior Research Program Coordinator II 
International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of 
Public Health. Baltimore, MD 
 
 Assist Principal Investigators in conduct of the following projects:  
o Randomized controlled trial of the impact of mobile phone-delivered 
unconditional incentives and reminders to improve measles vaccination 
coverage and timeliness in Western Kenya and post-trial follow-up of the 
Mobile Solutions for Immunization (M-SIMU) study. Responsibilities: 




in Kenya, communicate with the IRB, conduct data analysis using Stata, 
interpret data and communicate results (2016 - present) 
o Evaluation of the accuracy and feasibility of oral fluid and dried blood 
spots for monitoring effective vaccination coverage. Responsibilities: 
coordinate study, liaise with study partners in Kenya, assist in preparation 
of progress reports to donor, and conduct data analysis using Stata (2014 – 
present)    
o Randomized controlled trial of the impact of mobile phone-delivered 
travel subsidies and reminders to improve childhood immunization rates 
and timeliness in Western Kenya (the M-SIMU study). Responsibilities: 
liaise with Kenya study partners, communicate with the IRB, assist in 
preparation of progress reports to donor, and assist with interpretation and 
communication of findings (2013-2016) 
o The Pneumonia Etiology Research for Child Health (PERCH) – a multi-
site study of pneumonia etiology. Responsibilities: coordinate IRB 
communication at central coordination center and with seven sites, provide 
operational support to sites, coordinate meetings of the study Executive 
Committee including development of meeting materials, conduct analysis 
of pertussis epidemiology in PERCH sites and contribute to manuscript 
write-up (2013-2016) 
o Assessing pneumococcal serotype epidemiology following introduction of 
pneumococcal conjugate vaccine (PCV7). Responsibilities: develop data 
abstraction instruments, organize data in a standardized format, contact 
and follow-up investigators at more than 30 sites, assess data quality, 
analyze data using Stata, assist in manuscript write-up (2011-2013) 
 
 
Jun 2015 – Oct 2015 
 
Patient Safety Intern, MedImmune/Astrazeneca, Gaithersburg, MD 
Kelly Services, INC. 
 Conducted analysis comparing the safety of quadrivalent influenza vaccines versus 
trivalent influenza vaccines using the Vaccine Adverse Events Reporting System 
(VAERS) data 
 
Feb 2009 – Feb 2011 
May 2007 - Feb 2009 
Senior Research Program Coordinator II 
Senior Research Program Coordinator 
Center for Immunization Research, Johns Hopkins Bloomberg School of Public 
Health.  Baltimore, MD 
 
Principal responsibilities 
 Coordinated Phase I Dengue vaccine trials within FDA and ICH GCP guidelines 
including: recruitment and screening of volunteers, coordination of study visits, 
data entry, quality assurance/quality control, maintenance of study essential 
documents, communication with the Sponsor and Sponsor representatives, assisting 
in the preparation of semi-annual and annual study reports.  
 Managed regulatory processes for study protocols including Phase I and Phase II 
Dengue, Malaria and West Nile vaccine trial protocols as well as a center-wide 




 Conducted Good Clinical Practice (GCP) training workshops for vaccine trials, 
including instruction and development and of didactic lectures, interactive exercises 





2010 Certified Clinical Research Professional (CCRP), Society for Clinical Research 
Associates (SoCRA)  
2007 Member, Delta Omega Honorary Society in Public Health, Alpha Chapter 
 
EDITORIAL ACTIVITIES 
Peer review activities  
2015 Tropical Medicine and Health 
2012 Microbial Drug Resistance 
 








Third place poster, Vaccine Day, Johns Hopkins Bloomberg School of Public Health 
(JHSPH) 
JHU Global mHealth Initiative Scholarship to attend the 2016 Global Digital Health 
Forum, JHSPH 
Clements-Mann Fellowship, Department of International Health, JHSPH 
Academic Scholarship, Department of International Health, JHSPH  
Academic Scholarship, Department of International Health, JHSPH 
2005 Durant Scholar magna cum laude, Wellesley College 
2001-2005 Davis United World College Scholar, Wellesley College 






2017 DeLuca AN, Hammitt LL, Kim J, Higdon MM, Baggett HC, Brooks WA, Howie 
SRC, Deloria Knoll M, Kotloff KL, Levine OS, Madhi SA, Murdoch DR, Scott JAG, 
Thea DM, Amornintapichet T, Awori JO, Chuananon S, Driscoll AJ, Ebruke BE, 
Hossain L, Jahan Y, Kagucia EW, Kazungu S, Moore DP, Mudau A, Mwananyanda 
L, Park DE, Prosperi C, Seidenberg P, Sylla M, Tapia MD, Zaman SMA, O’Brien 
KL, The PERCH Study Group. Safety of the induced sputum procedure in children 
hospitalized with severe or very severe pneumonia. Clin Infect Dis 2017; 64(suppl 
3):S301–8 
 
2017 Gibson DG, Ochieng B, Kagucia EW, et al. Mobile phone-delivered reminders and 
incentives to improve childhood immunisation coverage and timeliness in Kenya (M-
SIMU): a cluster randomised controlled trial. Lancet Glob Heal. 2017;5(4):e428-e438. 
 
2016 Barger-Kamate B, Deloria Knoll M, Kagucia EW, et al. Pertussis-Associated 
Pneumonia in Infants and Children From Low- and Middle-Income Countries 






2016 Gibson DG, Kagucia EW, Ochieng B, Hariharan N, Obor D, Moulton LH, Winch PJ, 
Levine OS, Odhiambo F, O'Brien KL, Feikin DR. The Mobile Solutions for 
Immunization (M-SIMU) Trial: A Protocol for a cluster randomized controlled trial 
that assesses the impact of mobile phone delivered reminders and travel subsidies to 
improve childhood immunization coverage rates and timeliness in western Kenya. 
JMIR Research Protocols. 2016; 5(2):e72 
 
2015 Gibson DG, Ochieng B, Kagucia EW, Obor D, Odhiambo F, O'Brien KL, Feikin DR. 
Individual level determinants for not receiving immunization, receiving immunization 
with delay, and being severely underimmunized among rural western Kenyan 
children. Vaccine. 2015 Nov 27;33(48):6778-85 
 
2013 Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, et al. (2013) Serotype-
Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate 
Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites. PLoS Med 
10(9): e1001517.  
 
2013 Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, 
Speicher J, Whitehead SS, Pletnev AG. The live attenuated chimeric vaccine 
rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult 
volunteers. Vaccine. 2013 Nov 19;31(48):5772-7. Epub 2013 Aug 19. 
 
  
CURRICULUM VITAE PART II 
E. Wangeci Kagucia 
 
TEACHING 
1. Introduction to International Health. Primary Instructors: William Brieger, Karen Charron, Anna 
Kalbarczyk (Online Course, JHSPH) 
Term 2 AY 2016-2017: Teaching Assistant 
2. Introduction to International Health. Primary Instructors: William Brieger, Karen Charron, Anna 
Kalbarczyk (Online Course, JHSPH) 
Term 3 AY 2015-2016: Teaching Assistant 
3. Clinical Vaccine Trials and Good Clinical Practice. Primary Instructor: Karen R. Charron (Online Course, 
JHSPH).  
Term 4 AY 2014-2015: Teaching Assistant 
4. Vaccine Trials: Methods and Best Practices. Primary Instructors: Karen R. Charron and Amber B. Cox 
(Online course, Coursera [https://www.coursera.org/course/vacctrials]) 
Fall 2012. Guest lecture on managing essential documents for clinical trials.  





Spring 2010 & Fall 2010: Course coordination including development of course materials, moderation of 
LiveTalks, and grading of student assignments. Recorded guest lecture, “Maintaining Clinical Trial 
Essential Documents”.   
 
RESEARCH GRANT PARTICIPATION 
2014 – Present Estimating Effective Vaccination Coverage with Immune Markers: Validation of anti-
tetanus toxoid IgG and anti-measles IgG assays for use with dried blood spots and 
oral fluid samples 
Sponsor: Bill and Melinda Gates Foundation 
Principal Investigators: Katherine O’Brien and Kyla Hayford 
Role: Graduate research assistant 
 
2012-Present Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders 
and Conditional Cash Transfers to Improve Childhood Immunization Coverage Rates 
and Timeliness in Kenya 
Sponsor: Bill and Melinda Gates Foundation 
Principal Investigators: Katherine O’Brien, MD and Daniel Feikin, MD 
Role: Project coordinator (2012-2014); Graduate research assistant (2014-present) 
 
2011-2012 Review of Changes in Incidence of Serotype-specific Pneumococcal Disease in 
Infants and Young Children Following Routine Pneumococcal Conjugate Vaccine 
Introduction 
Sponsor: Bill and Melinda Gates Foundation 
Principal Investigators: Katherine O’Brien, MD and Daniel Feikin, MD 
Role: Project coordinator 
 
Study coordinator for the following studies: 
2009 Phase I Study of the Safety and Immunogenicity of rDEN4Δ30-200,201 a Live 
Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 
Sponsor: NIH/NIAID/RCHSPB 
Principal Investigator: Anna P Durbin, MD 
 
2009 Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine 
with Boosting at 4 Versus 6 Months 
Sponsor: NIH/NIAID/RCHSPB 
PI: Anna P Durbin, MD 
 
2008 Safety and Immunogenicity of a 2-Dose Regimen of rDEN1Δ30 Dengue Serotype 1 
Vaccine with Boosting at 4 versus 6 Months 
Sponsor: NIH/NIAID/RCHSPB 
Principal Investigator: Anna P Durbin, MD 
 
2008 Phase I Study of the Safety and Immunogenicity of rDEN3/4Δ30(ME), a Live Phase 




Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 
Sponsor: NIH/NIAID/RCHSPB 





Apr 2018 Poster 
E. Wangeci Kagucia, Benard O. Ochieng, Joyce A Were, Kyla Hayford, Katherine L. 
O’Brien, Dustin G. Gibson 
“Evaluation of the impact of text message reminders with or without unconditional 
monetary incentives on infant measles vaccination timeliness and coverage in rural 
western Kenya”  
2018 Annual Conference on Vaccinology Research (ACVR), Bethesda, MD 
 
Apr 2018 Oral abstract 
K. Hayford, B. Ochieng Omondi, J.A.Were, E. Kagucia, D. Gibson, M. Pasetti, K. 
O’Brien, M.R. Odiere 
“Can IgG antibodies to tetanus toxoid distinguish fully vaccinated children form 
under- and unvaccinated children? An opportunity to use serology to monitor 
vaccination programs”  
2018 Annual Conference on Vaccinology Research (ACVR), Bethesda, MD 
 
Apr 2018 Poster 
Lindsay R. Grant, Wangeci Kagucia, Carolynn DeByle, Karen Rudolph, Kate Gould, 
Robert C. Weatherholtz, Raymond Reid, Katherine L. O’Brien, Jason Hinds, Laura L. 
Hammitt 
“Serotype-specific pneumococcal colonization prevalence and density among 
American Indians in the PCV13 era using PCR and microarray” 
11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), 
Melbourne, Australia 
 
Apr 2017 Poster 
E. Wangeci Kagucia, Dustin Gibson  
“Use of text message reminders to improve pediatric vaccination in low- and middle-
income countries: A systematic review and meta-analysis” 
Vaccine Day 2017, Johns Hopkins Vaccine Initiative, Baltimore, MD 
 
Apr 2015 Platform Session (oral presentation) 
Breanna Barger-Kamate, Eunice Kagucia, Maria Knoll, Katherine O’Brien, Karen 
Kotloff 
“Burden of Pertussis Pneumonia from 1-6 Months of Age in Seven African and Asian 
Countries” 





Mar 2015 Oral Abstract Presentation 
Gibson D, Kagucia E, Omondi B, O'Brien K, Feikin D.  
“Association between delayed pentavalent vaccination and immunization drop-out in 
rural western Kenya: Findings from a cross-sectional survey”  
Consortium of Universities for Global Health (CUGH) 6th Annual Global Health 
Conference, Boston, MA 
 
Apr 2010 Poster Presentation 
Lok JK, Kagucia EW, Allen MA, Andrada A, Chavis S, Cox AB, Drayton-Weaver 
SL, DiLorenzo S, Elwood DT, Hentrich A, Lewis RT, Lovchik J, Sabundayo BP, 
Shaffer D, Perry H, Thumar B, Wanionek K, Yoder N, Durbin AP.  
“Clinical Development of the NIH Live Attenuated Tetravalent Dengue Vaccine 
Candidate, TetraVax-DV” 
The Thirteenth Annual Conference on Vaccine Research, Bethesda, MD 
 
Nov 2009 Scientific Session 
Anna P. Durbin, Stephen S. Whitehead, Daniel Elwood, Wangeci Kagucia, Bhavin 
Thumar, Kimberli A. Wanionek, Dennis Pierro, Brian R. Murphy, Alexander C. 
Schmidt 
“Safety and Immunogenicity of a 2-Dose Regimen of rDEN1Δ30 Dengue Serotype 1 
Vaccine with Boosting at four versus six Months” 
American Society of Tropical Medicine and Hygiene 58th Annual Meeting, 
Washington DC 
 
 
 
 
